 Global Health Metrics
1260 
www.thelancet.com   Vol 390   September 16, 2017
Global, regional, and national disability-adjusted life-years 
(DALYs) for 333 diseases and injuries and healthy life 
expectancy (HALE) for 195 countries and territories, 
1990–2016: a systematic analysis for the Global Burden of 
Disease Study 2016
GBD 2016 DALYs and HALE Collaborators*
Summary
Background Measurement of changes in health across locations is useful to compare and contrast changing 
epidemiological patterns against health system performance and identify specific needs for resource allocation in 
research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and 
Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population 
health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track 
trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI).
Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, 
cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories 
from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each 
location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability 
per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric 
mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate.
Findings The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years 
(95% uncertainty interval 71·9–78·6) for females and 72·0 years (68·8–75·1) for males. The lowest for females was 
in the Central African Republic (45·6 years [42·0–49·5]) and for males was in Lesotho (41·5 years [39·0–44·0]). From 
1990 to 2016, global HALE increased by an average of 6·24 years (5·97–6·48) for both sexes combined. Global HALE 
increased by 6·04 years (5·74–6·27) for males and 6·49 years (6·08–6·77) for females, whereas HALE at age 65 years 
increased by 1·78 years (1·61–1·93) for males and 1·96 years (1·69–2·13) for females. Total global DALYs remained 
largely unchanged from 1990 to 2016 (–2·3% [–5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and 
nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The 
exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were 
Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic 
heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs 
and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY 
burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. 
Interpretation At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that 
many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative 
years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression 
of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace 
with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and 
their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. 
Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform 
health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for 
health, including financial and research investments for all countries, regardless of their level of sociodemographic 
development. The presence of countries that substantially outperform others suggests the need for increased scrutiny 
for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming 
countries suggests the need for devotion of extra attention to health systems that need more robust support.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Lancet 2017; 390: 1260–344
*Collaborators listed at the end 
of the Article
Correspondence to: 
Prof Simon Iain Hay, Institute for 
Health Metrics and Evaluation, 
Seattle, WA 98121, USA 
sihay@uw.edu 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1261
Introduction
Objective measurement of population health is a fun­
damental requirement of good governance that allows 
international, regional, national, and local actors to frame 
evidence­based policy informed by past trends and current 
performance of health systems.1–4 Summary measures of 
population health include techniques that measure the 
overall burden of health loss due to fatal and non­fatal 
diseases, as well as measures of expected fatal and non­
fatal disease burden based on Socio­demographic Index 
(SDI).5 The disability­adjusted life­year (DALY) measures 
health loss due to both fatal and non­fatal disease burden. 
DALYs are the sum of the years of life lost (YLLs) due to 
premature mortality and years of life lived with disability 
(YLDs).6 The YLL is based on remaining life expectancy 
when compared with a reference standard life table at age 
of death,7 and the YLD is calculated by multiplying the 
prevalence of a disease or injury and its main disabling 
outcomes by its weighted level of severity.6,8 One DALY 
represents 1 year of healthy life lost. Examination of levels 
and trends of DALYs facilitates quick comparison between 
different diseases and injuries. Conversely, healthy life 
expectancy (HALE), a metric based on methods by 
Sullivan,9 provides a single summary measure of popu­
lation health across all causes combined by weighting 
years lived with a measure of functional health loss before 
death and is the most comprehensive among competing 
expectancy metrics.1–4 Together, DALYs and HALE enable 
comparisons of the magnitude of functional health loss 
across societies due to diseases, injuries, and risk factors, 
against which provisioning and performance of health 
systems can be calibrated.4
Research in context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
2015 (GBD 2015) provided disability-adjusted 
life-year (DALY) estimates for 315 diseases and injuries for 
195 countries and territories, including subnational 
assessments for 11 countries and, thus, for a total of 
519 locations, from 1990 to 2015. GBD 2015 also introduced 
analyses of DALYs and healthy life expectancy (HALE) in 
relation to the Socio-demographic Index (SDI). Only the WHO 
Global Health Estimates has published updated estimates of 
DALYs, and these estimates were heavily reliant on GBD 2015 
results.
Added value of this study
This study, the Global Burden of Diseases, Injuries, and Risk 
Factors Study 2016 (GBD 2016), updates and improves the 
first of the annual Global Burden of Disease iterations, 
GBD 2015. GBD 2016 is, to our knowledge, the only peer-
reviewed, Guidelines for Accurate and Transparent Health 
Estimates Reporting-compliant, comprehensive, and annual 
assessment of DALYs and HALE by age group, sex, cause, and 
location, analysed consistently from 1990 to 2016. The 
improved approaches to the analysis and refinements in data 
(gap fills, updates, and revisions), as well as the widening of 
scope by cause, location, age, and time are all relevant to this 
study. The summary population health metrics of DALYs and 
HALE synthesise the cumulative effect of all of these 
improvements, the most notable of which are as follows. First, 
we added substantial location-years of cause-specific mortality 
data and non-fatal data for GBD 2016. The added data 
progressively fill gaps in the period of estimation, most 
substantially for India. Second, many analytical methods have 
been improved, such as improvement of mortality to incidence 
ratios for cancers to better reflect lower survival than in 
GBD 2015 and for non-fatal tuberculosis to better reflect 
higher incidence in low-income and middle-income countries 
based on SDI. Third, we included new subnational assessments 
for Indonesia at the provincial level and further disaggregated 
subnational estimation in England to the local government 
area level. Fourth, we refined our estimation of age-specific 
outcomes for ages 80 years and older into 5 year groups 
extending to age 95 years and older to better account for 
disease burden in elderly populations than in GBD 2015. Fifth, 
we estimated DALYs for several additional causes for the first 
time. Sixth, we improved our analysis of the epidemiological 
transition as a function of SDI, which allowed for a more 
nuanced interpretation of global health trends against the 
sociodemographic development spectrum than in GBD 2015. 
Finally, we used these analyses to identify the exemplar 
countries that exceeded population health summary metric 
expectations relative to their SDI position alone. The GBD 2016 
iteration supersedes all previous GBD studies of DALYs and 
HALE and re-estimates these measures for the complete time 
series from 1990 to 2016. We focus on new methods and 
approaches since GBD 2015 and highlight nations that 
overperformed or underperformed on the basis of what would 
be expected on the basis of their SDI. 
Implications of all the available evidence
The epidemiological transition continues apace globally, with 
a shift from DALYs attributable to communicable, maternal, 
neonatal, and nutritional diseases to those attributable to 
non-communicable diseases. This progression is concomitant 
with improvements in SDI and thus improvements in 
education, fertility rates, and economic status. A more 
detailed analysis than in this study of the epidemiological 
changes that have occurred in countries that have consistently 
exceeded expectations could provide improved insights into 
good practice in public health policy, which might be 
emulated elsewhere. A similarly detailed appraisal of countries 
that are lagging in DALYs and HALE relative to expectations 
on the level of SDI alone will help identify countries in most 
need of domestic and international attention across the 
development continuum.
 Global Health Metrics
1262 
www.thelancet.com   Vol 390  September 16, 2017
As the second in a series7,8,10,11 of now annual updates, 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study 2016 (GBD 2016) is the most comprehensive and 
current source of summary health metrics. The Global 
Burden of Disease (GBD) is based on development of the 
largest available database of health outcomes, risk factor 
exposure, intervention coverage, and sociodemographic 
factors related to health. We applied analytical techniques 
to reduce data biases and support comparability, propa­
gated the uncertainty in these estimates, and provided 
insights at the highest temporal and spatial resolution 
afforded by the data.
The purpose of this study is to present the results of 
GBD 2016 for DALYs and HALE, building on updated 
estimates of mortality, causes of death, and non­fatal 
health loss7,10 to identify nations with notable variation in 
health performance from that expected on the basis of 
SDI. Approaches to the analysis have been previously 
described.2–4,12 GBD 2016 improvements include addition 
of newly available retrospective data, refined analytical 
methods (such as improvement to mortality to incidence 
ratios [MIRs] for cancers to better reflect lower survival in 
low­income and middle­income countries based on SDI), 
new subnational estimation for England and Indonesia, 
disaggregation of certain cause groupings to capture 
greater detail, and expansion of older age groups to 
enhance relevance for a wider range of health policy 
decisions.6
Methods
Overview
We used the results of GBD 2016 to evaluate trends in 
epidemiological patterns and health performance on a 
global, regional, national, and subnational scale using 
DALYs and HALE as summary measures of changes in 
health states. Greater detail than presented in this section 
for methods used to estimate DALYs and HALE, 
including analytic approaches for assessment of relative 
morbidity and mortality from individual diseases and 
injuries, is provided in related publications in this 
series8,10 and the appendix.
This analysis follows the Guidelines for Accurate and 
Transparent Health Estimates Reporting,13,14 which include 
recommendations on documentation of data sources, 
estimation methods, and statistical analysis. We did 
analyses using Python version 2.7
.12 and 2.7
.3, Stata 
version 13.1, and R version 3.2.2. For more information on 
Guidelines for Accurate and Transparent Health Estimates 
Reporting compliance, please refer to the appendix 
(pp 13–15). Additionally, interactive online tools are 
available to explore GBD 2016 data sources in detail. 
Cause­specific estimation for GBD 2016 covers the years 
1990–2016. For a subset of analyses, we focus on the last 
decade, from 2006 to 2016, to address current policy 
priorities. The GBD 2016 results for all years and by 
location can be explored further with dynamic data 
visualisations.
Cause and location hierarchies
In the GBD 2016 study, causes of mortality and morbidity 
are structured with use of a four­level classification 
hierarchy to produce levels that are mutually exclusive and 
collectively exhaustive. GBD 2016 estimates 333 causes of 
DALYs, 68 of which are a source of disability but not a 
cause of death (such as trachoma, hookworm, and low 
back and neck pain) and five of which are causes of death 
but not sources of morbidity (sudden infant death 
syndrome, aortic aneurysm, late maternal deaths, indirect 
maternal deaths, and maternal deaths aggravated by 
HIV
/AIDS). Within each level of the hierarchy, the 
number of collectively exhaustive and mutually exclusive 
fatal and non­fatal causes for which the GBD study 
estimates is three at Level 1, 21 at Level 2, 168 at Level 3, 
and 276 at Level 4. The full GBD cause hierarchy, including 
corresponding International Classification of Diseases 
(ICD)­9 and ICD­10 codes, is detailed in GBD 2016 
publications on cause­specific mortality10 and non­fatal 
health outcomes,8 with cause­specific methods detailed in 
the corresponding appendices.
The GBD study is organised by a geographical hierarchy 
of seven super­regions containing 21 regions, with 
195 countries and territories nested within those regions.12 
GBD 2016 included new subnational assessments for 
Indonesia by province and for England by local govern­
ment area. In this study, we present subnational data for 
the five countries with a population greater than 
200 million people in 2016: Brazil, China, India, Indonesia, 
and the USA.
Estimation of mortality and non-fatal health loss
To estimate all­cause and cause­specific mortality, the 
GBD study first systematically addressed known data 
challenges—such as variation in coding of causes or 
age group reporting, misclassification of deaths from 
HIV
/AIDS, or methods for incorporation of population­
based cancer registry data—using standardised methods 
described in detail in the GBD 2016 mortality7 and causes 
of death10 publications. As noted in other GBD 
publications, each death is attributed to a single underlying 
cause in accordance with the ICD. We take steps to 
standardise cause of death data to address the small 
fraction of deaths that are not assigned an age or sex, 
deaths assigned to broad age groups that are not 5 year 
age groups, and various revisions and national variants of 
the ICD. Additionally, we identify and redistribute deaths 
assigned to ICD codes that cannot be underlying causes of 
death, are intermediate causes of death rather than the 
underlying causes, or lack specificity in coding.10 We 
estimated cause­specific mortality using standardised 
modelling processes—most commonly, the Cause of 
Death Ensemble model, which uses covariate selection 
and out­of­sample validity analyses and generates 
estimates for each location­year, age, and sex.10 Additional 
detail, including model specifications and data availability 
for each cause­specific model, can be found in the 
See Online for appendix
For the online tools see 
http://ghdx.healthdata.org
For the data visualisations see 
https://vizhub.healthdata.org/
gbd-compare
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1263
appendix of the GBD 2016 mortality7 and causes of death10 
publications. We used the all­cause mortality estimates to 
establish a reference life table from the lowest death rates 
for each age group among locations with total populations 
greater than 5 million.7 From this reference life table, we 
multiplied life expectancy at the age of death by cause­
specific deaths to calculate cause­specific YLLs. We then 
used the GBD world population age standard to calculate 
age­standardised rates for deaths and YLLs.7 The GBD 
world population age standard and the standard life 
expectancies are available in the appendix of the GBD 2016 
mortality publication.7
Changes implemented since the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) 
for cause­specific mortality include incorporation of 
substantial sources of new mortality data; important model 
improvements for HIV, malaria, tuberculosis, injuries, 
diabetes, and cancers; disaggregation of specific causes 
into subgroupings to provide additional detail (the 
following were all estimated separately for the first time: 
alcoholic cardiomyopathy; urogenital, musculoskeletal, 
and digestive congenital anomalies; Zika virus disease; 
Guinea worm disease; self­harm by firearm; sexual 
violence; myocarditis; and the following types of tuberc­
ulosis: extensively drug­resistant tuberculosis, multidrug­
resistant tuberculosis without extensive drug resistance, 
drug­susceptible tuberculosis, extensively drug­resistant 
HIV
/AIDS­tuberculosis, multidrug­resis 
tant HIV
/AIDS­
tuberculosis without extensive drug resistance, and 
drug­susceptible HIV
/AIDS­tuberculosis); modelling of 
anti 
retroviral therapy (ART) coverage for each location­
year by CD4­positive cell count at initiation; breakdown of 
terminal age groups from 80 years and older to 80–84 years, 
85–89 years, 90–94 years, and 95 years and older; expansion 
of the GBD location hierarchy; and changes in the 
calculation of SDI.10 The database for GBD 2016 now 
includes data for the 333 causes estimated for DALYs and 
new subnational units for Indonesia (n=34) and England 
(n=150). For GBD 2016, we included substantial amounts 
of additional data sources from new studies and our 
network of collaborators; details of the types of data added 
can be found in the GBD 2016 cause of death10 and non­
fatal8 publications. Additionally, research teams did 
systematic reviews to incorporate literature data into fatal 
and non­fatal models. Further details on search strings are 
available in the GBD 2016 non­fatal8 and cause of death10 
publication appendices. The Registrar General of India 
provided improved verbal autopsy data collected through 
their Sample Registration System, enabling a more 
detailed and thorough analysis of subnational data for 
India than in GBD 2015. The methods for constructing the 
SDI, initially developed for GBD 2015,15 were revised for 
GBD 2016 to account for expansion in the number of 
subnational estimates and the effect of a growing time 
period of estimation given fixed limits for index 
components.10 The components of SDI—total fertility rate 
(TFR), educational attainment in the population aged older 
than 15 years, and lag­distributed income (LDI)—are based 
on new systematic assessments of educational attainment, 
LDI, and fertility, and each component is scaled relative to 
maximum effect on health outcomes.10
In most cases, we estimated non­fatal health loss using 
the Bayesian meta­regression tool DisMod­MR 2.1 to 
synthesise variable data sources to produce internally 
consistent estimates of incidence, prevalence, remission, 
and excess mortality.16 Cause­specific data availability 
and epidemiological characteristics required additional 
analytical techniques in some cases (details are available 
in the appendix of the GBD 2016 non­fatal publication8); 
these causes include many neglected tropical diseases 
(NTDs) such as dengue, as well as injuries, malaria, and 
HIV
/AIDS.17,18
We estimated each non­fatal sequela separately and 
assessed the occurrence of comorbidity in each age group, 
sex, location, and year separately using a microsimulation 
framework. We distributed disability estimated for 
comorbid conditions to each contributing cause during the 
comorbidity estimation process. Although the distribution 
of sequelae—and therefore the severity and cumulative 
disability per case of a condition—can be different by age, 
sex, location, and year, previous studies have found that 
disability weights do not substantially vary across locations, 
income, or levels of educational attainment.19,20 In the GBD 
study, disability weights were based on population surveys 
with 60 890 respondents and held invariant between 
locations and over time.20 Additional details, including 
model specifications and data availability for each cause­
specific model and development of disability weights by 
cause and their use in the estimation of non­fatal health 
loss, are available in the appendix of the GBD 2016 non­
fatal publication.8
For non­fatal estimation, several methodological 
changes were made for GBD 2016. New data for the main 
causes of YLDs were identified through our collaboration 
with the Indian Council of Medical Research and the 
Public Health Foundation of India. For particular risk 
factors and diseases, the volume of available data 
increased substantially, such as child growth failure 
(stunting, wasting, or underweight), anaemia, congenital 
anomalies, schistosomiasis, intestinal helminths, and 
lymphatic filariasis. We have improved our analysis of 
total admissions per person by country, year, age, and 
sex, which facilitated incorporation of additional hospital 
data sources that were previously excluded because of 
incomplete knowledge of catchment population size. We 
extended our analyses of linked USA medical claims data 
to impute age­specific and sex­specific ratios for multiple 
admissions per illness episode, ICD code appearance in 
the non­primary position, and inpatient versus outpatient 
use.8 We applied each of the three ratios sequentially to 
non­linked hospital inpatient data from elsewhere that 
only had a single ICD code per visit to adjust prevalence 
and incidence data. We have incorporated more 
predictive covariates into our non­fatal disease models to 
 Global Health Metrics
1264 
www.thelancet.com   Vol 390  September 16, 2017
better predict variation in disease levels rather than 
measurement error as the source of variation, and we 
improved our analysis of the MIRs for cancers, resulting 
in considerably higher ratios in lower SDI quintiles and 
thus substantially lower YLD estimates for cancer.
Estimation of DALYs, HALE, and corresponding 
uncertainty
We calculated DALYs as the sum of YLLs and YLDs for 
each cause, location, age group, sex, and year.8,10 The same 
estimates of YLDs per person for each location, age, sex, 
and year from 1990 to 2016 are used to establish HALE by 
age group within abridged multiple­decrement life tables 
with use of methods developed by Sullivan.9
For all results, we report 95% uncertainty intervals (UIs) 
derived from 1000 draws from the posterior distribution of 
each step in the estimation process. Unlike confidence 
intervals, UIs capture uncertainty from multiple modelling 
steps, as well as from sources such as model estimation 
and model specification, rather than from sampling error 
alone. Uncertainty associated with estimation of mortality 
and YLLs reflects sample sizes of data sources, adjustment 
and standardisation methods applied to data, parameter 
uncertainty in model estimation, and uncertainty within 
all­cause and cause­specific mortality models. For esti­
mation of prevalence, incidence, and YLDs, UIs incor­
porated variability from sample sizes within data sources, 
adjustments to data to account for non­reference def­
initions, parameter uncertainty in model estimation, and 
uncertainty associated with establishment of disability 
weights. Because direct information about the correlation 
between uncertainty in YLLs and YLDs was scarce, we 
assumed that uncertainty in age­specific YLDs was 
independent of age­specific YLLs or death rates.
Epidemiological transition and relationship between 
DALYs, HALE, and SDI
For GBD 2016, the composite indicator of SDI was 
again based on the geometric mean of three measures—
LDI per person, average years of schooling among 
populations aged 15 years or older, and TFR—but the 
analysis was strengthened in three important ways.10 
First, we substantially revised estimates of education, 
adding new data and improved methods for subnational 
locations. Second, instead of using estimates of TFR 
from the UN Population Division, we systematically 
reviewed, extracted, and analysed fertility data from all 
available locations to derive a time series of TFR for 
each national and subnational GBD location.7 Third, 
rather than rescaling SDI on the basis of the full range 
of observed values within the time series, we developed 
a fixed scale for GBD 2016; details on development of 
this fixed scale are available in the GBD 2016 mortality 
publication.7 We examined the average relationship 
between DALYs, HALE, and SDI using a Gaussian 
process regression model; we used these regressions to 
estimate expected values of these summary measures 
at each level of SDI. Additional detail on SDI calculation 
and location­specific SDI values are available in the 
appendix of the GBD 2016 mortality publication.7
Data sharing
The statistical code used in the entire process is available 
through an online repository. 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
Global levels of and trends for DALYs and HALE
The total number of all­age DALYs in 2016 was 
2·39 billion (95% UI 2·18 billion to 2·63 billion). Total 
all­age DALY counts for CMNN causes fell by 40·1% 
(37·4–42·7) from 1·11 billion (1·07 billion to 1·16 billion) 
in 1990 to 668 million (632 million to 708 million) in 
2016, whereas total all­age DALY counts from NCDs 
increased by 36·6% from 1·07 billion (958 million to 
1·20 billion) in 1990 to 1·47 billion (1·30 billion to 
1·66 billion) in 2016 (table 1). Total DALYs from injuries 
decreased by 1·6% (–3·8 to 6·2) from 260 million 
(243 million to 277 million) in 1990 to 255 million 
(236 million to 281 million) in 2016. Age groups older 
than 80 years had 149 million (139 million to 159 million) 
all­age DALYs in 2016 compared with 75·1 million 
(71·1 million to 79·5 million) in 1990, with increases 
across all SDI quintiles. Of these, 87·8% were due to 
NCDs in 2016 compared with 86·8% in 1990. 
From 1990 to 2016, global HALE at birth increased 
from 56·9 years to 63·1 years, with 160 of 195 locations 
registering significant improvements. Global HALE 
increased by an average of 6·24 years (95% UI 
5·97–6·48) for both sexes combined. Globally, HALE at 
birth increased from 55·38 years (53·27–57·31) in 1990 
to 61·42 years (59·01–63·58) in 2016 for males and from 
58·42 years (55·80–60·77) to 64·91 years (61·88–67·54) 
for females, rising 6·04 years (5·74–6·27) for males and 
6·49 years (6·08–6·77) for females (tables 2 and 3). The 
total number of years of functional health lost (life 
expectancy minus HALE) increased from 1990 to 2016, 
from 8·22 years to 9·34 years. The gap between life 
expectancy at birth and HALE, which represents years 
of functional health lost, grew between 1990 and 2016 
from 7·32 years (life expectancy 62·70 [62·42–62·99] vs 
HALE 55·38 [53·27–57·31]) to 8·37 years (69·79 
[69·29–70·22] vs 61·42 [59·01–63·58]) for males and 
from 9·15 years (67·57 [67·33–67·77] vs 58·42 
[55·80–60·77]) to 10·42 years (75·33 [74·95–75·64] vs 
64·91 [61·88–67·54]) for females. Globally, in 2016, life 
expectancy at age 65 years was 18·57 years (18·37–18·72) 
for females and 15·72 years (15·61–15·83) for males, 
For the statistical code see 
https://github.com/ihmeuw/
ihme-modeling
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1265
whereas HALE was 13·88 years (12·57–15·02) for 
females and 11·87 years (10·83–12·80) for males. HALE 
increased by 1·96 years (1·69–2·13) from 11·92 
(10·88–12·89) in 1990 for females and by 1·78 years 
(1·61–1·93) from 10·09 years (9·22–10·87) for males.
Global trends for all­age DALYs and age­standardised 
DALY rates for Level 1 causes by SDI quintile are shown in 
figure 1. Trends in total DALYs, which show the absolute 
burden at each SDI quintile, are shown in figure 1A. The 
figure highlights the large burden and subsequent declines 
in low­middle­SDI (decreased by 44·5% [95% UI 
41·3–47·6]) and middle­SDI (decreased by 56·2% 
[53·6–59·0]) locations for CMNN DALYs from 1990 to 2016, 
offset by large increases for NCD DALYs over the same 
time period in low­middle SDI (increased by 54·4% 
[47·9–60·8]) and middle­SDI (increased by 36·5% 
[39·9–32·8]) locations. Progress has been made in low­SDI 
countries for CMNN DALYs, which decreased by 20·7% 
(16·8–24·7) since 2006. At all levels of SDI, total NCD 
DALYs have increased since 1990. Trends in age­
standardised rates—which account for both population 
size and age structure—emphasise the reduction in the 
contribution of CMNN causes to DALYs, both over time 
and with increasing SDI (figure 1B). These rapid decreases 
in age­standardised rates were fastest at low SDI, where 
age­standardised DALY rates from CMNN causes decreased 
by 51·5% (49·0–54·1) between 1990 and 2016 to be on par 
with age­standardised DALY rates for NCDs in 2016. At 
low­middle SDI, age­standardised CMNN DALY rates were 
more than double those for NCDs in 1990 (31·7 thousand 
[30·3 thousand to 33·3 thousand] per 100 000), but 
decreased to 14·1 thousand (13·2 thousand to 15·1 thousand) 
per 100 000 in 2016. At all other levels of SDI, age­
standardised DALY rates for CMNN causes were lower 
than those for NCDs and lower than those of injuries in the 
high­SDI quintile. Reductions in age­standardised rates for 
NCDs occurred across all levels of SDI between 1990 and 
2016, a trend that was also evident, albeit less strongly, for 
age­standardised DALY rates from injuries.
Global causes of DALYs
Age­standardised DALY rates for all causes decreased by 
30·5% (95% UI 28·6–32·6) between 1990 and 2016 
(appendix pp 49–62). In 2016, CMNN causes accounted 
for 28·0% (26·4–29·7) of global DALYs, NCDs 
contributed 61·4% (59·4–63·2), and injuries contributed 
10·7% (10·1–11·3; appendix pp 35–48). From 2006 to 
2016, CMNN causes decreased by 31·9% (29·7–34·2), 
with 48 Level 4 CMNN causes experiencing decreases in 
age­standardised DALY rates of greater than 20% 
(table 1). Decreases were greater than 70% for 
three infectious diseases: Guinea worm disease 
(decreased by 99·6% [99·5–99·7]), human African 
trypanosomiasis (decreased by 78·2% [68·8–84·6]), and 
measles (decreased by 73·6% [68·8–77·8]). By contrast 
with the overall trend of decreasing DALYs, a subset of 
Level 4 CMNN causes had increases in age­standardised 
DALY rates, including dengue (50·5% [24·7–97·7]) and 
cutaneous and mucocutaneous leishmaniasis (12·5% 
[1·7–26·1]). Overall, total all­age DALYs attributable to 
maternal disorders decreased by 23·9% (17·4–29·3) 
between 2006 and 2016 and by 30·4% (24·4–35·4) in 
terms of age­standardised DALY rates. As a cause group, 
neonatal disorders decreased by 22·8% (18·9–26·8) in 
all­age DALYs and 23·1% (19·2–27·0) in terms of age­
standardised DALY rates over the same time period; 
however, this decrease was not significant for neonatal 
sepsis. Total DALYs from the London Declaration NTDs 
was 9·0 million (5·3 million to 14·5 million) in 2016.
In 2016, the leading Level 3 causes of total DALYs 
among 
NCDs 
included 
ischaemic 
heart 
disease 
(175 million [95% UI 170 million to 180 million] DALYs), 
cerebrovascular disease (116 million [111 million to 
121 million]), and low back and neck pain (87 million 
[61 
million 
to 
114 
million]), 
comprising 
16·1% 
(13·99–17·67) of all DALYs (table 1). Among chronic 
respiratory diseases, all causes, with the exception of 
interstitial lung disease, pulmonary sarcoidosis, and 
other chronic respiratory diseases, decreased in age­
standardised DALY rates between 2006 and 2016, whereas 
total all­age DALY counts increased from 2006 to 2016 for 
all chronic respiratory diseases, with the exception of 
silicosis. Cirrhosis and other chronic liver diseases had a 
mean change of 7·6% (2·5–13·7) from 2006 to 2016 in 
total all­age DALY counts, but had a mean decrease in 
age­standardised DALY rates of 12·0% (7·2–16·1) over the 
same period. Age­standardised DALY rates of digestive 
diseases decreased from 2006 to 2016, with a mean 
percentage decrease of 13·6% (10·8–16·4); however, all­
age DALY counts for digestive diseases increased by 4·1% 
(0·4–7·7) over the same period. Total DALYs associated 
with most neurological disorders increased from 
2006 to 2016, with Alzheimer’s disease and other de­
mentias (increase of 37·5% [35·3–39·7]) and Parkinson’s 
disease (increase of 35·6% [32·9–38·2]) increasing by 
more than 30% each. Between 2006 and 2016, various 
NCDs significantly increased in terms of both total 
burden and age­standardised DALY rates. Several mental 
and substance use disorders followed this pattern, 
including eating disorders (age­standardised DALY rates 
increased by 8·9% [7·6–10·1]) and bipolar disorder 
(increased by 0·8% [0·2–1·4]). Diabetes (all­age DALY 
count increased by 24·4% [22·7–26·2]) and chronic 
kidney disease (increased by 20·0% [17·4–22·7]) both also 
increased in all­age DALY counts, as did musculoskeletal 
disorders (increased by 19·6% [18·5–20·8]).
Percentage change in age­standardised DALY rates of 
unintentional injuries (decreased by 15·1% [95% UI 
12·2–18·0]), road injuries (decreased by 14·7% [12·8–16·8]), 
and transport injuries (decreased by 14·3% [12·3–16·4]) 
each decreased substantially between 2006 and 2016 
(table 1). Among unintentional injuries, drowning had the 
largest reduction in both all­age DALY burden (26·6% 
[20·1–30·1]) and age­standardised DALY rates (32·1% 
 Global Health Metrics
1266 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
All causes
2 448 430·5 
(2 305 218·2 to 
2 608 339·5)
2 490 698·9 
(2 308 527·1 
to 
2 689 861·1)
2 391 258·0 
(2 184 254·1 to 
2 631 699·0)
–2·3 
(–5·9 to 
0·9)
–4·0 
(–6·0 to 
–2·1)*
48 407·8 
(45 385·4 to 
51 762·0)
40 485·1 
(37 556·0 to 
43 679·3)
33 641·0 
(30 808·7 to 
36 924·3)
–30·5 
(–32·6 to 
–28·6)*
–16·9 
(–18·6 to 
–15·3)*
Communicable, maternal, 
neonatal, and nutritional 
diseases
1 114 176·6 
(1 073 948·8 to 
1 156 050·2)
918 804·8 
(885 242·1 to 
959 452·3)
667 823·7 
(632 212·4 to 
708 405·1)
–40·1 
(–42·7 to 
–37·4)*
–27·3 
(–29·8 to 
–24·9)*
18 071·6 
(17 386·0 to 
18 790·5)
13 801·1 
(13 286·8 to 
14 406·5)
9396·8 
(8894·5 to 
9956·2)
–48·0 
(–50·1 to 
–45·8)*
–31·9 
(–34·2 to 
–29·7)*
HIV/AIDS and 
tuberculosis
84 184·5 
(79 728·6 to 
89 558·0)
159 063·9 
(152 851·5 to 
165 139·0)
101 133·3 
(97 487·1 to 
105 092·9)
20·1 
(13·0 to 
26·7)*
–36·4 
(–37·9 to 
–34·7)*
1788·1 
(1690·1 to 
1918·3)
2439·5 
(2345·8 to 
2531·5)
1355·2 
(1306·2 to 
1407·5)
–24·2 
(–29·7 to 
–20·1)*
–44·5 
(–45·7 to 
–43·0)*
Tuberculosis
68 029·7 
(64 153·4 to 
73 066·3)
56 881·5 
(54 312·6 to 
59 442·6)
43 557·9 
(41 529·0 to 
45 716·5)
–36·0 
(–41·3 to 
–32·4)*
–23·4 
(–26·1 to 
–20·6)*
1480·1 
(1390·4 to 
1613·6)
916·5 
(874·7 to 
956·7)
593·1 
(565·5 to 
621·7)
–59·9 
(–63·7 to 
–57·7)*
–35·3 
(–37·6 to 
–32·9)*
Drug-susceptible 
tuberculosis
67 560·5 
(63 730·5 to 
72 611·6)
51 760·2 
(49 194·0 to 
54 289·2)
39 869·8 
(38 054·8 to 
41 916·2)
–41·0 
(–45·6 to 
–37·5)*
–23·0 
(–25·7 to 
–20·0)*
1469·5 
(1380·7 to 
1603·6)
834·1 
(791·6 to 
873·6)
543·0 
(517·8 to 
571·1)
–63·0 
(–66·4 to 
–60·8)*
–34·9 
(–37·2 to 
–32·5)*
Multidrug-resistant 
tuberculosis without 
extensive drug 
resistance
469·2 
(378·3 to 
578·8)
4886·9 
(4122·2 to 
5829·2)
3319·4 
(2787·6 to 
3910·3)
607·5 
(511·8 to 
717·0)*
–32·1 
(–38·5 to 
–24·8)*
10·6 
(8·5 to 
13·1)
78·7 
(66·3 to 
93·9)
45·1 
(37·9 to 
53·2)
327·6 
(267·7 to 
394·1)*
–42·7 
(–48·1 to 
–36·5)*
Extensively 
drug-resistant 
tuberculosis
··
234·5 
(194·6 to 
279·1)
368·8 
(301·1 to 
444·5)
··
57·3 
(36·1 to 
82·1)*
··
3·8 
(3·1 to 
4·5)
5·0 
(4·1 to 
6·0)
··
32·5 
(14·8 to 
53·2)*
Latent tuberculosis 
infection
··
··
··
··
··
··
··
··
··
··
HIV/AIDS
16 154·8 
(14 497·1 to 
18 106·5)
102 182·3 
(96 751·1 to 
107 544·2)
57 575·4 
(54 618·5 to 
60 967·9)
256·4 
(220·1 to 
293·5)*
–43·6 
(–45·4 to 
–41·6)*
308·1 
(276·2 to 
345·6)
1522·9 
(1443·6 to 
1601·3)
762·1 
(723·6 to 
806·2)
147·4 
(121·5 to 
173·2)*
–50·0 
(–51·5 to 
–48·2)*
Drug-susceptible 
HIV/AIDS-
Tuberculosis
4668·5 
(3624·4 to 
5760·2)
24 070·5 
(16 708·0 to 
31 379·1)
11 724·0 
(8154·4 to 
15 522·4)
151·1 
(116·8 to 
191·3)*
–51·3 
(–54·0 to 
–48·6)*
88·2 
(68·0 to 
109·1)
359·7 
(249·9 to 
468·7)
155·5 
(108·2 to 
205·9)
76·2 
(52·6 to 
103·8)*
–56·8 
(–59·2 to 
–54·4)*
Multidrug-resistant 
HIV/AIDS-
Tuberculosis without 
extensive drug 
resistance
25·9 
(16·0 to 
40·6)
2051·8 
(1282·8 to 
3070·2)
979·2 
(597·7 to 
1481·6)
3673·4 
(2732·2 to 
4952·8)*
–52·3 
(–61·7 to 
–41·2)*
0·5 
 (0·3 to 
0·8)
30·7 
(19·2 to 
45·8)
13·0 
(7·9 to 
19·7)
2486·4 
(1853·0 to 
3358·6)*
–57·6 
(–66·1 to 
–47·8)*
Extensively drug-
resistant HIV/AIDS-
Tuberculosis
··
39·9 
(24·8 to 
61·1)
57·3 
(34·5 to 
89·4)
··
43·5 
(25·5 to 
65·4)*
··
0·6 
(0·4 to 
0·9)
0·8 
(0·5 to 
1·2)
··
26·8 
(10·8 to 
46·4)*
HIV/AIDS resulting in 
other diseases
11 460·3 
(9938·9 to 
13 435·6)
76 020·0 
(67 021·8 to 
86 026·2)
44 814·9 
(39 932·9 to 
50 112·4)
291·1 
(245·9 to 
337·5)*
–41·0 
(–43·6 to 
–38·2)*
219·3 
(189·8 to 
257·4)
1131·9 
(999·9 to 
1280·9)
592·9 
(528·6 to 
663·0)
170·3 
(138·2 to 
203·1)*
–47·6 
(–49·9 to 
–45·1)*
Diarrhoea, lower 
respiratory, and other 
common infectious 
diseases
557 388·0 
(522 551·7 to 
600 325·4)
337 062·8 
(317 957·5 to 
359 176·2)
229 961·4 
(213 682·3 to 
247 975·2)
–58·7 
(–61·9 to 
–55·2)*
–31·8 
(–35·3 to 
–27·8)*
8951·2 
(8378·0 to 
9601·7)
5152·7 
(4858·8 to 
5514·9)
3275·6 
(3051·7 to 
3531·8)
–63·4 
(–66·0 to 
–60·7)*
–36·4 
(–39·7 to 
–33·0)*
Diarrhoeal diseases
175 168·6 
(150 592·6 to 
201 351·3)
113 944·8 
(99 183·9 to 
135 659·8)
74 414·6 
(63 402·0 to 
93 414·9)
–57·5 
(–62·8 to 
–50·1)*
–34·7 
(–41·0 to 
–28·1)*
2914·2 
(2482·9 to 
3469·2)
1768·5 
(1526·0 to 
2136·7)
1063·1 
(907·5 to 
1332·3)
–63·5 
(–67·6 to 
–58·3)*
–39·9 
(–45·2 to 
–34·3)*
Intestinal infectious 
diseases
15 662·6 
(8797·4 to 
25 360·4)
12 822·7 
(7207·6 to 
20 879·4)
10 601·7 
(6041·1 to 
17 309·3)
–32·3 
(–43·5 to 
–21·8)*
–17·3 
(–25·1 to 
–10·8)*
249·7 
(140·6 to 
404·8)
184·6 
(103·8 to 
300·4)
144·3 
(82·3 to 
235·2)
–42·2 
(–51·5 to 
–33·7)*
–21·9 
(–29·4 to 
–15·6)*
Typhoid fever
13 362·8 
(7235·9 to 
22 248·3)
10 793·8 
(5876·4 to 
17 717·0)
8843·0 
(4901·5 to 
14 436·1)
–33·8 
(–44·0 to 
–23·6)*
–18·1 
(–25·7 to 
–12·1)*
212·5  
(115·0 to 
353·9)
155·3 
(84·8 to 
254·0)
120·4 
(66·6 to 
196·8)
–43·3 
(–51·9 to 
–35·1)*
–22·4 
(–29·7 to 
–16·6)*
Paratyphoid fever
1867·3 
(850·2 to 
3711·1)
1773·6 
(826·8 to 
3439·6)
1607·0 
(759·0 to 
3109·8)
–13·9 
(–27·1 to 
–1·5)*
–9·4 
(–17·9 to 
–1·8)*
30·6 
(13·9 to 
60·4)
25·6 
(11·9 to 
49·6)
21·7 
(10·2 to 
42·0)
–29·0 
(–39·4 to 
–19·2)*
–15·1 
(–22·9 to 
–8·0)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1267
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Other intestinal 
infectious diseases
432·5 
(107·2 to 
1290·8)
255·4 
(58·5 to 
753·4)
151·7 
(42·1 to 
412·1)
–64·9 
(–90·6 to 
42·1)
–40·6 
(–84·7 to 
126·3)
6·7 
(1·7 to 
19·5)
3·8 
(0·9 to 
11·2)
2·2 
(0·6 to 
5·9)
–67·5 
(–91·3 to 
31·5)
–42·9 
(–85·2 to 
114·5)
Lower respiratory 
infections
202 365·5 
(182 794·4 to 
220 607·6)
131 015·4 
(121 489·8 to 
139 228·6)
91 844·6 
(84 674·4 to 
98 252·6)
–54·6 
(–58·7 to 
–49·4)*
–29·9 
(–34·4 to 
–25·3)*
3237·1 
(2942·1 to 
3515·4)
2022·6 
(1879·0 to 
2147·6)
1326·7 
(1221·8 to 
1419·7)
–59·0 
(–62·5 to 
–54·6)*
–34·4 
(–38·6 to 
–30·2)*
Upper respiratory 
infections
4868·6 
(3012·8 to 
7444·9)
5551·2 
(3380·7 to 
8488·2)
5991·2 
(3621·1 to 
9193·8)
23·1 
(19·0 to 
26·3)*
7·9 
(6·2 to 
9·4)*
88·2 
(54·9 to 
134·0)
83·0 
(50·8 to 
126·9)
81·0 
(49·0 to 
124·0)
–8·3 
(–10·5 to 
–6·9)*
–2·5 
(–3·8 to 
–1·5)*
Otitis media
3111·7 
(2057·2 to 
4485·0)
3171·4 
(2005·0 to 
4675·3)
3187·5 
(1993·2 to 
4716·5)
2·4 
(–3·8 to 
7·0)
0·5 
(–2·1 to 
3·0)
53·4 
(35·3 to 
76·9)
46·7 
(29·6 to 
68·9)
43·3 
(27·1 to 
64·2)
–18·9 
(–23·7 to 
–15·1)*
–7·3 
(–9·8 to 
–4·9)*
Meningitis
30 239·3 
(23 939·3 to 
34 552·6)
24 957·4 
(21 655·0 to 
28 764·2)
21 865·9 
(18 204·6 to 
28 280·5)
–27·7 
(–41·7 to 
3·1)
–12·4 
(–23·9 to 
7·8)
481·8 
(385·6 to 
549·0)
369·9 
(321·3 to 
426·1)
306·1 
(254·0 to 
398·0)
–36·5 
(–48·5 to 
–9·7)*
–17·2 
(–28·1 to 
2·1)
Pneumococcal 
meningitis
2187·5 
(1808·2 to 
2576·0)
1940·0 
(1649·9 to 
2287·4)
1902·8 
(1569·5 to 
2382·2)
–13·0 
(–26·3 to 
10·0)
–1·9 
(–11·5 to 
12·0)
37·2 
(31·0 to 
43·4)
29·1 
(24·8 to 
34·2)
26·2 
(21·6 to 
32·7)
–29·6 
(–39·6 to 
–11·3)*
–9·9 
(–18·7 to 
3·2)
Haemophilus influenzae 
type B meningitis
3330·3 
(2606·2 to 
3982·2)
2725·7 
(2276·3 to 
3165·4)
2426·0 
(1967·2 to 
3212·2)
–27·1 
(–41·5 to 
3·7)
–11·0 
(–23·9 to 
9·3)
52·4 
(41·5 to 
62·0)
40·3 
(33·7 to 
46·8)
34·1 
(27·6 to 
45·1)
–34·8 
(–47·4 to 
–7·4)*
–15·3 
(–27·6 to 
3·9)
Meningococcal 
meningitis
14 191·0 
(11 094·1 to 
16 492·1)
11 548·6 
(9913·5 to 
13 418·2)
8327·1 
(6806·4 to 
10 911·9)
–41·3 
(–53·1 to 
–16·3)*
–27·9 
(–37·7 to 
–12·2)*
224·2 
(177·0 to 
259·3)
170·8 
(146·7 to 
199·1)
116·6 
(95·2 to 
152·9)
–48·0 
(–58·4 to 
–26·0)*
–31·7 
(–41·1 to 
–16·8)*
Other meningitis
10 530·5 
(8030·6 to 
12 434·2)
8743·1 
(7350·6 to 
10 148·8)
9210·0 
(7559·7 to 
12 250·5)
–12·5 
(–30·3 to 
28·9)
5·3 
(–9·4 to 
33·0)
168·1 
(129·1 to 
197·5)
129·7 
(109·2 to 
150·4)
129·2 
(105·5 to 
173·3)
–23·1 
(–38·2 to 
12·4)
–0·4 
(–14·4 to 
26·1)
Encephalitis
7918·4 
(5206·9 to 
10 751·2)
7380·9 
(6422·5 to 
9033·9)
6704·1 
(5469·3 to 
8574·2)
–15·3 
(–44·0 to 
40·6)
–9·2 
(–24·4 to 
10·8)
135·5 
(91·8 to 
180·2)
111·5 
(97·1 to 
136·5)
92·7 
(75·7 to 
118·4)
–31·6 
(–53·6 to 
10·0)
–16·9 
(–30·8 to 
1·2)
Diphtheria
842·7 
(611·3 to 
1167·2)
263·8 
(183·1 to 
374·7)
86·9 
(62·5 to 
123·4)
–89·7 
(–93·2 to 
–84·0)*
–67·0 
(–78·6 to 
–47·7)*
12·9 
(9·4 to 
17·9)
3·9 
(2·7 to 
5·6)
1·2 
(0·9 to 
1·8)
–90·5 
(–93·7 to 
–85·3)*
–68·6 
(–79·8 to 
–49·7)*
Whooping cough
14 651·2 
(6598·0 to 
28 290·2)
9778·0 
(4727·9 to 
17 764·8)
6249·9 
(3360·7 to 
10 754·7)
–57·3 
(–77·1 to 
–19·2)*
–36·1 
(–63·1 to 
17·1)
219·5 
(98·9 to 
424·0)
144·6 
(69·9 to 
262·6)
89·4 
(48·1 to 
153·9)
–59·3 
(–78·1 to 
–22·8)*
–38·1 
(–64·3 to 
13·3)
Tetanus
24 893·6 
(14 235·3 to 
33 445·8)
6340·9 
(3695·4 to 
7940·5)
2366·6 
(1446·0 to 
3062·9)
–90·5 
(–92·7 to 
–87·7)*
–62·7 
(–68·8 to 
–55·4)*
385·3 
(222·8 to 
516·6)
93·3 
(54·4 to 
116·8)
33·6 
(20·3 to 
43·4)
–91·3 
(–93·2 to 
–88·9)*
–64·0 
(–70·0 to 
–57·1)*
Measles
76 350·8 
(31 267·6 to 
147 358·9)
20 794·3 
(8237·6 to 
43 871·3)
5724·8 
(2148·6 to 
12 257·6)
–92·5 
(–94·4 to 
–90·5)*
–72·5 
(–76·9 to 
–67·7)*
1150·7 
(471·2 to 
2220·4)
307·9 
(122·0 to 
649·2)
81·3 
(30·5 to 
174·2)
–92·9 
(–94·7 to 
–91·0)*
–73·6 
(–77·8 to 
–69·0)*
Varicella and herpes 
zoster
1314·9 
(1138·7 to 
1509·6)
1042·2 
(909·6 to 
1205·0)
923·5 
(779·5 to 
1098·7)
–29·8 
(–40·3 to 
–18·8)*
–11·4 
(–20·6 to 
–2·8)*
22·8 
(19·8 to 
25·9)
16·2 
(14·1 to 
18·9)
13·0 
(11·0 to 
15·4)
–42·8 
(–50·3 to 
–35·4)*
–19·7 
(–27·6 to 
–12·2)*
Neglected tropical 
diseases and malaria
87 294·8 
(71 756·4 to 
103 455·7)
99 229·2 
(85 820·3 to 
113 978·1)
74 995·1 
(63 114·8 to 
86 650·7)
–14·1 
(–31·0 to 
6·2)
–24·4 
(–37·6 to 
–8·6)*
1423·8 
(1183·4 to 
1676·5)
1478·5 
(1280·4 to 
1696·3)
1050·5 
(882·7 to 
1217·9)
–26·2 
(–40·4 to 
–9·3)*
–28·9 
(–41·5 to 
–14·0)*
Malaria
60 389·3 
(46 548·2 to 
74 912·5)
77 253·7 
(64 810·3 to 
91 256·8)
56 201·2 
(45 785·6 to 
67 880·8)
–6·9 
(–30·5 to 
26·5)
–27·2 
(–43·3 to 
–6·7)*
931·0 
(722·1 to 
1150·5)
1147·0 
(963·0 to 
1354·6)
794·7 
(646·5 to 
962·2)
–14·6 
(–36·1 to 
15·2)
–30·7 
(–46·2 to 
–11·1)*
Chagas disease
309·8 
(286·3 to 
334·8)
226·1 
(204·9 to 
251·3)
219·0 
(194·6 to 
250·7)
–29·3 
(–34·4 to 
–23·7)*
–3·1 
(–8·2 to 
2·7)
7·7 
(7·1 to 
8·3)
4·0 
(3·7 to 
4·5)
3·1 
(2·8 to 
3·6)
–59·3 
(–62·2 to 
–56·0)*
–22·6 
(–26·7 to 
–17·8)*
Leishmaniasis
2531·5 
(1470·2 to 
4203·0)
1897·2 
(1151·9 to 
3064·4)
981·0 
(658·3 to 
1480·6)
–61·2 
(–67·2 to 
–52·0)*
–48·3 
(–54·0 to 
–39·6)*
45·7 
(27·0 to 
75·4)
28·4 
(17·2 to 
45·7)
13·4 
(9·0 to 
20·3)
–70·6 
(–74·9 to 
–64·1)*
–52·6 
(–57·7 to 
–44·9)*
(Table 1 continues on next page)
 Global Health Metrics
1268 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Visceral leishmaniasis
2406·1 
(1350·5 to 
4080·8)
1684·8 
(943·7 to 
2878·0)
707·9 
(400·1 to 
1206·2)
–70·6 
(–74·4 to 
–66·4)*
–58·0 
(–61·9 to 
–53·9)*
43·1 
(24·4 to 
72·6)
25·1 
(14·1 to 
42·9)
9·8 
(5·5 to 
16·6)
–77·4 
(–79·9 to 
–74·6)*
–61·1 
(–64·7 to 
–57·2)*
Cutaneous and 
mucocutaneous 
leishmaniasis
125·3 
(67·7 to 
217·2)
212·4 
(131·6 to 
329·4)
273·1 
(177·2 to 
398·9)
117·9 
(67·5 to 
215·8)*
28·6 
(16·8 to 
42·9)*
2·6 
(1·4 to 
4·4)
3·3 
(2·0 to 
5·0)
3·7 
(2·4 to 
5·4)
43·5 
(11·8 to 
103·5)*
12·5 
(1·7 to 
26·1)*
African trypanosomiasis
1046·8 
(559·1 to 
1711·5)
539·0 
(288·0 to 
876·8)
128·4 
(64·7 to 
215·0)
–87·7 
(–91·3 to 
–82·2)*
–76·2 
(–83·2 to 
–65·9)*
19·2 
(10·3 to 
31·6)
7·8 
(4·2 to 
12·8)
1·7 
(0·9 to 
2·9)
–91·1 
(–93·6 to 
–87·2)*
–78·2 
(–84·6 to 
–68·8)*
Schistosomiasis
2096·8 
(1340·2 to 
3410·1)
2464·8 
(1447·7 to 
4194·7)
1863·6 
(1122·0 to 
3175·2)
–11·1 
(–17·5 to 
–6·7)*
–24·4 
(–26·2 to 
–21·9)*
42·8 
(27·5 to 
69·2)
37·5 
(22·2 to 
63·5)
24·9 
(15·0 to 
42·3)
–41·9 
(–46·3 to 
–38·9)*
–33·7 
(–35·4 to 
–31·6)*
Cysticercosis
489·0 
(363·4 to 
621·4)
500·8 
(359·2 to 
657·1)
468·1 
(322·8 to 
625·8)
–4·3 
(–13·5 to 
3·9)
–6·5 
(–12·4 to 
–0·9)*
10·5 
(7·8 to 
13·4)
8·0 
(5·7 to 
10·5)
6·3 
(4·4 to 
8·4)
–40·0 
(–45·2 to 
–35·0)*
–21·0 
(–26·0 to 
–16·5)*
Cystic echinococcosis
326·8 
(237·4 to 
449·1)
226·2 
(161·3 to 
313·8)
136·5 
(95·3 to 
193·7)
–58·2 
(–68·4 to 
–44·3)*
–39·6 
(–53·9 to 
–16·3)*
6·3 
(4·5 to 
8·7)
3·5 
(2·5 to 
4·8)
1·8 
(1·3 to 
2·6)
–70·6 
(–77·7 to 
–61·1)*
–46·6 
(–59·1 to 
–26·5)*
Lymphatic filariasis
1595·7 
(733·4 to 
2983·5)
1897·7 
(873·9 to 
3542·8)
1189·0 
(587·7 to 
2114·9)
–25·5 
(–41·4 to 
–9·3)*
–37·4 
(–52·4 to 
–26·0)*
32·5 
(14·9 to 
60·7)
28·9 
(13·3 to 
54·0)
15·8 
(7·8 to 
28·1)
–51·5 
(–61·8 to 
–41·2)*
–45·3 
(–58·4 to 
–35·5)*
Onchocerciasis
1420·4 
(777·0 to 
2254·9)
1266·4 
(705·0 to 
2003·3)
962·5 
(452·3 to 
1672·1)
–32·2 
(–47·6 to 
–16·8)*
–24·0 
(–41·6 to 
–6·5)*
28·4 
(16·0 to 
45·4)
19·1 
(11·0 to 
30·1)
12·9 
(6·1 to 
22·4)
–54·6 
(–65·7 to 
–43·4)*
–32·6 
(–48·5 to 
–17·5)*
Trachoma
231·1 
(156·9 to 
324·3)
246·5 
(166·2 to 
348·4)
245·2 
(162·4 to 
353·6)
6·1 
(–2·6 to 
14·6)
–0·5 
(–6·5 to 
5·2)
6·7 
(4·5 to 
9·4)
4·9 
(3·3 to 
6·9)
3·7 
(2·5 to 
5·3)
–44·3 
(–49·0 to 
–39·6)*
–23·8 
(–28·5 to 
–19·3)*
Dengue
822·8 
(308·1 to 
1364·0)
1798·2 
(789·6 to 
2494·8)
2956·9 
(1359·2 to 
4146·9)
259·4 
(104·2 to 
683·3)*
64·4 
(36·2 to 
115·9)*
13·9 
(5·2 to 
23·2)
26·7 
(11·7 to 
37·1)
40·2 
(18·6 to 
56·3)
189·0 
(65·5 to 
523·4)*
50·5 
 (24·7 to 
97·7)*
Yellow fever
784·5 
(170·6 to 
2314·6)
424·5 
(89·8 to 
1247·2)
374·0 
(80·8 to 
1075·1)
–52·3 
(–61·3 to 
–41·2)*
–11·9 
(–26·9 to 
7·4)
13·2 
(2·9 to 
39·0)
6·1 
(1·3 to 
18·0)
5·0 
(1·1 to 
14·5)
–61·8 
(–68·5 to 
–52·9)*
–17·1 
(–31·3 to 
1·3)
Rabies
2979·4 
(1867·4 to 
4076·4)
1451·6 
(867·1 to 
1868·0)
744·2 
(383·8 to 
1106·3)
–75·0 
(–82·7 to 
–61·4)*
–48·7 
(–58·9 to 
–34·1)*
51·3 
(32·6 to 
71·3)
21·5 
(12·9 to 
27·5)
10·1 
(5·2 to 
15·1)
–80·3 
(–86·5 to 
–69·9)*
–52·9 
(–62·4 to 
–39·5)*
Intestinal nematode 
infections
7460·9 
(4726·6 to 
11 584·0)
4083·3 
(2617·1 to 
6154·1)
3331·2 
(2076·2 to 
5158·6)
–55·4 
(–57·9 to 
–52·6)*
–18·4 
(–22·9 to 
–14·3)*
132·8 
(83·2 to 
206·9)
60·8 
(39·0 to 
91·6)
45·0 
(28·2 to 
69·6)
–66·1 
(–68·0 to 
–64·0)*
–25·9 
(–30·0 to 
–22·2)*
Ascariasis
4634·7 
(2996·9 to 
7119·9)
1902·0 
(1325·4 to 
2758·9)
1308·8 
(883·2 to 
1942·4)
–71·8 
(–74·6 to 
–68·4)*
–31·2 
(–37·6 to 
–24·8)*
80·3 
(51·4 to 
124·0)
28·3 
(19·8 to 
41·1)
17·9 
(12·1 to 
26·4)
–77·8 
(–79·9 to 
–74·9)*
–37·0 
(–42·8 to 
–31·0)*
Trichuriasis
671·4 
(364·9 to 
1142·9)
421·5 
(233·0 to 
717·2)
337·0 
(186·2 to 
573·6)
–49·8 
(–55·2 to 
–44·3)*
–20·0 
(–27·9 to 
–11·6)*
12·5 
(6·8 to 
21·2)
6·3 
(3·5 to 
10·7)
4·5 
(2·5 to 
7·7)
–63·7 
(–67·8 to 
–59·7)*
–27·8 
(–34·9 to 
–20·2)*
Hookworm disease
2154·8 
(1278·7 to 
3371·1)
1759·8 
(1058·9 to 
2739·1)
1685·4 
(1001·5 to 
2648·9)
–21·8 
(–26·7 to 
–16·6)*
–4·2 
(–9·5 to 
1·3)
40·0 
(23·7 to 
62·8)
26·2 
(15·7 to 
40·7)
22·6 
(13·5 to 
35·5)
–43·4 
(–47·2 to 
–39·6)*
–13·5 
(–18·2 to 
–8·5)*
Food-borne 
trematodiases
1425·0 
(591·7 to 
2937·7)
1659·6 
(832·5 to 
3083·5)
1771·2 
(923·9 to 
3158·4)
24·3 
(–3·9 to 
71·7)
6·7 
(1·3 to 
15·7)*
27·9 
(12·0 to 
56·7)
25·4 
 (12·9 to 
46·8)
23·7 
(12·2 to 
42·0)
–15·3 
(–34·0 to 
13·1)
–7·0 
(–11·4 to 
0·5)
Leprosy
23·0 
(15·5 to 
32·3)
31·3 
(21·3 to 
44·0)
31·6 
(21·4 to 
44·0)
37·5 
(34·0 to 
40·9)*
1·1 
(–1·3 to 
3·6)
0·6 
(0·4 to 
0·8)
0·5 
(0·4 to 
0·8)
0·4 
(0·3 to 
0·6)
–20·7 
(–22·7 to 
–18·8)*
–18·1 
(–20·0 to 
–16·2)*
Ebola virus disease 
··
··
0·3 
(0·2 to 
1·1)
··
··
··
··
··
··
··
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1269
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Zika virus disease
··
··
5·1 
(3·4–8·0)
··
··
··
··
0·1 
(0·0–0·1)
··
··
Guinea worm disease
50·7 
(35·3 to 
69·2)
0·2 
(0·1 to 
0·3)
··
–100·0 
(–100·0 to 
–100·0)*
–99·5 
(–99·7 to 
–99·4)*
1·1 
(0·7 to 
1·4)
··
··
–100·0 
(–100·0 to 
–100·0)*
–99·6 
(–99·7 to 
–99·5)*
Other neglected tropical 
diseases
3311·2 
(2409·7 to 
4421·6)
3262·2 
(2470·4 to 
4130·1)
3386·0 
(2569·6 to 
4260·7)
2·3 
(–22·0 to 
31·6)
3·8 
(–14·9 to 
23·9)
52·2 
(38·2 to 
69·0)
48·3 
(36·6 to 
61·2)
47·4 
(35·9 to 
59·7)
–9·1 
(–29·8 to 
15·8)
–1·9 
(–19·5 to 
17·3)
Maternal disorders
21 597·1 
(20 063·6 to 
22 834·1)
18 093·0 
(16 785·8 to 
19 171·8)
13 763·0 
(12 668·6 to 
15 064·0)
–36·3 
(–41·3 to 
–31·0)*
–23·9 
(–29·3 to 
–17·4)*
388·6 
(361·4 to 
411·5)
257·2 
(238·8 to 
272·5)
179·0 
(164·7 to 
195·8)
–53·9 
(–57·6 to 
–50·2)*
–30·4 
(–35·4 to 
–24·4)*
Maternal haemorrhage
6945·7 
(5770·8 to 
8257·7)
5416·4 
(4627·6 to 
6301·7)
4078·3 
(3311·7 to 
5035·2)
–41·3 
(–47·4 to 
–34·9)*
–24·7 
(–32·5 to 
–16·0)*
124·4 
(103·1 to 
148·1)
77·0 
(65·8 to 
89·7)
53·0 
(43·1 to 
65·4)
–57·4 
(–61·7 to 
–53·0)*
–31·2 
(–38·2 to 
–23·3)*
Maternal sepsis and 
other maternal 
infections
2102·5 
(1614·0 to 
2721·4)
1562·3 
(1223·7 to 
1984·3)
1139·4 
(833·1 to 
1525·2)
–45·8 
(–51·9 to 
–39·7)*
–27·1 
(–35·7 to 
–18·1)*
37·6 
(29·0 to 
48·2)
22·1 
(17·3 to 
28·0)
14·8 
(10·9 to 
19·8)
–60·6 
(–64·8 to 
–56·1)*
–33·0 
(–40·9 to 
–24·8)*
Maternal hypertensive 
disorders
2469·0 
(1945·4 to 
3125·5)
2478·1 
(1983·1 to 
3052·0)
1996·8 
(1569·9 to 
2483·1)
–19·1 
(–26·0 to 
–11·2)*
–19·4 
(–27·3 to 
–11·1)*
44·0 
(34·8 to 
55·2)
35·1 
(28·2 to 
43·2)
26·0 
(20·5 to 
32·3)
–40·9 
(–45·8 to 
–35·4)*
–25·8 
(–33·1 to 
–17·9)*
Maternal obstructed 
labour and uterine 
rupture
1440·8 
(1086·2 to 
1865·8)
1240·4 
(944·6 to 
1582·8)
969·0 
(716·6 to 
1270·1)
–32·8 
(–37·4 to 
–27·7)*
–21·9 
(–27·4 to 
–15·9)*
27·0 
(20·4 to 
35·0)
17·9 
(13·6 to 
22·9)
12·6 
(9·3 to 
16·5)
–53·3 
(–56·5 to 
–50·0)*
–29·5 
(–34·5 to 
–24·1)*
Maternal abortion, 
miscarriage, and ectopic 
pregnancy
1743·4 
(1338·9 to 
2235·5)
1469·0 
(1150·0 to 
1845·5)
1145·1 
(855·9 to 
1541·6)
–34·3 
(–40·9 to 
–26·8)*
–22·1 
(–30·6 to 
–12·6)*
31·9 
(24·6 to 
40·6)
20·9 
(16·4 to 
26·3)
14·9 
(11·1 to 
19·9)
–53·3 
(–57·8 to 
–48·0)*
–28·8 
(–36·6 to 
–20·4)*
Indirect maternal deaths
2611·6 
(1943·4 to 
3385·8)
2577·2 
(1949·1 to 
3277·1)
1987·9 
(1463·8 to 
2619·8)
–23·9 
(–30·7 to 
–16·4)*
–22·9 
(–30·1 to 
–14·8)*
47·0 
(35·2 to 
60·4)
36·7 
(27·7 to 
46·6)
25·8 
(19·1 to 
34·0)
–45·0 
(–49·7 to 
–39·9)*
–29·6 
(–36·2 to 
–22·1)*
Late maternal deaths
374·2 
(244·4 to 
552·4)
298·2 
(178·6 to 
480·8)
228·5 
(134·6 to 
370·9)
–39·0 
(–50·1 to 
–28·8)*
–23·4 
(–29·9 to 
–16·2)*
6·7 
(4·4 to 
9·8)
4·2 
(2·5 to 
6·8)
3·0 
(1·8 to 
4·8)
–55·8 
 (–63·7 to 
–49·2)*
–29·9 
(–35·5 to 
–23·5)*
Maternal deaths 
aggravated by HIV/AIDS
36·9 
(21·5 to 
52·5)
128·5 
(81·8 to 
169·0)
105·4 
(66·7 to 
142·9)
185·9 
(142·7 to 
243·7)*
–17·9 
(–27·8 to 
–6·0)*
0·7 
(0·4 to 
0·9)
1·9 
(1·2 to 
2·4)
1·4 
(0·9 to 
1·9)
104·5 
(73·6 to 
146·1)*
–26·1 
(–35·0 to 
–15·3)*
Other maternal disorders
3872·9 
(3015·3 to 
4777·9)
2923·1 
(2365·7 to 
3539·5)
2112·5 
(1628·9 to 
2673·2)
–45·5 
(–50·6 to 
–39·9)*
–27·7 
(–34·7 to 
–19·7)*
69·3 
(54·4 to 
84·9)
41·5 
(33·6 to 
50·0)
27·5 
(21·2 to 
34·8)
–60·4 
(–64·0 to 
–56·5)*
–33·7 
(–40·1 to 
–26·4)*
Neonatal disorders
261 357·2 
(248 875·2 to 
282 758·2)
211 984·8 
(203 477·1 to 
221 317·2)
163 569·7 
(154 643·2 to 
172 756·7)
–37·4 
(–42·7 to 
–32·7)*
–22·8 
(–26·8 to 
–18·9)*
3818·4 
(3635·3 to 
4130·2)
3073·5 
(2949·7 to 
3208·5)
2364·2 
(2237·5 to 
2493·4)
–38·1 
(–43·2 to 
–33·5)*
–23·1 
(–27·0 to 
–19·2)*
Neonatal preterm birth 
complications
112 767·2 
(105 488·9 to 
124 122·5)
81 159·7 
(76 378·0 to 
89 409·0)
62 031·6 
(57 062·9 to 
67 530·0)
–45·0 
(–50·3 to 
–39·5)*
–23·6 
(–29·9 to 
–17·4)*
1652·8 
(1546·2 to 
1819·4)
1176·6 
(1107·3 to 
1296·0)
892·7 
(822·1 to 
970·7)
–46·0 
(–51·2 to 
–40·7)*
–24·1 
(–30·4 to 
–18·1)*
Neonatal encephalopathy 
due to birth asphyxia, and 
trauma
68 251·9 
(61 749·3 to 
76 860·5)
60 334·8 
(55 822·8 to 
65 138·9)
47 031·7 
(41 794·2 to 
51 919·1)
–31·1 
(–41·3 to 
–20·8)*
–22·1 
(–29·3 to 
–14·6)*
993·0 
(897·9 to 
1117·7)
874·2 
(808·8 to 
943·9)
682·2 
(606·6 to 
751·3)
–31·3 
(–41·4 to 
–21·4)*
–22·0 
(–29·1 to 
–14·6)*
Neonatal sepsis and 
other neonatal infections
24 573·0 
(18 972·5 to 
31 156·6)
25 874·0 
(21 266·6 to 
32 360·3)
23 675·8 
(20 056·0 to 
30 684·5)
–3·6 
(–22·7 to 
20·9)
–8·5 
(–19·1 to 
4·0)
360·8 
(278·4 to 
460·0)
375·7 
(308·9 to 
469·6)
341·7 
(291·0 to 
444·5)
–5·3 
(–23·7 to 
18·6)
–9·0 
(–19·5 to 
3·2)
Haemolytic disease and 
other neonatal jaundice
12 277·3 
(10 225·3 to 
15 113·1)
7996·0 
(7149·5 to 
9006·9)
4912·8 
(4310·5 to 
5605·8)
–60·0 
(–69·1 to 
–50·4)*
–38·6 
(–46·2 to 
–30·3)*
179·9 
(149·9 to 
221·4)
116·1 
(103·8 to 
130·8)
70·7 
(62·0 to 
80·7)
–60·7 
(–69·6 to 
–51·4)*
–39·1 
(–46·6 to 
–30·8)*
Other neonatal disorders
43 487·8 
(37 402·4 to 
50 951·9)
36 620·3 
(33 314·2 to 
40 250·5)
25 917·7 
(23 440·4 to 
28 405·4)
–40·4 
(–50·6 to 
–28·5)*
–29·2 
(–36·1 to 
–21·0)*
631·9 
(543·4 to 
740·9)
530·9 
(483·0 to 
583·6)
376·8 
(340·8 to 
413·1)
–40·4 
(–50·6 to 
–28·4)*
–29·0 
(–35·9 to 
–20·7)*
(Table 1 continues on next page)
 Global Health Metrics
1270 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Nutritional deficiencies
69 823·3 
(57 049·4 to 
85 126·9)
64 648·9 
(51 489·2 to 
80 980·6)
60 936·1  
(46 656·8 to 
79 062·8)
–12·7 
(–23·8 to 
–1·2)*
–5·7 
(–12·3 to 
0·1)
1167·8 
(949·2 to 
1434·1)
971·1 
(775·1 to 
1213·5)
844·3 
(649·4 to 
1090·3)
–27·7 
(–35·9 to 
–19·1)*
–13·1 
(–18·9 to 
–7·7)*
Protein-energy 
malnutrition
35 843·1 
(29 589·9 to 
41 569·5)
26 417·6 
(23 896·5 to 
29 406·0)
20 718·9 
(18 009·6 to 
24 194·8)
–42·2 
(–51·8 to 
–26·7)*
–21·6 
(–32·3 to 
–8·8)*
561·0 
(467·3 to 
647·0)
398·8 
(361·7 to 
443·4)
296·7 
(258·1 to 
346·4)
–47·1 
(–55·8 to 
–33·4)*
–25·6 
(–35·7 to 
–13·6)*
Iodine deficiency
4355·1 
(2983·7 to 
6048·6)
3453·9 
(2363·8 to 
4790·9)
3240·6 
(2213·3 to 
4488·7)
–25·6 
(–28·2 to 
–22·9)*
–6·2 
(–8·7 to 
–3·5)*
84·5 
(58·0 to 
117·3)
52·4 
(35·9 to 
72·6)
43·5 
(29·8 to 
60·3)
–48·5 
(–50·2 to 
–46·7)*
–16·9 
(–19·2 to 
–14·5)*
Vitamin A deficiency
188·5 
(116·6 to 
294·4)
225·3 
 (139·7 to 
348·3)
252·4 
(158·8 to 
388·3)
33·9 
(27·4 to 
41·0)*
12·0 
(8·7 to 
15·5)*
3·2 
(2·0 to 
4·9)
3·4 
(2·1 to 
5·2)
3·4 
(2·2 to 
5·3)
7·0 
(2·2 to 
11·4)*
2·6 
(–0·3 to 
5·6)
Iron-deficiency anaemia
27 097·5 
(18 018·7 to 
38 749·1)
32 422·9 
(21 535·8 to 
46 668·3)
34 841·8 
(23 085·2 to 
49 693·9)
28·6 
(26·5 to 
30·4)*
7·5 
(6·2 to 
8·9)*
475·7 
(317·4 to 
679·7)
482·7 
(320·9 to 
693·0)
474·1 
(314·1 to 
676·0)
–0·3 
(–1·5 to 
0·7)
–1·8 
(–3·0 to 
–0·5)*
Other nutritional 
deficiencies
2339·1 
(1908·0 to 
2766·9)
2129·2 
(1791·2 to 
2366·5)
1882·4 
(1592·2 to 
2158·7)
–19·5 
(–32·9 to 
5·7)
–11·6 
(–20·4 to 
0·7)
43·3 
(36·7 to 
50·2)
33·8 
(28·4 to 
37·4)
26·4 
(22·4 to 
30·3)
–38·9 
(–48·1 to 
–24·3)*
–21·7 
(–29·1 to 
–11·6)*
Other communicable, 
maternal, neonatal, and 
nutritional diseases
32 531·7 
(25 112·3 to 
42 021·4)
28 722·2 
(22 674·6 to 
36 833·4)
23 465·1 
(18 762·9 to 
29 098·8)
–27·9 
(–36·2 to 
–18·6)*
–18·3 
(–25·2 to 
–10·6)*
533·7 
(424·3 to 
675·0)
428·7 
(340·1 to 
547·4)
328·0 
(261·3 to 
409·8)
–38·5 
(–44·8 to 
–31·3)*
–23·5 
(–29·8 to 
–16·4)*
Sexually transmitted 
diseases excluding HIV
16 447·6 
(9960·1 to 
25 590·4)
15 145·5 
(9416·5 to 
22 818·4)
12 016·0 
(7764·9 to 
17 118·7)
–26·9 
(–37·6 to 
–13·9)*
–20·7 
(–30·2 to 
–9·4)*
254·0 
 (157·8 to 
389·9)
222·6 
(138·7 to 
335·0)
169·4 
(108·1 to 
242·8)
–33·3 
(–42·1 to 
–22·6)*
–23·9  
(–32·8 to 
–13·4)*
Syphilis
14 613·8 
(8275·0 to 
23 755·0)
12 825·3 
(7321·4 to 
20 493·5)
9415·8 
(5467·7 to 
14 602·8)
–35·6 
(–45·5 to 
–23·1)*
–26·6 
(–35·8 to 
–14·9)*
217·9 
(124·4 to 
352·0)
188·3 
(107·7 to 
300·6)
135·5 
(78·6 to 
210·2)
–37·8 
(–47·4 to 
–25·8)*
–28·1 
(–37·1 to 
–16·8)*
Chlamydial infection
425·2 
(287·5 to 
639·0)
519·6 
(341·4 to 
782·1)
562·4 
(370·3 to 
851·1)
32·3 
(25·6 to 
39·6)*
8·2 
(5·9 to 
10·4)*
8·0 
(5·4 to 
11·8)
7·5 
(5·0 to 
11·3)
7·3 
(4·8 to 
11·0)
–8·6  
(–14·2 to 
–3·4)*
–3·3 
(–5·6 to 
–1·4)*
Gonococcal infection
465·0 
(334·8 to 
630·0)
582·3 
(412·5 to 
824·5)
675·2 
(467·7 to 
974·9)
45·2 
(26·9 to 
64·5)*
16·0 
(10·3 to 
21·8)*
9·2 
(6·8 to 
12·4)
8·6 
(6·1 to 
12·1)
8·8 
(6·1 to 
12·7)
–4·3 
(–17·1 to 
9·2)
2·7 
(–2·7 to 
7·8)
Trichomoniasis
125·7 
(48·3 to 
265·4)
170·9 
(65·2 to 
362·0)
198·2 
(75·9 to 
420·8)
57·7 
(55·1 to 
60·5)*
15·9 
(14·8 to 
17·1)*
2·5 
(0·9 to 
5·2)
2·5 
(1·0 to 
5·4)
2·6 
(1·0 to 
5·5)
4·7 
(3·6 to 
5·8)*
1·8 
(0·9 to 
2·7)*
Genital herpes
132·8 
(43·0 to 
302·2)
187·9 
(61·0 to 
428·1)
221·4 
(71·2 to 
507·1)
66·8 
(61·5 to 
70·0)*
17·8 
(15·5 to 
19·7)*
2·9 
(0·9 to 
6·6)
3·0 
(1·0 to 
6·8)
3·0 
(1·0 to 
6·8)
2·9 
(1·3 to 
4·8)*
–0·2 
(–1·6 to 
1·5)
Other sexually 
transmitted diseases
685·1 
(474·3 to 
964·9)
859·5 
(589·4 to 
1221·9)
943·0 
(643·7 to 
1349·4)
37·6 
(30·6 to 
44·7)*
9·7 
(7·4 to 
12·2)*
13·5 
(9·4 to 
18·9)
12·6 
(8·7 to 
17·9)
12·3 
(8·4 to 
17·6)
–8·7 
(–13·7 to 
–4·0)*
–2·6 
(–4·8 to 
–0·4)*
Hepatitis
9017·2 
(8255·1 to 
9723·9)
7718·6 
(7259·2 to 
8169·0)
5777·8 
(5492·2 to 
6078·9)
–35·9 
(–41·5 to 
–30·1)*
–25·1 
(–29·2 to 
–21·0)*
163·7 
(151·1 to 
175·3)
117·8 
(111·0 to 
124·6)
78·6 
(74·8 to 
82·7)
–52·0 
(–55·9 to 
–48·3)*
–33·3  
(–36·8 to 
–29·6)*
Acute hepatitis A
1271·9 
(1017·1 to 
1540·7)
849·3 
(677·0 to 
1036·3)
450·7 
(364·0 to 
544·8)
–64·6 
(–72·1 to 
–55·0)*
–46·9 
(–58·9 to 
–32·0)*
19·5 
(15·7 to 
23·5)
12·6 
(10·1 to 
15·3)
6·4 
(5·2 to 
7·8)
–67·1 
(–74·0 to 
–58·4)*
–49·0 
(–60·6 to 
–34·6)*
Hepatitis B
4656·5 
(4209·1 to 
5096·9)
4373·2 
(4013·0 to 
4741·4)
3823·8 
(3543·7 to 
4119·0)
–17·9 
(–24·6 to 
–10·7)*
–12·6 
(–17·9 to 
–7·0)*
94·2 
(86·2 to 
102·2)
68·7 
(63·5 to 
74·3)
51·6 
(47·9 to 
55·6)
–45·2 
(–49·2 to 
–40·9)*
–24·9 
(–29·2 to 
–20·4)*
Hepatitis C
88·4 
(72·0 to 
107·8)
90·9 
(73·8 to 
112·2)
83·7 
(66·3 to 
104·2)
–5·3 
(–17·1 to 
7·5)
–7·9 
(–17·6 to 
3·0)
1·8 
(1·5 to 
2·3)
1·5 
(1·2 to 
1·9)
1·1 
(0·9 to 
1·4)
–37·1 
(–44·2 to 
–29·1)*
–22·3 
(–30·4 to 
–13·0)*
Acute hepatitis E
3000·4 
(2479·7 to 
3449·1)
2405·2 
(2090·1 to 
2702·9)
1419·6 
(1230·3 to 
1610·1)
–52·7 
(–60·4 to 
–44·5)*
–41·0 
(–47·5 to 
–33·9)*
48·1 
(40·0 to 
55·0)
35·1 
(30·5 to 
39·4)
19·4 
(16·9 to 
22·0)
–59·6 
(–65·9 to 
–52·9)*
–44·6 
(–50·6 to 
–38·0)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1271
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Other infectious diseases
7066·9 
(4328·0 to 
9252·2)
5858·1 
(4069·7 to 
7316·8)
5671·3 
(3883·9 to 
7280·7)
–19·8 
(–39·1 to 
6·8)
–3·2 
(–20·2 to 
20·7)
116·1 
(74·8 to 
148·6)
88·2 
(61·7 to 
109·9)
80·0 
(54·2 to 
103·5)
–31·1 
(–46·9 to 
–10·6)*
–9·4 
(–25·1 to 
13·1)
Non-communicable 
diseases
1 074 539·5 
(957 634·8 to 
1 197 008·3)
1 312 102·0 
(1 163 063·8 
to 
1 472 494·4)
1 468 000·0 
(1 296 535·4 to 
1 658 537·7)
36·6 
(32·9 to 
39·9)*
11·9 
(10·3 to 
13·2)*
25 460·8 
(22 961·5 to 
28 096·0)
22 707·2 
(20 288·0 to 
25 308·0)
20 786·9 
(18 438·7 to 
23 410·0)
–18·4 
(–20·6 to 
–16·4)*
–8·5 
(–9·9 to 
–7·3)*
Neoplasms
151 550·6 
(148 429·7 to 
155 144·0)
189 094·4 
(185 939·0 to 
192 035·5)
213 221·0 
(208 458·6 to 
217 584·4)
40·7 
(36·8 to 
44·9)*
12·8 
(10·8 to 
15·0)*
3812·1 
(3739·6 to 
3895·3)
3377·2 
(3321·1 to 
3427·3)
3024·9 
(2956·4 to 
3086·9)
–20·6 
(–22·7 to 
–18·4)*
–10·4 
(–12·0 to 
–8·7)*
Lip and oral cavity 
cancer
2583·8 
(2488·9 to 
2719·1)
3668·0 
(3546·8 to 
3781·2)
4634·7 
(4429·7 to 
4823·4)
79·4 
(64·8 to 
88·9)*
26·4 
(20·8 to 
31·5)*
65·9 
(63·5 to 
69·2)
64·6 
(62·5 to 
66·6)
64·4 
(61·6 to 
67·0)
–2·2 
(–10·0 to 
2·9)
–0·2 
(–4·5 to 
3·8)
Nasopharynx cancer
1590·5 
(1506·1 to 
1686·4)
1785·6 
(1722·8 to 
1842·5)
1906·0 
(1809·3 to 
2011·6)
19·8 
(13·1 to 
28·0)*
6·7 
(0·2 to 
13·1)*
37·7 
(35·7 to 
40·0)
30·1 
(29·1 to 
31·0)
26·0 
(24·7 to 
27·4)
–31·1 
(–34·9 to 
–26·4)*
–13·5 
(–18·7 to 
–8·5)*
Other pharynx cancer
1794·9 
(1683·0 to 
1987·4)
2530·4 
(2412·5 to 
2620·7)
3209·6 
(2949·9 to 
3393·4)
78·8 
(51·1 to 
97·1)*
26·8 
(15·8 to 
34·9)*
45·5 
(42·7 to 
50·3)
44·5 
 (42·4 to 
46·1)
44·4 
(40·8 to 
46·9)
–2·3 
 (–17·3 to 
7·5)
–0·2 
(–8·7 to 
6·2)
Oesophageal cancer
7809·6 
(7554·6 to 
8065·4)
9206·9 
(9018·2 to 
9394·6)
9276·1 
(9019·5 to 
9564·2)
18·8 
(13·7 to 
24·4)*
0·8 
(–2·2 to 
4·3)
207·4 
(200·7 to 
214·2)
170·0 
(166·6 to 
173·5)
132·7 
(129·1 to 
136·8)
–36·0 
(–38·8 to 
–33·1)*
–22·0 
(–24·2 to 
–19·3)*
Stomach cancer
19 027·0 
(18463·7 to 
19 584·4)
19 048·8 
(18 712·9 to 
19 405·6)
18 345·5 
(17 888·0 to 
18 860·9)
–3·6 
(–6·8 to 
0·4)
–3·7 
(–6·2 to 
–1·2)*
499·4 
(485·0 to 
513·6)
348·1 
(342·0 to 
354·6)
262·9 
(256·2 to 
270·1)
–47·4 
(–49·1 to 
–45·3)*
–24·5 
(–26·5 to 
–22·6)*
Colon and rectum 
cancer
11 021·7 
(10 741·7 to 
11 482·7)
14 637·5 
(14 356·4 to 
14 918·1)
17 197·2 
(16 480·2 to 
17 851·9)
56·0 
(44·5 to 
63·5)*
17·5 
(11·6 to 
22·3)*
297·6 
290·6 to 
309·1)
272·4 
(267·2 to 
277·4)
249·0 
(238·6 to 
258·4)
–16·4 
(–22·3 to 
–12·5)*
–8·6 
(–13·0 to 
–4·8)*
Liver cancer
13 311·9 
(12 450·1 to 
14 010·2)
18 332·3 
(17 719·9 to 
18 813·2)
21 143·8 
(20 268·1 to 
21 985·9)
58·8 
(49·2 to 
70·4)*
15·3 
(11·5 to 
19·9)*
331·7 
(311·0 to 
348·5)
321·7 
(310·9 to 
329·8)
295·2 
(283·0 to 
306·7)
–11·0 
(–16·4 to 
–4·6)*
–8·2 
(–11·3 to 
–4·7)*
Due to hepatitis B
6537·7 
(5718·9 to 
7253·4)
8838·7 
(7823·1 to 
9718·0)
9802·3 
(8568·3 to 
10 960·1)
49·9 
(39·7 to 
63·4)*
10·9 
(6·3 to 
16·3)*
158·5 
(138·5 to 
176·2)
151·2 
(133·7 to 
167·0)
134·7 
(118·2 to 
150·6)
–15·0 
(–20·6 to 
–7·6)*
–10·9 
(–14·4 to 
–6·6)*
Due to hepatitis C
1850·2 
(1639·8 to 
2057·7)
2735·7 
(2447·6 to 
3011·7)
3310·5 
(2930·7 to 
3673·3)
78·9 
(69·0 to 
86·6)*
21·0 
(16·9 to 
24·9)*
49·6 
(44·1 to 
55·3)
51·2 
(45·9 to 
56·4)
47·9 
(42·5 to 
53·0)
–3·6 
(–8·7 to 
0·3)
–6·5 
(–9·8 to 
–3·7)*
Due to alcohol use
1686·3 
(1384·8 to 
2013·9)
2282·2 
(1912·1 to 
2710·9)
2925·7 
(2463·2 to 
3400·9)
73·5 
(55·4 to 
102·0)*
28·2 
(20·4 to 
38·5)*
45·0 
(36·9 to 
53·3)
42·1 
(35·2 to 
49·9)
41·8 
(35·4 to 
48·5)
–7·0 
(–16·5 to 
7·8)
–0·6 
 (–6·7 to 
7·2)
Due to other causes
3237·7 
(2880·7 to 
3688·9)
4475·8 
(4004·8 to 
5058·9)
5105·3 
(4527·7 to 
5757·7)
57·7 
(46·9 to 
68·8)*
14·1 
(8·5 to 
19·1)*
78·6 
(70·0 to 
89·7)
77·2 
(69·0 to 
87·0)
70·8 
(62·9 to 
79·7)
–9·9 
(–15·9 to 
–3·8)*
–8·3 
(–12·4 to 
–4·6)*
Gallbladder and biliary 
tract cancer
2311·8 
(2201·3 to 
2555·0)
2885·3 
(2655·7 to 
3078·8)
3311·1 
(3002·9 to 
3530·9)
43·2 
(26·0 to 
53·5)*
14·8 
(9·7 to 
19·8)*
63·2 
(60·3 to 
69·5)
53·9 
(49·7 to 
57·4)
47·8 
(43·5 to 
50·9)
–24·3 
(–33·2 to 
–19·0)*
–11·2 
(–15·0 to 
–7·5)*
Pancreatic cancer
4505·6 
(4423·5 to 
4576·2)
6492·4 
(6404·8 to 
6602·1)
8230·7 
(8008·2 to 
8445·8)
82·7 
(78·3 to 
87·1)*
26·8 
(22·7 to 
30·4)*
122·8 
(120·5 to 
124·6)
122·1 
(120·5 to 
124·1)
119·5 
(116·2 to 
122·6)
–2·6 
(–5·0 to 
–0·3)*
–2·1 
(–5·2 to 
0·7)
Larynx cancer
2290·5 
(2207·2 to 
2369·6)
2505·6 
(2431·0 to 
2569·8)
2749·8 
(2661·2 to 
2845·7)
20·1 
(14·9 to 
25·6)*
9·8 
(6·0 to 
13·6)*
59·6 
(57·5 to 
61·6)
45·3 
(44·0 to 
46·5)
38·7 
(37·4 to 
40·0)
–35·1 
(–37·9 to 
–32·1)*
–14·6 
(–17·5 to 
–11·7)*
Tracheal, bronchus, 
and lung cancer
24 411·4 
(23 862·3 to 
25 086·9)
32 059·3 
(31 518·1 to 
32 631·0)
36 441·0 
(35 401·2 to 
37 462·8)
49·3 
(43·0 to 
54·5)*
13·7 
(10·1 to 
16·9)*
650·6 
(636·2 to 
667·8)
596·0 
(586·5 to 
606·2)
526·1 
(511·2 to 
540·8)
–19·1 
(–22·5 to 
–16·4)*
–11·7 
(–14·4 to 
–9·2)*
Malignant skin 
melanoma
947·1 
(853·4 to 
1081·6)
1296·7 
(1166·4 to 
1434·0)
1550·5 
(1378·4 to 
1714·1)
63·7 
(46·0 to 
74·9)*
19·6 
(13·6 to 
25·4)*
23·6 
(21·3 to 
27·2)
22·8 
(20·5 to 
25·1)
21·8 
(19·4 to 
24·0)
–7·4 
 (–17·8 to 
–1·3)*
–4·3 
(–9·0 to 
0·3)
(Table 1 continues on next page)
 Global Health Metrics
1272 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Non-melanoma skin 
cancer
635·7 
(611·9 to 
658·6)
864·4 
(841·4 to 
887·8)
1022·6 
(981·1 to 
1068·7)
60·9 
(54·6 to 
70·1)*
18·3 
(14·0 to 
23·6)*
17·0 
(16·4 to 
17·7)
16·1 
(15·7 to 
16·6)
14·9 
(14·3 to 
15·6)
–12·3 
(–15·6 to 
–7·5)*
–7·6 
(–10·8 to 
–3·5)*
Non-melanoma skin 
cancer (squamous-
cell carcinoma)
635·2 
(611·4 to 
658·1)
863·5 
(839·9 to 
886·8)
1021·5 
(980·2 to 
1067·6)
60·8 
(54·6 to 
70·1)*
18·3 
(14·0 to 
23·6)*
17·0 
(16·4 to 
17·7)
16·1 
(15·7 to 
16·6)
14·9 
(14·3 to 
15·6)
–12·3 
(–15·6 to 
–7·5)*
–7·6 
(–10·8 to 
–3·5)*
Non-melanoma skin 
cancer (basal-cell 
carcinoma)
0·5 
(0·2 to 
1·0)
0·9 
(0·4 to 1·8)
1·1 
(0·4 to 
2·2)
122·9 
(109·6 to 
138·3)
23·8 (16·1 
to 31·7)
··
··
··
15·8 
(10·3 to 
21·7)
-5·6 
(-11·5 to 
0·4)
Breast cancer
9804·9 
(9186·6 to 
10 790·8)
13 209·0 
(12 668·7 to 
13 875·4)
15 107·8 
(14 264·6 to 
16 175·8)
54·1 
(34·8 to 
70·0)*
14·4 
(6·3 to 
22·2)*
248·6 
(233·7 to 
272·3)
229·4 
(220·2 to 
240·7)
208·5 
(196·9 to 
223·1)
–16·2 
(–26·2 to 
–8·2)*
–9·1 
(–15·4 to 
–3·2)*
Cervical cancer
6047·7  
(5226·5 to 
7655·0)
7040·2 
(5878·2 to 
7516·1)
7390·0 
(6019·9 to 
7868·6)
22·2 
(2·0 to 
41·2)*
5·0 
(–1·3 to 
13·2)
149·0 
(129·1 to 
188·6)
119·3 
(99·8 to 
127·4)
100·6 
(82·0 to 
107·1)
–32·5 
(–43·5 to 
–22·0)*
–15·7 
(–20·8 to 
–9·2)*
Uterine cancer
1573·9 
(1480·6 to 
1651·3)
1955·1 
(1868·8 to 
2035·2)
2122·8 
(2010·4 to 
2229·7)
34·9 
(26·3 to 
47·1)*
8·6 
(2·7 to 
16·4)*
41·3 
(39·0 to 
43·3)
35·6 
(34·0 to 
37·0)
30·1 
(28·5 to 
31·7)
–27·1 
(–31·6 to 
–20·6)*
–15·3 
(–19·9 to 
–9·3)*
Ovarian cancer
2661·5 
(2531·2 to 
2741·5)
3523·0 
(3393·4 to 
3660·7)
4258·1 
(4035·8 to 
4459·3)
60·0 
(51·8 to 
68·2)*
20·9 
(13·9 to 
27·0)*
68·3 
(65·3 to 
70·2)
62·5 
 (60·2 to 
64·8)
59·3 
(56·2 to 
62·1)
–13·2 
(–17·5 to 
–8·8)*
–5·0 
(–10·4 to 
–0·2)*
Prostate cancer
3226·7 
(2808·5 to 
3505·0)
4765·1 
(4006·7 to 
5107·8)
6073·7 
(4992·7 to 
6582·3)
88·2 
(67·8 to 
100·9)*
27·5 
(20·3 to 
33·4)*
97·5 
(85·4 to 
105·9)
97·2 
(82·2 to 
104·2)
93·9 
(77·2 to 
101·8)
–3·7 
(–13·6 to 
2·7)
–3·4 
(–8·7 to 
1·3)
Testicular cancer
400·0 
(380·0 to 
423·9)
393·1 
(378·2 to 
412·0)
391·8 
(372·4 to 
412·0)
–2·0 
(–8·2 to 
3·7)
–0·3 
(–4·4 to 
4·0)
7·9 
(7·5 to 
8·3)
5·9 
(5·7 to 
6·2)
5·2 
(4·9 to 
5·4)
–34·3 
(–38·5 to 
–30·5)*
–12·3 
(–15·8 to 
–8·6)*
Kidney cancer
1753·1 
(1707·2 to 
1806·3)
2476·1 
(2418·4 to 
2528·9)
3023·6 
(2911·4 to 
3135·9)
72·5 
(64·5 to 
80·9)*
22·1 
(17·6 to 
26·5)*
44·2 
(43·2 to 
45·4)
45·0 
(44·0 to 
46·0)
43·4 
(41·8 to 
45·0)
–1·9 
(–6·1 to 
2·2)
–3·7 
(–7·2 to 
–0·2)*
Bladder cancer
2235·8 
(2157·3 to 
2326·8)
2796·3 
(2735·8 to 
2859·6)
3315·2 
(3193·2 to 
3425·5)
48·3 
(38·9 to 
53·9)*
18·6 
(13·9 to 
22·4)*
63·3 
(61·2 to 
65·7)
54·3 
(53·1 to 
55·6)
49·5 
(47·7 to 
51·1)
–21·8 
(–26·6 to 
–19·0)*
–9·0 
(–12·4 to 
–6·1)*
Brain and nervous 
system cancer
5620·2 
(4833·4 to 
5997·6)
6729·7 
(6094·9 to 
7049·7)
7660·0 
(6922·8 to 
8280·4)
36·3 
(25·9 to 
54·7)*
13·8 
(9·4 to 
20·8)*
116·8 
(101·5 to 
123·9)
109·1 
(98·5 to 
114·1)
105·0 
(94·9 to 
113·3)
–10·0 
(–16·4 to 
2·6)
–3·7 
(–7·3 to 
2·3)
Thyroid cancer
768·4 
(713·7 to 
817·8)
960·7 
(918·0 to 
1004·4)
1122·8 
(1071·3 to 
1183·5)
46·1 
(35·1 to 
60·9)*
16·9 
(11·0 to 
23·8)*
19·1 
(17·9 to 
20·3)
16·9 
(16·2 to 
17·6)
15·8 
(15·0 to 
16·6)
–17·6 
(–23·5 to 
–9·7)*
–6·8 
(–11·4 to 
–1·3)*
Mesothelioma
398·9 
(361·5 to 
440·9)
535·4 
(509·7 to 
569·4)
660·9 
(619·4 to 
700·6)
65·7 
(43·6 to 
81·4)*
23·4 
(17·8 to 
28·2)*
10·5 
(9·5 to 
11·7)
9·8 
(9·3 to 
10·3)
9·5 
(8·9 to 
10·1)
–9·3 
(–21·7 to 
–0·8)*
–2·8 
(–7·1 to 
0·9)
Hodgkin’s lymphoma
1589·4 
(1176·0 to 
1775·3)
1269·1 
(1048·1 to 
1466·8)
1126·8 
(943·7 to 
1337·1)
–29·1 
(–35·9 to 
–15·9)*
–11·2 
(–14·5 to 
–8·0)*
31·8 
(23·8 to 
35·5)
19·7 
(16·4 to 
22·9)
15·2 
(12·8 to 
18·1)
–52·1 
(–56·7 to 
–43·2)*
–22·7 
(–25·4 to 
–20·1)*
Non-Hodgkin 
lymphoma
4095·3 
(3844·4 to 
4377·0)
5528·6 
(5174·2 to 
5736·3)
6783·0 
(6172·5 to 
7083·3)
65·6 
(49·2 to 
74·7)*
22·7 
(16·0 to 
27·2)*
92·8 
(88·3 to 
98·0)
93·6  
(88·1 to 
96·9)
94·9 
(86·6 to 
99·1)
2·3 
(–7·4 to 
7·3)
1·4 
(–4·1 to 
5·0)
Multiple myeloma
1141·8 
(1032·1 to 
1308·8)
1664·3 
(1489·5 to 
1831·8)
2114·0 
(1901·5 to 
2339·1)
85·2 
(72·6 to 
98·4)*
27·0 
(22·6 to 
32·6)*
30·7 
(27·9 to 
35·5)
31·0 
(27·6 to 
34·0)
30·5 
(27·4 to 
33·9)
–0·7  
(–8·6 to 
5·8)
–1·5 
(–4·9 to 
2·7)
Leukaemia
10 455·3 
(9415·6 to 
12 242·4)
10 401·6 
(9581·8 to 
11 171·9)
10 204·0 
(9319·4 to 
10 809·1)
–2·4 
(–14·2 to 
7·2)
–1·9 
(–6·2 to 
2·3)
204·7 
(186·8 to 
234·4)
166·3 
(153·6 to 
178·1)
141·6 
(129·3 to 
149·9)
–30·9 
(–38·4 to 
–25·0)*
–14·9 
(–18·4 to 
–11·3)*
Acute lymphoid 
leukaemia
2158·2 
(1900·3 to 
3001·6)
2339·9 
 (2178·5 to 
2794·3)
2426·6 
(2216·0 to 
2688·8)
12·4 
(–15·5 to 
28·2)
3·7 
(–7·8 to 
9·9)
37·8 
(33·5 to 
51·5)
35·0  
(32·7 to 
41·7)
33·1 
(30·2 to 
36·6)
–12·5 
(–33·3 to 
–1·5)*
–5·7 
(–15·9 to 
–0·2)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1273
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Chronic lymphoid 
leukaemia
468·8 
(434·3 to 
553·7)
617·1 
(580·4 to 
709·0)
703·1 
(654·0 to 
805·0)
50·0 
(38·9 to 
61·4)*
13·9 
(9·2 to 
19·1)*
12·6 
(11·7 to 
14·6)
11·6 
(10·9 to 
13·3)
10·3 
(9·7 to 
11·8)
–17·6 
(–22·8 to 
–12·2)*
–11·1 
 (–14·6 to 
–7·2)*
Acute myeloid 
leukaemia
1707·6 
(1577·2 to 
2023·1)
2327·1 
(2152·7 to 
2540·6)
2651·6 
(2444·2 to 
2838·1)
55·3 
(34·6 to 
68·5)*
13·9 
(8·7 to 
18·2)*
35·4 
(33·1 to 
41·0)
38·0 
(35·2 to 
41·2)
36·9 
(34·1 to 
39·4)
4·3 
(–8·5 to 
12·2)
–2·9 
(–7·0 to 
0·6)
Chronic myeloid 
leukaemia
706·2 
(639·5 to 
775·2)
654·3 
(596·6 to 
723·6)
609·6 
(550·3 to 
676·0)
–13·7 
(–21·0 to 
–6·6)*
–6·8 
(–11·1 to 
–2·2)*
16·6 
(15·2 to 
18·1)
11·0 
(10·1 to 
12·1)
8·4 
(7·6 to 
9·3)
–49·5 
(–53·5 to 
–45·7)*
–23·5 
(–26·9 to 
–20·1)*
Other leukaemia
5414·4 
(4487·0 to 
6178·9)
4463·2 
(3848·9 to 
4762·2)
3813·1 
(3326·8 to 
4039·8)
–29·6 
(–38·9 to 
–18·9)*
–14·6  
(–19·6 to 
–9·0)*
102·3 
(86·4 to 
114·9)
70·6 
(60·9 to 
75·1)
52·9 
(46·2 to 
56·0)
–48·4 
(–54·7 to 
–41·5)*
–25·1 
(–29·4 to 
–20·4)*
Other neoplasms
7536·4 
(7307·3 to 
7843·6)
10 533·8 
(9864·9 to 
10 811·8)
12 847·7 
(11 679·5 to 
13 268·0)
70·5 
(52·9 to 
78·0)*
22·0 
(17·2 to 
25·3)*
163·6 
(158·9 to 
170·2)
174·2 
(163·3 to 
178·5)
178·5 
(162·3 to 
184·3)
9·2 
(–2·3 to 
13·4)
2·5 
(–1·5 to 
5·2)
Cardiovascular diseases
266 709·6 
(258 611·1 to 
274 986·6)
321 851·2 
(312 966·3 to 
330 487·6)
353 120·9 
(341 794·5 to 
364 965·3)
32·4 
(28·8 to 
36·2)*
9·7 
(7·4 to 
12·2)*
7267·3 
(7049·6 to 
7496·0)
6046·0 
(5878·1 to 
6208·3)
5178·4 
(5010·6 to 
5352·2)
–28·7 
(–30·7 to 
–26·8)*
–14·3 
(–16·1 to 
–12·4)*
Rheumatic heart disease
13 277·2 
(11 854·4 to 
14 558·1)
11 235·5 
(10 229·5 to 
12 162·0)
9803·1 
(9154·5 to 
10 556·6)
–26·2 
(–32·8 to 
–18·5)*
–12·8 
(–18·3 to 
–6·9)*
296·4 
(263·4 to 
324·9)
185·4 
(169·1 to 
199·9)
135·9 
(127·1 to 
145·8)
–54·2 
(–58·2 to 
–49·1)*
–26·7 
(–31·3 to 
–21·7)*
Ischaemic heart disease
118 996·9 
(115 809·8 to 
122 723·6)
153 547·6 
(149 867·7 to 
156 971·0)
174 611·1 
(169 736·1 to 
179 827·6)
46·7 
(42·5 to 
51·5)*
13·7 
(10·7 to 
16·7)*
3344·1 
(3255·9 to 
3448·7)
2908·3 
(2840·4 to 
2971·7)
2562·8 
(2491·4 to 
2640·8)
–23·4 
(–25·6 to 
–21·0)*
–11·9 
(–14·2 to 
–9·6)*
Cerebrovascular disease
95 306·8 
(91 616·6 to 
100 606·2)
111 916·0 
(108 069·6 to 
115 501·2)
116 445·1 
(111 385·4 to 
121 406·9)
22·2 
(16·7 to 
27·0)*
4·0 
(1·6 to 
6·5)*
2600·1 
(2496·3 to 
2744·0)
2116·6 
(2041·9 to 
2186·6)
1711·2 
(1635·3 to 
1784·4)
–34·2 
(–37·2 to 
–31·5)*
–19·1 
(–21·0 to 
–17·2)*
Ischaemic stroke
37 687·2 
(35 505·5 to 
39 624·6)
46 909·9 
(44 168·6 to 
49 455·6)
51 897·4 
(47 896·6 to 
55 567·7)
37·7 
(32·2 to 
43·4)*
10·6 
(7·1 to 
14·0)*
1112·1 
(1049·6 to 
1169·6)
934·8 
(880·6 to 
985·5)
787·5 
(728·4 to 
843·2)
–29·2 
(–32·0 to 
–26·2)*
–15·8 
(–18·4 to 
–13·1)*
Haemorrhagic stroke
57 619·6 
(55 206·4 to 
61 574·1)
65 006·1 
(63 154·6 to 
66 941·1)
64 547·7 
(62 622·3 to 
66 497·6)
12·0 
(6·3 to 
17·0)*
–0·7 
(–2·8 to 
1·5)
1488·0 
(1427·4 to 
1594·8)
1181·8 
(1148·5 to 
1216·2)
923·6 
(896·2 to 
951·9)
–37·9 
(–41·3 to 
–35·2)*
–21·8 
 (–23·5 to 
–20·1)*
Hypertensive heart 
disease
12 136·6 
(9824·4 to 
13 763·9)
13 571·4 
(11 603·8 to 
15 049·4)
16 335·1 
(13 456·6 to 
17 843·7)
34·6 
(24·7 to 
52·5)*
20·4 
(10·2 to 
32·9)*
338·6 
(274·9 to 
382·5)
259·6 
(221·8 to 
287·4)
242·5 
(199·7 to 
265·0)
–28·4 
(–33·4 to 
–19·1)*
–6·6 
(–14·6 to 
2·8)
Cardiomyopathy and 
myocarditis
6713·9 
(5820·8 to 
7248·0)
8576·8 
(7305·3 to 
9168·4)
8718·2 
(7574·9 to 
9628·0)
29·9 
(16·7 to 
44·8)*
1·6 
(–7·1 to 
12·9)
159·0 
(133·6 to 
171·9)
145·7 
(123·9 to 
155·8)
122·7 
(106·4 to 
135·1)
–22·9 
(–30·0 to 
–13·5)*
–15·8  
(–22·8 to 
–6·8)*
Myocarditis
1253·7 
(1032·8 to 
1618·8)
1422·2 
(1132·2 to 
1574·2)
1367·5 
(1118·2 to 
1513·1)
9·1 
(–20·2 to 
28·8)
–3·9 
(–12·7 to 
5·6)
24·8 
(20·8 to 
30·4)
23·0  
(18·1 to 
25·4)
19·1 
(15·6 to 
21·1)
–22·8 
(–41·0 to 
–11·7)*
–16·8 
(–24·3 to 
–8·0)*
Alcoholic 
cardiomyopathy
1815·2 
(1512·9 to 
2177·5)
2878·5 
(2414·3 to 
3221·2)
2591·2 
(2055·7 to 
3240·6)
42·8 
(11·8 to 
80·0)*
–10·0 
(–27·6 to 
14·3)
44·5 
(37·1 to 
53·3)
47·8 
(40·1 to 
53·2)
35·2 
(28·0 to 
43·9)
–21·0 
(–37·8 to 
–0·8)*
–26·3 
(–40·4 to 
–7·6)*
Other cardiomyopathy
3644·9 
(2878·4 to 
4234·4)
4276·1 
(3615·3 to 
4655·1)
4759·4 
(4089·9 to 
5094·4)
30·6 
(14·5 to 
52·0)*
11·3 
(4·3 to 
19·4)*
89·7 
(68·9 to 
103·1)
75·0 
(63·1 to 
81·5)
68·3 
(58·5 to 
73·2)
–23·8 
(–32·3 to 
–9·1)*
–8·8 
(–14·3 to 
–2·7)*
Atrial fibrillation and 
flutter
3044·8 
(2345·7 to 
3888·0)
4460·7 
(3484·6 to 
5666·6)
5951·3 
(4649·6 to 
7516·9)
95·5 
(91·1 to 
100·0)*
33·4 
(31·8 to 
35·1)*
97·8 
(76·0 to 
123·5)
93·7  
(73·6 to 
118·1)
93·4 
(73·2 to 
118·1)
–4·5 
 (–6·5 to 
–2·4)*
–0·2 
(–1·3 to 
0·8)
Aortic aneurysm
1942·5 
(1855·5 to 
2068·9)
2510·2 
(2437·9 to 
2611·8)
2881·8 
(2800·8 to 
2975·5)
48·4 
(39·9 to 
58·1)*
14·8 
(10·7 to 
20·1)*
54·4 
(52·1 to 
57·6)
47·8 
(46·5 to 
49·6)
42·6 
(41·4 to 
44·0)
–21·7 
(–25·8 to 
–17·0)*
–10·9 
(–13·9 to 
–7·1)*
Peripheral artery disease
678·4 
(486·1 to 
948·0)
970·9 
(719·7 to 
1325·7)
1235·1 
(922·2 to 
1683·9)
82·1 
(68·0 to 
103·9)*
27·2 
(20·9 to 
35·7)*
21·4 
(15·4 to 
29·7)
20·3  
(15·1 to 
27·9)
19·3 
(14·4 to 
26·3)
–9·4 
(–17·0 to 
0·5)
–4·9 
(–9·6 to 
1·3)
(Table 1 continues on next page)
 Global Health Metrics
1274 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Endocarditis
1536·3 
(1320·2 to 
1751·3)
1998·3 
(1748·2 to 
2320·0)
2368·7 
(2104·5 to 
2797·1)
54·2 
(39·0 to 
69·5)*
18·5 
(12·0 to 
23·8)*
34·6 
(29·7 to 
39·2)
34·0 
(29·6 to 
39·2)
33·6 
(29·8 to 
39·7)
–3·0 
(–11·4 to 
5·3)
–1·3 
(–6·7 to 
2·9)
Other cardiovascular and 
circulatory diseases
13 076·2 
(10 976·0 to 
14 815·8)
13 063·8 
(11 561·4 to 
15 422·4)
14 771·4 
(13 010·9 to 
17 397·0)
13·0 
(3·2 to 
31·9)*
13·1 
(9·8 to 
17·3)*
320·9 
(269·6 to 
364·9)
234·7 
(208·1 to 
276·1)
214·5 
(189·4 to 
251·8)
–33·2 
(–38·7 to 
–22·3)*
–8·6 
(–11·2 to 
–5·3)*
Chronic respiratory 
diseases
86 833·7 
(79 815·5 to 
92 631·5)
86 665·1 
(81 193·2 to 
92 630·9)
92 528·7 
(86 142·3 to 
99 725·6)
6·6  
(2·0 to 
15·4)*
6·8 
(4·5 to 
9·7)*
2256·8 
(2079·1 to 
2386·5)
1601·5 
(1507·8 to 
1698·0)
1351·7 
(1261·3 to 
1452·3)
–40·1 
(–43·1 to 
–34·6)*
–15·6 
(–17·6 to 
–13·2)*
Chronic obstructive 
pulmonary disease
59 810·7 
(53 271·2 to 
64 128·3)
59 572·5 
(56 816·4 to 
62 571·2)
63 434·3 
(60 586·3 to 
66 676·3)
6·1 
(0·6 to 
18·4)*
6·5 
(3·8 to 
10·1)*
1666·8 
(1486·0 to 
1780·7)
1151·0 
(1098·0 to 
1205·8)
945·3 
(904·1 to 
994·8)
–43·3 
(–46·2 to 
–36·8)*
–17·9 
(–19·9 to 
–15·1)*
Pneumoconiosis
568·0 
(494·8 to 
787·9)
560·3 
(506·1 to 
635·2)
577·1 
(517·2 to 
647·3)
1·6 
(–25·7 to 
16·9)
3·0 
(–4·5 to 
8·4)
15·0 
(13·2 to 
20·5)
10·4 
(9·4 to 
11·8)
8·4 
(7·6 to 
9·4)
–44·0 
(–58·3 to 
–36·2)*
–19·1 
(–24·6 to 
–15·0)*
Silicosis
303·5 
(251·4 to 
461·0)
273·2 
(247·2 to 
310·8)
270·6 
(243·6 to 
301·5)
–10·8 
(–43·4 to 
6·3)
–0·9 
(–14·2 to 
5·7)
8·0 
(6·7 to 
11·9)
5·0 
(4·5 to 
5·7)
3·9 
(3·5 to 
4·4)
–50·9 
(–68·2 to 
–42·0)*
–22·1 
(–32·2 to 
–17·1)*
Asbestosis
50·9 
(40·8 to 
70·6)
73·0 
(57·2 to 
86·9)
83·9 
(67·9 to 
97·5)
64·8 
(29·6 to 
83·7)*
14·8 
(9·2 to 
21·8)*
1·3 
(1·1 to 
1·9)
1·4 
(1·1 to 
1·6)
1·2 
(1·0 to 
1·4)
–5·8 
(–26·4 to 
4·6)
–9·2 
(–13·7 to 
–3·3)*
Coal workers’ 
pneumoconiosis
103·4 
(70·5 to 
127·8)
87·5 
(65·5 to 
104·6)
89·1 
(70·2 to 
108·9)
–13·9 
(–30·6 to 
15·1)
1·8 
(–6·8 to 
12·7)
2·9 
(1·9 to 
3·5)
1·7 
(1·2 to 
2·0)
1·3 
(1·0 to 
1·6)
–54·3 
(–63·3 to 
–38·6)*
–21·6 
(–28·2 to 
–13·5)*
Other pneumoconiosis
110·2 
(80·0 to 
173·3)
126·6 
(104·4 to 
161·8)
133·5 
(112·1 to 
165·9)
21·2 
(–8·3 to 
52·8)
5·5 
(–2·2 to 
13·2)
2·9 
(2·1 to 
4·5)
2·3 
(1·9 to 
3·0)
1·9 
 (1·6 to 
2·4)
–32·1  
(–47·9 to 
–15·2)*
–16·7 
(–22·7 to 
–10·6)*
Asthma
23 840·9 
(19 339·2 to 
28 695·4)
22 827·4 
(18 531·6 to 
27 887·8)
23 720·5 
(18 911·2 to 
29 790·8)
–0·5 
(–11·3 to 
9·8)
3·9 
(–0·8 to 
8·2)
514·7 
(419·4 to 
621·4)
375·2 
(305·9 to 
454·5)
329·2 
(263·1 to 
413·2)
–36·0 
(–44·1 to 
–28·2)*
–12·2 
(–16·9 to 
–7·7)*
Interstitial lung disease 
and pulmonary 
sarcoidosis
1285·5 
(924·8 to 
1966·3)
2052·5 
(1506·0 to 
2609·2)
2721·6 
(2075·3 to 
3177·4)
111·7 
(55·3 to 
165·5)*
32·6 
(18·7 to 
43·0)*
33·8 
(24·7 to 
50·2)
38·7 
(28·4 to 
48·6)
40·2  
(30·5 to 
46·9)
19·0 
(–11·4 to 
49·3)
3·9 
(–6·4 to 
11·7)
Other chronic respiratory 
diseases
1328·6 
(906·1 to 
1714·7)
1652·5 
(1286·3 to 
1932·2)
2075·2 
(1697·7 to 
2315·1)
56·2 
(27·5 to 
93·2)*
25·6 
(17·5 to 
34·0)*
26·6 
(18·3 to 
33·4)
26·2 
(20·3 to 
30·5)
28·5 
(23·3 to 
31·8)
7·4 
(–10·0 to 
30·2)
9·0 
(2·1 to 
16·4)*
Cirrhosis and other 
chronic liver diseases
28 184·1 
(26 769·7 to 
29 706·9)
36 122·1 
(34 848·4 to 
39 549·1)
38 856·7 
(36 890·5 to 
42 795·8)
37·9 
(28·7 to 
49·4)*
7·6 
(2·5 to 
13·7)*
659·0 
(627·6 to 
693·9)
603·3 
(582·6 to 
657·4)
531·1 
 (504·3 to 
584·5)
–19·4 
(–24·6 to 
–12·8)*
–12·0 
(–16·1 to 
–7·2)*
Due to hepatitis B
7875·2 
(7193·4 to 
8627·5)
10 373·1 
(9525·8 to 
11 593·2)
11 240·7 
(10 162·6 to 
13 138·6)
42·7 
(31·8 to 
58·9)*
8·4 
(2·5 to 
15·3)*
189·9 
(173·4 to 
208·5)
173·9 
(160·1 to 
195·5)
153·3 
(138·5 to 
178·9)
–19·3 
(–25·4 to 
–10·3)*
–11·8 
(–16·5 to 
–6·1)*
Due to hepatitis C
6333·5 
(5732·9 to 
7049·7)
8709·0 
(7906·3 to 
9751·8)
9769·1 
(8819·4 to 
10 985·0)
54·2 
(44·4 to 
66·7)*
12·2 
(6·8 to 
18·5)*
155·1  
(139·9 to 
172·8)
147·4 
(133·6 to 
164·2)
133·5 
(120·7 to 
150·0)
–13·9 
(–19·3 to 
–7·3)*
–9·4 
(–13·8 to 
–4·4)*
Due to alcohol use
6466·4 
(5920·0 to 
7057·2)
8878·9 
(8112·9 to 
9688·5)
9754·0 
(8873·6 to 
10 861·8)
50·8 
(42·0 to 
61·5)*
9·9 
(4·8 to 
15·9)*
161·5 
(148·2 to 
175·7)
151·3 
(138·5 to 
165·1)
133·5 
(121·6 to 
148·2)
–17·3 
(–22·0 to 
–11·6)*
–11·8 
(–15·7 to 
–6·9)*
Due to other causes
7509·0 
(6800·3 to 
8254·4)
8161·1 
(7451·7 to 
9036·0)
8092·8 
(7310·3 to 
9160·6)
7·8 
(–1·9 to 
20·4)
–0·8 
(–5·9 to 
5·0)
152·5 
(138·5 to 
167·9)
130·7 
(119·2 to 
144·8)
110·8 
(100·2 to 
125·3)
–27·4 
(–32·9 to 
–19·2)*
–15·3 
(–19·4 to 
–10·9)*
Digestive diseases
32 345·7 
(28 585·3 to 
34 769·7)
33 020·0 
(30 716·0 to 
35 440·1)
34 368·9 
(31 754·4 to 
37 405·9)
6·3 
(–0·5 to 
17·9)
4·1 
(0·4 to 
7·7)*
720·8 
(640·2 to 
770·7)
561·3 
(523·0 to 
601·8)
484·9 
(448·4 to 
526·8)
–32·7 
(–36·3 to 
–26·0)*
–13·6 
(–16·4 to 
–10·8)*
Peptic ulcer disease
10 011·0 
(8963·1 to 
10 836·7)
7708·0 
(7085·6 to 
8454·8)
7106·0 
(6459·4 to 
8011·1)
–29·0 
(–35·4 to 
–20·6)*
–7·8 
(–11·8 to 
–3·8)*
237·1 
(212·3 to 
257·4)
134·0 
(123·2 to 
146·5)
100·2 
(91·2 to 
112·5)
–57·8 
(–61·6 to 
–52·7)*
–25·2 
(–28·4 to 
–22·0)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1275
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Gastritis and duodenitis
1952·5 
(1571·5 to 
2395·4)
2235·1 
(1806·0 to 
2810·5)
2689·8 
(2104·0 to 
3454·3)
37·8 
(24·2 to 
50·6)*
20·4 
(13·5 to 
26·7)*
45·9 
(37·1 to 
56·0)
38·4 
(31·2 to 
48·1)
37·7 
(29·6 to 
48·3)
–17·8 
(–25·0 to 
–10·7)*
–1·7 
(–7·2 to 
3·2)
Appendicitis
2200·3 
(1726·6 to 
2565·2)
2412·3 
(2109·1 to 
2744·1)
2150·0 
(1928·1 to 
2484·8)
–2·3 
(–16·9 to 
19·1)
–10·9 
(–18·1 to 
–3·0)*
41·3 
(32·8 to 
47·4)
37·2 
(32·3 to 
42·2)
29·3 
(26·3 to 
33·9)
–29·0 
(–38·5 to 
–15·1)*
–21·1 
(–27·5 to 
–14·2)*
Paralytic ileus and 
intestinal obstruction
6853·7 
(5275·8 to 
7778·5)
7379·6 
(6085·8 to 
7981·1)
7626·5 
(6380·0 to 
8328·6)
11·3 
(–1·7 to 
32·7)
3·4 
(–2·8 to 
10·6)
131·2 
(101·5 to 
146·5)
120·6 
(99·3 to 
130·0)
108·0 
(90·5 to 
117·7)
–17·7 
(–25·7 to 
–3·7)*
–10·5 
(–15·4 to 
–5·0)*
Inguinal, femoral, and 
abdominal hernia
2405·0 
(1863·4 to 
3003·9)
2854·3 
 (2251·5 to 
3551·6)
3106·1 
(2401·1 to 
3932·1)
29·1 
(19·9 to 
39·6)*
8·8 
(5·5 to 
11·4)*
54·2 
(42·2 to 
67·3)
48·2 
(38·2 to 
59·9)
43·5 
(33·7 to 
55·0)
–19·7 
(–26·4 to 
–12·2)*
–9·7 
(–12·8 to 
–7·6)*
Inflammatory bowel 
disease
1217·7 
(916·1 to 
1735·5)
1606·7 
(1305·0 to 
2000·0)
1844·4 
(1541·5 to 
2195·5)
51·5 
(14·2 to 
81·3)*
14·8 
(2·7 to 
22·6)*
27·4 
(21·5 to 
36·3)
27·4 
(22·3 to 
33·5)
25·8 
(21·6 to 
30·7)
–6·0 
(–23·3 to 
7·3)
–5·9 
(–14·8 to 
0·3)
Vascular intestinal 
disorders
1012·2 
(904·2 to 
1107·2)
1457·8 
(1317·3 to 
1656·0)
1702·6 
(1568·9 to 
1943·4)
68·2 
(55·2 to 
86·2)*
16·8 
(10·4 to 
23·5)*
28·1 
(25·5 to 
30·5)
28·1 
(25·7 to 
31·8)
25·5 
(23·4 to 
29·0)
–9·3 
(–15·3 to 
0·2)
–9·4 
(–14·1 to 
–4·6)*
Gallbladder and biliary 
diseases
1665·1 
(1368·2 to 
1821·1)
1851·7 
(1729·6 to 
2093·8)
2098·0 
(1953·3 to 
2401·6)
26·0 
(14·4 to 
56·3)*
13·3 
(9·8 to 
17·6)*
42·8 
(35·5 to 
47·3)
33·9 
(31·8 to 
38·2)
30·5 
(28·4 to 
35·0)
–28·8 
(–36·1 to 
–12·3)*
–10·0 
(–12·8 to 
–6·6)*
Pancreatitis
2035·5 
(1723·4 to 
2341·3)
3046·0 
(2707·5 to 
3380·8)
3347·0 
(2910·4 to 
3722·1)
64·4 
(44·7 to 
82·4)*
9·9 
(2·9 to 
16·8)*
47·5 
(40·4 to 
54·7)
50·5 
(44·9 to 
56·2)
45·8 
(39·8 to 
50·9)
–3·6 
(–15·1 to 
6·6)
–9·4 
(–15·1 to 
–3·9)*
Other digestive diseases
2992·8 
(2482·9 to 
3546·7)
2468·6 
(2189·1 to 
2834·9)
2698·5 
(2428·7 to 
3008·7)
–9·8 
(–24·4 to 
4·2)
9·3 
(1·9 to 
17·8)*
65·2 
(56·4 to 
75·0)
43·0 
(38·7 to 
48·8)
38·6 
(34·8 to 
43·0)
–40·8 
(–49·1 to 
–33·3)*
–10·2 
(–15·5 to 
–4·2)*
Neurological disorders
64 973·1 
(50 343·0 to 
80 732·5)
87 251·9 
(67 830·9 to 
107 955·1)
103 580·0 
(81 171·2 to 
128 122·4)
59·4 
(55·2 to 
64·6)*
18·7 
(17·0 to 
20·7)*
1500·6 
(1192·1 to 
1832·8)
1491·2 
(1182·9 to 
1824·0)
1478·4 
(1171·9 to 
1813·0)
–1·5 
 (–3·3 to 
0·4)
–0·9 
(–2·1 to 
0·3)
Alzheimer’s disease and 
other dementias
13 024·5 
(11 052·7 to 
15 479·9)
20 912·2 
(17 919·7 to 
24 689·5)
28 764·1 
(24 510·8 to 
33 952·4)
120·8 
(115·3 to 
126·5)*
37·5 
(35·3 to 
39·7)*
460·9 
(394·5 to 
544·4)
469·6 
(403·2 to 
552·4)
470·6 
(401·2 to 
556·3)
2·1 
(0·1 to 
3·8)*
0·2 
(–1·1 to 
1·5)
Parkinson’s disease
1304·3 
(1024·7 to 
1606·9)
2385·3 
(1901·1 to 
2910·3)
3234·5 
(2563·6 to 
4012·8)
148·0 
(139·8 to 
155·8)*
35·6 
(32·9 to 
38·2)*
42·0 
(33·2 to 
51·9)
49·9 
(39·7 to 
61·0)
51·3 
(40·6 to 
63·4)
22·1 
(18·2 to 
25·9)*
2·7 
(1·0 to 
4·5)*
Epilepsy
12 420·8 
(10 285·4 to 
14 852·0)
13 435·2 
(11 142·0 to 
16 031·4)
13 492·2 
(11 014·7 to 
16 503·1)
8·6 
(–2·9 to 
23·7)
0·4 
(–7·0 to 
8·6)
226·5 
(187·9 to 
269·3)
201·6 
(166·8 to 
240·4)
182·6 
(148·9 to 
223·5)
–19·4 
(–27·6 to 
–9·0)*
–9·4 
(–16·1 to 
–2·2)*
Multiple sclerosis
694·0 
(586·0 to 
807·1)
974·2 
(827·1 to 
1123·9)
1151·5 
(968·6 to 
1345·8)
65·9 
(45·2 to 
74·8)*
18·2 
(12·8 to 
21·9)*
16·3 
(13·8 to 
18·9)
16·2 
(13·8 to 
18·6)
15·6 
(13·2 to 
18·3)
–4·2 
(–16·4 to 
0·8)
–3·2 
(–7·3 to 
–0·2)*
Motor neuron disease
582·3 
(527·8 to 
651·4)
774·9 
(745·5 to 
817·5)
926·1 
(881·6 to 
961·8)
59·0 
(44·5 to 
71·6)*
19·5 
(14·7 to 
22·4)*
13·4 
(12·5 to 
14·6)
13·7 
(13·2 to 
14·3)
13·2 
(12·5 to 
13·7)
–1·5 
(–9·3 to 
2·9)
–3·6 
(–7·3 to 
–1·3)*
Migraine
29 843·4 
(19 092·9 to 
41 793·9)
39 485·3 
(25 341·5 to 
55 187·3)
45 121·9 
(29 045·8 to 
62 826·9)
51·2 
(49·7 to 
52·8)*
14·3 
(13·7 to 
14·9)*
599·9 
(385·7 to 
839·1)
597·8 
(384·6 to 
833·2)
598·6 
(385·9 to 
833·3)
–0·2 
(–0·8 to 
0·4)
0·1 
(–0·2 to 
0·5)
Tension-type headache
4700·9 
(2968·1 to 
6989·3)
6236·2 
(3972·6 to 
9204·2)
7195·1 
(4614·6 to 
10 499·9)
53·1 
(47·5 to 
58·4)*
15·4 
(13·7 to 
17·0)*
96·2 
(61·1 to 
142·5)
95·5 
(61·2 to 
139·9)
95·9 
(61·5 to 
140·0)
–0·2 
(–2·5 to 
1·9)
0·4 
(–0·5 to 
1·4)
Other neurological 
disorders
2402·9 
(2004·0 to 
2829·7)
3048·7 
(2593·3 to 
3555·3)
3694·5 
(3114·1 to 
4353·4)
53·8 
(38·5 to 
67·8)*
21·2 
(14·0 to 
28·5)*
45·5 
38·7 to 
52·8)
46·9 
(40·2 to 
54·4)
50·6 
(42·7 to 
59·5)
11·2 
(2·1 to 
20·0)*
7·9 
(1·9 to 
14·2)*
Mental and substance use 
disorders
110 918·3 
(83 056·1 to 
141 228·0)
145 067·1 
(108 650·3 to 
183 887·6)
162 509·3 
(121 886·4 to 
206 517·4)
46·5 
(44·9 to 
48·7)*
12·0 
(11·2 to 
12·9)*
2240·8 
(1681·3 to 
2844·2)
2226·6 
(1669·0 to 
2821·8)
2172·7 
(1629·4 to 
2761·5)
–3·0 
(–4·1 to 
–1·8)*
–2·4 
(–3·2 to 
–1·7)*
(Table 1 continues on next page)
 Global Health Metrics
1276 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Schizophrenia
8447·6 
(6181·9 to 
10 521·3)
11 492·6 
(8420·0 to 
14 326·7)
13 414·3 
(9858·7 to 
16 714·0)
58·8 
(55·8 to 
62·0)*
16·7 
(15·5 to 
18·0)*
179·6 
(132·2 to 
222·3)
178·9 
(132·0 to 
222·3)
177·2 
(130·5 to 
220·3)
–1·3 
(–2·2 to 
–0·5)*
–0·9 
(–1·7 to 
–0·2)*
Alcohol use disorders
11 264·3 
(9057·6 to 
14 013·8)
15 561·7 
(12 607·6 to 
19 100·6)
16 244·7 
(13 003·1 to 
19 955·3)
44·2 
(37·4 to 
51·0)*
4·4 
(0·4 to 
8·6)*
237·3 
(192·3 to 
292·7)
240·9 
(196·4 to 
293·9)
214·4 
(172·0 to 
262·9)
–9·6 
(–14·3 to 
–5·5)*
–11·0 
(–14·6 to 
–7·5)*
Drug use disorders
14 247·5 
(11 250·4 to 
17 370·8)
18 009·0 
(14 444·2 to 
21 739·6)
20 394·2 
(16 204·4 to 
24 670·3)
43·1 
(36·5 to 
58·5)*
13·2 
(9·8 to 
16·9)*
278·6 
(221·2 to 
337·7)
270·5 
(217·3 to 
325·1)
268·4 
(213·5 to 
324·0)
–3·6 
(–8·1 to 
6·7)
–0·8 
(–3·8 to 
2·4)
Opioid use disorders
10 261·8 
(8052·7 to 
12 572·0)
12 817·5 
(10 018·1 to 
15 694·7)
14 788·8 
(11 380·5 to 
18 259·7)
44·1 
(37·5 to 
56·0)*
15·4 
(11·2 to 
19·5)*
202·0 
(159·3 to 
247·4)
193·1 
(151·2 to 
236·4)
194·3 
(149·8 to 
239·6)
–3·8 
(–8·3 to 
3·8)
0·7 
(–3·0 to 
4·2)
Cocaine use disorders
790·1 
(568·0 to 
1051·1)
1060·8 
(780·4 to 
1375·9)
1154·2 
(847·2 to 
1512·1)
46·1 
(38·4 to 
65·1)*
8·8 
(5·1 to 
12·2)*
15·7 
(11·3 to 
20·8)
16·1 
(11·8 to 
20·8)
15·3 
(11·2 to 
20·0)
–2·6 
(–7·8 to 
9·6)
–4·9 
(–8·3 to 
–1·7)*
Amphetamine use 
disorders
660·3 
(430·6 to 
985·6)
834·2 
(567·1 to 
1190·4)
881·7 
(599·5 to 
1243·1)
33·5 
(23·0 to 
54·2)*
5·7 
(1·8 to 
10·2)*
11·8 
(7·8 to 
17·3)
12·0 
(8·2 to 
17·0)
11·5 
(7·8 to 
16·2)
–1·9 
(–8·8 to 
13·2)
–3·7 
(–7·5 to 
0·3)
Cannabis use disorders
514·5 
(321·8 to 
757·2)
623·9 
(389·2 to 
905·4)
646·9 
(400·9 to 
945·5)
25·7 
(21·7 to 
29·8)*
3·7 
(1·2 to 
6·0)*
9·1 
(5·7 to 
13·3)
8·8 
(5·5 to 
12·9)
8·5 
(5·2 to 
12·4)
–6·9 
(–8·9 to 
–5·0)*
–4·2 
(–5·9 to 
–2·4)*
Other drug use 
disorders
2020·8 
(1550·8 to 
2453·2)
2672·5 
(2235·2 to 
3177·1)
2922·5 
(2425·1 to 
3504·3)
44·6 
(31·6 to 
89·2)*
9·3 
(3·8 to 
14·5)*
40·0 
(30·8 to 
48·3)
40·5 
(34·0 to 
47·8)
38·8 
(32·3 to 
46·4)
–3·0 
(–12·0 to 
26·0)
–4·3 
(–9·3 to 
0·2)
Depressive disorders
29 503·5 
(20 318·2 to 
40 109·0)
39 052·4 
(26 930·5 to 
52 535·2)
44 208·4 
(30 573·2 to 
59 878·5)
49·8 
(46·9 to 
53·1)*
13·2 
(12·2 to 
14·4)*
630·6 
(438·2 to 
852·5)
620·1 
(430·6 to 
831·7)
597·9 
(414·5 to 
806·2)
–5·2 
(–6·2 to 
–4·1)*
–3·6 
(–4·3 to 
–2·9)*
Major depressive 
disorder
23 423·5 
(16 150·4 to 
31 868·1)
30 670·3 
(21 102·1 to 
41 462·3)
34 104·6 
(23 469·5 to 
46 039·4)
45·6 
(42·4 to 
49·2)*
11·2 
(10·1 to 
12·3)*
495·7 
(341·2 to 
671·8)
484·6 
(334·7 to 
655·2)
461·1 
(317·9 to 
622·5)
–7·0 
(–8·1 to 
–5·8)*
–4·9 
(–5·6 to 
–4·1)*
Dysthymia
6080·0 
(4134·8 to 
8839·6)
8382·0 
(5676·3 to 
12 123·1)
10 103·8 
(6860·6 to 
14 611·5)
66·2 
(62·6 to 
69·8)*
20·5 
(18·3 to 
23·1)*
134·9 
(91·8 to 
195·5)
135·5 
(91·6 to 
196·3)
136·8 
(93·0 to 
197·6)
1·4 
(0·5 to 
2·3)*
1·0 
(–0·5 to 
2·7)
Bipolar disorder
5873·0 
(3645·7 to 
8618·8)
7795·1 
(4869·3 to 
11 432·4)
8954·0 
(5588·3 to 
13 186·4)
52·5 
(50·0 to 
55·0)*
14·9 
(13·8 to 
16·0)*
118·2 
(73·8 to 
173·0)
118·3 
(74·1 to 
173·1)
119·3 
(74·7 to 
175·1)
0·9 
(0·1 to 
1·8)*
0·8 
(0·2 to 
1·4)*
Anxiety disorders
17 893·2 
(12 472·9 to 
24 294·6)
23 364·5 
(16 285·6 to 
31 632·0)
26 417·4 
(18 440·4 to 
35 634·4)
47·6 
(45·4 to 
49·8)*
13·1 
(11·9 to 
14·3)*
357·0 
(249·8 to 
482·4)
356·6 
(248·7 to 
481·7)
354·2 
(247·1 to 
477·8)
–0·8 
(–1·8 to 
0·2)
–0·7 
(–1·7 to 
0·2)
Eating disorders
1400·4 
(920·5 to 
2016·6)
1861·9 
(1222·9 to 
2684·6)
2180·1 
(1420·8 to 
3122·9)
55·7 
(52·2 to 
59·3)*
17·1 
(15·2 to 
18·8)*
24·6 
(16·2 to 
35·3)
26·2 
(17·2 to 
37·7)
28·6 
(18·6 to 
40·8)
16·1 
(14·3 to 
17·7)*
8·9 
(7·6 to 
10·1)*
Anorexia nervosa
418·9 
(263·0 to 
626·4)
523·9 
(329·8 to 
776·8)
584·7 
(367·2 to 
859·0)
39·6 
(36·1 to 
43·4)*
11·6 
(9·2 to 
14·0)*
7·1 
(4·5 to 
10·6)
7·3 
(4·6 to 
10·8)
7·7 
(4·8 to 
11·3)
8·1 
(5·6 to 
10·5)*
5·4 
(3·2 to 
7·4)*
Bulimia nervosa
981·5 
(602·8 to 
1471·9)
1338·0 
(818·2 to 
1997·1)
1595·4 
(974·5 to 
2394·5)
62·5 
(58·5 to 
66·9)*
19·2 
(16·9 to 
21·1)*
17·5 
(10·6 to 
26·3)
18·9 
(11·5 to 
28·4)
20·9 
(12·7 to 
31·2)
19·4 
(17·5 to 
21·2)*
10·2 
(8·7 to 
11·7)*
Autistic spectrum 
disorders
6525·8 
(4418·6 to 
9180·8)
8104·7 
(5491·2 to 
11 393·0)
9025·7 
(6119·0 to 
12 681·1)
38·3 
(37·3 to 
39·4)*
11·4 
(10·8 to 
12·0)*
120·6 
(81·9 to 
169·6)
121·1 
(82·1 to 
170·2)
121·4 
(82·3 to 
170·6)
0·6 
(0·0 to 
1·2)*
0·3 
(–0·2 to 
0·8)
Autism
3371·4 
(2170·7 to 
4891·2)
4178·3 
(2693·8 to 
6041·1)
4649·0 
(2976·6 to 
6699·0)
37·9 
(36·3 to 
39·6)*
11·3 
(10·3 to 
12·3)*
62·8 
(40·4 to 
90·9)
62·6 
(40·3 to 
90·4)
62·5 
(40·0 to 
90·2)
–0·4 
(–1·3 to 
0·5)
–0·1 
(–0·9 to 
0·8)
Asperger syndrome 
and other autistic 
spectrum disorders
3154·3 
(2078·1 to 
4617·6)
3926·4 
(2574·5 to 
5735·4)
4376·7 
(2864·1 to 
6392·9)
38·8 
(37·5 to 
40·1)*
11·5 
(10·9 to 
12·1)*
57·8 
(38·0 to 
84·2)
58·5 
(38·3 to 
85·2)
58·9 
(38·5 to 
85·9)
1·8 
(1·2 to 
2·3)*
0·6 
(0·1 to 
1·1)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1277
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Attention-deficit 
hyperactivity disorder
599·7 
(359·0 to 
952·7)
711·9 
(426·0 to 
1134·5)
755·2 
(452·2 to 
1196·6)
25·9 
(23·5 to 
28·3)*
6·1 
(5·0 to 
7·1)*
10·2 
(6·1 to 
16·1)
10·1 
(6·0 to 
16·1)
10·1 
(6·0 to 
15·9)
–1·3 
(–3·0 to 
0·5)
–0·5 
(–1·4 to 
0·4)
Conduct disorder
5072·5 
(3154·4 to 
7682·5)
5820·5 
(3615·8 to 
8803·8)
5947·3 
(3701·9 to 
8998·5)
17·2 
(15·6 to 
18·7)*
2·2 
(0·9 to 
3·4)*
79·5 
(49·4 to 
120·5)
79·4 
(49·4 to 
120·6)
81·2 
(50·5 to 
122·9)
2·1 
(0·7 to 
3·4)*
2·3 
(1·1 to 
3·4)*
Idiopathic 
developmental 
intellectual disability
3629·4 
(1741·7 to 
6242·4)
4500·4 
(2160·1 to 
7650·1)
4610·9 
(2201·5 to 
7932·1)
27·1 
(21·7 to 
30·9)
2·5 
(–0·9 to 
4·6)
66·2 
(31·8 to 
113·6)
66·1 
(31·8 to 
112·4)
61·6 
(29·4 to 
105·9)
–7·0 
(–11·0 to 
–4·1)
–6·9 
(–10·0 to 
–4·9)
Other mental and 
substance use disorders
6461·6 
(4417·8 to 
9255·4)
8792·3 
(5989·8 to 
12 580·6)
10 357·1 
(7059·0 to 
14 807·2)
60·3 
(59·0 to 
61·9)*
17·8 
(17·2 to 
18·5)*
138·5 
(94·5 to 
197·7)
138·4 
(94·3 to 
197·8)
138·5 
(94·4 to 
197·7)
0·0 
(–0·5 to 
0·5)
0·1 
(–0·4 to 
0·5)
Diabetes, urogenital, 
blood, and endocrine 
diseases
81 744·6 
(71 204·2 to 
94 535·9)
112 751·7 
(98 101·9 to 
131 367·5)
133 747·8 
(115 976·8 to 
155 676·1)
63·6 
(59·4 to 
68·0)*
18·6 
(17·4 to 
20·0)*
1882·2 
(1642·5 to 
2163·3)
1942·7 
(1699·4 to 
2247·3)
1887·6 
(1641·9 to 
2192·9)
0·3 
(–1·8 to 
2·3)
–2·8 
(–3·9 to 
–1·7)*
Diabetes mellitus
27 475·9 
(23 282·7 to 
32 608·1)
45 989·7 
(38 695·1 to 
54 713·4)
57 233·7 
(47 967·9 to 
68 279·3)
108·3 
(104·2 to 
112·1)*
24·4 
(22·7 to 
26·2)*
708·6 
(604·0 to 
837·1)
827·9 
(700·5 to 
977·9)
814·2 
(686·6 to 
965·4)
14·9 
(12·6 to 
16·9)*
–1·6 
(–3·0 to 
–0·2)*
Acute 
glomerulonephritis
560·5 
(521·8 to 
610·3)
337·8 
(325·7 to 
355·6)
325·6 
(310·5 to 
343·1)
–41·9 
(–46·6 to 
–37·0)*
–3·6 
(–8·4 to 
1·5)
11·6 
(10·8 to 
12·5)
5·5 
(5·3 to 
5·8)
4·5 
(4·3 to 
4·8)
–60·9 
(–63·9 to 
–57·6)*
–17·4 
(–21·5 to 
–13·2)*
Chronic kidney disease
21 597·2 
(20 094·0 to 
23 354·9)
29 187·2 
(27 250·7 to 
31 463·0)
35 032·4 
(32 622·1 to 
37 954·3)
62·2 
(56·5 to 
68·0)*
20·0 
(17·4 to 
22·7)*
521·4 
(484·6 to 
565·3)
515·4 
(480·9 to 
555·7)
500·1 
(465·5 to 
541·4)
–4·1 
(–7·5 to 
–1·2)*
–3·0 
(–5·0 to 
–1·0)*
Due to diabetes 
mellitus
7860·2 
(7048·8 to 
8711·8)
11 731·4 
(10 615·3 to 
12 891·9)
14 660·6 
(13 206·6 to 
16 203·7)
86·5 
(77·5 to 
92·6)*
25·0 
(21·9 to 
27·6)*
202·9 
(182·1 to 
225·3)
212·1 
(191·8 to 
233·4)
209·2 
(188·8 to 
230·8)
3·1 
(–1·4 to 
6·1)
–1·4 
(–3·5 to 
0·5)
Due to hypertension
3481·1 
(3030·8 to 
3987·5)
5169·1 
(4520·8 to 
5845·6)
6606·7 
(5760·2 to 
7493·9)
89·8 
(80·4 to 
96·3)*
27·8 
(24·7 to 
30·6)*
97·3 
(84·5 to 
110·8)
99·2 
(87·0 to 
112·3)
98·2 
(85·5 to 
111·1)
0·9 
(–3·9 to 
4·0)
–1·0 
(–3·3 to 
0·9)
Due to 
glomerulonephritis
4609·2 
(4053·1 to 
5203·8)
5467·8 
(4843·2 to 
6157·1)
5932·9 
(5226·4 to 
6746·0)
28·7 
(22·3 to 
36·4)*
8·5 
(5·5 to 
11·8)*
96·8 
(85·7 to 
109·7)
89·0 
(79·1 to 
100·4)
82·2 
(72·8 to 
93·3)
–15·1 
(–18·2 to 
–11·3)*
–7·7 
(–9·8 to 
–5·4)*
Due to other causes
5646·7 
(5024·1 to 
6347·1)
6819·0 
(6061·0 to 
7661·1)
7832·1 
(6915·6 to 
8848·7)
38·7 
(31·1 to 
47·3)*
14·9 
(11·6 to 
18·4)*
124·5 
(110·6 to 
141·4)
115·1 
(102·5 to 
129·8)
110·6 
(97·5 to 
125·5)
–11·2 
(–14·7 to 
–7·3)*
–4·0 
(–6·2 to 
–1·4)*
Urinary diseases and 
male infertility
6451·7 
(5595·1 to 
7476·6)
8383·8 
(7248·0 to 
9800·2)
9965·5 
(8532·5 to 
11 725·6)
54·5 
(43·5 to 
61·3)*
18·9 
(14·9 to 
21·6)*
152·8 
(131·3 to 
179·4)
148·8 
(128·2 to 
175·0)
143·5 
(122·7 to 
169·2)
–6·1 
(–11·5 to 
–2·8)*
–3·6 
(–6·5 to 
–1·5)*
Interstitial nephritis 
and urinary tract 
infections
2443·8 
(2111·8 to 
2752·8)
3457·4 
(3137·6 to 
3688·9)
4269·2 
(4005·5 to 
4529·9)
74·7 
(54·0 to 
95·1)*
23·5 
(15·5 to 
30·3)*
55·6 
(48·9 to 
61·3)
60·7 
(55·4 to 
64·5)
61·9 
(58·2 to 
65·6)
11·3 
(–0·3 to 
22·0)
1·9 
(–4·2 to 
7·3)
Urolithiasis
496·9 
(352·4 to 
588·4)
566·9 
(491·0 to 
658·3)
622·5 
(523·5 to 
778·9)
25·3 
(7·1 to 
86·6)*
9·8 
(2·6 to 
25·5)*
11·9 
(8·6 to 
14·1)
9·7 
(8·4 to 
11·2)
8·8 
(7·4 to 
11·0)
–26·5 
(–36·9 to 
8·6)
–9·8 
(–15·6 to 
3·0)
Benign prostatic 
hyperplasia
1818·5 
(1164·2 to 
2622·2)
2625·2 
(1692·9 to 
3763·4)
3383·9 
(2178·0 to 
4835·1)
86·1 
(82·2 to 
90·8)*
28·9 
(27·6 to 
30·3)*
50·4 
(32·4 to 
72·4)
49·9 
(32·2 to 
72·1)
49·2 
(31·8 to 
71·0)
–2·3 
(–4·2 to 
–0·1)*
–1·3 
(–2·2 to 
–0·3)*
Male infertility
104·7 
(42·2 to 
207·7)
138·3 
(55·3 to 
275·1)
165·1 
(66·1 to 
327·1)
57·7 
(52·9 to 
62·6)*
19·3 
(15·7 to 
22·6)*
2·0 
(0·8 to 
3·9)
2·0 
(0·8 to 
4·0)
2·1 
(0·9 to 
4·3)
9·5 
(6·8 to 
12·1)*
7·9 
(4·9 to 
10·6)*
Other urinary diseases
1587·8 
(1231·6 to 
1910·8)
1596·0 
(1346·0 to 
1852·1)
1524·9 
(1353·8 to 
1722·1)
–4·0 
(–17·5 to 
18·2)
–4·5 
(–12·0 to 
7·6)
32·9 
(25·7 to 
39·6)
26·5 
(22·4 to 
30·7)
21·4 
(19·1 to 
24·2)
–34·7 
(–44·6 to 
–20·4)*
–19·0 
(–25·5 to 
–9·1)*
Gynaecological diseases
7068·6 
(4854·9 to 
10 047·8)
9365·7 
(6439·4 to 
13 315·0)
10 460·2 
(7184·1 to 
14 928·1)
48·0 
(45·8 to 
50·2)*
11·7 
(10·4 to 
13·1)*
145·2 
(99·4 to 
206·1)
140·4 
(96·1 to 
200·0)
136·8 
(94·0 to 
195·1)
–5·8 
(–7·2 to 
–4·3)*
–2·5 
(–3·5 to 
–1·4)*
(Table 1 continues on next page)
 Global Health Metrics
1278 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Uterine fibroids
882·6 
(552·9 to 
1378·7)
1237·0 
(765·6 to 
1961·3)
1462·5 
(897·4 to 
2340·2)
65·7 
(59·0 to 
71·2)*
18·2 
(16·3 to 
19·8)*
20·1 
(12·6 to 
31·5)
19·3 
(12·0 to 
30·7)
19·2 
(11·8 to 
30·7)
–4·6 
(–8·6 to 
–1·5)*
–0·6 
(–2·2 to 
0·7)
Polycystic ovarian 
syndrome
98·7 
(53·5 to 
166·2)
108·9 
(57·8 to 
188·7)
112·4 
(59·4 to 
198·0)
14·0 
(–4·7 to 
29·3)
3·3 
(–4·0 to 
8·3)
1·9 
(1·1 to 
3·3)
1·6 
(0·8 to 
2·7)
1·5 
(0·8 to 
2·6)
–24·7 
(–39·1 to 
–12·8)*
–7·3 
(–14·5 to 
–2·3)*
Female infertility
103·8 
(37·9 to 
234·0)
129·8 
(47·2 to 
288·4)
179·8 
(66·2 to 
399·0)
73·2 
(58·8 to 
91·0)*
38·5 
(29·4 to 
49·5)*
1·9 
(0·7 to 
4·3)
1·9 
(0·7 to 
4·2)
2·3 
(0·9 to 
5·2)
23·2 
(13·8 to 
35·5)*
25·3 
(17·7 to 
34·8)*
Endometriosis
233·8 
(156·3 to 
325·3)
310·3 
(209·4 to 
429·1)
334·9 
(226·3 to 
461·8)
43·2 
(36·4 to 
50·6)*
7·9 
(5·3 to 
10·9)*
4·4 
(3·0 to 
6·2)
4·5 
(3·0 to 
6·2)
4·3 
(2·9 to 
6·0)
–2·3 
(–5·9 to 
1·4)
–3·8 
(–6·1 to 
–1·4)*
Genital prolapse
586·6 
(297·3 to 
1051·1)
694·7 
(348·9 to 
1246·0)
792·6 
(394·6 to 
1424·8)
35·1 
(31·0 to 
38·0)*
14·1 
(12·5 to 
15·4)*
14·9 
(7·5 to 
26·6)
12·3 
(6·2 to 
22·0)
11·1 
(5·5 to 
19·8)
–25·8 
(–27·9 to 
–24·3)*
–10·0 
(–11·2 to 
–9·0)*
Premenstrual 
syndrome
2632·6 
(1628·3 to 
4036·0)
3470·7 
(2146·2 to 
5295·9)
3791·1 
(2344·6 to 
5812·9)
44·0 
(42·4 to 
45·5)*
9·2 
(7·7 to 
10·6)*
50·7 
(31·3 to 
77·2)
50·3 
(31·1 to 
76·7)
49·3 
(30·5 to 
75·6)
–2·7 
(–3·7 to 
–1·9)*
–2·0 
(–3·3 to 
–0·8)*
Other gynaecological 
diseases
2530·6 
(1722·7 to 
3505·2)
3414·2 
(2325·2 to 
4737·6)
3786·8 
(2576·9 to 
5232·9)
49·6 
(44·5 to 
55·1)*
10·9 
(8·6 to 
13·8)*
51·2 
(34·8 to 
71·6)
50·5 
(34·4 to 
70·1)
49·2 
(33·5 to 
67·9)
–4·1 
(–6·9 to 
–0·6)*
–2·7 
(–4·7 to 
–0·1)*
Haemoglobinopathies 
and haemolytic anaemias
12 160·7 
(9789·5 to 
14 856·4)
12 033·2 
(9847·5 to 
14 691·3)
12 321·6 
(9916·9 to 
15 372·2)
1·3 
(–8·3 to 
15·8)
2·4 
(–2·6 to 
8·3)
213·4 
(174·0 to 
258·9)
181·7 
(148·9 to 
221·9)
169·7 
(136·9 to 
211·4)
–20·5 
(–27·2 to 
–10·5)*
–6·6 
(–10·9 to 
–1·3)*
Thalassaemias
1432·0 
(961·6 to 
1835·3)
771·2 
(639·7 to 
918·5)
516·0 
(443·5 to 
633·5)
–64·0 
(–70·0 to 
–40·5)*
–33·1 
(–39·9 to 
–18·8)*
21·7 
(14·6 to 
27·8)
11·2 
(9·3 to 
13·4)
7·2 
(6·2 to 
8·9)
–66·6 
(–72·1 to 
–45·0)*
–35·5 
(–42·1 to 
–21·6)*
Thalassaemias trait
2703·8 
(1770·0 to 
3974·9)
2957·1 
(1959·0 to 
4290·6)
3280·4 
(2156·8 to 
4823·8)
21·3 
(17·3 to 
25·1)*
10·9 
(8·0 to 
13·9)*
49·7 
(32·6 to 
73·1)
44·9 
(29·7 to 
65·2)
44·6 
(29·3 to 
65·5)
–10·2 
(–12·1 to 
–8·4)*
–0·6 
(–3·1 to 
2·0)
Sickle cell disorders
4349·9 
(3163·6 to 
5209·6)
4224·4 
(3414·2 to 
4951·4)
4117·9 
(3587·8 to 
4842·0)
–5·3 
(–20·7 to 
19·9)
–2·5 
(–11·6 to 
10·5)
68·7 
(50·4 to 
81·8)
60·8 
(49·0 to 
71·5)
56·6 
(49·1 to 
66·5)
–17·7 
(–30·6 to 
3·8)
–6·9 
(–15·9 to 
6·1)
Sickle cell trait
1119·1 
(726·0 to 
1651·0)
1331·4 
(871·9 to 
1959·4)
1555·0 
(1014·1 to 
2282·9)
39·0 
(36·2 to 
41·7)*
16·8 
(14·8 to 
18·8)*
19·5 
(12·8 to 
28·8)
19·7 
(12·9 to 
28·9)
21·1 
(13·8 to 
31·0)
8·1 
(6·2 to 
9·7)*
7·2 
(5·4 to 
9·1)*
G6PD deficiency
577·8 
(488·8 to 
691·1)
702·7 
(606·1 to 
834·8)
737·8 
(637·7 to 
875·0)
27·7 
(18·3 to 
42·4)*
5·0 
(1·2 to 
10·1)*
10·9 
(9·2 to 
13·1)
10·7 
(9·3 to 
12·7)
9·9 
(8·6 to 
11·8)
–8·8 
(–14·7 to 
1·2)
–7·3 
(–10·7 to 
–2·8)*
G6PD trait
0·4 
(0·3 to 
0·6)
0·5 
(0·3 to 
0·7)
0·6 
(0·4 to 
0·8)
37·0 
(30·4 to 
43·2)*
17·6 
(14·9 to 
20·7)*
··
··
··
–3·0 
(–6·5 to 
0·1)
4·9 
(2·6 to 
7·5)*
Other 
haemoglobinopathies 
and haemolytic 
anaemias
1977·7 
(1591·8 to 
2467·5)
2046·0 
(1610·7 to 
2612·6)
2113·9 
(1640·0 to 
2730·4)
6·9 
(0·9 to 
13·2)*
3·3 
(0·6 to 
5·8)*
42·9 
(35·4 to 
52·5)
34·4 
(27·5 to 
43·3)
30·2 
(23·6 to 
38·9)
–29·4 
(–34·6 to 
–23·9)*
–12·1 
(–15·2 to 
–9·4)*
Endocrine, metabolic, 
blood, and immune 
disorders
6430·0 
(5399·9 to 
7454·1)
7454·3 
(6326·0 to 
8750·0)
8408·8 
(7025·4 to 
9979·2)
30·8 
(20·9 to 
40·9)*
12·8 
(9·0 to 
16·5)*
129·3 
(108·6 to 
151·1)
123·0 
(104·1 to 
144·5)
118·7 
(99·1 to 
140·9)
–8·2 
(–13·4 to 
–3·2)*
–3·5 
(–6·4 to 
–0·8)*
Musculoskeletal disorders
86 655·4 
(63 137·9 to 
112 703·8)
117 031·2 
(85 442·0 to 
152 359·0)
140 030·6 
(102 331·5 to 
181 687·7)
61·6 
(59·1 to 
63·9)*
19·6 
(18·5 to 
20·8)*
2014·2 
(1474·2 to 
2609·4)
1944·7 
(1422·3 to 
2518·0)
1918·7 
(1404·4 to 
2493·3)
–4·7 
(–5·7 to 
–3·9)*
–1·3 
(–2·0 to 
–0·6)*
Rheumatoid arthritis
3329·7 
(2458·2 to 
4257·7)
4443·0 
(3238·4 to 
5693·1)
5563·4 
(3985·9 to 
7171·2)
67·1 
(60·8 to 
72·7)*
25·2 
(22·4 to 
27·6)*
82·8 
(61·6 to 
104·8)
77·7 
(56·9 to 
99·3)
78·0 
(55·8 to 
100·1)
–5·7 
(–9·4 to 
–2·9)*
0·4 
(–1·8 to 
2·2)
Osteoarthritis
7947·9 
(5593·8 to 
10 856·2)
12 385·2 
(8735·1 to 
16 806·2)
16 282·9 
(11 486·0 to 
22 047·2)
104·9 
(102·9 to 
107·2)*
31·5 
(30·8 to 
32·2)*
213·4 
(150·2 to 
291·8)
226·6 
(159·7 to 
308·0)
232·1 
(163·7 to 
313·9)
8·8 
(7·6 to 
10·2)*
2·4 
(1·9 to 
3·0)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1279
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Low back and neck pain
55 941·4 
(39 562·5 to 
73 187·3)
72 599·3 
(51 532·0 to 
94 807·4)
86 584·5 
(61 335·4 to 
113 628·5)
54·8 
(51·8 to 
57·4)*
19·3 
(17·7 to 
20·7)*
1294·3 
(914·6 to 
1702·0)
1198·9 
(855·0 to 
1573·7)
1182·7 
(837·4 to 
1550·6)
–8·6 
(–9·6 to 
–7·7)*
–1·4 
(–2·4 to 
–0·5)*
Low back pain
39 129·9 
(27 512·7 to 
51 797·6)
48 853·4 
(34 564·0 to 
64 073·6)
57 648·2 
(40 820·5 to 
75 877·0)
47·3 
(44·4 to 
50·1)*
18·0 
(16·0 to 
20·1)*
897·3 
(637·6 to 
1178·5)
805·3 
(574·2 to 
1053·7)
788·9 
(558·7 to 
1034·6)
–12·1 
(–12·9 to 
–11·3)*
–2·0 
(–3·6 to 
–0·9)*
Neck pain
16 811·5 
(11 404·8 to 
23 792·2)
23 745·9 
(16 214·4 to 
33 438·2)
28 936·3 
(19 578·5 to 
40 543·1)
72·1 
(68·5 to 
76·2)*
21·9 
(19·9 to 
24·0)*
397·0 
(268·6 to 
556·8)
393·6 
(269·1 to 
549·8)
393·8 
(267·8 to 
550·2)
–0·8 
(–2·2 to 
0·7)
0·1 
(–1·3 to 
1·4)
Gout
596·8 
(413·3 to 
810·6)
848·9 
(589·9 to 
1155·4)
1071·2 
(742·4 to 
1455·0)
79·5 
(76·2 to 
82·9)*
26·2 
(24·3 to 
27·9)*
15·4 
(10·6 to 
21·1)
15·2 
(10·4 to 
20·6)
15·2 
(10·4 to 
20·6)
–1·8 
(–3·3 to 
–0·2)*
–0·1 
(–1·3 to 
1·1)
Other musculoskeletal 
disorders
18 839·6 
(13 162·2 to 
26 102·7)
26 754·8 
(18 664·4 to 
36 839·1)
30 528·6 
(21 196·7 to 
42 458·6)
62·0 
(57·4 to 
67·0)*
14·1 
(11·4 to 
16·8)*
408·3 
(285·4 to 
564·2)
426·3 
(298·3 to 
586·2)
410·6 
(285·6 to 
568·6)
0·6 
(–1·3 to 
2·1)
–3·7 
(–5·7 to 
–1·8)*
Other non-communicable 
diseases
164 624·2 
(127 834·6 to 
209 136·6)
183 247·3 
(141 607·2 to 
236 700·6)
196 036·1 
(148 295·9 to 
258 150·6)
19·1 
(6·3 to 
31·0)*
7·0 
(2·4 to 
10·8)*
3107·0 
(2367·7 to 
4005·6)
2912·8 
(2241·2 to 
3781·4)
2758·6 
(2096·2 to 
3616·8)
–11·2 
(–17·7 to 
–5·3)*
–5·3 
(–8·4 to 
–2·6)*
Congenital birth defects
68 393·0 
(53 592·7 to 
84 283·8)
58 286·5 
(48 759·3 to 
66 905·7)
50 429·8 
(44 114·0 to 
56 200·2)
–26·3 
(–38·1 to 
–8·0)*
–13·5 
(–20·8 to 
–5·2)*
1042·0 
(821·5 to 
1280·7)
853·9 
(714·0 to 
980·0)
716·0 
(626·4 to 
798·7)
–31·3 
(–42·1 to 
–15·1)*
–16·1 
(–23·1 to 
–8·3)*
Neural tube defects
10 315·0 
(7239·9 to 
14 462·5)
6150·2 
(4476·4 to 
8763·9)
5130·9 
(3867·1 to 
7016·1)
–50·3 
(–58·8 to 
–39·9)*
–16·6 
(–27·1 to 
–5·4)*
156·9 
(111·4 to 
218·6)
90·3 
(65·8 to 
128·5)
72·6 
(54·5 to 
99·5)
–53·8 
(–61·3 to 
–44·5)*
–19·6 
(–29·7 to 
–9·2)*
Congenital heart 
anomalies
27 581·3 
(21 339·9 to 
34 673·0)
22 936·6 
(19 833·8 to 
26 150·9)
18 563·8 
(16 539·0 to 
21 464·8)
–32·7 
(–44·5 to 
–7·0)*
–19·1 
(–26·5 to 
–6·9)*
413·5 
(320·8 to 
519·5)
334·6 
(289·1 to 
381·8)
264·7 
(235·7 to 
305·9)
–36·0 
(–47·0 to 
–11·7)*
–20·9 
(–28·1 to 
–9·0)*
Orofacial clefts
480·8 
(242·6 to 
688·3)
320·2 
(200·3 to 
468·4)
238·7 
(148·0 to 
369·6)
–50·4 
(–67·5 to 
–18·4)*
–25·5 
(–41·3 to 
–8·5)*
7·2 
(3·7 to 
10·2)
4·7 
(2·9 to 
6·8)
3·4 
(2·1 to 
5·3)
–52·4 
(–68·8 to 
–22·9)*
–27·0 
(–42·6 to 
–10·0)*
Down’s syndrome
1325·4 
(767·0 to 
3069·7)
1240·1 
(945·4 to 
2039·8)
1166·0 
(1005·7 to 
1482·8)
–12·0 
(–54·8 to 
41·0)
–6·0 
(–30·4 to 
12·8)
20·7 
(12·4 to 
46·5)
18·3 
(14·0 to 
30·1)
16·3 
(14·0 to 
20·7)
–21·4 
(–58·2 to 
22·5)
–11·2 
(–33·7 to 
6·2)
Turner syndrome
37·8 
(18·1 to 
60·9)
44·2 
(21·1 to 
71·5)
47·3 
(22·1 to 
76·5)
25·2 
(20·6 to 
30·2)*
6·9 
(3·2 to 
10·4)*
0·7 
(0·3 to 
1·1)
0·6 
(0·3 to 
1·0)
0·6 
(0·3 to 
1·0)
–3·4 
(–6·7 to 
–0·1)*
–1·0 
(–4·3 to 
2·1)
Klinefelter syndrome
13·0 
(6·3 to 
24·4)
15·7 
(7·6 to 
29·6)
17·1 
(8·2 to 
32·3)
32·1 
(28·5 to 
35·8)*
9·0 
(6·2 to 
11·7)*
0·2 
(0·1 to 
0·4)
0·2 
(0·1 to 
0·4)
0·2 
(0·1 to 
0·4)
–0·3 
(–2·6 to 
2·3)
–0·1 
(–2·5 to 
2·5)
Other chromosomal 
abnormalities
1668·6 
(1053·4 to 
3061·2)
1851·6 
(1371·3 to 
2805·1)
1952·2 
(1542·5 to 
2587·9)
17·0 
(–18·1 to 
54·2)
5·4 
(–10·1 to 
18·4)
24·9 
(15·8 to 
45·4)
26·8 
(19·9 to 
40·8)
27·9 
(22·0 to 
37·1)
12·2 
(–20·7 to 
47·3)
4·0 
(–11·4 to 
16·7)
Congenital 
musculoskeletal and 
limb anomalies
2120·7 
(1465·8 to 
3497·7)
2234·9 
(1621·0 to 
3167·4)
2258·4 
(1661·2 to 
2988·8)
6·5 
(–21·7 to 
26·8)
1·1 
(–12·2 to 
9·4)
36·6 
(25·7 to 
57·3)
33·6 
(24·4 to 
47·1)
31·2 
(23·0 to 
41·5)
–14·6 
(–32·7 to 
–2·5)*
–7·0 
(–17·7 to 
–0·0)*
Urogenital congenital 
anomalies
1277·1 
(845·2 to 
1639·7)
1202·0 
(877·2 to 
1462·4)
1085·9 
(858·1 to 
1305·3)
–15·0 
(–35·6 to 
10·8)
–9·7 
(–19·8 to 
3·1)
19·4 
(12·9 to 
24·9)
17·6 
(12·8 to 
21·4)
15·4 
(12·2 to 
18·6)
–20·4 
(–39·5 to 
2·8)
–12·1 
(–21·9 to 
0·3)
Digestive congenital 
anomalies
4666·6 
(3171·1 to 
8658·0)
3973·4 
(3024·5 to 
6520·3)
3343·0 
(2674·6 to 
4964·7)
–28·4 
(–49·5 to 
–3·2)*
–15·9 
(–27·9 to 
–1·6)*
69·9 
(47·8 to 
128·5)
58·2 
(44·3 to 
95·3)
48·0 
(38·3 to 
71·5)
–31·3 
(–51·3 to 
–8·1)*
–17·5 
(–29·3 to 
–3·8)*
Other congenital birth 
defects
18 906·7 
(10 942·1 to 
30 995·8)
18 317·5 
(12 204·8 to 
26 209·6)
16 626·6 
(12 154·3 to 
21 604·2)
–12·1 
(–33·0 to 
18·4)
–9·2 
(–20·5 to 
3·7)
291·9 
(171·4 to 
473·1)
268·9 
(179·1 to 
384·4)
235·6 
(172·4 to 
307·3)
–19·3 
(–37·5 to 
5·5)
–12·4 
(–22·8 to 
–0·2)*
Skin and subcutaneous 
diseases
41 366·2 
(28 152·7 to 
59 346·6)
51 550·5 
(35 306·4 to 
73 530·7)
57 394·0 
(39 334·2 to 
81 653·4)
38·8 
(37·0 to 
41·0)*
11·3 
(10·6 to 
12·4)*
756·7 
(518·9 to 
1081·9)
770·3 
(529·3 to 
1097·1)
781·3 
(535·8 to 
1110·4)
3·2 
(2·5 to 
4·4)*
1·4 
(0·8 to 
2·2)*
(Table 1 continues on next page)
 Global Health Metrics
1280 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Dermatitis
8427·2 
(5021·7 to 
13 797·8)
10 043·3 
(6010·8 to 
16 327·0)
11 210·2 
(6714·5 to 
18 218·1)
33·0 
(31·2 to 
35·0)*
11·6 
(10·8 to 
12·4)*
151·8 
(91·0 to 
246·4)
151·3 
(90·6 to 
245·3)
153·0 
(91·6 to 
248·4)
0·7 
(–0·3 to 
1·8)
1·1 
(0·2 to 
1·8)*
Psoriasis
3321·0 
(2384·1 to 
4347·4)
4638·9 
(3323·7 to 
6084·4)
5643·4 
(4039·7 to 
7377·2)
69·9 
(68·4 to 
71·5)*
21·7 
(20·8 to 
22·6)*
69·7 
(50·0 to 
91·2)
73·5 
(52·6 to 
96·1)
76·6 
(54·9 to 
100·0)
9·8 
(9·1 to 
10·6)*
4·2 
(3·5 to 
5·0)*
Cellulitis
254·1 
(179·0 to 
320·6)
451·3 
(288·9 to 
558·2)
607·6 
(398·4 to 
739·6)
139·1 
(103·8 to 
168·2)*
34·6 
(25·1 to 
48·9)*
5·5 
(3·9 to 
6·9)
7·6 
(4·8 to 
9·4)
8·6 
(5·6 to 
10·4)
56·3 
(32·3 to 
74·2)*
13·1 
(5·5 to 
24·8)*
Pyoderma
1094·9 
(615·2 to 
1411·5)
1577·2 
(930·0 to 
1948·5)
1944·8 
(1249·8 to 
2603·1)
77·6 
(42·6 to 
123·0)*
23·3 
(7·9 to 
40·5)*
22·1 
(12·9 to 
27·9)
26·0 
(15·4 to 
32·2)
27·7 
(17·8 to 
37·0)
25·1 
(3·6 to 
51·2)*
6·5 
(–6·4 to 
20·8)
Scabies
3332·5 
(1844·4 to 
5364·2)
3670·6 
(2034·7 to 
5849·4)
3787·8 
(2103·6 to 
6029·0)
13·7 
(10·8 to 
16·7)*
3·2 
(1·8 to 
4·6)*
58·6 
(32·4 to 
93·0)
53·9 
(29·8 to 
85·6)
51·0 
(28·3 to 
81·0)
–13·0 
(–13·9 to 
–12·2)*
–5·4 
(–6·2 to 
–4·8)*
Fungal skin diseases
2267·4 
(900·2 to 
4720·9)
2973·4 
(1184·9 to 
6172·3)
3508·8 
(1403·0 to 
7271·0)
54·8 
(51·8 to 
57·7)*
18·0 
(17·0 to 
19·1)*
46·1 
(18·3 to 
95·7)
47·7 
(18·9 to 
98·8)
48·9 
(19·5 to 
101·4)
6·0 
(5·3 to 
6·8)*
2·5 
(2·2 to 
2·9)*
Viral skin diseases
4543·4 
(2823·8 to 
6780·1)
5425·8 
(3369·5 to 
8082·0)
5915·2 
(3674·3 to 
8828·1)
30·2 
(29·2 to 
31·2)*
9·0 
(8·6 to 
9·5)*
80·2 
(49·9 to 
119·5)
80·0 
(49·8 to 
119·1)
79·9 
(49·6 to 
119·3)
–0·4 
(–0·8 to 
0·0)
–0·1 
(–0·5 to 
0·2)
Acne vulgaris
12 086·8 
(8150·7 to 
17 552·7)
15 067·6 
(10 169·9 to 
21 752·0)
15 836·0 
(10 643·5 to 
22 842·6)
31·0 
(29·7 to 
32·4)*
5·1 
(4·3 to 
5·8)*
202·3 
(136·5 to 
292·9)
207·8 
(140·1 to 
300·1)
212·1 
(143·0 to 
306·4)
4·9 
(4·2 to 
5·6)*
2·1 
(1·5 to 
2·6)*
Alopecia areata
350·9 
(224·8 to 
530·5)
447·0 
(286·2 to 
675·8)
504·2 
(322·7 to 
760·0)
43·7 
(42·1 to 
45·3)*
12·8 
(11·8 to 
13·9)*
6·9 
(4·4 to 
10·4)
6·8 
(4·3 to 
10·2)
6·7 
(4·3 to 
10·1)
–3·5 
(–4·4 to 
–2·6)*
–1·3 
(–2·2 to 
–0·5)*
Pruritus
452·1 
(211·1 to 
825·5)
599·8 
(278·6 to 
1087·3)
709·1 
(329·7 to 
1298·7)
56·8 
(52·5 to 
61·0)*
18·2 
(16·7 to 
19·8)*
9·4 
(4·4 to 
17·2)
9·6 
(4·5 to 
17·5)
9·7 
(4·5 to 
17·8)
2·9 
(2·4 to 
3·5)*
1·3 
(0·8 to 
1·8)*
Urticaria
3155·2 
(2020·3 to 
4556·7)
3684·4 
(2348·7 to 
5265·8)
4029·9 
(2575·9 to 
5745·3)
27·7 
(24·9 to 
31·0)*
9·4 
(8·3 to 
10·5)*
55·1 
(35·3 to 
78·7)
55·0 
(35·1 to 
78·7)
54·9 
(35·1 to 
78·6)
–0·5 
(–1·1 to 
0·1)
–0·3 
(–0·8 to 
0·3)
Decubitus ulcer
377·1 
(291·5 to 
475·3)
553·3 
(411·4 to 
680·3)
670·4 
(513·0 to 
836·1)
77·8 
(65·5 to 
86·8)*
21·2 
(17·1 to 
27·4)*
10·7 
(8·2 to 
13·6)
10·8 
(8·0 to 
13·3)
10·2 
(7·8 to 
12·6)
–5·1 
(–11·6 to 
0·4)
–5·7 
(–9·0 to 
–0·4)*
Other skin and 
subcutaneous diseases
1703·5 
(851·6 to 
3091·8)
2417·9 
(1203·9 to 
4377·1)
3026·6 
(1513·0 to 
5474·6)
77·7 
(76·2 to 
79·3)*
25·2 
(24·5 to 
25·9)*
38·1 
(19·1 to 
69·0)
40·4 
(20·2 to 
72·9)
42·2 
(21·1 to 
76·3)
10·8 
(10·1 to 
11·7)*
4·5 
(4·1 to 
5·1)*
Sense organ diseases
39 443·2 
(27 342·1 to 
54 552·7)
54 826·6 
(38 158·5 to 
76 040·8)
66 701·9 
(46 534·4 to 
92 391·9)
69·1 
(67·3 to 
71·0)*
21·7 
(20·7 to 
22·5)*
977·4 
(686·1 to 
1356·7)
977·9 
(685·8 to 
1355·9)
959·3 
(670·2 to 
1331·0)
–1·9 
(–2·5 to 
–1·2)*
–1·9 
(–2·6 to 
–1·3)*
Glaucoma
211·5 
(142·7 to 
292·9)
339·7 
(230·3 to 
471·3)
461·1 
(311·4 to 
642·1)
118·0 
(114·5 to 
121·8)*
35·7 
(33·7 to 
38·0)*
6·3 
(4·3 to 
8·7)
6·9 
(4·7 to 
9·5)
7·0 
(4·8 to 
9·8)
12·1 
(10·4 to 
14·0)*
2·1 
(0·8 to 
3·6)*
Cataract
2698·3 
(1924·0 to 
3682·2)
4418·1 
(3157·8 to 
5992·5)
5789·0 
(4134·6 to 
7915·3)
114·5 
(111·4 to 
117·9)*
31·0 
(29·4 to 
32·6)*
80·1 
(57·2 to 
108·9)
88·3 
(63·4 to 
119·6)
88·3 
(63·3 to 
120·5)
10·3 
(9·0 to 
11·7)*
0·0 
(–1·1 to 
1·1)
Macular degeneration
174·5 
(118·9 to 
238·7)
297·1 
(202·1 to 
406·9)
408·6 
(277·9 to 
555·6)
134·1 
(129·3 to 
139·0)*
37·5 
(34·7 to 
40·4)*
5·3 
(3·6 to 
7·3)
6·1 
(4·2 to 
8·4)
6·3 
(4·3 to 
8·6)
17·8 
(15·3 to 
20·4)*
2·7 
(0·7 to 
4·7)*
Refraction and 
accommodation 
disorders
10 172·5 
(6357·4 to 
15 852·4)
13 035·5 
(8163·5 to 
20 302·0)
14 972·5 
(9340·6 to 
23 361·5)
47·2 
(45·2 to 
49·0)*
14·9 
(13·7 to 
15·9)*
230·6 
(144·4 to 
359·2)
220·0 
(137·9 to 
342·1)
209·1 
(130·4 to 
326·0)
–9·3 
(–10·0 to 
–8·7)*
–5·0 
(–5·8 to 
–4·3)*
Age-related and other 
hearing loss
21 193·7 
(14 943·8 to 
29 581·7)
29 673·0 
(20  837·2 to 
41 494·7)
36 287·5 
(25 341·8 to 
50 893·6)
71·2 
(67·0 to 
75·3)*
22·3 
(20·4 to 
24·0)*
534·7 
(379·0 to 
745·0)
533·4 
(375·3 to 
743·4)
524·3 
(368·0 to 
734·0)
–1·9 
(–3·5 to 
–0·7)*
–1·7 
(–2·9 to 
–0·6)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1281
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Other vision loss
1205·2 
(853·2 to 
1628·8)
1776·9 
(1256·9 to 
2396·0)
2241·2 
(1578·3 to 
3016·4)
86·0 
(80·7 to 
91·0)*
26·1 
(23·9 to 
28·1)*
30·1 
(21·3 to 
40·6)
31·8 
(22·4 to 
42·9)
32·0 
(22·5 to 
43·1)
6·3 
(4·6 to 
8·0)*
0·7 
(–0·8 to 
2·0)
Other sense organ 
diseases
3787·5 
(2395·1 to 
5704·0)
5286·3 
(3336·8 to 
7935·4)
6542·0 
(4132·0 to 
9828·4)
72·7 
(71·6 to 
73·9)*
23·8 
(23·1 to 
24·4)*
90·3 
(57·2 to 
136·3)
91·4 
(57·9 to 
137·9)
92·3 
(58·4 to 
139·0)
2·1 
(1·7 to 
2·5)*
0·9 
(0·6 to 
1·3)*
Oral disorders
11 294·7 
(6848·2 to 
17 556·0)
15 552·8 
(9435·9 to 
24 158·8)
19 006·2 
(11 586·8 to 
29 629·5)
68·3 
(65·8 to 
70·6)*
22·2 
(21·2 to 
23·3)*
270·1 
(165·4 to 
420·1)
266·3 
(162·9 to 
413·0)
265·7 
(162·8 to 
413·4)
–1·6 
(–2·3 to 
–0·9)*
–0·2 
(–0·7 to 
0·2)
Caries of deciduous 
teeth
120·6 
(53·2 to 
233·0)
119·1 
(52·5 to 
231·1)
127·2 
(55·9 to 
249·1)
5·5 
(2·8 to 
7·3)*
6·8 
(4·5 to 
8·5)*
1·8 
(0·8 to 
3·5)
1·8 
(0·8 to 
3·4)
1·8 
(0·8 to 
3·4)
–3·7 
(–5·9 to 
–2·1)*
0·2 
(–1·9 to 
1·8)
Caries of permanent 
teeth
1295·7 
(581·5 to 
2521·8)
1571·3 
(699·0 to 
3047·3)
1707·6 
(760·1 to 
3324·9)
31·8 
(29·7 to 
33·9)*
8·7 
(8·0 to 
9·4)*
25·7 
(11·4 to 
50·0)
24·0 
(10·7 to 
46·5)
23·0 
(10·2 to 
44·6)
–10·6 
(–11·9 to 
–9·3)*
–4·2 
(–4·8 to 
–3·6)*
Periodontal diseases
2676·0 
(1065·8 to 
5539·9)
3893·0 
(1550·5 to 
8078·4)
4898·0 
(1946·8 to 
10 208·7)
83·0 
(80·9 to 
84·8)*
25·8 
(24·7 to 
26·8)*
64·2 
(25·6 to 
134·6)
65·1 
(25·9 to 
136·6)
66·6 
(26·6 to 
139·4)
3·8 
(3·0 to 
4·4)*
2·3 
(1·8 to 
2·9)*
Edentulism and severe 
tooth loss
4603·5 
(3028·6 to 
6528·4)
6553·4 
(4335·5 to 
9234·5)
8338·4 
(5467·4 to 
11 760·4)
81·1 
(79·7 to 
82·5)*
27·2 
(26·0 to 
28·4)*
125·7 
(82·1 to 
177·4)
122·8 
(80·3 to 
172·5)
121·7 
(79·6 to 
171·1)
–3·2 
(–3·6 to 
–2·8)*
–0·9 
(–1·6 to 
–0·3)*
 Other oral disorders
2598·9 
(1602·8 to 
3894·8)
3416·0 
(2109·2 to 
5128·9)
3935·0 
(2427·2 to 
5907·9)
51·4 
(50·0 to 
52·8)
15·2 
(14·6 to 
15·8)
52·7 
(32·6 to 
79·0)
52·7 
(32·5 to 
79·2)
52·7 
(32·5 to 
79·2)
–0·0 
(–0·4 to 
0·3)
0·0 
(–0·3 to 
0·3)
Sudden infant death 
syndrome
4127·1 
(3107·6 to 
6179·4)
3031·0 
(2487·9 to 
3993·4)
2504·2 
(2015·2 to 
3003·1)
–39·3 
(–57·8 to 
–20·1)*
–17·4 
(–33·2 to 
–1·1)*
60·8 
(45·8 to 
91·0)
44·4 
(36·4 to 
58·4)
36·4 
(29·3 to 
43·6)
–40·1 
(–58·4 to 
–21·2)*
–18·0 
(–33·7 to 
–1·9)*
Injuries
259 714·5 
(242 647·1 to 
276 817·9)
259 792·1 
(242 234·6 to 
280 976·8)
255 434·3 
(236 089·5 to 
280 689·1)
–1·6 
(–6·2 to 
3·8)
–1·7 
(–4·7 to 
1·4)
4875·4 
(4544·8 to 
5239·0)
3976·8 
(3692·0 to 
4319·2)
3457·3 
(3192·1 to 
3803·2)
–29·1 
(–32·0 to 
–25·9)*
–13·1 
(–15·6 to 
–10·6)*
Transport injuries
70 430·3 
(67 012·4 to 
74 545·4)
80 802·1 
(76 835·3 to 
85 315·6)
78 051·8 
(73 391·8 to 
83 700·8)
10·8 
(6·4 to 
15·9)*
–3·4 
(–5·8 to 
–0·9)*
1320·1 
(1253·5 to 
1399·1)
1218·5 
(1155·7 to 
1292·0)
1044·0 
(980·2 to 
1120·6)
–20·9 
(–23·9 to 
–17·8)*
–14·3 
(–16·4 to 
–12·3)*
Road injuries
64 788·4 
(61 744·3 to 
68 397·9)
74 299·1 
(71 021·9 to 
78 088·0)
71 395·0 
(67 520·8 to 
76 128·0)
10·2 
(5·5 to 
15·2)*
–3·9 
(–6·3 to 
–1·6)*
1210·6 
(1151·7 to 
1279·9)
1119·1 
(1066·5 to 
1179·6)
954·5 
(901·8 to 
1019·0)
–21·1 
(–24·1 to 
–18·0)*
–14·7 
(–16·8 to 
–12·8)*
Pedestrian road 
injuries
24 717·6 
(22 795·5 to 
28 090·8)
26 131·7 
(24 588·0 to 
28 158·5)
24 001·5 
(22 518·2 to 
25 750·8)
–2·9 
(–15·1 to 
4·8)
–8·2 
(–13·1 to 
–5·0)*
459·3 
(424·8 to 
520·6)
398·7 
(375·0 to 
429·0)
323·3 
(303·6 to 
346·5)
–29·6 
(–38·3 to 
–24·6)*
–18·9 
(–23·2 to 
–16·2)*
Cyclist road injuries
3390·5 
(2919·1 to 
3889·2)
4747·7 
(4149·8 to 
5488·4)
4968·2 
(4229·6 to 
5946·9)
46·5 
(30·4 to 
67·8)*
4·6 
(–0·2 to 
10·0)
68·7 
(58·8 to 
79·8)
74·3 
(64·8 to 
86·2)
67·2 
(57·1 to 
80·7)
–2·2 
(–12·4 to 
11·4)
–9·5 
(–13·4 to 
–4·7)*
Motorcyclist road 
injuries
11 467·4 
(10 510·3 to 
12 944·1)
15 105·0 
(13 758·6 to 
16 396·3)
14 937·5 
(13 499·8 to 
16 289·9)
30·3 
(18·2 to 
40·1)*
–1·1 
(–5·4 to 
2·6)
211·8 
(194·4 to 
239·6)
222·6 
(202·8 to 
242·2)
197·3 
(178·6 to 
215·4)
–6·8 
(–15·5 to 
0·2)
–11·3 
(–15·1 to 
–8·2)*
Motor vehicle road 
injuries
24 319·9 
(20 644·9 to 
27 442·2)
27 217·7 
(24 983·6 to 
30 653·8)
26 211·8 
(24 325·0 to 
29 404·9)
7·8 
(0·7 to 
25·4)*
–3·7 
(–7·2 to 
2·4)
452·8 
(386·1 to 
509·4)
406·3 
(372·9 to 
455·6)
349·4 
(324·1 to 
391·5)
–22·9 
(–27·6 to 
–11·0)*
–14·0 
(–17·0 to 
–8·9)*
Other road injuries
893·0 
(714·6 to 
1103·6)
1097·0 
(919·3 to 
1343·6)
1275·9 
(1026·6 to 
1626·3)
42·9 
(23·2 to 
73·5)*
16·3 
(9·2 to 
23·7)*
17·9 
(14·3 to 
22·2)
17·2 
(14·3 to 
21·1)
17·3 
(13·9 to 
22·1)
–3·3 
(–15·0 to 
15·3)
0·8 
(–4·9 to 
6·7)
Other transport injuries
5641·9 
(4761·1 to 
6609·6)
6503·0 
(5751·7 to 
7477·8)
6656·8 
(5797·7 to 
7707·3)
18·0 
(5·2 to 
38·4)*
2·4 
(–3·0 to 
8·9)
109·5 
(92·6 to 
128·2)
99·4 
(87·3 to 
114·9)
89·5 
(77·8 to 
103·9)
–18·3 
(–26·4 to 
–5·1)*
–10·0 
(–14·5 to 
–4·4)*
Unintentional injuries
121 695·5 
(109 006·9 to 
134 119·5)
111 226·3 
(98 814·1 to 
125 226·5)
107 423·5 
(94 550·6 to 
124 015·0)
–11·7 
(–18·4 to 
–4·3)*
–3·4 
(–7·1 to 
0·1)
2282·2 
(2056·3 to 
2530·5)
1750·0 
(1549·2 to 
1975·9)
1486·2 
(1306·5 to 
1716·5)
–34·9 
(–39·0 to 
–30·6)*
–15·1 
(–18·0 to 
–12·2)*
(Table 1 continues on next page)
 Global Health Metrics
1282 
www.thelancet.com   Vol 390  September 16, 2017
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Falls
26 607·6 
(22 592·9 to 
31 276·8)
31 258·7 
(26 220·2 to 
37 276·0)
35 773·8 
(29 777·6 to 
43 175·7)
34·5 
(22·3 to 
44·8)*
14·4 
(9·0 to 
18·1)*
589·1 
(498·2 to 
700·1)
530·8 
(444·1 to 
630·7)
506·5 
(422·1 to 
610·0)
–14·0 
(–20·6 to 
–9·2)*
–4·6 
(–8·8 to 
–1·8)*
Drowning
34 779·0 
(29 934·2 to 
37 903·4)
22 886·7 
(20 014·2 to 
24 143·1)
16 809·0 
(15 206·1 to 
18 047·4)
–51·7 
(–55·6 to 
–43·2)*
–26·6 
(–30·1 to 
–20·1)*
567·0 
(491·4 to 
614·9)
337·6 
(295·4 to 
356·2)
229·2 
(207·1 to 
246·3)
–59·6 
(–62·8 to 
–53·0)*
–32·1 
(–35·4 to 
–26·1)*
Fire, heat, and hot 
substances
10 059·5 
(7875·0 to 
11 492·7)
8822·8 
(7294·7 to 
10 004·2)
8150·8 
(6763·6 to 
9476·2)
–19·0 
(–28·2 to 
–5·5)*
–7·6 
(–13·1 to 
–0·1)*
186·1 
(150·6 to 
212·3)
135·9 
(113·3 to 
154·4)
111·4 
(92·4 to 
129·4)
–40·2 
(–46·0 to 
–31·7)*
–18·1 
(–22·7 to 
–11·8)*
Poisonings
5471·1 
(3951·1 to 
6579·7)
3747·9 
(2956·8 to 
4213·0)
3149·4 
(2379·7 to 
3574·1)
–42·4 
(–53·8 to 
–21·9)*
–16·0 
(–25·9 to 
–2·9)*
95·1 
(69·4 to 
112·2)
56·3 
(44·5 to 
63·3)
43·0 
(32·5 to 
48·9)
–54·8 
(–63·8 to 
–39·4)*
–23·6 
(–32·8 to 
–11·8)*
Exposure to mechanical 
forces
12 931·3 
(11 440·5 to 
14 960·9)
12 360·8 
(10 580·5 to 
14 181·8)
11 921·2 
(9836·7 to 
14 174·8)
–7·8 
(–25·2 to 
2·4)
–3·6 
(–8·0 to 
1·0)
239·6 
(211·3 to 
277·2)
189·7 
(162·2 to 
219·0)
162·2 
(133·8 to 
193·1)
–32·3 
(–44·1 to 
–26·6)*
–14·4 
(–18·0 to 
–11·0)*
Unintentional firearm 
injuries
1681·2 
(1345·7 to 
1839·8)
1415·5 
(1182·3 to 
1575·2)
1351·5 
(1104·3 to 
1513·3)
–19·6 
(–26·2 to 
–12·4)*
–4·5 
(–10·9 to 
0·7)
30·9 
(24·8 to 
34·1)
21·1 
(17·6 to 
23·5)
18·1 
(14·8 to 
20·3)
–41·5 
(–46·1 to 
–36·4)*
–14·3 
(–19·9 to 
–9·9)*
Unintentional 
suffocation
3239·4 
(2677·8 to 
4135·3)
2101·3 
(1713·6 to 
2425·9)
1757·1 
(1410·8 to 
2041·2)
–45·8 
(–59·1 to 
–34·4)*
–16·4 
(–23·6 to 
–8·8)*
50·6 
(42·1 to 
63·9)
31·2 
(25·4 to 
36·0)
24·7 
(19·8 to 
28·7)
–51·2 
(–63·0 to 
–41·5)*
–20·8 
(–27·6 to 
–13·7)*
Other exposure to 
mechanical forces
8010·6 
(6937·0 to 
9470·1)
8844·1 
(7355·1 to 
10 402·4)
8812·6 
(7062·9 to 
10 749·0)
10·0 
(–10·2 to 
20·3)
–0·4 
(–5·0 to 
4·2)
158·1 
(135·5 to 
187·8)
137·4 
(113·9 to 
162·8)
119·5 
(96·0 to 
145·9)
–24·4 
(–37·5 to 
–19·1)*
–13·1 
(–16·6 to 
–9·6)*
Adverse effects of medical 
treatment
5352·0 
(3741·7 to 
6317·4)
5077·1 
(4014·2 to 
5746·0)
4991·7 
(4229·9 to 
5575·1)
–6·7 
(–17·7 to 
15·4)
–1·7 
(–8·0 to 
7·5)
99·5 
(73·7 to 
114·5)
80·2 
(64·1 to 
90·4)
69·7 
(59·2 to 
77·9)
–30·0 
(–36·6 to 
–18·4)*
–13·2 
(–18·2 to 
–6·2)*
Animal contact
6346·7 
(4715·4 to 
7403·2)
6241·9 
(4797·7 to 
7155·5)
5936·0 
(4650·5 to 
6820·3)
–6·5 
(–17·4 to 
13·4)
–4·9 
(–10·6 to 
3·5)
118·2 
(89·0 to 
138·0)
95·1 
(73·2 to 
109·3)
80·7 
(63·2 to 
92·7)
–31·7 
(–38·8 to 
–18·1)*
–15·1 
(–20·1 to 
–7·7)*
Venomous animal 
contact
5129·9 
(3648·8 to 
6063·6)
5170·5 
(3898·3 to 
5979·9)
4865·9 
(3689·6 to 
5640·6)
–5·2 
(–16·8 to 
17·5)
–5·9 
(–12·1 to 
3·0)
94·9 
(68·3 to 
111·9)
78·4 
(59·1 to 
90·7)
66·0 
(50·0 to 
76·6)
–30·4 
(–37·9 to 
–14·7)*
–15·7 
(–21·1 to 
–7·9)*
Non-venomous animal 
contact
1216·9 
(949·1 to 
1693·5)
1071·3 
(835·4 to 
1440·4)
1070·1 
(837·8 to 
1396·1)
–12·1 
(–25·2 to 
–0·4)*
–0·1 
(–7·7 to 
7·1)
23·3 
(18·2 to 
31·6)
16·7 
(13·0 to 
22·4)
14·7 
(11·5 to 
19·1)
–37·1 
(–44·5 to 
–30·2)*
–12·3 
(–18·3 to 
–6·4)*
Foreign body
7078·1 
(5242·3 to 
9108·8)
6599·7 
(5467·6 to 
7941·9)
6742·8 
(5709·7 to 
7921·3)
–4·7 
(–20·0 to 
18·0)
2·2 
(–6·6 to 
11·3)
127·2 
(98·0 to 
159·1)
102·2 
(84·9 to 
122·5)
94·0 
(79·8 to 
110·3)
–26·1 
(–35·1 to 
–12·1)*
–8·0 
(–15·0 to 
–0·3)*
Pulmonary aspiration 
and foreign body in 
airway
5386·2 
(4058·7 to 
7061·1)
5309·7 
(4303·9 to 
6377·5)
5327·3 
(4587·3 to 
6136·5)
–1·1 
(–17·2 to 
20·3)
0·3 
(–8·8 to 
11·6)
96·0 
(74·8 to 
121·0)
82·1 
(66·9 to 
98·0)
74·6 
(64·3 to 
86·0)
–22·3 
(–31·9 to 
–8·3)*
–9·1 
(–16·7 to 
0·6)
Foreign body in eyes
124·2 
(63·7 to 
213·3)
146·6 
(78·2 to 
243·6)
185·8 
(100·2 to 
310·1)
49·6 
(41·7 to 
57·3)*
26·8 
(24·1 to 
30·1)*
2·6 
(1·4 to 
4·3)
2·4 
(1·3 to 
3·9)
2·5 
(1·4 to 
4·2)
–2·5 
(–4·3 to 
–0·8)*
8·2 
(6·3 to 
10·3)*
Foreign body in other 
body part
1567·7 
(948·1 to 
2028·4)
1143·5 
(869·3 to 
1474·9)
1229·7 
(929·1 to 
1602·4)
–21·6 
(–36·7 to 
11·6)
7·5 
(0·6 to 
13·4)*
28·6 
(18·2 to 
36·8)
17·7 
(13·4 to 
22·9)
16·8 
(12·7 to 
21·9)
–41·3 
(–50·8 to 
–21·5)*
–5·2 
(–10·6 to 
–0·8)*
Environmental heat and 
cold exposure
4613·3 
(3492·7 to 
5757·7)
4712·3 
(3611·7 to 
5881·4)
4676·7 
(3520·0 to 
5993·7)
1·4 
(–9·2 to 
11·5)
–0·8 
(–7·9 to 
6·3)
96·6 
(74·1 to 
121·0)
75·7 
(58·1 to 
94·5)
64·1 
(48·3 to 
82·0)
–33·6 
(–40·8 to 
–27·6)*
–15·3 
(–21·8 to 
–9·7)*
Other unintentional 
injuries
8456·9 
(7319·9 to 
10 038·8)
9518·6 
(8199·6 to 
11 247·0)
9272·1 
(7666·7 to 
11 405·2)
9·6 
(–6·2 to 
20·4)
–2·6 
(–7·2 to 
1·8)
163·8 
(140·6 to 
195·7)
146·4 
(124·8 to 
174·5)
125·5 
(103·7 to 
154·8)
–23·4 
(–33·6 to 
–17·0)*
–14·3 
(–18·0 to 
–10·8)*
Self-harm and 
interpersonal violence
57 011·9 
(52 622·2 to 
60 351·8)
61 630·8 
(56 736·9 to 
64 509·4)
58 717·9 
(53 866·4 to 
62 809·6)
3·0 
(–3·5 to 
11·0)
–4·7 
(–8·4 to 
–0·1)*
1091·2 
(1007·5 to 
1153·3)
919·1 
(845·6 to 
962·8)
776·8 
(712·6 to 
830·8)
–28·8 
(–33·2 to 
–23·4)*
–15·5 
(–18·7 to 
–11·4)*
(Table 1 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1283
[26·1–35·4]) from 2006 to 2016. Age­standardised DALY 
rates from self­harm (decreased by 17·7% [12·9–21·2]) and 
interpersonal violence (12·0% [7·0–16·1]) have both 
decreased by more than 10% since 2006. Age­standardised 
DALY rates resulting from conflict and terrorism increased 
by 97·4% (25·7–240·9) from 2006 to 2016; this rise was 
primarily driven by ongoing conflicts in north Africa, the 
Middle East, and sub­Saharan Africa. This result represents 
an increase in all­age DALYs of 114·0% (36·2–271·3) from 
2006 to 2016.
Global DALY counts in 2016 for causes that were 
estimated separately for the first time are as follows: 
alcoholic 
cardiomyopathy 
2·59 
million 
(95% 
UI 
2·06 million to 3·24 million), urogenital congenital 
anomalies 1·09 million (0·86 million to 1·31 million), 
congenital 
musculoskeletal 
and 
limb 
anomalies 
2·26 million (1·66 million to 2·99 million), digestive 
congenital anomalies 3·34 million (2·67 million to 
4·96 million), Zika virus disease 5100 (3400–8000), Guinea 
worm disease 0·87 (0·5–1·35), self­harm by firearm 
2·85 million (2·39 million to 3·59 million), sexual 
violence 1·37 million (0·92 million to 1·95 million), 
myocarditis 1·37 million (1·12 million to 1·51 million), 
drug­susceptible tuberculosis 39·9 million (38·1 million 
to 41·9 million), multidrug­resistant tuberculosis without 
extensive drug resistance 3·32 million (2·79 million to 
All-age DALYs (thousands)
Age-standardised DALY rate (per 100 000)
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
1990
2006
2016
Percentage 
change, 
1990–2016
Percentage 
change, 
2006–16
(Continued from previous page)
Self-harm
36 069·6 
(33 180·8 to 
38 321·5)
37 517·7 
(34 901·0 to 
39 462·7)
35 149·6 
(32 845·1 to 
37 938·3)
–2·5 
(–8·5 to 
6·3)
–6·3 
(–10·4 to 
–0·9)*
705·3 
(650·2 to 
753·4)
565·6 
(526·2 to 
594·0)
465·7 
(434·7 to 
502·5)
–34·0 
(–37·9 to 
–28·2)*
–17·7 
(–21·2 to 
–12·9)*
Self-harm by firearm
2951·5 
(2377·2 to 
3829·1)
2875·2 
(2348·6 to 
3710·6)
2853·2 
(2386·0 to 
3589·2)
–3·3 
(–13·1 to 
13·8)
–0·8 
(–7·5 to 
9·7)
57·9 
(47·4 to 
75·0)
43·2 
(35·6 to 
55·7)
37·8 
(31·6 to 
47·6)
–34·8 
(–41·0 to 
–24·0)*
–12·6 
(–18·4 to 
–3·9)*
Self-harm by other 
specified means
33 118·1 
(30 211·8 to 
35 109·1)
34 642·5 
(32 074·6 to 
36 526·4)
32 296·4 
(30 216·7 to 
34 924·8)
–2·5 
(–8·5 to 
6·3)
–6·8 
(–11·0 to 
–1·3)*
647·4 
(590·9 to 
686·4)
522·4 
(481·9 to 
549·9)
427·9 
(399·9 to 
462·6)
–33·9 
(–37·9 to 
–28·1)*
–18·1 
(–21·8 to 
–13·3)*
Interpersonal violence
20 942·3 
(17 360·5 to 
23 608·2)
24 113·2 
(19 792·0 to 
26 579·9)
23 568·3 
(19 646·6 to 
26 479·2)
12·5 
(3·6 to 
22·4)*
–2·3 
(–6·9 to 
3·5)
385·9 
(318·6 to 
436·9)
353·5 
(290·4 to 
391·3)
311·1 
(259·7 to 
349·8)
–19·4 
(–25·8 to 
–12·5)*
–12·0 
(–16·1 to 
–7·0)*
Physical violence by 
firearm
6529·3 
(4689·4 to 
7918·7)
8381·5 
(5616·3 to 
9307·9)
8720·1 
(5844·7 to 
9853·4)
33·5 
(15·0 to 
48·5)*
4·0 
(–0·7 to 
9·0)
119·1 
(84·7 to 
144·7)
120·5 
(80·8 to 
133·8)
114·3 
(76·6 to 
129·1)
–4·1 
(–17·5 to 
6·7)
–5·2 
(–9·6 to 
–0·6)*
Physical violence by 
sharp object
5070·8 
(3833·9 to 
6262·5)
5886·3 
(4626·0 to 
7279·7)
5288·2 
(4290·5 to 
6922·3)
4·3 
(–8·9 to 
25·1)
–10·2 
(–16·5 to 
–0·5)*
94·5 
(71·8 to 
117·5)
86·4 
(67·6 to 
106·7)
69·5 
(56·4 to 
90·9)
–26·5 
(–36·0 to 
–12·1)*
–19·6 
(–25·1 to 
–10·7)*
Sexual violence
1162·6 
(774·9 to 
1647·4)
1319·4 
(884·1 to 
1879·0)
1365·8 
(917·1 to 
1946·0)
17·5 
(14·4 to 
20·6)*
3·5 
(2·2 to 
4·8)*
21·2 
(14·2 to 
30·0)
19·1 
(12·9 to 
27·3)
18·1 
(12·2 to 
25·8)
–14·5 
(–15·6 to 
–13·3)*
–5·5 
(–6·2 to 
–4·9)*
Physical violence by 
other means
8179·6 
(6388·8 to 
9519·2)
8526·0 
(7045·4 to 
10 132·6)
8194·1 
(7011·8 to 
10 058·4)
0·2 
(–15·5 to 
20·3)
–3·9 
(–12·3 to 
4·9)
151·1 
(120·0 to 
176·2)
127·5 
(105·6 to 
151·6)
109·3 
(93·5 to 
133·9)
–27·7 
(–38·2 to 
–14·0)*
–14·3 
(–21·6 to 
–6·5)*
Forces of nature, conflict 
and terrorism, and 
executions and police 
conflict
10 576·7 
(8362·5 to 
12 866·6)
6132·8 
(4005·8 to 
8352·3)
11 241·1 
(8003·1 to 
14 753·8)
6·3 
(–25·0 to 
46·5)
83·3 
(24·2 to 
183·3)*
181·9 
(143·2 to 
221·0)
89·3 
(58·2 to 
121·9)
150·3 
(107·0 to 
197·3)
–17·4 
(–41·4 to 
14·1)
68·3 
(14·3 to 
159·6)*
Exposure to forces of 
nature
3090·2 
(1185·9 to 
4943·3)
946·7 
(636·1 to 
1276·6)
617·1 
(369·5 to 
992·6)
–80·0 
(–90·2 to 
–49·1)*
–34·8 
(–50·5 to 
–15·8)*
53·5 
(20·8 to 
85·5)
14·0 
(9·4 to 
19·0)
8·3 
(5·0 to 
13·4)
–84·5 
(–92·3 to 
–60·9)*
–40·9 
(–54·9 to 
–24·4)*
Conflict and terrorism
6889·0 
(5852·1 to 
7909·2)
4824·1 
(2855·5 to 
6799·0)
10 326·0 
(7176·9 to 
13 627·5)
49·9 
(5·2 to 
100·3)*
114·0 
(36·2 to 
271·3)*
117·4 
(99·2 to 
135·3)
69·9 
(41·6 to 
98·8)
138·1 
(95·9 to 
182·2)
17·6 
(–17·4 to 
57·1)
97·4 
(25·7 to 
240·9)*
Executions and police 
conflict
733·5 
(292·1 to 
958·6)
418·5 
(263·0 to 
654·0)
355·7 
(221·1 to 
576·5)
–51·5 
(–65·3 to 
–12·8)*
–15·0 
(–22·4 to 
–7·5)*
13·4 
(5·4 to 
17·6)
6·2 
(3·9 to 
9·9)
4·7 
(2·9 to 
7·7)
–64·8 
(–74·6 to 
–37·4)*
–24·2 
(–30·2 to 
–17·8)*
Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. ··=not defined (used for asymptomatic causes, epidemics, and outbreaks). 
DALYs=disability-adjusted life-years. G6PD=glucose-6-phosphate dehydrogenase. *Percentage changes that are statistically significant.
Table 1: Global all-age DALYs and age-standardised DALY rates in 1990, 2006, and 2016 with mean percentage changes between 1990 and 2016, 2006 and 2016, and 1990 and 2016 for 
all causes  
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org/node/311214
 Global Health Metrics
1284 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Global
67·57 
(67·33–
67·77)
58·42 
(55·80–
60·77)
62·70 
(62·42–
62·99)
55·38 
(53·27–
57·31)
71·44 
(71·25–
71·65)
61·73 
(58·91–
64·21)
66·35 
(66·05–
66·63)
58·51 
(56·27–
60·55)
75·33 
(74·95–
75·64)
64·91 
(61·88–
67·54)
69·79 
(69·29–
70·22)
61·42 
(59·01–
63·58)
High SDI
79·15 
(79·05–
79·24)
68·23 
(65·08–
71·02)
72·32 
(72·21–
72·44)
63·82 
(61·37–
66·00)
82·13 
(82·06–
82·21)
70·61 
(67·28–
73·57)
76·32 
(76·23–
76·41)
66·98 
(64·32–
69·32)
83·37 
(83·18–
83·57)
71·49 
(68·03–
74·53)
78·06 
(77·81–
78·29)
68·33 
(65·60–
70·82)
High-middle SDI
73·54 
(73·16–
73·92)
63·64 
(60·78–
66·23)
66·44 
(65·99–
66·90)
58·73 
(56·43–
60·76)
76·76 
(76·39–
77·11)
66·53 
(63·49–
69·12)
69·36 
(68·83–
69·82)
61·45 
(59·13–
63·51)
79·86 
(78·65–
80·80)
68·96 
(65·69–
71·84)
73·12 
(72·09–
74·05)
64·57 
(62·03–
67·04)
Middle SDI
68·75 
(68·41–
69·09)
60·16 
(57·68–
62·37)
64·15 
(63·79–
64·50)
57·36 
(55·31–
59·11)
73·67 
(73·45–
73·88)
64·32 
(61·62–
66·73)
68·32 
(68·06–
68·58)
60·95 
(58·80–
62·90)
77·28 
(76·99–
77·57)
67·19 
(64·26–
69·70)
71·06 
(70·68–
71·40)
63·21 
(60·91–
65·16)
Low-middle SDI
60·39 
(59·94–
60·81)
51·69 
(49·11–
53·94)
58·41 
(57·92–
58·90)
51·03 
(48·92–
52·98)
65·55 
(65·17–
65·94)
56·12 
(53·36–
58·47)
62·39 
(61·93–
62·85)
54·51 
(52·29–
56·57)
70·26 
(69·74–
70·74)
60·11 
(57·16–
62·70)
66·25 
(65·64–
66·79)
57·90 
(55·43–
60·03)
Low SDI
53·71 
(53·24–
54·20)
46·18 
(43·95–
48·11)
51·14 
(50·52–
51·75)
44·45 
(42·48–
46·30)
57·62 
(57·12–
58·15)
49·75 
(47·41–
51·86)
55·98 
(55·32–
56·59)
48·81 
(46·70–
50·76)
64·10 
(63·33–
64·82)
55·44 
(52·83–
57·79)
61·63 
(60·68–
62·52)
53·86 
(51·50–
56·11)
High income
79·34 
(79·24–
79·43)
68·40 
(65·23–
71·19)
72·64 
(72·54–
72·75)
64·15 
(61·70–
66·33)
82·31 
(82·23–
82·38)
70·76 
(67·43–
73·73)
76·62 
(76·52–
76·70)
67·29 
(64·63–
69·64)
83·48 
(83·28–
83·67)
71·61 
(68·12–
74·66)
78·27 
(78·04–
78·49)
68·58 
(65·82–
71·06)
High-income 
North America
79·04 
(78·94–
79·13)
67·67 
(64·44–
70·61)
72·15 
(72·03–
72·26)
63·25 
(60·75–
65·49)
80·67 
(80·58–
80·76)
68·83 
(65·45–
71·90)
75·63 
(75·54–
75·74)
65·87 
(63·11–
68·29)
81·50 
(81·28–
81·72)
69·34 
(65·86–
72·43)
76·79 
(76·54–
77·04)
66·71 
(63·87–
69·21)
Canada
80·64 
(80·33–
80·93)
69·83 
(66·72–
72·67)
74·23 
(73·91–
74·55)
65·75 
(63·26–
67·95)
82·75 
(82·46–
83·01)
71·51 
(68·28–
74·46)
78·10 
(77·84–
78·42)
68·86 
(66·17–
71·23)
83·89 
(83·49–
84·30)
72·30 
(69·00–
75·27)
79·76 
(79·30–
80·22)
70·04 
(67·23–
72·61)
Greenland
66·09 
(64·72–
67·48)
57·28 
(54·54–
59·83)
57·74 
(56·27–
59·11)
51·39 
(49·21–
53·48)
68·78 
(67·50–
70·02)
59·52 
(56·78–
62·08)
65·08 
(63·83–
66·20)
57·69 
(55·47–
59·79)
72·82 
(70·37–
75·59)
62·90 
(59·41–
66·12)
67·80 
(64·69–
70·64)
60·03 
(56·88–
63·34)
USA
78·87 
(78·77–
78·98)
67·45 
(64·20–
70·42)
71·93 
(71·81–
72·05)
62·99 
(60·48–
65·23)
80·45 
(80·35–
80·54)
68·54 
(65·16–
71·62)
75·37 
(75·26–
75·48)
65·54 
(62·79–
67·99)
81·23 
(80·99–
81·46)
69·01 
(65·50–
72·12)
76·45 
(76·19–
76·73)
66·34 
(63·49–
68·86)
Australasia
79·85 
(79·63–
80·08)
68·90 
(65·74–
71·70)
73·76 
(73·52–
74·00)
64·95 
(62·38–
67·23)
83·32 
(83·13–
83·52)
71·69 
(68·27–
74·72)
78·76 
(78·55–
78·99)
69·05 
(66·22–
71·56)
84·39 
(83·80–
84·99)
72·55 
(69·07–
75·61)
80·32 
(79·63–
81·02)
70·28 
(67·38–
72·83)
Australia
80·11 
(79·87–
80·39)
69·11 
(65·92–
71·94)
73·97 
(73·69–
74·25)
65·10 
(62·51–
67·40)
83·58 
(83·35–
83·80)
71·88 
(68·45–
74·96)
78·93 
(78·68–
79·19)
69·17 
(66·31–
71·70)
84·58 
(83·84–
85·27)
72·70 
(69·18–
75·75)
80·48 
(79·67–
81·21)
70·38 
(67·51–
72·95)
New Zealand
78·55 
(78·18–
78·89)
67·90 
(64·78–
70·66)
72·73 
(72·38–
73·08)
64·24 
(61·75–
66·50)
82·05 
(81·73–
82·34)
70·75 
(67·40–
73·65)
77·93 
(77·60–
78·25)
68·50 
(65·75–
70·98)
83·40 
(82·25–
84·62)
71·83 
(68·56–
74·89)
79·55 
(78·27–
80·83)
69·78 
(66·84–
72·44)
High-income Asia 
Pacific
80·68 
(80·38–
80·95)
70·30 
(67·29–
73·05)
74·10 
(73·68–
74·48)
65·82 
(63·48–
67·98)
84·95 
(84·70–
85·18)
73·64 
(70·34–
76·57)
78·06 
(77·75–
78·37)
68·88 
(66·28–
71·30)
86·42 
(85·62–
87·09)
74·70 
(71·14–
77·75)
80·07 
(79·10–
80·94)
70·47 
(67·66–
73·06)
Brunei
75·39 
(73·88–
76·73)
65·61 
(62·70–
68·40)
71·68 
(70·69–
72·82)
63·24 
(60·71–
65·65)
78·90 
(77·93–
79·65)
68·72 
(65·74–
71·51)
74·64 
(73·89–
75·45)
65·84 
(63·47–
68·18)
79·48 
(77·79–
81·73)
69·34 
(66·13–
72·26)
74·56 
(72·51–
77·34)
65·84 
(62·82–
68·69)
Japan
81·81 
(81·76–
81·85)
71·31 
(68·26–
74·00)
75·91 
(75·86–
75·96)
67·45 
(65·01–
69·60)
85·57 
(85·51–
85·64)
74·20 
(70·86–
77·10)
78·76 
(78·71–
78·81)
69·51 
(66·85–
71·84)
86·94 
(86·73–
87·16)
75·10 
(71·59–
78·08)
80·83 
(80·57–
81·08)
71·11 
(68·36–
73·60)
Singapore
78·10 
(76·47–
79·73)
68·51 
(65·44–
71·31)
72·86 
(71·33–
74·39)
65·11 
(62·52–
67·52)
83·71 
(82·39–
84·98)
73·34 
(70·20–
76·23)
78·55 
(77·18–
79·92)
69·99 
(67·44–
72·54)
86·08 
(83·92–
88·42)
75·16 
(71·85–
78·57)
81·26 
(78·75–
83·67)
72·01 
(68·76–
75·05)
South Korea
76·33 
(74·99–
77·68)
66·56 
(63·56–
69·48)
67·74 
(66·18–
69·33)
60·30 
(57·86–
62·70)
82·11 
(81·07–
83·18)
71·18 
(67·93–
74·18)
75·48 
(74·23–
76·96)
66·63 
(64·01–
69·40)
84·22 
(81·22–
87·13)
72·97 
(68·98–
76·74)
77·67 
(74·32–
81·52)
68·49 
(64·84–
72·03)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1285
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Western Europe
79·50 
(79·34–
79·65)
68·49 
(65·28–
71·34)
72·94 
(72·77–
73·11)
64·52 
(62·05–
66·70)
82·79 
(82·66–
82·92)
71·24 
(67·89–
74·22)
77·24 
(77·10–
77·39)
68·07 
(65·41–
70·45)
84·10 
(83·84–
84·38)
72·27 
(68·78–
75·35)
79·21 
(78·90–
79·49)
69·69 
(66·89–
72·13)
Andorra
82·80 
(80·33–
85·33)
70·60 
(66·75–
74·37)
76·19 
(73·96–
78·77)
66·81 
(63·64–
70·01)
85·95 
(83·76–
87·60)
73·11 
(69·15–
76·73)
79·16 
(77·43–
80·82)
69·25 
(65·99–
72·17)
85·77 
(82·96–
87·69)
73·03 
(69·09–
76·68)
79·33 
(77·41–
81·92)
69·42 
(66·07–
72·49)
Austria
78·86 
(78·61–
79·12)
68·23 
(65·16–
71·00)
72·15 
(71·87–
72·41)
63·91 
(61·49–
66·04)
82·53 
(82·30–
82·75)
71·30 
(68·06–
74·20)
77·00 
(76·74–
77·24)
67·80 
(65·05–
70·15)
83·85 
(83·20–
84·52)
72·24 
(68·88–
75·30)
79·12 
(78·50–
79·87)
69·55 
(66·69–
72·18)
Belgium
79·26 
(78·82–
79·66)
68·29 
(65·15–
71·13)
72·65 
(72·14–
73·14)
64·27 
(61·68–
66·46)
82·17 
(81·80–
82·56)
70·29 
(66·89–
73·26)
76·57 
(76·13–
77·01)
67·17 
(64·45–
69·56)
83·37 
(82·33–
84·52)
71·40 
(67·92–
74·49)
78·42 
(77·24–
79·54)
68·80 
(65·77–
71·49)
Cyprus
76·97 
(76·52–
77·41)
66·64 
(63·65–
69·30)
72·89 
(72·36–
73·42)
64·67 
(62·30–
66·83)
81·02 
(80·57–
81·48)
69·93 
(66·72–
72·78)
76·30 
(75·77–
76·81)
67·41 
(64·75–
69·72)
82·82 
(82·27–
83·36)
71·45 
(68·14–
74·43)
78·12 
(77·46–
78·82)
68·97 
(66·28–
71·45)
Denmark
77·96 
(77·13–
78·75)
67·14 
(64·04–
70·04)
72·44 
(71·66–
73·31)
64·02 
(61·53–
66·33)
80·55 
(79·78–
81·31)
69·19 
(65·95–
72·08)
76·12 
(75·38–
76·89)
66·84 
(64·10–
69·41)
82·85 
(81·51–
84·23)
70·83 
(67·40–
74·11)
78·79 
(77·31–
80·14)
68·92 
(66·08–
71·68)
Finland
79·00 
(78·66–
79·33)
67·73 
(64·43–
70·69)
70·97 
(70·60–
71·34)
62·36 
(59·81–
64·66)
82·59 
(82·27–
82·88)
70·51 
(66·95–
73·66)
75·68 
(75·31–
76·06)
66·02 
(63·18–
68·51)
84·58 
(83·85–
85·41)
72·21 
(68·52–
75·49)
78·85 
(77·95–
79·76)
68·81 
(65·95–
71·54)
France
81·22 
(80·93–
81·50)
69·93 
(66·71–
72·84)
73·09 
(72·73–
73·46)
64·82 
(62·36–
66·98)
84·09 
(83·78–
84·36)
72·51 
(69·07–
75·52)
77·11 
(76·77–
77·52)
68·28 
(65·62–
70·59)
85·39 
(84·85–
85·99)
73·42 
(69·88–
76·59)
79·20 
(78·58–
79·84)
69·93 
(67·19–
72·37)
Germany
78·53 
(77·95–
79·07)
67·63 
(64·42–
70·49)
72·04 
(71·38–
72·70)
63·62 
(61·19–
65·80)
82·13 
(81·67–
82·62)
70·57 
(67·24–
73·61)
76·67 
(76·12–
77·27)
67·43 
(64·78–
69·89)
83·34 
(82·47–
84·29)
71·52 
(68·00–
74·73)
78·47 
(77·44–
79·52)
68·90 
(66·03–
71·51)
Greece
79·54 
(79·22–
79·86)
68·72 
(65·64–
71·45)
74·48 
(74·11–
74·88)
66·03 
(63·54–
68·20)
82·64 
(82·36–
82·92)
71·22 
(67·96–
74·12)
77·11 
(76·75–
77·46)
68·17 
(65·55–
70·47)
83·50 
(82·77–
84·25)
72·02 
(68·77–
75·06)
78·43 
(77·45–
79·46)
69·22 
(66·58–
71·70)
Iceland
80·41 
(79·80–
81·00)
69·17 
(65·92–
72·04)
75·68 
(75·14–
76·24)
66·75 
(64·15–
69·07)
83·15 
(82·53–
83·81)
71·45 
(68·04–
74·44)
79·55 
(79·05–
80·05)
69·93 
(67·10–
72·36)
83·99 
(82·92–
85·02)
72·17 
(68·76–
75·31)
80·56 
(79·65–
81·40)
70·79 
(67·97–
73·50)
Ireland
77·64 
(77·03–
78·27)
67·08 
(63·98–
69·89)
72·18 
(71·58–
72·85)
63·93 
(61·51–
66·08)
81·54 
(80·95–
82·14)
70·17 
(66·93–
73·15)
76·97 
(76·34–
77·55)
67·74 
(65·08–
70·24)
83·33 
(81·96–
84·72)
71·59 
(68·10–
74·73)
78·97 
(77·45–
80·41)
69·34 
(66·29–
72·10)
Israel
77·55 
(76·40–
78·64)
67·25 
(64·05–
70·06)
74·11 
(73·01–
75·34)
65·62 
(63·00–
68·01)
81·96 
(80·91–
83·03)
70·70 
(67·35–
73·75)
77·60 
(76·42–
78·76)
68·37 
(65·55–
71·00)
84·14 
(82·16–
85·93)
72·46 
(68·90–
75·73)
80·03 
(77·74–
82·35)
70·37 
(67·28–
73·45)
Italy
80·26 
(80·02–
80·51)
69·20 
(66·00–
72·03)
73·69 
(73·41–
73·97)
65·23 
(62·77–
67·52)
83·75 
(83·51–
83·96)
72·24 
(68·85–
75·22)
78·24 
(77·97–
78·51)
69·07 
(66·42–
71·48)
84·62 
(83·96–
85·28)
72·93 
(69·56–
76·04)
79·92 
(79·14–
80·69)
70·48 
(67·66–
72·99)
Luxembourg
78·49 
(77·99–
78·99)
67·27 
(63·97–
70·15)
71·77 
(71·28–
72·25)
63·07 
(60·55–
65·33)
82·91 
(82·40–
83·38)
70·86 
(67·36–
73·97)
77·78 
(77·29–
78·27)
67·96 
(65·12–
70·51)
83·89 
(82·76–
85·25)
71·72 
(68·23–
74·88)
80·27 
(79·11–
81·45)
70·13 
(67·02–
72·92)
Malta
77·78 
(76·65–
78·88)
67·36 
(64·26–
70·34)
73·69 
(72·64–
74·75)
65·33 
(62·75–
67·78)
81·65 
(80·63–
82·66)
70·51 
(67·17–
73·48)
77·15 
(76·16–
78·14)
68·10 
(65·44–
70·44)
83·83 
(82·07–
85·79)
72·16 
(68·59–
75·60)
79·04 
(77·13–
81·02)
69·70 
(66·63–
72·57)
Netherlands
80·09 
(79·62–
80·59)
68·69 
(65·39–
71·61)
73·87 
(73·37–
74·35)
65·23 
(62·77–
67·50)
81·91 
(81·47–
82·33)
70·14 
(66·76–
73·22)
77·65 
(77·23–
78·12)
68·24 
(65·57–
70·67)
83·61 
(82·62–
84·52)
71·53 
(67·93–
74·73)
79·63 
(78·57–
80·58)
69·85 
(67·02–
72·51)
Norway
80·06 
(79·58–
80·53)
69·28 
(66·16–
72·13)
73·63 
(73·13–
74·20)
65·00 
(62·42–
67·32)
82·62 
(82·16–
83·03)
71·46 
(68·27–
74·40)
78·08 
(77·63–
78·52)
68·58 
(65·80–
71·04)
84·10 
(82·90–
85·35)
72·67 
(69·39–
75·72)
80·07 
(78·99–
81·28)
70·29 
(67·42–
73·13)
Portugal
77·88 
(77·56–
78·20)
67·18 
(64·16–
70·00)
70·74 
(70·33–
71·13)
62·69 
(60·23–
64·73)
82·14 
(81·79–
82·47)
70·72 
(67·42–
73·65)
75·35 
(74·92–
75·78)
66·65 
(64·07–
68·98)
84·03 
(83·35–
84·77)
72·27 
(68·81–
75·39)
77·76 
(76·94–
78·65)
68·65 
(65·82–
71·07)
(Table 2 continues on next page)
 Global Health Metrics
1286 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Spain
80·63 
(80·44–
80·83)
69·85 
(66·61–
72·64)
73·59 
(73·33–
73·86)
65·44 
(63·01–
67·60)
84·03 
(83·84–
84·19)
72·75 
(69·43–
75·70)
77·60 
(77·37–
77·82)
68·86 
(66·28–
71·16)
85·59 
(85·13–
86·05)
73·98 
(70·65–
77·05)
80·28 
(79·67–
80·83)
71·20 
(68·55–
73·64)
Sweden
80·43 
(80·06–
80·79)
68·95 
(65·54–
71·97)
74·85 
(74·47–
75·27)
66·02 
(63·36–
68·35)
82·83 
(82·53–
83·14)
70·85 
(67·42–
73·87)
78·66 
(78·30–
78·99)
69·03 
(66·24–
71·48)
83·96 
(82·63–
85·19)
71·69 
(68·22–
75·14)
80·13 
(78·83–
81·40)
70·06 
(66·89–
72·76)
Switzerland
80·87 
(80·18–
81·52)
69·16 
(65·79–
72·25)
74·01 
(73·23–
74·76)
65·09 
(62·45–
67·47)
83·77 
(83·16–
84·33)
71·23 
(67·55–
74·56)
78·98 
(78·26–
79·69)
68·95 
(66·07–
71·59)
85·23 
(82·61–
87·65)
72·86 
(68·72–
76·47)
81·01 
(78·06–
83·61)
70·96 
(67·24–
74·23)
UK
78·47 
(78·35–
78·61)
67·45 
(64·27–
70·31)
72·85 
(72·72–
72·98)
64·24 
(61·72–
66·47)
81·48 
(81·36–
81·62)
69·89 
(66·55–
72·82)
77·17 
(77·04–
77·29)
67·68 
(64·93–
70·16)
82·86 
(82·65–
83·07)
70·97 
(67·58–
74·07)
78·92 
(78·71–
79·13)
69·11 
(66·28–
71·60)
England
78·69 
(78·60–
78·78)
67·57 
(64·37–
70·43)
73·12 
(73·03–
73·21)
64·43 
(61·91–
66·67)
81·72 
(81·63–
81·81)
70·01 
(66·66–
73·02)
77·47 
(77·38–
77·57)
67·89 
(65·12–
70·36)
83·11 
(82·96–
83·25)
71·12 
(67·68–
74·16)
79·24 
(79·09–
79·38)
69·35 
(66·49–
71·87)
Northern 
Ireland
77·86 
(76·97–
78·86)
67·25 
(64·19–
70·16)
71·89 
(70·92–
72·94)
63·72 
(61·27–
65·96)
81·13 
(80·33–
82·04)
69·82 
(66·50–
72·92)
76·24 
(75·24–
77·20)
67·16 
(64·47–
69·69)
82·42 
(80·83–
83·98)
70·89 
(67·48–
74·17)
77·85 
(76·04–
79·70)
68·48 
(65·52–
71·38)
Scotland
76·82 
(75·91–
77·71)
66·36 
(63·34–
69·05)
70·91 
(69·99–
71·81)
62·73 
(60·22–
65·05)
79·71 
(78·83–
80·64)
68·79 
(65·75–
71·68)
74·88 
(73·94–
75·77)
65·93 
(63·25–
68·37)
81·19 
(79·67–
82·62)
69·85 
(66·62–
73·15)
76·88 
(75·38–
78·37)
67·50 
(64·51–
70·41)
Wales
78·36 
(77·53–
79·18)
67·60 
(64·53–
70·42)
72·57 
(71·70–
73·35)
64·21 
(61·67–
66·48)
81·17 
(80·50–
81·98)
70·03 
(66·82–
73·00)
76·81 
(75·88–
77·63)
67·61 
(64·93–
70·14)
82·21 
(80·81–
83·50)
70·78 
(67·46–
73·99)
77·93 
(76·40–
79·41)
68·50 
(65·45–
71·32)
Southern Latin 
America
76·13 
(75·77–
76·51)
66·19 
(63·23–
68·81)
68·97 
(68·53–
69·40)
61·19 
(58·93–
63·23)
79·48 
(79·14–
79·86)
68·97 
(65·87–
71·78)
72·79 
(72·37–
73·22)
64·40 
(62·02–
66·62)
80·88 
(79·86–
81·84)
70·09 
(66·75–
72·91)
74·36 
(73·26–
75·41)
65·72 
(63·11–
68·16)
Argentina
75·75 
(75·29–
76·26)
65·95 
(63·01–
68·56)
68·54 
(68·00–
69·07)
60·85 
(58·59–
62·95)
78·76 
(78·29–
79·23)
68·49 
(65·47–
71·24)
71·82 
(71·27–
72·35)
63·67 
(61·27–
65·87)
79·99 
(79·07–
80·94)
69·45 
(66·22–
72·26)
73·31 
(72·28–
74·38)
64·91 
(62·40–
67·25)
Chile
76·84 
(76·09–
77·67)
66·46 
(63·38–
69·30)
70·19 
(69·28–
71·14)
62·03 
(59·52–
64·35)
81·54 
(80·87–
82·23)
70·29 
(67·00–
73·23)
75·82 
(75·07–
76·66)
66·64 
(63·96–
69·06)
83·19 
(80·15–
86·14)
71·75 
(67·58–
75·74)
77·28 
(73·98–
80·51)
67·98 
(64·16–
71·77)
Uruguay
76·50 
(76·12–
76·91)
66·84 
(63·99–
69·27)
69·10 
(68·67–
69·52)
61·72 
(59·57–
63·65)
79·58 
(79·19–
79·94)
69·39 
(66·41–
71·92)
72·02 
(71·61–
72·46)
64·20 
(61·87–
66·23)
81·08 
(80·22–
81·94)
70·49 
(67·40–
73·37)
73·45 
(72·58–
74·37)
65·28 
(62·78–
67·50)
Central Europe, 
eastern Europe, 
and central Asia
73·62 
(73·15–
74·08)
63·68 
(60·79–
66·31)
64·56 
(63·90–
65·19)
56·76 
(54·42–
58·84)
74·26 
(73·67–
74·80)
64·48 
(61·53–
67·03)
63·87 
(63·03–
64·67)
56·45 
(54·24–
58·54)
77·22 
(75·05–
78·94)
66·83 
(63·42–
69·95)
68·17 
(66·08–
70·23)
59·99 
(57·07–
62·92)
Eastern Europe
74·39 
(73·62–
75·17)
64·24 
(61·30–
67·02)
64·17 
(63·08–
65·26)
56·40 
(54·03–
58·61)
73·71 
(72·78–
74·57)
64·01 
(61·00–
66·60)
61·30 
(59·98–
62·59)
54·31 
(52·14–
56·50)
76·64 
(73·16–
79·74)
66·36 
(62·34–
70·18)
66·07 
(62·56–
69·75)
58·32 
(54·75–
62·09)
Belarus
75·42 
(74·82–
76·01)
65·14 
(62·14–
67·87)
65·70 
(64·92–
66·48)
57·89 
(55·55–
60·12)
75·38 
(74·79–
75·96)
65·33 
(62·38–
67·97)
63·34 
(62·55–
64·18)
56·18 
(53·89–
58·22)
78·76 
(76·56–
81·04)
67·94 
(64·17–
71·31)
68·18 
(65·61–
70·84)
60·07 
(56·96–
63·14)
Estonia
75·26 
(74·76–
75·78)
64·68 
(61·52–
67·39)
64·84 
(64·18–
65·52)
56·91 
(54·53–
59·04)
78·54 
(78·03–
79·08)
67·67 
(64·52–
70·51)
67·68 
(66·99–
68·32)
59·59 
(57·26–
61·84)
81·79 
(80·70–
83·50)
70·24 
(66·74–
73·49)
72·96 
(71·30–
74·75)
63·79 
(60·86–
66·60)
Latvia
74·65 
(74·03–
75·21)
64·20 
(61·13–
66·92)
64·27 
(63·36–
65·20)
56·36 
(53·96–
58·53)
75·93 
(75·33–
76·57)
65·68 
(62·67–
68·35)
64·98 
(64·20–
65·77)
57·45 
(55·16–
59·55)
79·79 
(78·21–
81·34)
68·63 
(65·36–
71·88)
69·96 
(68·13–
72·10)
61·53 
(58·62–
64·29)
Lithuania
76·37 
(75·92–
76·81)
65·66 
(62·50–
68·43)
66·40 
(65·75–
67·05)
58·20 
(55·89–
60·35)
77·25 
(76·78–
77·69)
66·55 
(63·41–
69·39)
65·08 
(64·46–
65·73)
57·47 
(55·20–
59·56)
80·35 
(79·43–
81·33)
69·08 
(65·80–
72·07)
69·74 
(68·57–
70·95)
61·15 
(58·32–
63·59)
Moldova
70·79 
(69·73–
71·89)
61·25 
(58·46–
63·91)
63·58 
(62·30–
65·03)
56·05 
(53·64–
58·31)
72·79 
(71·81–
73·84)
63·39 
(60·49–
66·05)
65·05 
(63·70–
66·39)
57·81 
(55·42–
60·17)
76·14 
(74·59–
77·77)
66·07 
(62·90–
69·03)
68·27 
(66·56–
70·28)
60·43 
(57·66–
63·22)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1287
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Russia
74·30 
(73·15–
75·53)
64·17 
(61·24–
67·09)
63·68 
(62·12–
65·35)
55·93 
(53·49–
58·36)
73·46 
(72·10–
74·72)
63·81 
(60·78–
66·50)
60·62 
(58·76–
62·48)
53·67 
(51·21–
56·11)
76·24 
(71·41–
80·77)
66·09 
(61·24–
70·37)
65·39 
(60·82–
70·72)
57·78 
(53·22–
62·52)
Ukraine
74·59 
(73·87–
75·29)
64·44 
(61·53–
67·12)
65·17 
(64·23–
66·02)
57·37 
(54·94–
59·57)
73·73 
(73·02–
74·47)
64·05 
(61·13–
66·66)
62·11 
(61·14–
63·17)
55·18 
(53·00–
57·24)
76·98 
(73·53–
80·45)
66·71 
(62·72–
70·66)
67·03 
(63·32–
71·46)
59·28 
(55·74–
63·20)
Central Europe
74·78 
(74·56–
74·99)
64·82 
(61·91–
67·34)
67·20 
(66·93–
67·47)
59·01 
(56·59–
61·15)
78·06 
(77·86–
78·26)
67·66 
(64·65–
70·33)
70·72 
(70·48–
70·96)
62·05 
(59·48–
64·26)
80·26 
(79·81–
80·73)
69·37 
(66·15–
72·15)
73·46 
(72·92–
74·01)
64·18 
(61·51–
66·52)
Albania
76·80 
(76·16–
77·40)
66·70 
(63·79–
69·40)
70·99 
(70·33–
71·57)
62·37 
(59·85–
64·70)
77·77 
(77·25–
78·26)
67·82 
(64·84–
70·51)
72·54 
(71·95–
73·05)
63·92 
(61·30–
66·25)
80·73 
(79·37–
82·15)
70·09 
(67·00–
73·06)
74·70 
(73·12–
76·39)
65·64 
(62·73–
68·36)
Bosnia and 
Herzegovina
75·13 
(73·76–
76·67)
65·36 
(62·38–
68·11)
69·04 
(67·54–
70·60)
60·82 
(58·20–
63·58)
78·49 
(77·21–
79·85)
68·19 
(65·07–
71·10)
73·34 
(71·84–
74·76)
64·16 
(61·33–
66·77)
80·22 
(78·35–
82·06)
69·40 
(66·06–
72·61)
74·92 
(73·02–
76·90)
65·25 
(62·10–
68·20)
Bulgaria
74·75 
(74·36–
75·12)
65·12 
(62·33–
67·64)
68·21 
(67·75–
68·62)
59·90 
(57·43–
62·08)
76·38 
(76·03–
76·73)
66·65 
(63·83–
69·18)
69·21 
(68·75–
69·66)
61·13 
(58·74–
63·22)
78·48 
(76·47–
80·36)
68·23 
(64·85–
71·41)
71·66 
(69·55–
73·90)
63·05 
(60·16–
66·08)
Croatia
76·05 
(75·15–
76·92)
66·16 
(63·16–
68·86)
68·33 
(67·25–
69·54)
60·18 
(57·73–
62·48)
78·93 
(78·19–
79·66)
68·66 
(65·57–
71·40)
71·76 
(70·89–
72·70)
63·07 
(60·52–
65·48)
80·48 
(79·01–
82·09)
69·84 
(66·51–
72·81)
74·18 
(72·61–
76·00)
64·97 
(62·11–
67·80)
Czech Republic
75·56 
(75·29–
75·80)
65·19 
(62·16–
67·81)
68·09 
(67·77–
68·40)
59·76 
(57·30–
61·86)
79·71 
(79·42–
79·96)
68·54 
(65·33–
71·43)
73·32 
(73·01–
73·66)
63·79 
(61·01–
66·25)
81·89 
(81·28–
82·51)
70·17 
(66·63–
73·22)
76·25 
(75·52–
76·95)
65·99 
(62·86–
68·76)
Hungary
73·86 
(73·19–
74·59)
63·70 
(60·67–
66·39)
65·29 
(64·49–
66·12)
57·37 
(55·04–
59·60)
77·51 
(76·87–
78·17)
66·99 
(64·02–
69·86)
69·15 
(68·34–
69·98)
60·82 
(58·29–
63·12)
79·08 
(77·74–
80·34)
68·25 
(65·05–
71·40)
72·24 
(70·72–
73·89)
63·29 
(60·37–
66·06)
Macedonia
72·90 
(72·13–
73·66)
63·75 
(61·00–
66·39)
68·25 
(67·47–
69·07)
60·33 
(57·97–
62·57)
75·51 
(74·84–
76·21)
66·07 
(63·33–
68·61)
70·72 
(70·05–
71·46)
62·54 
(60·07–
64·69)
77·38 
(76·62–
78·14)
67·46 
(64·51–
70·11)
72·36 
(71·51–
73·31)
63·78 
(61·12–
66·12)
Montenegro
77·78 
(76·60–
78·77)
67·53 
(64·55–
70·39)
72·15 
(70·99–
73·33)
63·20 
(60·35–
65·67)
78·22 
(77·57–
78·80)
68·03 
(64·91–
70·75)
72·32 
(71·56–
73·15)
63·53 
(60·90–
65·94)
79·74 
(78·74–
81·20)
69·19 
(65·84–
72·36)
74·35 
(73·14–
75·51)
65·09 
(62·29–
67·77)
Poland
75·45 
(75·00–
75·89)
65·44 
(62·51–
68·02)
66·52 
(65·99–
67·14)
58·50 
(56·18–
60·68)
79·51 
(79·12–
79·95)
68·82 
(65·68–
71·57)
71·08 
(70·52–
71·66)
62·28 
(59·68–
64·58)
81·70 
(80·62–
82·78)
70·53 
(67·24–
73·68)
74·08 
(72·83–
75·37)
64·61 
(61·82–
67·22)
Romania
73·19 
(72·61–
73·78)
63·48 
(60·52–
66·01)
66·61 
(65·86–
67·30)
58·28 
(55·79–
60·54)
76·46 
(75·89–
77·05)
66·33 
(63·40–
69·05)
69·22 
(68·56–
69·89)
60·81 
(58·29–
63·07)
78·88 
(77·68–
80·08)
68·33 
(65·15–
71·19)
71·66 
(70·14–
73·15)
62·82 
(60·01–
65·52)
Serbia
75·57 
(74·59–
76·72)
65·60 
(62·61–
68·47)
69·62 
(68·54–
70·89)
61·20 
(58·60–
63·73)
76·21 
(75·52–
76·87)
66·32 
(63·47–
68·92)
70·89 
(70·13–
71·71)
62·34 
(59·78–
64·74)
78·78 
(78·14–
79·39)
68·21 
(65·12–
70·93)
73·03 
(72·20–
73·92)
63·93 
(61·27–
66·40)
Slovakia
75·40 
(74·92–
75·91)
65·48 
(62·55–
68·09)
66·74 
(66·12–
67·40)
58·67 
(56·21–
60·75)
78·32 
(77·86–
78·82)
68·02 
(65·01–
70·67)
70·47 
(69·87–
71·01)
61·80 
(59·17–
64·11)
80·39 
(79·07–
81·78)
69·59 
(66·48–
72·65)
73·43 
(71·87–
75·05)
64·10 
(61·10–
66·96)
Slovenia
77·54 
(76·57–
78·53)
66·71 
(63·55–
69·70)
69·54 
(68·45–
70·81)
60·68 
(57·92–
63·14)
81·53 
(80·68–
82·48)
69·77 
(66·41–
72·88)
74·22 
(73·07–
75·34)
64·26 
(61·17–
67·11)
83·82 
(82·53–
85·29)
71·49 
(67·82–
74·79)
77·82 
(76·19–
79·51)
67·16 
(63·87–
70·44)
Central Asia
70·96 
(70·47–
71·43)
61·67 
(58·93–
64·15)
63·41 
(62·78–
64·01)
56·13 
(53·81–
58·15)
71·21 
(70·56–
71·85)
62·21 
(59·51–
64·62)
63·14 
(62·28–
63·98)
56·21 
(54·16–
58·20)
75·11 
(74·09–
76·00)
65·35 
(62·41–
68·00)
67·50 
(66·36–
68·69)
59·80 
(57·45–
62·23)
Armenia
73·65 
(72·86–
74·55)
64·21 
(61·39–
66·67)
66·84 
(65·87–
67·83)
58·93 
(56·53–
61·07)
75·86 
(75·06–
76·62)
66·28 
(63·53–
68·81)
69·04 
(68·00–
70·04)
61·17 
(58·69–
63·40)
79·32 
(77·99–
80·71)
69·06 
(65·86–
71·81)
71·97 
(70·46–
73·52)
63·59 
(60·90–
66·11)
Azerbaijan
70·14 
(68·89–
71·42)
61·29 
(58·55–
63·91)
62·31 
(60·84–
63·68)
55·45 
(53·04–
57·80)
71·21 
(69·75–
72·64)
62·51 
(59·64–
65·19)
64·79 
(63·25–
66·29)
57·83 
(55·48–
60·13)
75·80 
(73·51–
77·94)
66·17 
(62·90–
69·11)
68·41 
(65·71–
71·21)
60·78 
(57·79–
63·89)
(Table 2 continues on next page)
 Global Health Metrics
1288 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Georgia
73·69 
(72·60–
74·77)
64·60 
(61·82–
67·19)
65·44 
(64·13–
66·83)
58·19 
(55·77–
60·33)
77·15 
(76·33–
77·91)
67·50 
(64·60–
70·01)
67·75 
(66·57–
68·93)
60·39 
(57·98–
62·58)
78·83 
(76·59–
81·37)
68·78 
(65·53–
71·92)
69·07 
(66·20–
72·20)
61·32 
(58·06–
64·46)
Kazakhstan
72·57 
(71·28–
73·83)
62·91 
(59·93–
65·60)
63·02 
(61·42–
64·78)
55·66 
(52·95–
58·03)
70·91 
(69·54–
72·39)
61·82 
(58·83–
64·44)
59·58 
(57·80–
61·41)
52·99 
(50·58–
55·46)
76·18 
(73·87–
78·50)
66·04 
(62·70–
69·28)
67·14 
(64·13–
69·98)
59·19 
(56·00–
62·47)
Kyrgyzstan
70·12 
(69·47–
70·74)
60·78 
(58·04–
63·25)
61·84 
(61·08–
62·69)
54·55 
(52·38–
56·53)
70·78 
(70·19–
71·40)
61·83 
(59·15–
64·16)
62·51 
(61·72–
63·27)
55·63 
(53·46–
57·56)
74·95 
(73·75–
76·12)
65·15 
(62·22–
67·95)
67·51 
(66·07–
68·99)
59·76 
(57·08–
62·16)
Mongolia
65·20 
(63·76–
66·84)
57·09 
(54·37–
59·60)
59·84 
(58·18–
61·22)
53·18 
(50·89–
55·48)
68·78 
(67·56–
69·88)
60·40 
(57·70–
62·78)
60·23 
(58·86–
61·76)
53·67 
(51·52–
55·83)
73·04 
(71·09–
75·10)
63·80 
(60·59–
66·78)
63·65 
(61·39–
65·84)
56·38 
(53·52–
59·08)
Tajikistan
67·42 
(65·76–
69·13)
58·79 
(56·10–
61·55)
62·44 
(60·73–
64·21)
55·20 
(52·77–
57·69)
70·35 
(68·77–
71·80)
61·69 
(58·89–
64·26)
65·68 
(64·11–
67·36)
58·31 
(55·63–
60·71)
74·34 
(72·42–
76·08)
64·95 
(61·89–
67·79)
69·41 
(67·10–
71·52)
61·41 
(58·46–
64·17)
Turkmenistan
67·10 
(66·05–
68·06)
58·73 
(55·99–
61·13)
60·29 
(59·01–
61·58)
53·72 
(51·34–
55·90)
69·90 
(68·65–
71·06)
61·43 
(58·65–
63·85)
61·78 
(60·32–
63·14)
55·19 
(52·77–
57·37)
74·00 
(72·71–
75·15)
64·86 
(62·01–
67·41)
66·48 
(65·09–
67·80)
59·26 
(56·77–
61·54)
Uzbekistan
71·30 
(70·34–
72·21)
61·69 
(58·72–
64·34)
65·26 
(64·22–
66·31)
57·73 
(55·40–
60·00)
70·16 
(68·96–
71·38)
61·23 
(58·40–
63·90)
64·02 
(62·34–
65·56)
57·06 
(54·76–
59·46)
73·50 
(71·85–
75·16)
63·99 
(60·85–
66·87)
67·08 
(65·28–
68·84)
59·63 
(56·99–
62·15)
Latin America 
and Caribbean
72·68 
(72·47–
72·88)
63·19 
(60·37–
65·62)
66·44 
(66·15–
66·70)
58·85 
(56·56–
60·86)
77·02 
(76·79–
77·24)
66·87 
(63·91–
69·49)
70·87 
(70·59–
71·12)
62·65 
(60·25–
64·80)
78·89 
(78·44–
79·29)
68·50 
(65·36–
71·17)
72·75 
(72·23–
73·22)
64·24 
(61·68–
66·39)
Central Latin 
America
74·27 
(74·01–
74·52)
64·94 
(62·15–
67·38)
68·10 
(67·78–
68·43)
60·43 
(58·05–
62·41)
77·98 
(77·72–
78·24)
68·23 
(65·34–
70·75)
72·07 
(71·74–
72·39)
63·97 
(61·57–
66·13)
79·44 
(78·96–
79·94)
69·42 
(66·40–
71·99)
73·58 
(72·90–
74·21)
65·21 
(62·67–
67·40)
Colombia
75·14 
(74·65–
75·61)
65·94 
(63·10–
68·39)
67·62 
(67·02–
68·16)
60·35 
(58·03–
62·34)
78·34 
(77·93–
78·75)
68·76 
(65·91–
71·28)
72·04 
(71·54–
72·55)
64·29 
(61·90–
66·41)
81·05 
(79·95–
82·12)
71·08 
(68·06–
73·83)
75·42 
(74·17–
76·72)
67·08 
(64·50–
69·48)
Costa Rica
78·90 
(78·33–
79·44)
69·10 
(66·16–
71·74)
74·24 
(73·67–
74·83)
66·15 
(63·73–
68·37)
82·16 
(81·63–
82·63)
71·73 
(68·60–
74·44)
77·09 
(76·50–
77·68)
68·42 
(65·76–
70·84)
83·57 
(82·65–
84·51)
72·85 
(69·62–
75·81)
78·47 
(77·41–
79·58)
69·52 
(66·66–
72·08)
El Salvador
72·47 
(71·78–
73·20)
63·57 
(60·78–
66·00)
63·87 
(62·97–
64·87)
56·75 
(54·59–
58·80)
77·36 
(76·76–
78·00)
67·83 
(64·98–
70·32)
69·32 
(68·50–
70·20)
61·47 
(59·00–
63·74)
79·07 
(77·61–
80·53)
69·30 
(66·19–
72·15)
71·46 
(69·33–
73·45)
63·36 
(60·64–
66·09)
Guatemala
66·49 
(64·79–
68·38)
58·05 
(55·25–
60·73)
62·75 
(60·95–
65·05)
55·37 
(52·93–
58·14)
73·75 
(71·64–
75·73)
64·16 
(60·86–
67·31)
66·57 
(64·06–
69·21)
58·78 
(55·71–
61·97)
76·03 
(72·36–
79·77)
66·34 
(62·24–
70·02)
69·40 
(65·37–
73·96)
61·41 
(57·28–
65·80)
Honduras
67·23 
(65·64–
68·91)
59·20 
(56·47–
61·74)
67·35 
(63·79–
70·22)
59·91 
(56·85–
63·19)
71·72 
(68·57–
75·52)
63·09 
(59·35–
66·67)
69·97 
(65·91–
74·24)
62·44 
(58·43–
66·60)
73·71 
(70·41–
77·70)
64·78 
(60·90–
68·63)
71·64 
(67·32–
75·82)
63·86 
(59·59–
67·72)
Mexico
74·77 
(74·46–
75·10)
65·19 
(62·44–
67·68)
68·33 
(67·95–
68·72)
60·44 
(58·05–
62·49)
78·14 
(77·79–
78·46)
68·29 
(65·38–
70·81)
72·79 
(72·42–
73·13)
64·44 
(61·96–
66·62)
79·11 
(78·65–
79·56)
69·00 
(65·92–
71·58)
73·71 
(73·20–
74·19)
65·17 
(62·59–
67·43)
Nicaragua
76·43 
(75·87–
77·02)
66·58 
(63·66–
69·19)
70·74 
(70·04–
71·41)
62·56 
(59·98–
64·83)
79·65 
(79·10–
80·27)
69·67 
(66·69–
72·42)
74·08 
(73·42–
74·74)
65·79 
(63·30–
68·12)
81·17 
(79·21–
83·22)
70·94 
(67·63–
74·13)
75·25 
(72·85–
77·72)
66·84 
(63·52–
69·99)
Panama
77·54 
(76·65–
78·49)
67·96 
(65·04–
70·56)
72·50 
(71·40–
73·60)
64·56 
(62·18–
66·83)
80·33 
(79·47–
81·20)
70·30 
(67·20–
73·04)
74·78 
(73·66–
75·91)
66·44 
(63·89–
68·76)
81·98 
(80·38–
83·60)
71·57 
(68·22–
74·62)
76·03 
(73·97–
78·07)
67·33 
(64·33–
70·19)
Venezuela
75·41 
(74·60–
76·29)
66·21 
(63·41–
68·75)
69·98 
(68·88–
70·90)
62·40 
(59·97–
64·62)
79·05 
(78·13–
79·89)
69·26 
(66·19–
71·84)
70·98 
(69·93–
72·11)
63·25 
(60·76–
65·44)
79·79 
(77·49–
81·84)
69·87 
(66·40–
73·26)
71·30 
(68·22–
73·83)
63·46 
(60·14–
66·42)
Andean Latin 
America
70·08 
(69·45–
70·78)
61·05 
(58·27–
63·48)
66·45 
(65·71–
67·13)
58·65 
(56·38–
60·66)
77·68 
(77·01–
78·35)
67·63 
(64·50–
70·22)
73·50 
(72·83–
74·19)
64·81 
(62·21–
67·09)
79·76 
(78·33–
81·16)
69·43 
(66·22–
72·41)
76·02 
(74·60–
77·53)
66·99 
(64·01–
69·65)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1289
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Bolivia
62·16 
(60·65–
63·60)
54·02 
(51·26–
56·57)
60·53 
(59·19–
61·86)
53·13 
(50·77–
55·31)
71·77 
(70·20–
73·10)
62·29 
(59·32–
65·00)
69·14 
(67·72–
70·73)
60·72 
(57·94–
63·35)
74·27 
(71·23–
76·97)
64·59 
(60·91–
67·96)
72·23 
(69·63–
75·00)
63·45 
(60·07–
66·93)
Ecuador
73·91 
(73·34–
74·50)
64·46 
(61·68–
67·01)
68·98 
(68·32–
69·61)
60·96 
(58·50–
63·15)
78·62 
(78·06–
79·21)
68·58 
(65·52–
71·15)
73·05 
(72·29–
73·76)
64·42 
(61·86–
66·79)
80·36 
(79·36–
81·30)
70·02 
(66·82–
72·77)
75·35 
(74·11–
76·49)
66·43 
(63·73–
69·03)
Peru
71·42 
(70·42–
72·50)
62·21 
(59·36–
64·81)
67·44 
(66·30–
68·55)
59·59 
(57·17–
61·81)
79·55 
(78·55–
80·63)
69·25 
(66·06–
72·00)
75·44 
(74·35–
76·53)
66·62 
(63·82–
69·13)
81·60 
(79·22–
83·98)
71·03 
(67·47–
74·59)
77·80 
(75·33–
80·32)
68·64 
(65·32–
71·83)
Caribbean
69·50 
(68·81–
70·13)
60·44 
(57·64–
62·88)
65·93 
(65·29–
66·61)
58·28 
(55·90–
60·50)
72·40 
(71·53–
73·27)
62·90 
(60·07–
65·48)
68·67 
(67·79–
69·54)
60·57 
(58·07–
62·88)
75·35 
(74·02–
76·61)
65·39 
(62·39–
68·26)
71·00 
(69·69–
72·33)
62·58 
(59·79–
65·00)
Antigua and 
Barbuda
76·68 
(75·47–
77·85)
66·92 
(63·82–
69·77)
70·84 
(69·63–
71·97)
62·64 
(60·04–
65·02)
78·76 
(77·61–
79·93)
68·43 
(65·23–
71·40)
73·34 
(72·15–
74·65)
64·53 
(61·68–
67·13)
79·92 
(78·32–
81·59)
69·37 
(65·99–
72·65)
74·65 
(72·67–
76·41)
65·61 
(62·64–
68·53)
The Bahamas
74·00 
(73·00–
74·89)
64·52 
(61·51–
67·24)
67·09 
(66·00–
68·09)
59·62 
(57·31–
61·77)
76·19 
(75·39–
77·01)
66·38 
(63·53–
69·02)
70·46 
(69·68–
71·19)
62·45 
(60·10–
64·62)
76·30 
(74·58–
77·97)
66·49 
(63·31–
69·38)
71·33 
(69·70–
72·93)
63·22 
(60·52–
65·91)
Barbados
76·16 
(75·12–
77·15)
66·36 
(63·33–
69·04)
70·92 
(69·66–
71·99)
62·90 
(60·42–
65·23)
78·49 
(77·53–
79·38)
68·02 
(64·90–
70·80)
73·54 
(72·47–
74·50)
64·95 
(62·20–
67·34)
78·68 
(77·25–
80·06)
68·10 
(64·80–
71·19)
74·38 
(72·78–
75·92)
65·64 
(62·79–
68·37)
Belize
73·93 
(72·68–
75·23)
64·26 
(61·15–
67·05)
69·38 
(67·81–
70·50)
61·39 
(58·70–
63·71)
73·29 
(72·38–
74·17)
63·80 
(60·87–
66·53)
67·40 
(66·22–
68·53)
59·76 
(57·23–
62·05)
74·95 
(73·10–
76·81)
65·15 
(61·97–
68·12)
69·11 
(67·10–
71·40)
61·25 
(58·23–
64·02)
Bermuda
72·90 
(71·87–
73·98)
63·98 
(61·26–
66·60)
66·78 
(65·67–
67·86)
59·48 
(57·02–
61·60)
78·00 
(76·91–
79·03)
68·18 
(65·20–
70·92)
72·81 
(71·81–
73·79)
64·62 
(62·21–
66·92)
82·39 
(80·69–
84·46)
71·70 
(68·30–
74·84)
75·74 
(74·10–
77·22)
67·03 
(64·10–
69·63)
Cuba
76·98 
(76·43–
77·56)
66·87 
(63·85–
69·51)
72·70 
(72·06–
73·27)
64·51 
(61·96–
66·78)
79·92 
(79·40–
80·40)
69·58 
(66·44–
72·32)
75·70 
(75·10–
76·28)
67·09 
(64·47–
69·42)
81·30 
(80·31–
82·36)
70·66 
(67·44–
73·66)
76·66 
(75·59–
77·74)
67·80 
(65·03–
70·35)
Dominica
73·68 
(72·69–
74·70)
64·65 
(61·88–
67·09)
70·44 
(69·45–
71·54)
62·42 
(59·96–
64·72)
75·98 
(74·80–
77·05)
66·47 
(63·56–
69·05)
70·83 
(69·73–
71·92)
62·68 
(60·23–
64·98)
75·84 
(73·91–
77·37)
66·21 
(63·22–
69·11)
70·19 
(67·89–
72·38)
62·08 
(59·01–
65·02)
Dominican 
Republic
72·72 
(72·03–
73·64)
63·61 
(60·92–
66·27)
68·92 
(67·91–
69·97)
61·20 
(58·76–
63·51)
76·56 
(75·18–
78·17)
66·72 
(63·43–
69·68)
70·72 
(69·57–
72·27)
62·60 
(60·06–
65·04)
78·57 
(76·90–
80·63)
68·47 
(65·35–
71·80)
72·88 
(71·17–
74·87)
64·51 
(61·65–
67·18)
Grenada
73·07 
(71·50–
74·35)
63·29 
(60·23–
66·00)
68·65 
(66·90–
70·37)
60·45 
(57·69–
63·13)
73·99 
(72·55–
75·31)
64·33 
(61·30–
67·01)
68·33 
(67·02–
69·71)
60·44 
(57·82–
62·97)
74·43 
(72·29–
76·68)
64·67 
(61·62–
67·69)
68·80 
(66·68–
71·09)
60·80 
(57·83–
63·61)
Guyana
67·79 
(66·80–
68·87)
58·86 
(56·01–
61·35)
60·94 
(59·78–
62·10)
53·86 
(51·57–
56·07)
68·30 
(67·14–
69·35)
59·16 
(56·33–
61·63)
61·77 
(60·64–
62·99)
54·48 
(52·07–
56·63)
71·17 
(69·59–
72·89)
61·60 
(58·62–
64·52)
64·67 
(62·99–
66·41)
57·01 
(54·30–
59·41)
Haiti
54·27 
(52·55–
56·07)
47·10 
(44·54–
49·51)
53·86 
(52·03–
55·82)
47·16 
(44·50–
49·59)
58·20 
(55·79–
60·80)
50·59 
(47·70–
53·48)
58·51 
(56·00–
61·09)
51·37 
(48·35–
54·31)
64·42 
(61·40–
67·53)
55·98 
(52·71–
59·53)
63·58 
(60·17–
66·93)
55·92 
(52·30–
59·54)
Jamaica
75·36 
(74·03–
76·62)
65·33 
(62·13–
68·20)
73·44 
(72·09–
74·70)
64·70 
(61·97–
67·25)
76·36 
(75·09–
77·66)
66·06 
(62·79–
69·00)
73·28 
(71·90–
74·66)
64·54 
(61·62–
67·13)
76·79 
(74·50–
79·15)
66·43 
(63·09–
69·99)
73·06 
(70·43–
75·53)
64·33 
(61·11–
67·43)
Puerto Rico
78·45 
(77·86–
79·07)
68·36 
(65·33–
71·06)
69·65 
(68·82–
70·46)
61·58 
(59·12–
63·83)
81·08 
(80·48–
81·63)
70·21 
(66·94–
73·17)
73·52 
(72·69–
74·23)
64·40 
(61·61–
66·85)
82·36 
(81·27–
83·54)
71·33 
(68·04–
74·29)
75·04 
(73·74–
76·39)
65·81 
(62·94–
68·39)
Saint Lucia
74·26 
(73·22–
75·19)
64·00 
(60·85–
66·81)
69·52 
(68·34–
70·56)
60·90 
(58·14–
63·36)
77·55 
(76·60–
78·37)
67·25 
(64·22–
70·02)
71·39 
(70·30–
72·29)
62·91 
(60·23–
65·30)
79·29 
(78·14–
80·36)
68·59 
(65·28–
71·52)
73·05 
(71·64–
74·27)
64·24 
(61·19–
66·75)
Saint Vincent 
and the 
Grenadines
72·72 
(71·69–
73·72)
63·32 
(60·36–
65·87)
68·54 
(67·17–
69·93)
60·62 
(58·00–
62·99)
73·96 
(73·29–
74·76)
64·30 
(61·47–
67·01)
68·62 
(67·69–
69·48)
60·56 
(58·17–
62·78)
74·80 
(73·67–
76·09)
65·00 
(62·00–
67·90)
68·80 
(67·42–
70·06)
60·65 
(58·05–
63·14)
(Table 2 continues on next page)
 Global Health Metrics
1290 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Suriname
72·53 
(71·89–
73·22)
62·93 
(59·91–
65·65)
67·75 
(66·99–
68·41)
59·79 
(57·40–
61·92)
72·46 
(71·60–
73·26)
62·79 
(59·75–
65·34)
66·70 
(65·95–
67·45)
58·89 
(56·40–
61·02)
74·37 
(73·12–
75·41)
64·32 
(61·24–
67·12)
68·41 
(67·13–
69·69)
60·24 
(57·53–
62·67)
Trinidad and 
Tobago
71·87 
(71·25–
72·56)
62·39 
(59·64–
64·91)
66·28 
(65·59–
66·97)
58·68 
(56·31–
60·87)
75·17 
(74·41–
75·89)
65·04 
(61·98–
67·79)
68·14 
(67·33–
68·96)
59·89 
(57·46–
62·16)
76·98 
(75·63–
78·20)
66·48 
(63·13–
69·33)
69·31 
(67·78–
70·76)
60·75 
(57·91–
63·36)
Virgin Islands
76·11 
(75·19–
77·53)
66·70 
(63·82–
69·42)
69·19 
(68·00–
70·51)
61·53 
(59·07–
63·76)
77·74 
(76·93–
78·51)
67·90 
(64·87–
70·49)
70·08 
(68·90–
71·14)
62·18 
(59·66–
64·42)
78·77 
(77·54–
80·06)
68·65 
(65·55–
71·60)
70·63 
(68·75–
72·91)
62·58 
(59·71–
65·48)
Tropical Latin 
America
72·47 
(72·03–
72·91)
62·56 
(59·56–
65·08)
64·85 
(64·34–
65·35)
57·38 
(55·02–
59·42)
76·95 
(76·51–
77·34)
66·18 
(62·94–
68·96)
69·57 
(69·10–
70·00)
61·27 
(58·86–
63·46)
78·92 
(78·42–
79·40)
67·98 
(64·72–
70·81)
71·59 
(70·97–
72·12)
62·99 
(60·40–
65·22)
Brazil
72·40 
(71·94–
72·85)
62·50 
(59·50–
65·07)
64·64 
(64·13–
65·16)
57·20 
(54·86–
59·22)
77·01 
(76·56–
77·40)
66·21 
(62·96–
69·01)
69·49 
(69·01–
69·92)
61·20 
(58·75–
63·39)
79·00 
(78·49–
79·49)
68·05 
(64·76–
70·88)
71·56 
(70·94–
72·10)
62·96 
(60·36–
65·16)
Paraguay
76·30 
(75·51–
76·96)
65·92 
(62·83–
68·70)
72·86 
(72·16–
73·63)
64·25 
(61·74–
66·64)
76·20 
(75·30–
77·15)
65·88 
(62·68–
68·75)
72·04 
(71·31–
72·71)
63·45 
(60·88–
65·75)
77·10 
(75·69–
78·52)
66·50 
(63·13–
69·55)
72·09 
(70·29–
73·53)
63·58 
(60·67–
66·17)
Southeast Asia, 
east Asia, and 
Oceania
68·81 
(68·39–
69·21)
60·57 
(58·22–
62·65)
64·47 
(64·04–
64·88)
57·98 
(56·05–
59·68)
74·53 
(74·29–
74·77)
65·49 
(62·86–
67·79)
69·18 
(68·89–
69·46)
62·13 
(60·08–
64·01)
78·37 
(78·08–
78·64)
68·55 
(65·74–
71·01)
72·11 
(71·76–
72·42)
64·57 
(62·36–
66·48)
East Asia
69·41 
(68·83–
69·96)
61·28 
(58·95–
63·37)
65·16 
(64·58–
65·69)
58·89 
(57·00–
60·58)
75·81 
(75·53–
76·10)
66·80 
(64·19–
69·11)
70·34 
(70·04–
70·64)
63·49 
(61·45–
65·35)
79·81 
(79·51–
80·12)
69·96 
(67·21–
72·47)
73·29 
(72·97–
73·63)
65·94 
(63·80–
67·83)
China
69·20 
(68·61–
69·76)
61·11 
(58·80–
63·20)
64·98 
(64·41–
65·53)
58·75 
(56·87–
60·44)
75·81 
(75·51–
76·11)
66·83 
(64·23–
69·14)
70·34 
(70·03–
70·65)
63·50 
(61·47–
65·37)
79·93 
(79·63–
80·24)
70·06 
(67·29–
72·55)
73·36 
(73·04–
73·69)
66·01 
(63·88–
67·91)
North Korea
74·06 
(72·75–
75·74)
65·06 
(62·20–
67·84)
69·18 
(67·60–
71·13)
62·46 
(60·03–
64·70)
72·48 
(71·28–
73·81)
63·39 
(60·56–
66·10)
67·13 
(66·02–
68·33)
60·62 
(58·62–
62·50)
73·59 
(72·47–
74·73)
64·70 
(61·97–
67·31)
67·88 
(66·67–
69·08)
61·17 
(58·94–
63·24)
Taiwan 
(Province of 
China)
76·89 
(76·37–
77·41)
67·05 
(64·12–
69·73)
71·51 
(70·87–
72·12)
63·93 
(61·56–
65·98)
81·18 
(80·69–
81·66)
70·66 
(67·64–
73·26)
74·93 
(74·33–
75·59)
66·97 
(64·74–
69·04)
82·84 
(81·44–
84·41)
72·06 
(68·74–
75·22)
76·68 
(74·97–
78·54)
68·36 
(65·70–
70·89)
Southeast Asia
67·54 
(67·07–
68·01)
59·01 
(56·53–
61·29)
63·14 
(62·68–
63·59)
55·93 
(53·88–
57·83)
72·13 
(71·76–
72·56)
63·04 
(60·38–
65·34)
67·15 
(66·61–
67·64)
59·50 
(57·41–
61·49)
75·51 
(75·03–
75·96)
65·84 
(63·04–
68·32)
69·96 
(69·31–
70·56)
61·94 
(59·60–
63·93)
Cambodia
59·25 
(58·26–
60·38)
51·14 
(48·49–
53·52)
55·50 
(54·32–
56·71)
48·59 
(46·34–
50·71)
66·38 
(65·50–
67·29)
57·46 
(54·75–
59·88)
61·11 
(59·88–
62·24)
53·61 
(51·44–
55·67)
71·60 
(70·52–
72·72)
62·14 
(59·37–
64·72)
65·72 
(64·50–
67·01)
57·97 
(55·56–
60·13)
Indonesia
64·90 
(64·34–
65·40)
56·93 
(54·56–
59·05)
62·37 
(61·83–
62·90)
55·36 
(53·33–
57·28)
70·24 
(69·77–
70·68)
61·59 
(58·97–
63·78)
67·39 
(66·80–
68·02)
59·74 
(57·49–
61·82)
73·56 
(72·96–
74·12)
64·15 
(61·36–
66·57)
69·82 
(68·83–
70·75)
61·78 
(59·34–
63·95)
Laos
54·18 
(52·72–
55·48)
47·28 
(44·92–
49·41)
50·74 
(49·16–
52·24)
44·90 
(42·56–
47·03)
63·14 
(61·87–
64·24)
55·13 
(52·55–
57·41)
58·71 
(57·49–
59·91)
51·99 
(49·78–
54·10)
69·70 
(68·04–
71·13)
60·82 
(57·98–
63·41)
64·82 
(62·91–
66·40)
57·37 
(54·73–
59·81)
Malaysia
73·70 
(73·40–
74·04)
64·48 
(61·72–
66·81)
69·61 
(69·27–
69·95)
61·94 
(59·67–
63·97)
75·99 
(75·74–
76·23)
66·58 
(63·75–
68·95)
72·12 
(71·80–
72·45)
63·96 
(61·61–
66·06)
78·05 
(77·50–
78·57)
68·14 
(65·17–
70·73)
73·16 
(72·41–
73·94)
64·78 
(62·37–
66·97)
Maldives
62·00 
(60·92–
63·23)
53·61 
(51·08–
56·05)
62·85 
(61·73–
64·05)
55·11 
(52·72–
57·26)
77·42 
(76·45–
78·47)
66·95 
(63·89–
69·74)
75·23 
(74·21–
76·20)
66·13 
(63·33–
68·64)
81·33 
(78·62–
83·96)
70·26 
(66·32–
73·72)
77·58 
(74·97–
80·31)
68·23 
(64·84–
71·50)
Mauritius
73·42 
(72·89–
73·94)
63·63 
(60·79–
66·22)
65·39 
(64·86–
65·92)
58·03 
(55·89–
59·98)
75·89 
(75·31–
76·40)
65·67 
(62·62–
68·28)
69·19 
(68·61–
69·83)
60·98 
(58·61–
63·08)
77·81 
(76·00–
79·57)
67·12 
(63·74–
70·36)
71·42 
(69·59–
73·36)
62·67 
(59·53–
65·47)
Myanmar
60·93 
(59·45–
62·34)
53·09 
(50·61–
55·57)
56·26 
(54·54–
57·98)
49·56 
(47·16–
51·97)
67·28 
(65·95–
68·50)
58·84 
(56·20–
61·27)
61·28 
(58·40–
63·10)
54·21 
(51·28–
56·61)
73·35 
(72·38–
74·34)
64·11 
(61·36–
66·65)
66·73 
(65·16–
67·87)
59·04 
(56·43–
61·32)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1291
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Philippines
70·92 
(70·24–
71·61)
61·69 
(58·96–
64·14)
63·45 
(62·60–
64·36)
55·80 
(53·48–
57·96)
72·07 
(71·24–
72·76)
62·73 
(59·95–
65·22)
64·58 
(63·69–
65·46)
57·07 
(54·88–
59·12)
73·87 
(72·05–
75·85)
64·47 
(61·52–
67·57)
66·64 
(64·58–
68·74)
59·07 
(56·50–
61·71)
Sri Lanka
75·38 
(74·55–
76·26)
65·51 
(62·68–
68·15)
67·77 
(66·67–
68·89)
59·80 
(57·30–
62·16)
78·31 
(77·17–
79·27)
68·15 
(65·22–
70·82)
70·46 
(69·17–
71·65)
62·27 
(59·85–
64·54)
81·09 
(78·67–
83·77)
70·47 
(66·87–
74·07)
73·72 
(70·53–
76·90)
65·07 
(61·57–
68·32)
Seychelles
74·15 
(73·50–
74·82)
65·14 
(62·54–
67·54)
64·48 
(63·41–
65·58)
57·71 
(55·61–
59·61)
76·20 
(75·56–
77·25)
66·77 
(63·92–
69·39)
68·64 
(67·74–
69·55)
61·10 
(58·91–
63·25)
77·40 
(76·02–
78·87)
67·72 
(64·76–
70·58)
70·25 
(68·17–
72·03)
62·41 
(59·83–
64·93)
Thailand
74·08 
(73·42–
74·68)
64·41 
(61·59–
66·96)
67·20 
(66·41–
68·01)
59·48 
(57·24–
61·59)
77·81 
(77·23–
78·38)
67·73 
(64·85–
70·31)
71·48 
(70·70–
72·29)
63·15 
(60·71–
65·36)
80·91 
(79·63–
82·00)
70·24 
(67·11–
73·26)
74·59 
(72·93–
76·22)
65·71 
(62·91–
68·38)
Timor-Leste
57·61 
(54·99–
60·60)
50·23 
(47·11–
53·26)
58·39 
(56·06–
60·79)
50·62 
(47·62–
53·51)
69·06 
(66·95–
71·25)
60·09 
(57·11–
63·16)
67·57 
(65·41–
69·81)
58·60 
(55·53–
61·71)
73·68 
(70·57–
76·59)
64·27 
(60·67–
67·86)
71·69 
(68·65–
74·73)
62·39 
(58·56–
65·67)
Vietnam
71·11 
(69·45–
73·05)
62·16 
(59·16–
65·03)
65·27 
(63·23–
67·12)
58·12 
(55·61–
60·67)
75·49 
(73·94–
77·73)
66·09 
(63·17–
69·01)
68·53 
(66·58–
70·74)
61·21 
(58·75–
63·77)
78·10 
(76·59–
79·12)
68·44 
(65·57–
71·08)
70·87 
(69·14–
72·67)
63·30 
(60·72–
65·77)
Oceania
60·31 
(58·44–
62·02)
52·36 
(49·47–
54·96)
56·79 
(55·08–
58·47)
50·27 
(47·85–
52·56)
61·11 
(58·80–
63·18)
53·01 
(49·94–
55·71)
58·35 
(56·00–
60·49)
51·58 
(48·75–
54·22)
63·76 
(61·41–
66·00)
55·16 
(51·88–
58·03)
60·72 
(58·24–
62·92)
53·57 
(50·64–
56·19)
American 
Samoa
75·02 
(73·75–
76·44)
64·48 
(61·29–
67·60)
66·93 
(65·44–
68·49)
58·64 
(56·07–
61·15)
74·38 
(72·61–
75·88)
63·93 
(60·72–
67·22)
69·25 
(67·72–
70·70)
60·50 
(57·64–
63·08)
74·43 
(71·97–
77·03)
63·94 
(60·47–
67·29)
70·37 
(67·82–
72·73)
61·39 
(58·12–
64·51)
Federated 
States of 
Micronesia
65·60 
(63·23–
67·73)
57·09 
(53·99–
59·87)
61·03 
(58·77–
63·16)
54·13 
(51·41–
56·65)
67·23 
(64·39–
69·83)
58·56 
(55·40–
61·67)
64·01 
(61·74–
66·18)
56·67 
(53·87–
59·30)
67·58 
(64·54–
70·55)
58·84 
(55·44–
62·17)
63·57 
(60·73–
66·27)
56·28 
(53·25–
59·28)
Fiji
68·04 
(63·85–
72·17)
58·99 
(54·86–
62·98)
62·73 
(59·19–
66·20)
55·32 
(51·72–
58·77)
67·12 
(65·31–
69·36)
58·07 
(54·97–
61·03)
62·61 
(60·57–
64·97)
55·23 
(52·53–
57·84)
67·67 
(63·49–
71·89)
58·63 
(54·64–
62·73)
63·27 
(59·17–
67·99)
56·00 
(52·16–
60·22)
Guam
76·44 
(75·25–
77·71)
66·30 
(63·15–
69·05)
70·34 
(68·94–
71·64)
62·61 
(60·08–
64·88)
76·69 
(75·63–
77·75)
66·43 
(63·41–
69·36)
70·14 
(68·50–
71·30)
62·27 
(59·67–
64·55)
76·09 
(74·28–
78·08)
65·75 
(62·62–
68·84)
69·05 
(66·86–
71·35)
61·20 
(58·42–
63·78)
Kiribati
60·87 
(58·96–
62·74)
52·77 
(49·98–
55·51)
55·53 
(53·76–
57·42)
49·42 
(47·04–
51·64)
63·92 
(61·83–
65·92)
55·29 
(52·20–
58·18)
56·63 
(54·56–
58·59)
50·15 
(47·47–
52·68)
65·59 
(62·39–
68·39)
56·70 
(53·26–
60·06)
58·17 
(55·44–
61·12)
51·49 
(48·39–
54·51)
Marshall 
Islands
67·99 
(66·53–
69·39)
58·54 
(55·60–
61·38)
61·47 
(59·95–
62·84)
54·23 
(51·81–
56·48)
65·11 
(63·20–
67·11)
56·14 
(53·04–
59·02)
61·00 
(59·18–
62·90)
53·70 
(51·07–
56·26)
67·26 
(64·36–
70·12)
57·87 
(54·25–
61·23)
62·75 
(60·08–
65·45)
55·07 
(52·11–
58·20)
Northern 
Mariana 
Islands
74·74 
(72·01–
77·56)
64·95 
(61·34–
68·42)
72·67 
(70·19–
75·43)
64·25 
(61·24–
67·37)
77·62 
(75·38–
79·86)
67·24 
(63·57–
70·35)
74·91 
(72·81–
76·87)
65·99 
(62·86–
68·76)
77·37 
(74·86–
79·95)
66·90 
(63·25–
70·24)
73·88 
(71·52–
76·20)
65·02 
(62·01–
67·86)
Papua New 
Guinea
57·55 
(55·23–
59·80)
49·98 
(47·04–
52·65)
54·45 
(52·17–
56·65)
48·22 
(45·54–
50·61)
58·93 
(55·93–
61·58)
51·16 
(47·90–
54·17)
56·57 
(53·58–
59·29)
50·03 
(46·91–
52·97)
62·17 
(59·37–
64·96)
53·81 
(50·34–
56·94)
59·50 
(56·53–
62·33)
52·50 
(49·24–
55·40)
Samoa
72·32 
(70·28–
74·30)
62·82 
(59·73–
65·93)
65·84 
(63·47–
67·86)
58·20 
(55·27–
60·85)
73·62 
(71·80–
75·57)
63·79 
(60·62–
66·81)
68·98 
(67·00–
70·99)
60·94 
(58·20–
63·63)
74·00 
(71·99–
76·12)
64·09 
(60·85–
67·24)
69·90 
(67·94–
72·24)
61·73 
(58·95–
64·39)
Solomon 
Islands
61·76 
(59·54–
64·33)
53·80 
(50·92–
56·89)
58·55 
(56·42–
61·01)
52·15 
(49·75–
54·77)
62·15 
(59·76–
64·69)
54·07 
(51·07–
56·93)
60·06 
(57·82–
62·35)
53·36 
(50·66–
55·92)
64·24 
(61·49–
66·86)
55·79 
(52·73–
58·68)
61·91 
(59·31–
64·32)
54·85 
(52·12–
57·46)
Tonga
70·12 
(67·56–
72·67)
60·50 
(57·17–
63·85)
65·71 
(63·10–
68·33)
58·15 
(55·13–
61·11)
72·43 
(70·40–
74·34)
62·32 
(58·91–
65·47)
66·85 
(64·60–
69·05)
59·07 
(56·15–
61·55)
73·33 
(70·85–
75·64)
63·03 
(59·33–
66·31)
67·50 
(65·23–
70·07)
59·46 
(56·61–
62·26)
Vanuatu
63·86 
(61·77–
66·01)
55·35 
(52·25–
58·43)
59·86 
(57·86–
61·86)
53·15 
(50·44–
55·83)
63·97 
(61·41–
66·27)
55·50 
(52·38–
58·48)
60·75 
(58·57–
62·89)
54·04 
(51·41–
56·65)
65·68 
(62·77–
68·20)
56·81 
(53·52–
60·12)
62·22 
(59·66–
64·66)
55·23 
(52·22–
58·05)
(Table 2 continues on next page)
 Global Health Metrics
1292 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
North Africa and 
Middle East
68·93 
(68·42–
69·38)
57·92 
(54·77–
60·69)
65·01 
(64·43–
65·60)
56·14 
(53·49–
58·51)
73·19 
(72·67–
73·67)
61·72 
(58·38–
64·77)
69·13 
(68·46–
69·80)
59·90 
(57·22–
62·30)
75·59 
(74·89–
76·29)
63·66 
(60·17–
66·71)
70·90 
(70·05–
71·78)
61·41 
(58·64–
63·99)
Afghanistan
51·35 
(49·83–
52·92)
42·97 
(40·24–
45·55)
51·87 
(50·14–
53·90)
44·20 
(41·28–
46·73)
54·51 
(53·00–
55·97)
46·03 
(43·31–
48·59)
53·80 
(51·93–
55·70)
46·34 
(43·59–
49·01)
59·16 
(57·45–
60·78)
49·95 
(46·99–
52·73)
56·83 
(54·45–
59·11)
49·11 
(46·21–
51·87)
Algeria
72·56 
(71·34–
73·76)
61·07 
(57·66–
64·19)
69·44 
(68·19–
70·72)
60·04 
(57·20–
62·71)
76·85 
(75·62–
77·68)
64·85 
(61·39–
68·08)
74·42 
(73·29–
75·58)
64·42 
(61·43–
67·15)
78·41 
(77·46–
79·34)
66·11 
(62·60–
69·36)
76·43 
(75·06–
77·66)
66·04 
(62·82–
68·90)
Bahrain
70·99 
(69·28–
72·59)
59·71 
(56·49–
63·00)
68·54 
(66·94–
70·18)
59·52 
(56·73–
62·36)
74·94 
(73·50–
76·48)
62·73 
(59·17–
66·14)
72·76 
(71·18–
74·39)
62·85 
(59·79–
65·88)
77·81 
(75·72–
80·15)
65·01 
(61·16–
68·83)
75·99 
(73·45–
78·51)
65·52 
(61·84–
68·99)
Egypt
67·29 
(66·32–
68·21)
56·84 
(53·88–
59·56)
63·32 
(62·42–
64·29)
55·04 
(52·44–
57·31)
72·89 
(72·08–
73·70)
61·63 
(58·41–
64·61)
67·66 
(66·77–
68·54)
59·00 
(56·40–
61·49)
74·98 
(73·15–
76·99)
63·54 
(60·05–
66·80)
69·44 
(67·60–
71·52)
60·64 
(57·89–
63·40)
Iran
71·07 
(68·91–
73·37)
59·86 
(56·10–
63·19)
65·24 
(62·58–
68·12)
56·37 
(53·08–
59·74)
75·20 
(72·96–
77·42)
63·59 
(59·94–
66·96)
70·75 
(68·00–
73·35)
61·37 
(57·97–
64·66)
78·38 
(76·58–
80·58)
66·03 
(62·27–
69·57)
73·78 
(71·23–
76·22)
63·72 
(60·16–
66·85)
Iraq
67·58 
(65·61–
69·71)
56·63 
(53·29–
59·79)
64·75 
(62·05–
67·37)
55·19 
(51·77–
58·30)
66·88 
(64·23–
69·42)
56·47 
(52·82–
59·86)
60·90 
(57·38–
65·04)
52·54 
(48·76–
56·43)
70·48 
(67·37–
73·54)
59·26 
(55·41–
62·99)
64·83 
(61·47–
69·19)
55·76 
(52·01–
59·74)
Jordan
72·58 
(70·91–
74·84)
60·94 
(57·41–
64·21)
71·03 
(69·24–
72·57)
61·11 
(58·15–
63·85)
74·23 
(71·88–
76·82)
62·75 
(59·00–
66·31)
73·34 
(70·65–
75·64)
63·51 
(60·19–
66·80)
77·99 
(74·85–
81·02)
65·70 
(61·49–
69·46)
74·71 
(71·39–
78·25)
64·59 
(60·97–
68·43)
Kuwait
76·70 
(74·82–
78·73)
65·00 
(61·29–
68·33)
74·54 
(72·38–
76·73)
64·65 
(61·43–
67·77)
77·12 
(75·72–
78·44)
65·38 
(61·84–
68·56)
76·93 
(75·01–
78·65)
66·54 
(63·23–
69·57)
79·47 
(76·63–
82·70)
67·37 
(63·50–
71·31)
79·96 
(76·38–
83·60)
69·01 
(65·03–
73·34)
Lebanon
71·92 
(70·05–
74·03)
60·87 
(57·53–
64·06)
66·38 
(64·58–
68·79)
57·36 
(54·50–
60·39)
78·72 
(77·82–
79·96)
66·52 
(62·98–
69·83)
77·22 
(75·61–
78·85)
66·63 
(63·32–
69·56)
81·42 
(79·91–
82·87)
68·66 
(64·94–
72·23)
78·79 
(77·11–
80·32)
67·94 
(64·59–
70·98)
Libya
74·68 
(73·33–
75·82)
62·95 
(59·53–
66·07)
71·59 
(70·34–
72·98)
61·97 
(59·12–
64·75)
77·01 
(75·27–
78·13)
65·03 
(61·54–
68·16)
73·87 
(72·63–
75·29)
64·02 
(60·99–
66·73)
77·59 
(76·21–
78·74)
65·47 
(61·78–
68·74)
72·62 
(71·01–
74·65)
63·00 
(59·92–
65·82)
Morocco
68·70 
(67·60–
69·73)
57·76 
(54·46–
60·75)
65·69 
(64·85–
66·57)
56·74 
(54·04–
59·15)
73·80 
(72·47–
74·96)
62·22 
(58·80–
65·42)
71·16 
(70·12–
72·08)
61·48 
(58·51–
64·21)
76·44 
(75·14–
77·71)
64·38 
(60·74–
67·77)
73·55 
(72·48–
74·54)
63·58 
(60·60–
66·20)
Palestine
71·78 
(69·66–
73·66)
61·01 
(57·61–
64·21)
70·13 
(68·34–
72·03)
60·77 
(57·75–
63·60)
74·19 
(73·77–
74·60)
63·12 
(59·87–
65·98)
69·54 
(69·07–
69·99)
60·50 
(57·83–
62·89)
73·48 
(72·75–
74·22)
62·56 
(59·49–
65·38)
70·23 
(69·47–
71·02)
61·05 
(58·38–
63·44)
Oman
71·89 
(70·46–
73·25)
60·59 
(57·11–
63·71)
69·50 
(68·12–
70·81)
59·95 
(56·92–
62·74)
78·21 
(77·27–
79·33)
66·25 
(62·72–
69·47)
74·05 
(72·92–
75·15)
64·33 
(61·45–
67·07)
79·93 
(79·21–
80·83)
67·64 
(63·95–
70·96)
75·28 
(74·48–
76·27)
65·29 
(62·36–
68·01)
Qatar
75·25 
(73·06–
77·85)
63·35 
(59·66–
67·15)
74·82 
(72·23–
77·11)
64·23 
(60·77–
67·49)
78·98 
(77·27–
80·91)
66·20 
(62·32–
69·81)
75·74 
(73·25–
78·54)
65·28 
(61·77–
68·76)
81·82 
(78·89–
85·16)
68·54 
(64·22–
72·79)
79·00 
(75·41–
82·65)
67·94 
(63·77–
72·07)
Saudi Arabia
73·52 
(72·07–
74·90)
61·62 
(58·14–
64·84)
70·62 
(69·03–
72·20)
61·15 
(58·17–
63·96)
74·85 
(74·23–
75·41)
63·49 
(60·33–
66·49)
73·41 
(72·66–
74·13)
64·07 
(61·36–
66·59)
78·67 
(77·83–
79·62)
66·61 
(63·09–
69·87)
75·97 
(74·95–
77·00)
66·21 
(63·34–
68·81)
Sudan
59·53 
(58·32–
60·64)
50·03 
(47·25–
52·75)
57·60 
(56·49–
58·74)
49·47 
(46·80–
51·85)
66·70 
(65·69–
67·70)
56·23 
(53·08–
58·98)
63·67 
(62·69–
64·72)
54·90 
(52·20–
57·27)
70·29 
(68·93–
71·52)
59·15 
(55·70–
62·35)
66·37 
(64·87–
67·67)
57·23 
(54·39–
60·00)
Syria
72·81 
(71·69–
73·94)
61·54 
(58·19–
64·52)
69·12 
(68·12–
70·07)
60·03 
(57·31–
62·60)
77·06 
(76·30–
77·70)
65·44 
(61·99–
68·51)
73·22 
(72·43–
73·99)
63·91 
(61·04–
66·43)
73·62 
(69·06–
78·25)
62·58 
(57·77–
67·20)
63·29 
(56·34–
71·29)
55·64 
(49·19–
62·44)
Tunisia
74·12 
(73·09–
75·18)
62·92 
(59·62–
66·06)
69·36 
(68·15–
70·56)
60·38 
(57·62–
62·91)
78·82 
(77·62–
80·64)
67·00 
(63·42–
70·58)
73·67 
(71·98–
75·57)
64·07 
(60·96–
67·00)
80·46 
(78·87–
82·70)
68·32 
(64·48–
72·01)
74·58 
(72·07–
77·24)
65·02 
(61·75–
68·47)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1293
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Turkey
73·48 
(72·41–
74·51)
61·46 
(58·05–
64·58)
66·84 
(65·71–
68·03)
57·77 
(55·03–
60·35)
80·56 
(79·58–
81·47)
67·67 
(63·94–
71·19)
73·90 
(73·02–
74·83)
64·15 
(61·44–
66·84)
82·33 
(80·42–
84·35)
69·20 
(65·37–
72·84)
75·84 
(73·66–
78·13)
65·94 
(62·76–
69·10)
United Arab 
Emirates
73·80 
(71·06–
76·69)
62·23 
(58·32–
65·78)
71·73 
(68·48–
74·76)
61·87 
(57·92–
65·75)
78·57 
(77·31–
79·40)
66·33 
(62·78–
69·58)
75·06 
(73·81–
76·25)
64·89 
(61·82–
67·73)
78·64 
(76·18–
80·63)
66·53 
(62·95–
70·18)
74·52 
(72·10–
76·83)
64·62 
(61·09–
67·66)
Yemen
58·84 
(57·63–
60·16)
48·28 
(45·15–
51·30)
58·57 
(57·40–
59·81)
49·39 
(46·58–
51·99)
65·68 
(64·61–
66·84)
54·20 
(50·83–
57·27)
65·37 
(64·18–
66·55)
55·43 
(52·41–
58·18)
67·94 
(66·60–
69·16)
56·24 
(52·77–
59·33)
65·51 
(63·70–
67·23)
55·81 
(52·76–
58·59)
South Asia
59·80 
(59·24–
60·35)
50·89 
(48·19–
53·20)
58·46 
(57·94–
58·97)
50·96 
(48·82–
52·90)
66·30 
(65·82–
66·79)
56·41 
(53·59–
58·90)
63·48 
(62·93–
64·03)
55·24 
(52·96–
57·29)
70·59 
(70·08–
71·12)
60·00 
(56·96–
62·75)
67·11 
(66·46–
67·67)
58·43 
(55·97–
60·54)
Bangladesh
58·61 
(57·32–
59·87)
49·95 
(47·23–
52·37)
57·61 
(56·57–
58·73)
50·10 
(47·67–
52·26)
70·37 
(69·36–
71·27)
59·79 
(56·76–
62·56)
66·64 
(65·79–
67·55)
58·08 
(55·57–
60·33)
75·10 
(73·49–
76·44)
64·04 
(60·88–
67·11)
70·47 
(68·82–
72·04)
61·69 
(58·94–
64·30)
Bhutan
59·12 
(57·08–
61·38)
50·11 
(47·16–
53·12)
60·68 
(58·50–
62·85)
52·49 
(49·55–
55·02)
71·21 
(69·51–
72·79)
60·17 
(56·70–
63·28)
69·12 
(67·36–
70·85)
59·86 
(57·04–
62·76)
75·91 
(73·78–
77·46)
64·06 
(60·43–
67·44)
72·23 
(70·06–
74·38)
62·56 
(59·32–
65·53)
India
59·69 
(59·02–
60·35)
50·75 
(48·01–
53·17)
58·29 
(57·68–
58·87)
50·81 
(48·69–
52·79)
66·01 
(65·38–
66·59)
56·09 
(53·27–
58·68)
63·22 
(62·59–
63·80)
54·96 
(52·71–
57·10)
70·33 
(69·59–
71·03)
59·67 
(56·62–
62·44)
66·93 
(66·24–
67·56)
58·18 
(55·72–
60·37)
Nepal
57·71 
(56·74–
58·64)
49·63 
(47·28–
51·88)
57·69 
(56·67–
58·72)
50·14 
(47·90–
52·23)
67·17 
(66·20–
68·21)
57·74 
(54·95–
60·24)
65·78 
(64·76–
66·74)
57·35 
(54·84–
59·72)
71·91 
(71·07–
72·81)
61·80 
(58·81–
64·42)
69·74 
(68·49–
71·04)
60·92 
(58·30–
63·39)
Pakistan
62·48 
(61·49–
63·45)
53·50 
(50·73–
55·99)
62·41 
(61·38–
63·42)
54·57 
(52·08–
56·85)
64·74 
(63·33–
66·23)
55·57 
(52·77–
58·33)
63·35 
(61·99–
64·79)
55·58 
(53·21–
57·94)
68·89 
(66·86–
71·19)
59·09 
(55·86–
62·20)
66·44 
(64·27–
68·45)
58·23 
(55·39–
60·97)
Sub-Saharan 
Africa
55·39 
(54·92–
55·80)
47·87 
(45·54–
49·89)
52·04 
(51·48–
52·68)
45·35 
(43·39–
47·24)
56·38 
(55·83–
56·89)
48·88 
(46·67–
50·96)
54·12 
(53·55–
54·65)
47·33 
(45·35–
49·21)
64·59 
(63·91–
65·26)
56·05 
(53·55–
58·32)
61·18 
(60·30–
62·02)
53·57 
(51·23–
55·82)
Southern 
sub-Saharan 
Africa
67·35 
(66·60–
68·16)
58·18 
(55·61–
60·63)
60·25 
(59·31–
61·19)
52·67 
(50·49–
54·85)
51·29 
(50·07–
52·53)
44·50 
(42·44–
46·63)
48·31 
(47·41–
49·22)
42·47 
(40·68–
44·15)
64·86 
(63·79–
65·96)
55·75 
(53·05–
58·36)
58·36 
(57·38–
59·33)
50·90 
(48·68–
53·04)
Botswana
67·60 
(65·60–
69·84)
58·83 
(55·88–
61·79)
61·23 
(58·34–
64·21)
53·70 
(50·51–
56·85)
51·04 
(45·54–
56·94)
44·50 
(39·85–
49·30)
47·99 
(44·54–
52·03)
42·16 
(38·85–
45·79)
69·21 
(64·51–
78·50)
59·74 
(54·95–
66·73)
61·69 
(58·43–
67·01)
53·88 
(50·27–
58·28)
Lesotho
64·20 
(62·27–
66·35)
55·55 
(52·72–
58·36)
56·59 
(54·64–
58·76)
49·82 
(47·38–
52·48)
45·45 
(41·73–
49·33)
39·46 
(36·03–
42·72)
41·01 
(38·66–
43·40)
36·16 
(33·65–
38·50)
53·67 
(49·88–
58·25)
46·37 
(42·72–
50·26)
47·13 
(44·61–
49·71)
41·46 
(38·97–
43·98)
Namibia
64·69 
(63·56–
65·91)
56·44 
(53·69–
58·78)
58·32 
(57·03–
59·62)
51·36 
(49·11–
53·52)
54·71 
(50·75–
58·90)
47·83 
(44·03–
51·74)
50·34 
(47·92–
52·74)
44·40 
(41·90–
46·92)
69·31 
(65·48–
75·19)
60·14 
(55·93–
65·17)
60·39 
(57·83–
63·37)
53·00 
(50·09–
56·01)
South Africa
68·05 
(67·23–
68·92)
58·59 
(55·83–
61·09)
60·72 
(59·85–
61·59)
52·98 
(50·78–
55·06)
52·28 
(50·85–
53·65)
45·25 
(42·99–
47·42)
49·72 
(48·70–
50·77)
43·60 
(41·64–
45·51)
65·51 
(64·17–
66·75)
56·09 
(53·35–
58·88)
59·24 
(57·90–
60·31)
51·47 
(49·14–
53·72)
Swaziland
65·42 
(63·35–
67·49)
56·99 
(54·16–
59·75)
59·06 
(56·88–
61·39)
51·93 
(49·38–
54·50)
44·30 
(40·61–
48·56)
38·50 
(35·00–
42·26)
41·59 
(38·83–
44·65)
36·49 
(33·84–
39·30)
62·16 
(57·33–
68·37)
53·38 
(48·49–
58·49)
53·25 
(50·19–
57·12)
46·38 
(43·19–
49·67)
Zimbabwe
64·36 
(62·06–
67·28)
56·31 
(53·45–
59·60)
59·02 
(55·45–
63·66)
51·98 
(48·42–
56·28)
47·07 
(43·92–
50·60)
41·38 
(38·39–
44·54)
44·34 
(42·25–
46·58)
39·39 
(37·15–
41·71)
61·87 
(59·24–
65·19)
54·11 
(51·15–
57·35)
56·66 
(54·38–
59·28)
50·19 
(47·52–
53·02)
Western 
sub-Saharan 
Africa
55·57 
(54·69–
56·34)
47·67 
(45·11–
49·96)
53·32 
(52·28–
54·31)
46·21 
(44·00–
48·31)
58·25 
(57·26–
59·21)
50·20 
(47·85–
52·54)
56·00 
(55·03–
56·96)
48·79 
(46·59–
50·96)
64·77 
(63·72–
65·90)
55·98 
(53·26–
58·55)
61·89 
(60·59–
63·06)
54·12 
(51·54–
56·44)
Benin
57·60 
(56·50–
58·70)
48·94 
(46·09–
51·36)
53·32 
(52·04–
54·64)
45·99 
(43·44–
48·17)
61·95 
(60·46–
63·47)
53·19 
(50·16–
55·83)
57·76 
(56·51–
59·08)
50·39 
(48·08–
52·79)
66·34 
(64·76–
68·10)
57·19 
(54·17–
60·02)
62·53 
(60·91–
64·06)
54·72 
(52·08–
57·28)
(Table 2 continues on next page)
 Global Health Metrics
1294 
www.thelancet.com   Vol 390  September 16, 2017
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burkina Faso
52·09 
(51·11–
53·19)
44·26 
(41·75–
46·61)
49·12 
(47·86–
50·52)
41·95 
(39·58–
44·21)
56·81 
(55·85–
57·76)
48·86 
(46·30–
51·19)
54·41 
(53·23–
55·54)
47·20 
(44·77–
49·52)
62·06 
(61·04–
63·05)
53·68 
(51·08–
56·24)
59·51 
(57·95–
60·84)
52·17 
(49·79–
54·55)
Cameroon
59·63 
(58·32–
61·10)
51·05 
(48·24–
53·59)
57·28 
(55·81–
58·81)
49·57 
(47·05–
51·91)
56·56 
(54·54–
58·87)
48·79 
(46·01–
51·46)
54·00 
(52·22–
55·70)
47·10 
(44·57–
49·48)
62·02 
(59·34–
65·18)
53·81 
(50·69–
57·12)
58·34 
(56·01–
60·59)
51·26 
(48·34–
54·11)
Cape Verde
71·55 
(70·49–
72·79)
61·66 
(58·62–
64·50)
64·09 
(62·76–
65·53)
56·21 
(53·78–
58·70)
76·48 
(74·84–
78·29)
65·95 
(62·49–
69·20)
66·27 
(64·07–
69·43)
58·27 
(55·46–
61·31)
78·50 
(77·22–
80·25)
67·83 
(64·48–
71·09)
68·79 
(66·61–
71·11)
60·61 
(57·69–
63·48)
Chad
54·43 
(53·27–
55·67)
46·62 
(44·13–
48·84)
52·10 
(50·71–
53·32)
45·17 
(42·76–
47·24)
55·55 
(53·89–
57·37)
47·63 
(45·00–
50·25)
52·59 
(50·96–
54·22)
45·68 
(43·28–
48·08)
61·36 
(59·50–
63·20)
52·71 
(49·91–
55·50)
58·32 
(56·39–
60·28)
50·74 
(48·15–
53·29)
Côte d’Ivoire
57·68 
(56·58–
58·79)
49·17 
(46·50–
51·82)
52·39 
(51·01–
53·58)
45·37 
(42·99–
47·51)
56·04 
(54·36–
57·85)
48·52 
(45·85–
50·93)
52·09 
(50·45–
53·67)
45·65 
(43·25–
47·87)
62·29 
(60·54–
64·01)
53·92 
(51·07–
56·57)
57·72 
(55·83–
59·48)
50·60 
(48·00–
53·01)
The Gambia
62·30 
(60·68–
64·02)
53·36 
(50·28–
56·14)
60·88 
(59·15–
62·62)
53·05 
(50·22–
55·72)
66·26 
(64·59–
68·06)
56·75 
(53·72–
59·73)
62·80 
(61·35–
64·29)
54·78 
(51·92–
57·28)
69·22 
(67·62–
71·33)
59·42 
(56·30–
62·46)
65·46 
(63·97–
66·94)
57·15 
(54·20–
59·62)
Ghana
59·84 
(58·36–
61·44)
51·82 
(49·16–
54·38)
57·78 
(56·18–
59·37)
50·59 
(48·06–
53·14)
61·92 
(60·12–
63·95)
54·01 
(51·22–
56·79)
59·01 
(57·79–
60·31)
52·03 
(49·63–
54·16)
67·53 
(65·97–
69·68)
58·98 
(56·19–
61·86)
64·49 
(62·75–
66·08)
56·90 
(54·34–
59·35)
Guinea
51·91 
(50·53–
53·30)
44·55 
(42·05–
46·92)
52·11 
(50·71–
53·57)
45·26 
(42·89–
47·43)
57·25 
(55·74–
58·97)
49·53 
(47·03–
51·96)
55·58 
(53·83–
57·33)
48·76 
(46·21–
51·09)
61·62 
(59·52–
64·00)
53·40 
(50·48–
56·36)
59·76 
(57·32–
62·13)
52·48 
(49·61–
55·35)
Guinea-Bissau
51·89 
(50·31–
53·78)
44·89 
(42·43–
47·26)
46·57 
(44·71–
48·57)
40·83 
(38·59–
43·17)
56·06 
(54·03–
58·01)
48·66 
(45·95–
51·27)
51·56 
(50·00–
53·30)
45·36 
(43·07–
47·54)
61·37 
(59·44–
63·33)
53·32 
(50·43–
56·03)
56·30 
(54·53–
58·20)
49·60 
(47·09–
52·04)
Liberia
51·76 
(50·48–
53·07)
43·77 
(41·14–
46·17)
47·99 
(46·63–
49·49)
40·93 
(38·51–
43·17)
58·82 
(57·58–
60·31)
49·98 
(47·20–
52·57)
58·52 
(57·29–
59·75)
49·98 
(47·27–
52·50)
64·82 
(63·59–
66·07)
55·40 
(52·50–
58·00)
64·00 
(62·76–
65·16)
55·19 
(52·43–
57·82)
Mali
49·39 
(48·14–
50·66)
42·49 
(40·11–
44·73)
49·41 
(48·04–
50·70)
42·56 
(40·19–
44·83)
57·72 
(56·20–
59·37)
49·75 
(47·12–
52·25)
56·46 
(54·86–
58·11)
48·81 
(46·21–
51·40)
62·74 
(60·01–
65·49)
54·29 
(51·16–
57·53)
61·02 
(58·09–
63·77)
53·18 
(49·98–
56·44)
Mauritania
60·41 
(59·05–
61·76)
52·16 
(49·49–
54·62)
59·50 
(58·11–
61·07)
51·87 
(49·30–
54·28)
65·99 
(64·25–
68·11)
57·15 
(54·23–
59·95)
66·83 
(64·96–
68·67)
58·11 
(55·20–
60·91)
70·21 
(67·56–
73·27)
60·85 
(57·43–
64·22)
70·29 
(67·75–
73·20)
61·28 
(57·96–
64·65)
Niger
48·07 
(46·57–
49·48)
41·61 
(39·47–
43·84)
46·19 
(44·61–
47·75)
40·45 
(38·31–
42·43)
57·00 
(55·24–
58·62)
49·47 
(46·71–
51·86)
55·43 
(53·62–
57·32)
48·68 
(46·27–
51·07)
62·83 
(60·16–
65·50)
54·70 
(51·47–
57·94)
60·60 
(58·25–
62·87)
53·42 
(50·58–
56·30)
Nigeria
55·80 
(53·93–
57·43)
47·83 
(45·05–
50·36)
53·99 
(51·98–
55·95)
46·72 
(44·09–
49·35)
58·29 
(56·34–
60·30)
50·06 
(47·39–
52·97)
56·69 
(54·87–
58·62)
49·22 
(46·60–
51·93)
66·41 
(64·30–
69·14)
57·17 
(53·86–
60·50)
63·69 
(61·16–
66·21)
55·46 
(52·16–
58·36)
São Tomé and 
Príncipe
64·55 
(62·95–
66·14)
56·13 
(53·44–
58·78)
61·94 
(60·46–
63·55)
54·06 
(51·51–
56·55)
68·04 
(66·93–
69·14)
59·38 
(56·77–
61·81)
65·63 
(64·35–
66·88)
57·37 
(54·72–
59·76)
72·09 
(70·52–
73·93)
62·86 
(59·84–
65·70)
69·04 
(66·71–
71·46)
60·40 
(57·08–
63·43)
Senegal
59·13 
(57·93–
60·29)
51·16 
(48·64–
53·57)
55·97 
(54·99–
56·95)
49·06 
(46·73–
51·08)
63·73 
(62·67–
64·93)
55·34 
(52·58–
57·81)
60·56 
(59·49–
61·69)
53·17 
(50·79–
55·42)
67·78 
(66·59–
68·83)
58·95 
(56·18–
61·49)
64·64 
(63·32–
65·97)
56·81 
(54·17–
59·31)
Sierra Leone
52·78 
(51·41–
54·15)
45·44 
(42·94–
47·75)
48·43 
(46·82–
50·02)
42·07 
(39·83–
44·17)
54·14 
(52·72–
55·61)
46·80 
(44·24–
49·05)
51·62 
(50·37–
52·85)
44·94 
(42·80–
47·02)
60·19 
(58·38–
62·14)
52·30 
(49·54–
55·01)
58·11 
(56·42–
59·82)
50·98 
(48·48–
53·42)
Togo
58·64 
(57·47–
59·92)
50·53 
(47·88–
52·99)
56·13 
(54·90–
57·39)
49·04 
(46·54–
51·27)
59·12 
(57·12–
61·53)
51·10 
(48·41–
53·75)
54·86 
(53·29–
56·46)
48·25 
(45·93–
50·52)
65·08 
(63·58–
66·82)
56·63 
(53·68–
59·26)
60·11 
(58·22–
61·70)
53·13 
(50·60–
55·49)
Eastern 
sub-Saharan 
Africa
52·92 
(52·39–
53·47)
46·24 
(44·24–
48·02)
49·46 
(48·81–
50·17)
43·47 
(41·58–
45·13)
56·64 
(55·91–
57·36)
49·56 
(47·39–
51·57)
54·57 
(53·86–
55·19)
48·01 
(46·07–
49·81)
65·08 
(64·13–
66·09)
56·97 
(54·43–
59·30)
61·72 
(60·63–
62·80)
54·35 
(52·04–
56·58)
(Table 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1295
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burundi
49·28 
(47·21–
51·62)
43·59 
(41·19–
46·03)
46·69 
(44·34–
49·16)
41·49 
(39·09–
43·99)
55·18 
(53·18–
57·01)
48·71 
(46·26–
51·06)
53·46 
(51·54–
55·47)
47·33 
(44·70–
49·70)
61·51 
(58·70–
64·10)
54·51 
(51·44–
57·29)
59·20 
(56·03–
62·28)
52·57 
(49·11–
55·76)
Comoros
59·46 
(57·78–
61·52)
51·92 
(49·20–
54·61)
57·80 
(55·88–
59·73)
50·47 
(47·88–
52·97)
65·30 
(63·79–
67·10)
57·14 
(54·36–
59·97)
63·78 
(62·30–
65·32)
55·98 
(53·42–
58·63)
68·52 
(66·78–
70·86)
60·05 
(57·27–
63·16)
66·61 
(64·38–
68·77)
58·57 
(55·52–
61·31)
Djibouti
64·10 
(62·77–
65·15)
55·99 
(53·27–
58·39)
58·43 
(57·21–
59·67)
51·61 
(49·41–
53·77)
64·36 
(61·78–
67·15)
56·34 
(53·15–
59·62)
59·51 
(57·39–
61·57)
52·59 
(49·86–
55·17)
68·80 
(66·11–
71·85)
60·24 
(56·93–
63·65)
64·67 
(62·50–
66·70)
57·03 
(54·20–
59·80)
Eritrea
53·74 
(52·30–
55·22)
47·10 
(44·78–
49·34)
50·96 
(49·44–
52·49)
45·01 
(42·76–
47·10)
61·51 
(59·71–
63·42)
54·15 
(51·29–
56·75)
60·05 
(58·00–
62·07)
52·98 
(50·39–
55·63)
64·53 
(62·75–
66·62)
56·84 
(54·01–
59·55)
62·88 
(60·62–
65·07)
55·54 
(52·73–
58·26)
Ethiopia
48·89 
(47·64–
50·20)
43·00 
(40·98–
44·98)
44·37 
(43·16–
45·76)
39·31 
(37·54–
41·04)
57·30 
(55·68–
59·03)
50·56 
(48·24–
52·87)
56·81 
(55·05–
58·31)
50·17 
(47·86–
52·43)
66·53 
(64·21–
68·96)
58·67 
(55·72–
61·51)
64·74 
(62·10–
67·59)
57·20 
(54·14–
60·45)
Kenya
62·63 
(61·99–
63·30)
55·07 
(52·71–
57·15)
60·25 
(59·41–
61·07)
53·14 
(50·93–
55·15)
59·91 
(59·18–
60·60)
52·60 
(50·41–
54·67)
57·04 
(56·37–
57·71)
50·40 
(48·34–
52·22)
69·03 
(68·24–
69·88)
60·30 
(57·58–
62·64)
64·72 
(63·89–
65·56)
56·94 
(54·49–
59·05)
Madagascar
56·76 
(55·42–
58·23)
49·55 
(47·22–
51·91)
54·43 
(53·13–
55·73)
47·74 
(45·56–
49·87)
61·40 
(59·57–
63·44)
53·79 
(50·81–
56·51)
59·41 
(57·47–
61·41)
52·19 
(49·62–
54·76)
63·88 
(60·78–
67·84)
56·22 
(52·80–
59·92)
61·51 
(58·34–
64·83)
54·29 
(51·18–
57·82)
Malawi
49·89 
(48·02–
51·91)
43·53 
(41·08–
46·03)
47·56 
(44·19–
51·16)
41·45 
(38·16–
44·72)
49·75 
(46·64–
53·37)
43·49 
(40·30–
46·97)
47·18 
(44·96–
49·62)
41·39 
(39·05–
44·13)
62·59 
(59·81–
65·90)
54·63 
(51·37–
57·95)
57·90 
(55·27–
60·52)
50·94 
(48·22–
53·98)
Mozambique
52·80 
(51·72–
53·94)
45·66 
(43·25–
47·89)
48·51 
(47·27–
49·70)
42·25 
(40·17–
44·09)
54·89 
(51·81–
58·00)
47·39 
(44·02–
50·59)
50·33 
(48·12–
52·56)
43·91 
(41·18–
46·35)
62·88 
(60·39–
65·36)
54·32 
(51·22–
57·53)
57·05 
(54·88–
59·18)
49·78 
(46·92–
52·53)
Rwanda
50·78 
(49·17–
52·31)
44·72 
(42·38–
46·96)
47·51 
(45·55–
49·50)
42·13 
(39·82–
44·32)
61·04 
(59·22–
62·93)
53·38 
(50·75–
55·88)
57·93 
(56·51–
59·53)
50·93 
(48·55–
53·13)
69·32 
(67·21–
71·54)
60·74 
(57·78–
63·78)
65·98 
(63·86–
67·95)
58·02 
(55·04–
60·77)
Somalia
51·72 
(50·09–
53·38)
45·34 
(42·86–
47·64)
49·60 
(47·49–
51·75)
43·81 
(41·26–
46·38)
54·55 
(52·80–
56·31)
47·93 
(45·51–
50·47)
53·54 
(51·26–
55·80)
47·33 
(44·72–
50·09)
57·74 
(55·75–
59·45)
50·75 
(48·08–
53·18)
56·64 
(54·11–
59·07)
50·10 
(47·03–
52·87)
South Sudan
53·28 
(51·20–
55·51)
44·83 
(41·62–
47·86)
49·85 
(47·40–
52·59)
42·34 
(39·34–
45·54)
57·77 
(54·98–
60·99)
49·35 
(45·93–
52·82)
55·76 
(53·13–
58·60)
47·94 
(44·83–
51·03)
60·72 
(57·90–
63·93)
52·40 
(49·04–
55·82)
58·71 
(56·05–
61·53)
50·96 
(47·77–
54·05)
Tanzania
55·98 
(54·76–
57·26)
48·69 
(46·28–
51·04)
53·74 
(52·07–
55·35)
47·08 
(44·67–
49·47)
56·72 
(54·77–
59·54)
49·54 
(46·90–
52·22)
55·30 
(53·82–
56·98)
48·68 
(46·36–
51·06)
66·05 
(64·28–
68·33)
57·79 
(54·94–
60·76)
62·59 
(60·50–
64·45)
55·33 
(52·61–
57·81)
Uganda
52·07 
(50·38–
53·44)
44·88 
(42·39–
47·10)
46·34 
(43·41–
48·89)
40·17 
(37·23–
43·06)
55·59 
(53·98–
57·23)
48·16 
(45·69–
50·66)
51·84 
(50·37–
53·29)
45·29 
(42·89–
47·31)
64·75 
(62·93–
67·01)
56·33 
(53·55–
59·24)
59·77 
(57·99–
61·40)
52·45 
(50·10–
54·90)
Zambia
52·33 
(50·38–
54·59)
45·94 
(43·52–
48·33)
52·21 
(49·34–
54·78)
45·87 
(42·88–
48·71)
48·21 
(45·39–
51·35)
42·34 
(39·62–
45·29)
45·23 
(43·18–
47·31)
40·12 
(37·88–
42·23)
61·95 
(58·22–
66·84)
54·14 
(50·45–
58·71)
55·58 
(52·54–
59·34)
49·10 
(46·12–
52·44)
Central sub-
Saharan Africa
54·41 
(53·25–
55·53)
46·46 
(43·99–
48·74)
50·83 
(49·71–
51·99)
43·71 
(41·49–
45·86)
56·35 
(55·20–
57·49)
48·42 
(45·79–
50·67)
54·80 
(53·60–
55·95)
47·29 
(44·88–
49·53)
62·80 
(61·19–
64·43)
54·20 
(51·34–
56·76)
60·62 
(58·87–
62·28)
52·58 
(49·77–
55·26)
Angola
52·16 
(49·57–
55·16)
45·20 
(42·37–
48·22)
48·27 
(45·63–
51·05)
42·20 
(39·52–
45·23)
57·13 
(54·31–
60·11)
49·77 
(46·75–
52·71)
56·77 
(53·90–
59·62)
49·56 
(46·60–
52·46)
65·37 
(61·78–
68·70)
56·85 
(53·28–
60·26)
63·94 
(60·34–
67·08)
55·76 
(52·30–
59·13)
Central African 
Republic
51·04 
(48·84–
53·26)
43·80 
(40·92–
46·39)
45·38 
(43·16–
47·67)
39·24 
(36·70–
41·72)
47·44 
(44·14–
51·09)
41·04 
(37·74–
44·37)
43·21 
(40·31–
46·22)
37·65 
(34·73–
40·63)
52·59 
(48·76–
56·64)
45·60 
(41·97–
49·45)
47·91 
(44·46–
51·58)
41·91 
(38·62–
45·46)
Congo 
(Brazzaville)
55·96 
(53·78–
58·10)
48·26 
(45·37–
51·06)
52·19 
(50·02–
54·61)
45·47 
(42·70–
48·24)
56·61 
(54·64–
58·58)
48·95 
(46·20–
51·56)
58·33 
(56·48–
60·14)
50·60 
(47·97–
53·23)
62·35 
(59·54–
65·61)
53·99 
(50·40–
57·77)
63·62 
(60·10–
67·33)
55·47 
(51·93–
59·12)
(Table 2 continues on next page)
 Global Health Metrics
1296 
www.thelancet.com   Vol 390  September 16, 2017
3·91 million), extensively drug­resistant tuberculosis 
369 000 (301 000–445 000), drug­susceptible HIV
/AIDS­
tuberculosis 11·7 million (8·15 million to 15·5 million), 
multidrug­resistant HIV
/AIDS­tuberculosis without ex­
tensive drug resistance 0·98 million (0·60 million to 
1·48 million), and extensively drug­resistant HIV
/AIDS­
tuberculosis 57 300 (34 500–89 400; table 1).
Changes in leading causes of disease burden over time 
and SDI quintiles
The leading Level 3 causes of global DALYs in 1990 were 
lower respiratory infections, diarrhoeal diseases, and 
ischaemic heart disease (figure 2A). By 2016, lower 
respiratory infections had decreased in relative rank to 
the third­leading cause, whereas diarrhoeal diseases were 
fifth and ischaemic heart disease rose to first. The leading 
30 causes of DALYs by SDI quintile varied considerably 
(figure 2B–F). CMNN causes were dominant in the low­
SDI quintile, occupying 11 of the top 15 causes in 2016. 
NCDs were more commonly among the leading causes of 
DALYs with successively higher levels of SDI, occupying 
12 of the top 15 causes in the high­SDI quintile in 2016.
For low SDI, only two NCD causes (congenital birth 
defects and ischaemic heart disease) ranked in the top 
ten in 2016, compared with all of the top ten for high 
SDI. Of the leading 30 causes from 2006 to 2016, 
HIV
/AIDS had the largest decrease in age­standardised 
DALY rates for low, low­middle, and middle SDI. For 
high­middle SDI, the largest decrease was for lower 
respiratory infection, and for high SDI, the largest 
decrease was for road injuries. At low­middle SDI, 14 of 
the leading 30 causes in 2016 were NCDs, whereas 
13 were CMNN causes and three were injuries, compared 
with middle SDI, where seven were CMNN causes, 19 
were NCDs, and four were injuries. The leading 
seven causes for low, low­middle, and middle SDI 
quintiles all decreased in age­standardised DALY rates 
from 2006 to 2016.
At high­middle and high SDI, the leading three causes 
of DALYs remained the same from 2006 to 2016 
(ischaemic heart disease, low back and neck pain, and 
cerebrovascular disease). Two of the leading 30 causes 
for high­middle SDI were CMNN causes in 2016, 
whereas 24 were NCDs and four were injuries, compared 
with high SDI, where one was a CMNN cause, 26 were 
NCDs, and three were injuries. The leading five causes 
for high­middle SDI decreased in age­standardised DALY 
rates from both 1990 to 2006 and 2006 to 2016, although 
this pattern did not hold for high SDI, where just the 
leading cause decreased over both intervals. Road 
injuries and falls are the only injuries that appear across 
all five SDI quintiles; self­harm appears in all quintiles 
except for low SDI. Ischaemic heart disease and 
cerebrovascular disease appear in the leading 13 causes 
across all SDI quintiles. HIV
/AIDS appears in the leading 
ten causes for all quintiles except for high and high­
middle SDI, where it did not appear in the leading 30.
Regional and country-specific HALE and DALYs in 2016
In 2016, HALE at birth was highest in Singapore for both 
females (75·2 years [95% UI 71·9–78·6]) and males 
(72·0 years [68·8–75·1]) and lowest for females in the 
Central African Republic (45·6 years [42·0–49·5]) and for 
males in Lesotho (41·5 [39·0–44·0]; table 2 and 3). In 2016, 
HALE at birth was greater than 70 years in only 12 locations 
for males and was greater than this threshold in 49 locations 
for females. HALE at birth was less than 50 years for both 
sexes in three locations: the Central African Republic, 
Lesotho, and Afghanistan. Between 1990 and 2016, HALE 
at birth increased for males in 160 locations and for females 
in 167 locations. For males, the largest increase occurred in 
Ethiopia, rising from 39·3 years (37·5–41·0) in 1990 to 
57·2 years (54·1–60·45) in 2016. For females, the largest 
increase occurred in the Maldives, rising from 53·6 
(51·1–56·1) in 1990 to 70·3 (66·3–73·7) in 2016. Over the 
same time period, HALE at birth decreased in just 
1990, at birth
2006, at birth
2016, at birth
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Democratic 
Republic of 
the Congo
55·32 
(53·74–
56·81)
46·96 
(44·23–
49·57)
52·33 
(50·71–
53·96)
44·65 
(42·09–
47·12)
56·75 
(55·28–
58·22)
48·53 
(45·70–
51·08)
55·03 
(53·48–
56·45)
47·24 
(44·61–
49·74)
62·72 
(60·80–
64·53)
53·99 
(50·96–
56·80)
60·44 
(58·33–
62·42)
52·26 
(49·34–
55·04)
Equatorial 
Guinea
49·82 
(47·16–
52·85)
43·11 
(40·10–
46·00)
46·54 
(43·66–
49·72)
40·62 
(37·58–
43·52)
59·26 
(54·70–
64·65)
51·26 
(47·01–
55·97)
58·66 
(54·71–
63·17)
50·91 
(46·94–
55·13)
66·55 
(62·28–
71·43)
57·44 
(53·04–
61·96)
64·49 
(60·25–
69·11)
55·97 
(51·95–
60·33)
Gabon
62·90 
(61·23–
64·49)
54·14 
(51·30–
56·75)
56·02 
(54·28–
57·83)
49·01 
(46·57–
51·43)
61·32 
(59·50–
63·25)
52·87 
(50·05–
55·57)
59·71 
(57·34–
61·77)
52·16 
(49·40–
54·83)
68·31 
(65·83–
71·18)
58·73 
(55·38–
62·22)
64·90 
(61·35–
68·37)
56·59 
(52·95–
60·04)
Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. GBD=Global Burden of Disease. HALE=healthy life expectancy. 
SDI=Socio-demographic index.
Table 2: Global, regional, and GBD location-specific life expectancy and HALE at birth, by sex, in 1990, 2006, and 2016
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1297
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Global
15·90 
(15·82–
15·98)
11·92 
(10·88–
12·89)
13·33 
(13·26–
13·39)
10·09 
(9·22–
10·87)
17·27 
(17·19–
17·35)
12·93 
(11·74–
13·98)
14·69 
(14·62–
14·75)
11·10 
(10·13–
11·97)
18·57 
(18·37–
18·72)
13·88 
(12·57–
15·02)
15·72 
(15·61–
15·83)
11·87 
(10·83–
12·80)
High SDI
18·57 
(18·50–
18·63)
14·06 
(12·85–
15·16)
14·79 
(14·73–
14·84)
11·22 
(10·27–
12·08)
20·72 
(20·67–
20·78)
15·69 
(14·31–
16·93)
17·22 
(17·17–
17·28)
13·00 
(11·86–
14·03)
21·67 
(21·53–
21·81)
16·38 
(14·91–
17·68)
18·37 
(18·22–
18·50)
13·86 
(12·65–
14·98)
High-middle SDI
16·31 
(16·07–
16·54)
12·15 
(11·02–
13·22)
13·35 
(13·16–
13·54)
10·09 
(9·20–
10·92)
17·39 
(17·15–
17·62)
13·00 
(11·78–
14·08)
14·27 
(14·06–
14·45)
10·81 
(9·86–
11·68)
19·19 
(18·36–
19·89)
14·32 
(12·85–
15·71)
15·84 
(15·39–
16·28)
12·01 
(10·90–
13·06)
Middle SDI
14·81 
(14·63–
14·98)
11·25 
(10·32–
12·13)
12·64 
(12·50–
12·78)
9·78 
(9·00–
10·50)
16·55 
(16·43–
16·67)
12·48 
(11·38–
13·50)
14·09 
(13·98–
14·21)
10·84 
(9·96–
11·66)
18·19 
(18·02–
18·35)
13·68 
(12·48–
14·77)
15·01 
(14·86–
15·17)
11·50 
(10·55–
12·33)
Low-middle SDI
13·08 
(12·90–
13·28)
9·47 
(8·51–
10·37)
12·48 
(12·32–
12·64)
9·15 
(8·28–
9·96)
14·35 
(14·16–
14·54)
10·40 
(9·36–
11·34)
13·24 
(13·10–
13·39)
9·74 
(8·83–
10·58)
15·50 
(15·26–
15·73)
11·24 
(10·13–
12·27)
13·95 
(13·75–
14·14)
10·27 
(9·28–
11·13)
Low SDI
11·65 
(11·45–
11·86)
8·54 
(7·67–
9·29)
11·75 
(11·52–
11·97)
8·59 
(7·72–
9·42)
12·29 
(12·02–
12·58)
9·08 
(8·19–
9·91)
12·43 
(12·20–
12·67)
9·17 
(8·24–
9·97)
13·32 
(13·00–
13·64)
9·90 
(8·94–
10·78)
13·22 
(12·89–
13·54)
9·80 
(8·82–
10·69)
High income
18·77 
(18·71–
18·84)
14·28 
(13·06–
15·39)
14·96 
(14·90–
15·01)
11·40 
(10·45–
12·27)
20·89 
(20·83–
20·95)
15·88 
(14·51–
17·12)
17·35 
(17·30–
17·40)
13·16 
(12·02–
14·18)
21·80 
(21·66–
21·94)
16·55 
(15·09–
17·85)
18·47 
(18·32–
18·60)
14·00 
(12·79–
15·11)
High-income North 
America
19·09 
(19·03–
19·16)
14·49 
(13·27–
15·62)
15·17 
(15·11–
15·24)
11·46 
(10·48–
12·36)
20·05 
(19·99–
20·12)
15·06 
(13·71–
16·29)
17·33 
(17·28–
17·40)
12·91 
(11·73–
13·98)
20·74 
(20·59–
20·89)
15·46 
(14·05–
16·73)
18·19 
(18·05–
18·34)
13·48 
(12·23–
14·63)
Canada
19·69 
(19·47–
19·89)
15·30 
(14·07–
16·43)
15·50 
(15·31–
15·70)
12·03 
(11·03–
12·93)
21·08 
(20·86–
21·27)
16·28 
(15·00–
17·49)
17·92 
(17·75–
18·13)
13·82 
(12·68–
14·86)
21·96 
(21·66–
22·27)
16·91 
(15·50–
18·21)
19·12 
(18·82–
19·44)
14·71 
(13·46–
15·88)
Greenland
11·30 
(10·69–
11·92)
8·66 
(7·82–
9·51)
8·95 
(8·51– 
9·40)
6·83 
(6·17–
7·45)
11·88 
(11·27–
12·47)
9·10 
(8·25–
9·92)
10·70 
(10·19–
11·17)
8·20 
(7·47–
8·92)
14·20 
(12·77–
15·95)
10·89 
(9·51–
12·36)
11·89 
(10·54–
13·29)
9·14 
(7·93–
10·46)
USA
19·04 
(18·97–
19·11)
14·41 
(13·19–
15·55)
15·14 
(15·07–
15·20)
11·41 
(10·43–
12·30)
19·94 
(19·88–
20·01)
14·93 
(13·57–
16·16)
17·27 
(17·21–
17·33)
12·80 
(11·62–
13·88)
20·60 
(20·44–
20·76)
15·30 
(13·89–
16·59)
18·09 
(17·93–
18·25)
13·34 
(12·08–
14·49)
Australasia
18·95 
(18·79–
19·12)
14·66 
(13·46–
15·73)
15·10 
(14·95–
15·25)
11·65 
(10·69–
12·53)
21·35 
(21·21–
21·49)
16·52 
(15·14–
17·76)
18·31 
(18·17–
18·46)
14·11 
(12·94–
15·15)
22·10 
(21·65–
22·56)
17·07 
(15·62–
18·38)
19·37 
(18·91–
19·84)
14·92 
(13·66–
16·08)
Australia
19·05 
(18·88–
19·25)
14·73 
(13·54–
15·81)
15·18 
(15·01–
15·35)
11·71 
(10·75–
12·59)
21·51 
(21·34–
21·68)
16·63 
(15·26–
17·91)
18·40 
(18·24–
18·58)
14·17 
(12·98–
15·23)
22·22 
(21·67–
22·74)
17·16 
(15·72–
18·49)
19·47 
(18·93–
19·96)
14·98 
(13·69–
16·17)
New Zealand
18·43 
(18·18–
18·66)
14·29 
(13·11–
15·34)
14·71 
(14·50–
14·92)
11·36 
(10·40–
12·22)
20·52 
(20·29–
20·73)
15·95 
(14·61–
17·11)
17·83 
(17·62–
18·03)
13·81 
(12·64–
14·85)
21·48 
(20·65–
22·40)
16·64 
(15·19–
18·03)
18·90 
(18·08–
19·77)
14·60 
(13·30–
15·87)
High-income Asia 
Pacific
19·46 
(19·31–
19·61)
15·03 
(13·80–
16·15)
15·65 
(15·51–
15·78)
11·91 
(10·90–
12·82)
22·73 
(22·57–
22·88)
17·47 
(15·99–
18·77)
17·93 
(17·80–
18·07)
13·50 
(12·30–
14·59)
23·79 
(23·27–
24·24)
18·30 
(16·64–
19·74)
19·20 
(18·75–
19·61)
14·51 
(13·22–
15·73)
Brunei
16·84 
(15·98–
17·54)
12·75 
(11·48–
13·92)
14·52 
(14·31–
14·78)
10·70 
(9·68–
11·64)
18·67 
(18·25–
19·03)
14·26 
(13·01–
15·41)
15·85 
(15·56–
16·19)
11·78 
(10·69–
12·79)
18·88 
(18·18–
20·19)
14·50 
(13·16–
15·79)
15·88 
(15·05–
17·40)
11·88 
(10·61–
13·13)
Japan
19·96 
(19·92–
20·00)
15·43 
(14·15–
16·55)
16·22 
(16·19–
16·25)
12·36 
(11·32–
13·29)
23·23 
(23·17–
23·28)
17·89 
(16·38–
19·22)
18·24 
(18·21–
18·28)
13·75 
(12·53–
14·83)
24·24 
(24·07–
24·40)
18·67 
(17·07–
20·03)
19·53 
(19·35–
19·70)
14·78 
(13·50–
15·95)
Singapore
17·64 
(16·49–
18·82)
13·74 
(12·40–
15·01)
14·65 
(13·72–
15·61)
11·26 
(10·13–
12·42)
21·50 
(20·48–
22·49)
16·78 
(15·30–
18·19)
17·71 
(16·77–
18·66)
13·67 
(12·45–
14·94)
23·33 
(21·62–
25·20)
18·16 
(16·31–
20·02)
19·70 
(17·89–
21·49)
15·13 
(13·37–
16·82)
South Korea
16·70 
(15·82–
17·56)
12·82 
(11·56–
14·06)
12·36 
(11·66–
13·12)
9·33 
(8·35–
10·31)
20·05 
(19·28–
20·86)
15·26 
(13·84–
16·68)
16·20 
(15·45–
17·11)
12·11 
(10·94–
13·41)
21·67 
(19·44–
23·94)
16·62 
(14·54–
18·80)
17·52 
(15·45–
20·08)
13·20 
(11·32–
15·13)
(Table 3 continues on next page)
 Global Health Metrics
1298 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Western Europe
18·48 
(18·37–
18·59)
13·98 
(12·75–
15·11)
14·70 
(14·61–
14·79)
11·25 
(10·32–
12·10)
20·81 
(20·71–
20·91)
15·80 
(14·41–
17·04)
17·26 
(17·17–
17·36)
13·23 
(12·12–
14·24)
21·76 
(21·56–
21·96)
16·54 
(15·08–
17·87)
18·49 
(18·29–
18·69)
14·21 
(13·00–
15·28)
Andorra
20·84 
(19·08–
22·79)
15·59 
(13·63–
17·52)
16·54 
(15·62–
17·99)
12·54 
(11·23–
13·98)
23·19 
(21·49–
24·44)
17·38 
(15·50–
19·13)
18·33 
(17·43–
19·29)
13·94 
(12·51–
15·26)
23·06 
(20·90–
24·50)
17·31 
(15·33–
19·16)
18·46 
(17·43–
20·09)
14·08 
(12·52–
15·58)
Austria
17·88 
(17·71–
18·06)
13·60 
(12·43–
14·67)
14·36 
(14·20–
14·51)
10·97 
(9·99–
11·81)
20·48 
(20·31–
20·63)
15·61 
(14·25–
16·81)
17·16 
(17·00–
17·32)
13·07 
(11·92–
14·08)
21·45 
(20·98–
21·95)
16·35 
(14·86–
17·69)
18·41 
(18·01–
18·90)
14·08 
(12·82–
15·30)
Belgium
18·47 
(18·16–
18·74)
13·84 
(12·59–
14·99)
14·29 
(14·00–
14·59)
10·86 
(9·84–
11·73)
20·49 
(20·24–
20·77)
15·22 
(13·79–
16·51)
16·87 
(16·60–
17·15)
12·70 
(11·54–
13·74)
21·38 
(20·63–
22·22)
16·00 
(14·41–
17·50)
17·99 
(17·22–
18·72)
13·62 
(12·27–
14·90)
Cyprus
15·67 
(15·34–
15·99)
11·88 
(10·80–
12·88)
14·03 
(13·70–
14·36)
10·77 
(9·81–
11·61)
18·99 
(18·64–
19·34)
14·41 
(13·09–
15·59)
16·52 
(16·19–
16·84)
12·64 
(11·53–
13·62)
20·17 
(19·74–
20·58)
15·38 
(14·04–
16·67)
17·44 
(17·01–
17·92)
13·39 
(12·22–
14·49)
Denmark
17·97 
(17·41–
18·50)
13·58 
(12·33–
14·73)
14·27 
(13·81–
14·80)
10·99 
(10·00–
11·87)
19·09 
(18·53–
19·65)
14·47 
(13·09–
15·70)
16·33 
(15·86–
16·81)
12·50 
(11·38–
13·56)
20·76 
(19·77–
21·83)
15·65 
(14·08–
17·10)
18·01 
(17·04–
18·92)
13·77 
(12·45–
15·05)
Finland
17·74 
(17·50–
17·98)
13·32 
(12·13–
14·43)
13·76 
(13·56–
13·97)
10·37 
(9·43–
11·23)
20·74 
(20·51–
20·94)
15·37 
(13·87–
16·74)
16·73 
(16·52–
16·95)
12·42 
(11·26–
13·46)
21·99 
(21·44–
22·62)
16·49 
(14·87–
18·00)
18·39 
(17·82–
18·97)
13·86 
(12·61–
15·07)
France
20·15 
(19·94–
20·34)
15·31 
(13·98–
16·52)
15·72 
(15·52–
15·93)
12·08 
(11·05–
13·01)
22·25 
(22·04–
22·44)
17·06 
(15·60–
18·34)
17·91 
(17·71–
18·15)
13·85 
(12·66–
14·89)
23·22 
(22·83–
23·66)
17·74 
(16·17–
19·19)
19·24 
(18·87–
19·63)
14·87 
(13·56–
16·01)
Germany
17·68 
(17·28–
18·06)
13·32 
(12·06–
14·47)
14·03 
(13·65–
14·41)
10·67 
(9·69–
11·56)
20·21 
(19·87–
20·57)
15·31 
(13·94–
16·58)
16·75 
(16·41–
17·13)
12·79 
(11·69–
13·86)
21·10 
(20·46–
21·82)
15·98 
(14·47–
17·42)
17·93 
(17·27–
18·62)
13·69 
(12·43–
14·90)
Greece
18·02 
(17·79–
18·26)
13·71 
(12·55–
14·78)
15·58 
(15·35–
15·83)
11·98 
(10·98–
12·88)
20·24 
(20·03–
20·46)
15·40 
(14·10–
16·59)
17·42 
(17·19–
17·64)
13·37 
(12·24–
14·38)
20·98 
(20·42–
21·55)
16·07 
(14·70–
17·39)
18·34 
(17·72–
18·99)
14·12 
(12·91–
15·28)
Iceland
19·13 
(18·70–
19·55)
14·48 
(13·19–
15·67)
16·16 
(15·82–
16·53)
12·37 
(11·30–
13·32)
20·76 
(20·29–
21·27)
15·73 
(14·34–
16·95)
18·31 
(17·99–
18·66)
14·02 
(12·79–
15·10)
21·35 
(20·53–
22·14)
16·24 
(14·78–
17·62)
18·98 
(18·37–
19·56)
14·60 
(13·28–
15·89)
Ireland
16·89 
(16·46–
17·33)
12·86 
(11·69–
13·94)
13·36 
(13·00–
13·78)
10·28 
(9·37–
11·12)
19·70 
(19·27–
20·16)
14·96 
(13·66–
16·21)
16·66 
(16·26–
17·04)
12·79 
(11·69–
13·85)
21·03 
(19·99–
22·10)
16·02 
(14·42–
17·48)
18·13 
(17·14–
19·09)
13·96 
(12·61–
15·28)
Israel
16·81 
(15·99–
17·61)
12·74 
(11·45–
13·98)
15·08 
(14·39–
15·87)
11·53 
(10·39–
12·59)
20·00 
(19·21–
20·82)
15·12 
(13·63–
16·54)
17·63 
(16·86–
18·41)
13·46 
(12·15–
14·68)
21·54 
(20·02–
22·96)
16·31 
(14·53–
17·97)
18·93 
(17·36–
20·55)
14·48 
(12·89–
16·15)
Italy
18·91 
(18·73–
19·10)
14·31 
(13·04–
15·46)
15·08 
(14·91–
15·25)
11·53 
(10·55–
12·45)
21·36 
(21·18–
21·52)
16·26 
(14·82–
17·57)
17·57 
(17·39–
17·76)
13·50 
(12·38–
14·54)
21·94 
(21·44–
22·46)
16·77 
(15·29–
18·16)
18·60 
(18·05–
19·13)
14·34 
(13·08–
15·50)
Luxembourg
17·75 
(17·43–
18·09)
13·25 
(12·00–
14·38)
14·01 
(13·75–
14·27)
10·51 
(9·54–
11·40)
20·82 
(20·44–
21·15)
15·60 
(14·14–
16·86)
17·44 
(17·14–
17·75)
13·13 
(11·92–
14·24)
21·49 
(20·63–
22·52)
16·16 
(14·62–
17·61)
18·95 
(18·21–
19·74)
14·32 
(12·93–
15·58)
Malta
16·55 
(15·73–
17·38)
12·60 
(11·35–
13·85)
14·28 
(13·61–
14·99)
10·99 
(9·95–
12·06)
19·57 
(18·79–
20·34)
14·93 
(13·49–
16·22)
16·55 
(15·89–
17·23)
12·76 
(11·64–
13·80)
21·34 
(19·94–
22·91)
16·28 
(14·58–
18·01)
18·03 
(16·76–
19·40)
13·92 
(12·45–
15·45)
Netherlands
18·96 
(18·64–
19·33)
14·26 
(12·98–
15·45)
14·43 
(14·11–
14·73)
10·98 
(10·03–
11·85)
20·17 
(19·85–
20·47)
15·21 
(13·82–
16·48)
16·73 
(16·45–
17·05)
12·72 
(11·62–
13·74)
21·38 
(20·65–
22·06)
16·12 
(14·61–
17·54)
18·11 
(17·36–
18·78)
13·79 
(12·53–
15·00)
Norway
18·81 
(18·47–
19·16)
14·30 
(13·04–
15·45)
14·80 
(14·50–
15·15)
11·24 
(10·21–
12·17)
20·62 
(20·28–
20·92)
15·74 
(14·38–
16·96)
17·42 
(17·12–
17·70)
13·20 
(12·02–
14·27)
21·57 
(20·67–
22·52)
16·49 
(14·89–
17·88)
18·68 
(17·94–
19·52)
14·21 
(12·90–
15·60)
Portugal
17·57 
(17·36–
17·79)
13·32 
(12·17–
14·41)
14·26 
(14·04–
14·47)
10·96 
(9·99–
11·76)
20·21 
(19·95–
20·46)
15·36 
(13·97–
16·55)
16·50 
(16·25–
16·75)
12·76 
(11·70–
13·73)
21·52 
(21·01–
22·08)
16·43 
(14·99–
17·78)
17·82 
(17·32–
18·37)
13·82 
(12·60–
14·92)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1299
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Spain
19·26 
(19·12–
19·40)
14·71 
(13·40–
15·84)
15·59 
(15·44–
15·74)
12·07 
(11·09–
12·98)
21·58 
(21·44–
21·70)
16·53 
(15·08–
17·79)
17·57 
(17·43–
17·71)
13·65 
(12·54–
14·65)
22·82 
(22·47–
23·17)
17·57 
(16·08–
18·94)
19·17 
(18·76–
19·56)
14·99 
(13·74–
16·09)
Sweden
19·05 
(18·78–
19·30)
14·38 
(13·12–
15·57)
15·34 
(15·10–
15·60)
11·77 
(10·74–
12·66)
20·58 
(20·36–
20·83)
15·53 
(14·13–
16·77)
17·58 
(17·35–
17·81)
13·36 
(12·20–
14·42)
21·37 
(20·36–
22·32)
16·05 
(14·52–
17·62)
18·64 
(17·74–
19·51)
14·12 
(12·67–
15·40)
Switzerland
19·57 
(19·09–
20·04)
14·64 
(13·24–
15·95)
15·38 
(14·93–
15·84)
11·70 
(10·61–
12·72)
21·55 
(21·10–
21·98)
16·14 
(14·60–
17·55)
18·22 
(17·74–
18·69)
13·82 
(12·60–
15·03)
22·51 
(20·50–
24·40)
17·02 
(14·97–
18·88)
19·47 
(17·46–
21·31)
14·90 
(12·94–
16·63)
UK
17·80 
(17·71–
17·89)
13·43 
(12·25–
14·50)
13·98 
(13·90–
14·05)
10·69 
(9·78–
11·49)
19·88 
(19·79–
19·97)
15·01 
(13·68–
16·19)
17·10 
(17·02–
17·18)
13·08 
(11·97–
14·10)
20·88 
(20·73–
21·04)
15·77 
(14·37–
17·07)
18·27 
(18·13–
18·40)
14·00 
(12·83–
15·05)
England
17·94 
(17·87–
18·00)
13·51 
(12·31–
14·61)
14·11 
(14·05–
14·17)
10·78 
(9·86–
11·60)
20·03 
(19·97–
20·10)
15·09 
(13·74–
16·30)
17·24 
(17·18–
17·30)
13·17 
(12·07–
14·18)
21·05 
(20·94–
21·16)
15·87 
(14·44–
17·17)
18·44 
(18·34–
18·54)
14·11 
(12·91–
15·18)
Northern 
Ireland
17·39 
(16·77–
18·11)
13·25 
(12·04–
14·43)
13·52 
(12·95–
14·16)
10·41 
(9·47–
11·31)
19·69 
(19·11–
20·35)
15·00 
(13·66–
16·35)
16·70 
(16·11–
17·30)
12·86 
(11·72–
13·93)
20·59 
(19·45–
21·77)
15·71 
(14·13–
17·25)
17·75 
(16·64–
18·93)
13·68 
(12·32–
15·06)
Scotland
16·75 
(16·13–
17·38)
12·77 
(11·63–
13·89)
12·99 
(12·46–
13·53)
10·02 
(9·10–
10·89)
18·69 
(18·06–
19·34)
14·30 
(13·06–
15·50)
16·00 
(15·44–
16·53)
12·38 
(11·31–
13·40)
19·71 
(18·66–
20·75)
15·02 
(13·60–
16·58)
17·16 
(16·23–
18·09)
13·24 
(11·94–
14·55)
Wales
17·67 
(17·07–
18·28)
13·40 
(12·18–
14·59)
13·68 
(13·14–
14·18)
10·51 
(9·55–
11·40)
19·67 
(19·19–
20·26)
15·00 
(13·70–
16·27)
16·92 
(16·34–
17·45)
13·03 
(11·95–
14·11)
20·43 
(19·42–
21·41)
15·58 
(14·14–
17·10)
17·70 
(16·71–
18·66)
13·65 
(12·32–
14·97)
Southern Latin 
America
17·74 
(17·50–
17·99)
13·79 
(12·63–
14·82)
14·03 
(13·79–
14·27)
10·84 
(9·94–
11·67)
19·34 
(19·11–
19·60)
15·03 
(13·83–
16·15)
15·30 
(15·05–
15·55)
11·83 
(10·86–
12·74)
20·24 
(19·54–
20·92)
15·72 
(14·32–
16·97)
16·14 
(15·49–
16·77)
12·50 
(11·38–
13·58)
Argentina
17·76 
(17·46–
18·08)
13·83 
(12·70–
14·89)
13·90 
(13·61–
14·19)
10·75 
(9·84–
11·59)
19·01 
(18·70–
19·33)
14·82 
(13·65–
15·91)
14·81 
(14·50–
15·12)
11·47 
(10·52–
12·36)
19·73 
(19·11–
20·39)
15·37 
(14·05–
16·56)
15·55 
(14·94–
16·19)
12·06 
(11·04–
13·05)
Chile
17·69 
(17·18–
18·26)
13·64 
(12·46–
14·77)
14·65 
(14·15–
15·19)
11·25 
(10·19–
12·25)
20·40 
(19·90–
20·91)
15·72 
(14·40–
16·95)
17·08 
(16·61–
17·62)
13·14 
(11·99–
14·23)
21·63 
(19·39–
23·86)
16·71 
(14·58–
18·88)
17·91 
(15·85–
20·06)
13·84 
(11·93–
15·86)
Uruguay
17·70 
(17·44–
17·95)
13·78 
(12·64–
14·77)
13·69 
(13·46–
13·92)
10·65 
(9·75–
11·44)
19·50 
(19·24–
19·74)
15·17 
(13·95–
16·22)
14·76 
(14·54–
15·01)
11·46 
(10·49–
12·30)
20·44 
(19·85–
21·02)
15·87 
(14·53–
17·10)
15·54 
(15·03–
16·08)
12·09 
(11·04–
13·07)
Central Europe, 
eastern Europe, 
and central Asia
15·81 
(15·50–
16·12)
11·59 
(10·43–
12·70)
12·43 
(12·17–
12·66)
9·08 
(8·14–
9·92)
16·22 
(15·89–
16·52)
11·99 
(10·77–
13·05)
12·41 
(12·12–
12·70)
9·12 
(8·21–
9·96)
17·80 
(16·51–
18·92)
13·16 
(11·60–
14·68)
14·07 
(13·21–
14·96)
10·33 
(9·14–
11·60)
Eastern Europe
15·85 
(15·36–
16·35)
11·64 
(10·50–
12·82)
12·20 
(11·76–
12·66)
8·92 
(8·01–
9·79)
15·81 
(15·30–
16·30)
11·74 
(10·53–
12·79)
11·57 
(11·10–
12·05)
8·53 
(7·66–
9·39)
17·37 
(15·46–
19·28)
12·90 
(10·99–
14·77)
13·26 
(11·85–
14·92)
9·79 
(8·39–
11·34)
Belarus
16·52 
(16·15–
16·86)
12·23 
(11·04–
13·34)
12·94 
(12·58–
13·28)
9·56 
(8·60–
10·48)
16·27 
(15·89–
16·65)
12·10 
(10·89–
13·16)
11·53 
(11·20–
11·88)
8·54 
(7·67–
9·35)
18·15 
(16·70–
19·71)
13·45 
(11·83–
15·17)
13·25 
(12·01–
14·60)
9·79 
(8·48–
11·19)
Estonia
16·11 
(15·79–
16·44)
11·79 
(10·58–
12·88)
12·21 
(11·91–
12·52)
8·91 
(7·98–
9·77)
18·25 
(17·93–
18·60)
13·55 
(12·24–
14·75)
13·28 
(12·96–
13·57)
9·78 
(8·80–
10·71)
20·14 
(19·43–
21·38)
14·90 
(13·28–
16·52)
15·65 
(14·85–
16·60)
11·50 
(10·22–
12·74)
Latvia
15·93 
(15·55–
16·30)
11·58 
(10·34–
12·70)
12·23 
(11·83–
12·64)
8·87 
(7·93–
9·75)
16·87 
(16·49–
17·26)
12·49 
(11·28–
13·60)
12·38 
(12·03–
12·74)
9·09 
(8·16–
9·96)
19·04 
(18·02–
20·10)
14·02 
(12·56–
15·56)
14·24 
(13·32–
15·35)
10·44 
(9·21–
11·68)
Lithuania
17·10 
(16·81–
17·39)
12·49 
(11·23–
13·64)
13·47 
(13·18–
13·78)
9·82 
(8·81–
10·74)
17·97 
(17·68–
18·24)
13·14 
(11·83–
14·34)
13·26 
(12·99–
13·56)
9·69 
(8·69–
10·62)
19·63 
(19·02–
20·27)
14·42 
(12·96–
15·79)
14·70 
(14·11–
15·31)
10·68 
(9·43–
11·81)
Moldova
14·43 
(13·82–
15·08)
10·67 
(9·61–
11·75)
12·09 
(11·51–
12·71)
8·94 
(7·98–
9·83)
14·59 
(13·99–
15·27)
11·00 
(9·86–
12·05)
11·89 
(11·28–
12·52)
8·95 
(8·01–
9·88)
16·35 
(15·32–
17·49)
12·29 
(10·95–
13·68)
13·35 
(12·40–
14·45)
10·01 
(8·85–
11·26)
(Table 3 continues on next page)
 Global Health Metrics
1300 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Russia
15·82 
(15·10–
16·62)
11·60 
(10·43–
12·83)
12·01 
(11·35–
12·78)
8·74 
(7·77–
9·73)
15·80 
(15·04–
16·52)
11·70 
(10·45–
12·88)
11·46 
(10·77–
12·20)
8·41 
(7·47–
9·38)
17·27 
(14·52–
20·14)
12·84 
(10·56–
15·28)
13·18 
(11·27–
15·67)
9·72 
(7·95–
11·73)
Ukraine
15·79 
(15·35–
16·24)
11·65 
(10·50–
12·72)
12·41 
(12·02–
12·80)
9·15 
(8·19–
10·04)
15·60 
(15·19–
16·00)
11·65 
(10·49–
12·71)
11·64 
(11·27–
12·04)
8·66 
(7·81–
9·49)
17·23 
(15·13–
19·48)
12·93 
(11·04–
15·00)
13·26 
(11·61–
15·48)
9·92 
(8·44–
11·63)
Central Europe
15·72 
(15·58–
15·85)
11·42 
(10·24–
12·46)
12·64 
(12·52–
12·77)
9·16 
(8·18–
10·03)
17·49 
(17·36–
17·64)
12·79 
(11·50–
13·94)
14·03 
(13·90–
14·16)
10·19 
(9·12–
11·12)
18·92 
(18·59–
19·25)
13·84 
(12·43–
15·11)
15·38 
(15·08–
15·69)
11·16 
(10·02–
12·19)
Albania
18·27 
(18·06–
18·51)
13·70 
(12·40–
14·86)
14·91 
(14·71–
15·13)
11·14 
(10·05–
12·10)
17·66 
(17·41–
17·91)
13·33 
(12·10–
14·47)
14·96 
(14·76–
15·17)
11·26 
(10·18–
12·19)
19·59 
(18·61–
20·63)
14·70 
(13·25–
16·22)
16·11 
(14·93–
17·27)
12·07 
(10·68–
13·40)
Bosnia and 
Herzegovina
15·47 
(14·56–
16·56)
11·53 
(10·22–
12·78)
12·83 
(12·00–
13·72)
9·57 
(8·51–
10·72)
17·32 
(16·38–
18·35)
12·84 
(11·52–
14·23)
14·66 
(13·73–
15·57)
10·78 
(9·57–
11·90)
18·56 
(17·17–
19·95)
13·69 
(12·11–
15·33)
15·58 
(14·44–
16·83)
11·39 
(10·05–
12·76)
Bulgaria
15·20 
(14·94–
15·45)
11·24 
(10·16–
12·23)
12·81 
(12·58–
13·03)
9·34 
(8·39–
10·22)
16·22 
(15·99–
16·46)
12·07 
(10·92–
13·12)
13·17 
(12·93–
13·41)
9·71 
(8·75–
10·59)
17·60 
(16·23–
18·93)
13·07 
(11·52–
14·58)
14·28 
(13·12–
15·58)
10·50 
(9·26–
11·91)
Croatia
15·96 
(15·35–
16·56)
11·68 
(10·40–
12·87)
12·72 
(12·18–
13·36)
9·26 
(8·25–
10·23)
17·50 
(16·97–
18·04)
12·88 
(11·53–
14·10)
13·90 
(13·41–
14·44)
10·18 
(9·10–
11·21)
18·57 
(17·49–
19·78)
13·66 
(12·08–
15·13)
15·15 
(14·20–
16·27)
11·04 
(9·76–
12·45)
Czech Republic
15·33 
(15·16–
15·49)
10·84 
(9·61–
11·93)
11·84 
(11·68–
12·01)
8·44 
(7·49–
9·26)
18·09 
(17·89–
18·26)
12·92 
(11·51–
14·19)
14·69 
(14·51–
14·89)
10·43 
(9·25–
11·46)
19·66 
(19·21–
20·11)
14·10 
(12·46–
15·53)
16·34 
(15·88–
16·79)
11·62 
(10·26–
12·83)
Hungary
15·43 
(15·02–
15·87)
10·85 
(9·57–
12·01)
12·08 
(11·72–
12·46)
8·58 
(7·59–
9·51)
17·48 
(17·05–
17·92)
12·56 
(11·22–
13·85)
13·54 
(13·12–
13·98)
9·70 
(8·60–
10·69)
18·34 
(17·45–
19·21)
13·25 
(11·82–
14·70)
14·74 
(13·88–
15·67)
10·61 
(9·36–
11·91)
Macedonia
14·55 
(14·03–
15·08)
10·86 
(9·76–
11·88)
12·61 
(12·18–
13·04)
9·36 
(8·42–
10·25)
14·93 
(14·49–
15·43)
11·14 
(10·05–
12·19)
12·71 
(12·32–
13·13)
9·44 
(8·50–
10·33)
16·26 
(15·79–
16·82)
12·08 
(10·86–
13·19)
13·67 
(13·22–
14·15)
10·13 
(9·08–
11·06)
Montenegro
18·05 
(17·25–
18·70)
13·38 
(12·05–
14·73)
15·39 
(14·78–
16·01)
11·28 
(10·01–
12·38)
17·80 
(17·45–
18·18)
13·23 
(11·83–
14·45)
14·76 
(14·34–
15·23)
10·88 
(9·78–
11·93)
18·50 
(17·59–
19·69)
13·73 
(12·17–
15·34)
15·72 
(14·87–
16·56)
11·56 
(10·30–
12·82)
Poland
16·07 
(15·76–
16·37)
11·70 
(10·48–
12·78)
12·40 
(12·15–
12·70)
9·02 
(8·08–
9·89)
18·64 
(18·37–
18·94)
13·56 
(12·18–
14·84)
14·52 
(14·22–
14·83)
10·51 
(9·40–
11·53)
20·10 
(19·32–
20·89)
14·69 
(13·06–
16·19)
16·03 
(15·32–
16·80)
11·61 
(10·31–
12·85)
Romania
15·37 
(15·00–
15·76)
11·32 
(10·16–
12·37)
13·17 
(12·78–
13·52)
9·57 
(8·57–
10·52)
16·86 
(16·48–
17·27)
12·44 
(11·23–
13·61)
13·89 
(13·54–
14·25)
10·13 
(9·06–
11·13)
18·11 
(17·30–
18·94)
13·40 
(12·02–
14·73)
14·78 
(13·93–
15·63)
10·79 
(9·53–
12·02)
Serbia
16·12 
(15·50–
16·90)
11·85 
(10·61–
13·13)
13·48 
(12·93–
14·25)
9·88 
(8·82–
10·96)
15·81 
(15·34–
16·26)
11·67 
(10·49–
12·76)
13·42 
(13·05–
13·85)
9·84 
(8·80–
10·81)
17·87 
(17·46–
18·22)
13·12 
(11·77–
14·30)
14·95 
(14·58–
15·45)
10·92 
(9·77–
11·97)
Slovakia
15·65 
(15·33–
15·99)
11·39 
(10·22–
12·44)
12·14 
(11·83–
12·46)
8·74 
(7·76–
9·58)
17·30 
(16·98–
17·65)
12·75 
(11·47–
13·88)
13·46 
(13·14–
13·76)
9·76 
(8·70–
10·71)
18·79 
(17·84–
19·81)
13·84 
(12·34–
15·36)
15·07 
(14·16–
16·02)
10·90 
(9·55–
12·23)
Slovenia
16·98 
(16·32–
17·66)
12·11 
(10·74–
13·47)
13·24 
(12·67–
13·90)
9·42 
(8·27–
10·46)
19·67 
(19·06–
20·38)
14·01 
(12·47–
15·47)
15·53 
(14·86–
16·18)
10·97 
(9·67–
12·25)
21·28 
(20·30–
22·41)
15·12 
(13·28–
16·79)
17·51 
(16·48–
18·62)
12·44 
(10·88–
14·05)
Central Asia
15·86 
(15·55–
16·14)
11·82 
(10·69–
12·85)
12·81 
(12·53–
13·07)
9·64 
(8·74–
10·45)
15·03 
(14·74–
15·32)
11·29 
(10·24–
12·21)
12·04 
(11·76–
12·30)
9·13 
(8·31–
9·91)
16·82 
(16·31–
17·33)
12·58 
(11·34–
13·68)
13·51 
(13·06–
14·02)
10·21 
(9·17–
11·16)
Armenia
16·36 
(15·90–
16·84)
12·21 
(11·01–
13·31)
13·96 
(13·48–
14·47)
10·43 
(9·38–
11·39)
16·46 
(15·89–
16·98)
12·35 
(11·12–
13·46)
13·65 
(13·18–
14·16)
10·26 
(9·26–
11·21)
18·31 
(17·42–
19·33)
13·70 
(12·15–
15·07)
14·76 
(14·01–
15·62)
11·09 
(9·93–
12·20)
Azerbaijan
15·87 
(15·41–
16·47)
11·96 
(10·82–
13·07)
12·45 
(12·04–
12·87)
9·48 
(8·59–
10·34)
14·90 
(14·14–
15·75)
11·31 
(10·09–
12·42)
12·22 
(11·59–
12·93)
9·37 
(8·51–
10·26)
17·26 
(15·65–
18·62)
12·98 
(11·35–
14·41)
13·75 
(12·53–
15·42)
10·48 
(9·13–
12·11)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1301
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Georgia
16·28 
(15·61–
16·95)
12·30 
(11·04–
13·42)
13·14 
(12·46–
13·87)
9·94 
(8·92–
10·88)
17·77 
(17·33–
18·20)
13·44 
(12·20–
14·58)
13·26 
(12·81–
13·78)
10·12 
(9·16–
11·03)
18·50 
(17·13–
20·32)
13·91 
(12·39–
15·46)
13·78 
(12·62–
15·14)
10·40 
(9·08–
11·74)
Kazakhstan
15·94 
(15·11–
16·76)
11·75 
(10·44–
12·93)
12·21 
(11·48–
13·01)
9·09 
(8·03–
10·08)
14·72 
(13·98–
15·51)
10·92 
(9·69–
12·05)
10·91 
(10·23–
11·64)
8·13 
(7·20–
9·07)
16·95 
(15·49–
18·45)
12·54 
(11·03–
14·06)
13·26 
(11·89–
14·72)
9·86 
(8·52–
11·34)
Kyrgyzstan
15·81 
(15·45–
16·19)
11·73 
(10·58–
12·80)
12·46 
(12·14–
12·82)
9·33 
(8·46–
10·13)
14·41 
(14·08–
14·76)
10·85 
(9·85–
11·76)
11·52 
(11·18–
11·83)
8·75 
(7·93–
9·49)
16·64 
(15·84–
17·41)
12·47 
(11·20–
13·72)
13·55 
(12·87–
14·30)
10·27 
(9·21–
11·28)
Mongolia
14·23 
(13·32–
15·22)
10·73 
(9·49–
11·90)
12·20 
(11·48–
12·78)
9·26 
(8·31–
10·19)
13·75 
(13·13–
14·34)
10·36 
(9·33–
11·37)
11·11 
(10·62–
11·75)
8·40 
(7·58–
9·23)
15·61 
(14·55–
16·74)
11·69 
(10·34–
13·01)
12·29 
(11·45–
13·25)
9·20 
(8·10–
10·27)
Tajikistan
15·87 
(15·14–
16·68)
11·88 
(10·66–
13·07)
13·64 
(12·79–
14·49)
10·28 
(9·21–
11·35)
14·52 
(13·56–
15·40)
11·01 
(9·92–
12·18)
13·00 
(12·29–
13·80)
9·92 
(8·89–
10·94)
16·92 
(15·66–
17·89)
12·78 
(11·34–
14·08)
14·90 
(13·58–
15·85)
11·34 
(10·05–
12·50)
Turkmenistan
15·09 
(14·84–
15·36)
11·39 
(10·31–
12·35)
12·42 
(12·23–
12·61)
9·49 
(8·65–
10·24)
15·60 
(15·30–
15·91)
11·86 
(10·77–
12·87)
12·73 
(12·48–
12·97)
9·79 
(8·93–
10·57)
16·95 
(16·34–
17·52)
12·85 
(11·60–
14·03)
13·73 
(13·31–
14·15)
10·54 
(9·62–
11·42)
Uzbekistan
15·72 
(15·18–
16·23)
11·69 
(10·51–
12·80)
13·19 
(12·71–
13·72)
9·97 
(9·00–
10·89)
14·18 
(13·65–
14·77)
10·68 
(9·59–
11·72)
11·93 
(11·30–
12·50)
9·11 
(8·24–
10·01)
15·76 
(14·90–
16·65)
11·84 
(10·59–
13·07)
13·13 
(12·43–
13·80)
10·02 
(8·97–
10·98)
Latin America and 
Caribbean
17·13 
(17·03–
17·22)
12·97 
(11·81–
13·99)
14·69 
(14·60–
14·78)
11·18 
(10·21–
12·06)
18·73 
(18·62–
18·83)
14·17 
(12·89–
15·31)
16·05 
(15·95–
16·14)
12·21 
(11·13–
13·19)
19·49 
(19·29–
19·68)
14·74 
(13·39–
15·94)
16·78 
(16·61–
16·95)
12·78 
(11·65–
13·77)
Central Latin 
America
17·96 
(17·84–
18·09)
13·61 
(12·38–
14·68)
15·76 
(15·64–
15·89)
11·94 
(10·84–
12·89)
19·16 
(19·01–
19·32)
14·60 
(13·31–
15·75)
16·71 
(16·55–
16·86)
12·72 
(11·58–
13·73)
19·75 
(19·46–
20·07)
15·03 
(13·67–
16·25)
17·30 
(17·00–
17·58)
13·17 
(12·00–
14·22)
Colombia
17·85 
(17·57–
18·11)
13·69 
(12·44–
14·78)
15·41 
(15·17–
15·66)
11·86 
(10·81–
12·78)
18·65 
(18·41–
18·89)
14·40 
(13·23–
15·45)
16·03 
(15·78–
16·27)
12·44 
(11·41–
13·35)
20·24 
(19·48–
21·04)
15·61 
(14·17–
16·91)
17·58 
(16·85–
18·33)
13·60 
(12·36–
14·77)
Costa Rica
18·86 
(18·53–
19·21)
14·42 
(13·13–
15·58)
16·38 
(16·04–
16·70)
12·66 
(11·59–
13·65)
21·26 
(20·90–
21·58)
16·21 
(14·75–
17·52)
18·52 
(18·19–
18·85)
14·24 
(13·01–
15·37)
22·29 
(21·64–
22·94)
16·99 
(15·40–
18·49)
19·50 
(18·88–
20·18)
15·00 
(13·61–
16·28)
El Salvador
17·51 
(17·14–
17·91)
13·43 
(12·21–
14·52)
15·26 
(14·91–
15·61)
11·67 
(10·65–
12·61)
18·74 
(18·39–
19·10)
14·36 
(13·07–
15·50)
17·54 
(17·20–
17·89)
13·35 
(12·13–
14·50)
19·56 
(18·61–
20·48)
14·99 
(13·49–
16·35)
17·95 
(17·06–
18·90)
13·68 
(12·29–
14·98)
Guatemala
15·45 
(14·53–
16·45)
11·75 
(10·45–
13·01)
14·76 
(13·91–
15·90)
11·23 
(10·11–
12·51)
18·05 
(16·81–
19·26)
13·60 
(12·08–
15·08)
16·33 
(15·32–
17·47)
12·40 
(11·06–
13·85)
18·76 
(16·58–
21·20)
14·24 
(12·19–
16·30)
16·86 
(15·14–
18·96)
12·84 
(11·08–
14·83)
Honduras
14·00 
(13·26–
14·84)
10·79 
(9·76–
11·81)
15·71 
(14·10–
16·95)
12·11 
(10·76–
13·48)
15·24 
(13·70–
17·73)
11·69 
(10·10–
13·62)
15·29 
(13·25–
17·63)
11·85 
(9·93–
13·82)
16·03 
(14·34–
18·60)
12·29 
(10·60–
14·36)
15·73 
(13·50–
17·94)
12·16 
(10·19–
14·03)
Mexico
18·45 
(18·33–
18·59)
13·87 
(12·60–
15·00)
16·04 
(15·91–
16·18)
12·00 
(10·87–
13·00)
19·42 
(19·24–
19·59)
14·71 
(13·38–
15·92)
16·91 
(16·77–
17·05)
12·74 
(11·55–
13·76)
19·48 
(19·23–
19·75)
14·72 
(13·35–
15·93)
17·20 
(16·99–
17·42)
12·97 
(11·74–
14·04)
Nicaragua
20·99 
(20·64–
21·35)
15·97 
(14·58–
17·26)
18·21 
(17·86–
18·57)
13·94 
(12·68–
15·09)
20·55 
(20·18–
20·95)
15·73 
(14·32–
17·00)
18·29 
(17·93–
18·63)
14·08 
(12·86–
15·23)
20·98 
(19·63–
22·42)
16·05 
(14·41–
17·73)
18·38 
(17·12–
19·75)
14·16 
(12·53–
15·71)
Panama
18·86 
(18·27–
19·48)
14·45 
(13·09–
15·71)
16·24 
(15·62–
16·85)
12·49 
(11·36–
13·54)
20·69 
(20·12–
21·25)
15·85 
(14·35–
17·10)
18·01 
(17·40–
18·61)
13·82 
(12·58–
14·95)
21·73 
(20·64–
22·85)
16·60 
(14·95–
18·18)
18·76 
(17·55–
19·96)
14·32 
(12·83–
15·78)
Venezuela
17·29 
(16·76–
17·88)
13·21 
(11·94–
14·34)
15·08 
(14·50–
15·59)
11·56 
(10·48–
12·58)
19·62 
(19·01–
20·20)
15·00 
(13·59–
16·26)
16·42 
(15·91–
16·98)
12·62 
(11·48–
13·67)
20·19 
(18·68–
21·62)
15·47 
(13·72–
17·22)
16·71 
(15·27–
17·97)
12·85 
(11·36–
14·26)
Andean Latin 
America
17·23 
(16·84–
17·65)
13·14 
(11·88–
14·26)
15·71 
(15·35–
16·06)
11·97 
(10·91–
12·93)
19·66 
(19·22–
20·09)
15·03 
(13·66–
16·22)
17·61 
(17·23–
18·01)
13·45 
(12·21–
14·55)
20·12 
(19·15–
21·07)
15·39 
(13·86–
16·86)
18·36 
(17·53–
19·23)
14·04 
(12·63–
15·41)
(Table 3 continues on next page)
 Global Health Metrics
1302 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Bolivia
13·86 
(12·86–
14·74)
10·46 
(9·25–
11·63)
13·76 
(13·09–
14·45)
10·31 
(9·25–
11·31)
16·68 
(15·58–
17·39)
12·62 
(11·19–
13·88)
15·79 
(15·11–
16·68)
11·92 
(10·69–
13·14)
16·93 
(14·96–
18·57)
12·88 
(10·99–
14·55)
16·60 
(15·49–
18·03)
12·55 
(11·04–
14·20)
Ecuador
18·27 
(17·92–
18·63)
13·99 
(12·74–
15·13)
16·17 
(15·84–
16·50)
12·33 
(11·20–
13·34)
20·21 
(19·87–
20·58)
15·46 
(14·06–
16·68)
17·90 
(17·50–
18·28)
13·57 
(12·33–
14·73)
20·84 
(20·21–
21·44)
15·93 
(14·44–
17·28)
18·67 
(18·02–
19·29)
14·19 
(12·88–
15·46)
Peru
18·20 
(17·64–
18·79)
13·91 
(12·58–
15·12)
16·24 
(15·61–
16·83)
12·45 
(11·36–
13·53)
20·54 
(19·91–
21·30)
15·75 
(14·26–
17·02)
18·13 
(17·46–
18·81)
13·96 
(12·60–
15·15)
21·06 
(19·44–
22·77)
16·17 
(14·35–
18·06)
18·88 
(17·36–
20·52)
14·55 
(12·85–
16·20)
Caribbean
16·54 
(16·30–
16·77)
12·69 
(11·53–
13·70)
15·12 
(14·93–
15·31)
11·66 
(10·65–
12·59)
17·99 
(17·59–
18·41)
13·73 
(12·50–
14·87)
16·16 
(15·91–
16·45)
12·40 
(11·31–
13·40)
18·59 
(18·05–
19·17)
14·19 
(12·92–
15·40)
16·50 
(16·08–
16·90)
12·66 
(11·51–
13·71)
Antigua and 
Barbuda
17·09 
(16·33–
17·88)
13·17 
(11·91–
14·43)
14·14 
(13·51–
14·78)
10·84 
(9·86–
11·83)
19·02 
(18·29–
19·74)
14·52 
(13·08–
15·89)
16·29 
(15·63–
17·05)
12·44 
(11·23–
13·63)
19·74 
(18·72–
20·85)
15·10 
(13·53–
16·61)
16·79 
(15·84–
17·78)
12·81 
(11·51–
14·18)
The Bahamas
16·94 
(16·60–
17·27)
13·01 
(11·83–
14·05)
13·96 
(13·64–
14·31)
10·79 
(9·87–
11·67)
17·81 
(17·35–
18·34)
13·66 
(12·44–
14·78)
15·53 
(15·21–
15·85)
11·99 
(10·96–
12·92)
17·58 
(16·57–
18·78)
13·50 
(12·09–
14·92)
15·74 
(15·06–
16·52)
12·16 
(11·02–
13·37)
Barbados
17·20 
(16·69–
17·72)
13·19 
(11·94–
14·35)
14·19 
(13·68–
14·60)
10·95 
(9·96–
11·88)
19·40 
(18·87–
19·90)
14·74 
(13·35–
15·99)
16·36 
(15·86–
16·88)
12·53 
(11·41–
13·56)
19·37 
(18·61–
20·22)
14·70 
(13·25–
16·03)
16·74 
(15·99–
17·50)
12·85 
(11·63–
14·06)
Belize
17·21 
(16·26–
18·14)
13·19 
(11·80–
14·46)
15·55 
(14·28–
16·17)
12·02 
(10·79–
13·10)
16·04 
(15·65–
16·40)
12·21 
(11·10–
13·28)
13·46 
(12·58–
14·25)
10·35 
(9·26–
11·43)
16·61 
(15·62–
17·69)
12·67 
(11·31–
14·03)
14·05 
(13·07–
15·19)
10·82 
(9·66–
11·98)
Bermuda
13·93 
(13·33–
14·58)
10·77 
(9·76–
11·75)
12·47 
(11·92–
13·01)
9·61 
(8·67–
10·44)
16·90 
(16·17–
17·60)
13·00 
(11·83–
14·16)
14·73 
(14·17–
15·26)
11·35 
(10·36–
12·31)
20·42 
(19·08–
22·13)
15·70 
(14·10–
17·46)
16·31 
(15·32–
17·25)
12·57 
(11·28–
13·80)
Cuba
18·18 
(17·83–
18·54)
13·94 
(12·70–
15·07)
15·72 
(15·35–
16·04)
12·19 
(11·13–
13·19)
19·45 
(19·10–
19·79)
14·87 
(13·50–
16·07)
16·88 
(16·52–
17·24)
13·07 
(11·93–
14·09)
20·23 
(19·53–
21·00)
15·44 
(13·98–
16·78)
17·31 
(16·65–
18·00)
13·37 
(12·10–
14·57)
Dominica
14·93 
(14·41–
15·55)
11·56 
(10·49–
12·53)
13·63 
(13·14–
14·30)
10·54 
(9·61–
11·48)
16·65 
(15·84–
17·31)
12·83 
(11·63–
13·89)
14·38 
(13·82–
15·01)
11·06 
(10·03–
12·02)
17·26 
(16·02–
18·20)
13·30 
(11·90–
14·66)
14·63 
(13·65–
15·80)
11·25 
(9·98–
12·51)
Dominican 
Republic
17·36 
(16·88–
18·08)
13·47 
(12·25–
14·65)
16·05 
(15·48–
16·60)
12·50 
(11·38–
13·60)
19·45 
(18·41–
20·68)
15·02 
(13·38–
16·68)
16·81 
(16·34–
17·89)
12·98 
(11·82–
14·26)
19·65 
(18·48–
21·24)
15·19 
(13·66–
17·00)
17·21 
(16·33–
18·48)
13·33 
(12·00–
14·63)
Grenada
15·64 
(14·97–
16·19)
11·90 
(10·74–
12·91)
13·71 
(12·95–
14·40)
10·50 
(9·44–
11·58)
16·05 
(15·32–
16·71)
12·17 
(10·94–
13·21)
13·79 
(13·16–
14·36)
10·54 
(9·50–
11·48)
16·29 
(15·19–
17·62)
12·37 
(11·08–
13·68)
13·96 
(13·11–
14·93)
10·67 
(9·53–
11·79)
Guyana
14·71 
(14·21–
15·34)
11·22 
(10·18–
12·19)
11·79 
(11·24–
12·38)
9·03 
(8·16–
9·91)
14·36 
(13·76–
14·92)
10·87 
(9·76–
11·87)
12·34 
(11·84–
12·84)
9·35 
(8·43–
10·20)
15·17 
(14·32–
16·19)
11·49 
(10·28–
12·70)
12·98 
(12·28–
13·74)
9·88 
(8·86–
10·85)
Haiti
10·84 
(10·21–
11·40)
8·24 
(7·41–
9·09)
12·30 
(11·78–
12·82)
9·34 
(8·43–
10·24)
12·27 
(11·18–
13·67)
9·35 
(8·20–
10·54)
13·25 
(12·48–
14·47)
10·10 
(8·98–
11·30)
13·04 
(11·71–
14·55)
9·95 
(8·74–
11·38)
13·75 
(12·36–
15·23)
10·52 
(9·14–
11·91)
Jamaica
17·83 
(17·01–
18·62)
13·63 
(12·25–
14·93)
16·83 
(16·27–
17·47)
12·99 
(11·83–
14·11)
18·14 
(17·52–
18·87)
13·71 
(12·37–
15·01)
16·79 
(16·09–
17·44)
12·85 
(11·59–
13·95)
17·93 
(16·46–
19·36)
13·55 
(11·91–
15·24)
16·28 
(14·77–
17·58)
12·45 
(10·95–
13·86)
Puerto Rico
18·89 
(18·50–
19·30)
14·53 
(13·27–
15·68)
15·88 
(15·48–
16·28)
12·17 
(11·08–
13·17)
20·52 
(20·09–
20·90)
15·59 
(14·12–
16·90)
17·38 
(16·94–
17·76)
13·14 
(11·88–
14·26)
21·13 
(20·34–
21·98)
16·10 
(14·54–
17·53)
17·57 
(16·86–
18·31)
13·29 
(12·00–
14·48)
Saint Lucia
17·07 
(16·72–
17·43)
12·89 
(11·64–
14·01)
14·99 
(14·66–
15·35)
11·40 
(10·43–
12·39)
18·95 
(18·51–
19·41)
14·43 
(13·08–
15·70)
16·32 
(15·93–
16·73)
12·49 
(11·38–
13·53)
20·02 
(19·49–
20·59)
15·26 
(13·84–
16·59)
17·16 
(16·60–
17·66)
13·15 
(11·94–
14·26)
Saint Vincent 
and the 
Grenadines
15·68 
(15·08–
16·14)
11·96 
(10·81–
12·98)
13·84 
(13·14–
15·13)
10·63 
(9·53–
11·84)
16·03 
(15·63–
16·49)
12·14 
(11·00–
13·20)
14·02 
(13·42–
14·51)
10·66 
(9·60–
11·67)
16·39 
(15·68–
17·33)
12·45 
(11·18–
13·74)
14·02 
(13·13–
14·60)
10·64 
(9·49–
11·70)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1303
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Suriname
16·97 
(16·61–
17·36)
12·97 
(11·75–
14·08)
15·17 
(14·98–
15·38)
11·64 
(10·64–
12·56)
16·22 
(15·66–
16·64)
12·32 
(11·14–
13·38)
14·05 
(13·80–
14·37)
10·74 
(9·75–
11·63)
17·14 
(16·40–
17·75)
12·99 
(11·71–
14·22)
14·49 
(13·84–
15·34)
11·05 
(9·99–
12·13)
Trinidad and 
Tobago
15·44 
(15·10–
15·81)
11·69 
(10·61–
12·67)
12·43 
(12·14–
12·73)
9·44 
(8·56–
10·27)
17·67 
(17·25–
18·11)
13·29 
(12·00–
14·44)
13·95 
(13·63–
14·31)
10·40 
(9·36–
11·37)
18·72 
(18·05–
19·41)
14·08 
(12·68–
15·41)
14·40 
(13·83–
15·02)
10·71 
(9·59–
11·83)
Virgin Islands
17·05 
(16·58–
18·07)
13·21 
(12·03–
14·43)
13·96 
(13·56–
14·49)
10·80 
(9·85–
11·68)
17·93 
(17·52–
18·31)
13·79 
(12·54–
14·86)
14·50 
(13·96–
14·99)
11·12 
(10·09–
12·08)
18·47 
(17·86–
19·07)
14·17 
(12·89–
15·45)
14·61 
(13·76–
15·71)
11·18 
(9·97–
12·37)
Tropical Latin 
America
16·41 
(16·23–
16·57)
12·34 
(11·22–
13·34)
13·16 
(13·01–
13·32)
10·04 
(9·15–
10·87)
18·28 
(18·11–
18·43)
13·67 
(12·37–
14·83)
15·00 
(14·84–
15·14)
11·35 
(10·35–
12·29)
19·31 
(19·02–
19·58)
14·45 
(13·09–
15·67)
15·99 
(15·74–
16·23)
12·14 
(11·05–
13·14)
Brazil
16·36 
(16·18–
16·52)
12·30 
(11·18–
13·29)
13·08 
(12·93–
13·24)
9·97 
(9·09–
10·80)
18·29 
(18·12–
18·45)
13·68 
(12·37–
14·84)
14·96 
(14·81–
15·11)
11·32 
(10·32–
12·26)
19·34 
(19·05–
19·61)
14·48 
(13·11–
15·69)
16·00 
(15·75–
16·24)
12·14 
(11·06–
13·15)
Paraguay
18·47 
(17·94–
18·88)
13·98 
(12·70–
15·17)
16·60 
(16·23–
17·00)
12·70 
(11·60–
13·80)
17·79 
(17·10–
18·51)
13·43 
(12·05–
14·74)
16·26 
(16·01–
16·45)
12·38 
(11·28–
13·37)
17·90 
(17·02–
18·91)
13·45 
(11·97–
14·85)
15·75 
(14·68–
16·54)
12·03 
(10·72–
13·30)
Southeast Asia, 
east Asia, and 
Oceania
14·53 
(14·35–
14·71)
11·16 
(10·28–
12·02)
12·44 
(12·30–
12·58)
9·76 
(9·02–
10·43)
16·47 
(16·33–
16·61)
12·53 
(11·46–
13·49)
14·06 
(13·93–
14·19)
10·95 
(10·09–
11·75)
18·48 
(18·30–
18·65)
13·99 
(12·81–
15·07)
15·09 
(14·93–
15·25)
11·69 
(10·79–
12·52)
East Asia
14·51 
(14·29–
14·73)
11·23 
(10·37–
12·07)
12·20 
(12·03–
12·37)
9·68 
(8·98–
10·32)
16·76 
(16·60–
16·93)
12·83 
(11·76–
13·80)
14·06 
(13·92–
14·20)
11·05 
(10·23–
11·84)
18·97 
(18·76–
19·18)
14·43 
(13·22–
15·51)
15·17 
(15·00–
15·35)
11·85 
(10·95–
12·67)
China
14·45 
(14·22–
14·68)
11·19 
(10·34–
12·02)
12·14 
(11·97–
12·31)
9·64 
(8·94–
10·28)
16·73 
(16·57–
16·90)
12·81 
(11·75–
13·78)
14·01 
(13·86–
14·15)
11·02 
(10·20–
11·81)
19·01 
(18·79–
19·22)
14·45 
(13·24–
15·53)
15·14 
(14·97–
15·32)
11·83 
(10·93–
12·65)
North Korea
16·18 
(15·40–
17·33)
12·48 
(11·32–
13·76)
14·00 
(13·20–
15·35)
11·05 
(9·93–
12·35)
15·59 
(14·98–
16·45)
11·94 
(10·80–
13·08)
13·41 
(13·04–
13·90)
10·56 
(9·72–
11·32)
15·93 
(15·36–
16·53)
12·26 
(11·20–
13·38)
13·49 
(13·10–
13·97)
10·60 
(9·77–
11·46)
Taiwan 
(Province of 
China)
16·63 
(16·27–
16·99)
12·55 
(11·40–
13·63)
14·61 
(14·28–
14·95)
11·31 
(10·35–
12·19)
19·85 
(19·50–
20·20)
14·95 
(13·63–
16·14)
17·05 
(16·70–
17·43)
13·14 
(12·09–
14·12)
20·99 
(19·97–
22·16)
15·88 
(14·32–
17·50)
17·87 
(16·87–
19·00)
13·79 
(12·50–
15·10)
Southeast Asia
14·63 
(14·34–
14·93)
10·95 
(9·93–
11·91)
13·39 
(13·16–
13·58)
10·08 
(9·14–
10·88)
15·69 
(15·50–
16·02)
11·73 
(10·66–
12·70)
14·13 
(13·90–
14·38)
10·62 
(9·71–
11·47)
17·13 
(16·85–
17·41)
12·79 
(11·63–
13·88)
14·84 
(14·52–
15·17)
11·12 
(10·12–
12·02)
Cambodia
11·93 
(11·51–
12·45)
8·69 
(7·75–
9·61)
11·75 
(11·15–
12·30)
8·65 
(7·71–
9·57)
13·52 
(13·24–
13·86)
9·80 
(8·78–
10·72)
12·67 
(12·01–
13·24)
9·25 
(8·30–
10·18)
15·07 
(14·62–
15·57)
11·06 
(9·97–
12·11)
13·07 
(12·57–
13·72)
9·67 
(8·71–
10·55)
Indonesia
13·72 
(13·37–
14·03)
10·32 
(9·32–
11·21)
13·37 
(13·21–
13·56)
10·08 
(9·19–
10·90)
14·55 
(14·29–
14·79)
10·90 
(9·87–
11·81)
14·29 
(13·98–
14·65)
10·73 
(9·75–
11·62)
15·81 
(15·48–
16·15)
11·76 
(10·69–
12·76)
14·60 
(14·01–
15·27)
10·89 
(9·83–
11·92)
Laos
11·73 
(11·39–
12·17)
8·67 
(7·78–
9·51)
11·77 
(11·57–
11·95)
8·73 
(7·87–
9·50)
13·68 
(13·19–
14·14)
10·13 
(9·09–
11·06)
12·67 
(12·50–
12·86)
9·38 
(8·48–
10·23)
15·17 
(14·61–
15·85)
11·23 
(10·07–
12·33)
13·73 
(13·34–
14·22)
10·19 
(9·23–
11·12)
Malaysia
14·92 
(14·72–
15·13)
11·19 
(10·19–
12·12)
13·52 
(13·33–
13·71)
10·25 
(9·33–
11·06)
15·32 
(15·15–
15·48)
11·54 
(10·47–
12·46)
14·82 
(14·64–
15·01)
11·18 
(10·22–
12·06)
16·88 
(16·51–
17·23)
12·69 
(11·48–
13·75)
15·29 
(14·84–
15·80)
11·52 
(10·48–
12·49)
Maldives
13·01 
(12·41–
13·75)
9·59 
(8·57–
10·60)
13·63 
(13·03–
14·33)
10·18 
(9·17–
11·15)
16·96 
(16·25–
17·74)
12·59 
(11·28–
13·86)
16·18 
(15·50–
16·86)
12·14 
(10·94–
13·28)
19·43 
(17·36–
21·50)
14·45 
(12·44–
16·33)
17·22 
(15·48–
19·16)
12·97 
(11·30–
14·71)
Mauritius
15·09 
(14·74–
15·43)
11·24 
(10·20–
12·24)
11·01 
(10·75–
11·27)
8·24 
(7·50–
8·94)
16·74 
(16·36–
17·09)
12·41 
(11·14–
13·51)
13·47 
(13·17–
13·81)
9·99 
(9·08–
10·83)
18·00 
(16·79–
19·13)
13·27 
(11·79–
14·82)
14·82 
(13·88–
15·88)
10·92 
(9·63–
12·24)
Myanmar
12·18 
(11·76–
12·67)
9·03 
(8·11–
9·93)
11·62 
(10·81–
12·30)
8·65 
(7·71–
9·53)
13·84 
(13·40–
14·39)
10·27 
(9·21–
11·25)
12·70 
(11·00–
13·42)
9·44 
(8·16–
10·46)
15·81 
(15·37–
16·33)
11·77 
(10·65–
12·85)
13·35 
(12·79–
13·87)
9·93 
(8·97–
10·86)
(Table 3 continues on next page)
 Global Health Metrics
1304 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Philippines
16·15 
(15·77–
16·56)
12·05 
(10·91–
13·14)
13·10 
(12·72–
13·52)
9·72 
(8·81–
10·60)
15·31 
(14·86–
15·73)
11·38 
(10·31–
12·43)
11·96 
(11·59–
12·37)
8·84 
(8·01–
9·64)
15·97 
(14·91–
17·14)
11·92 
(10·64–
13·33)
12·57 
(11·61–
13·58)
9·33 
(8·33–
10·43)
Sri Lanka
17·52 
(17·00–
18·08)
13·19 
(11·99–
14·37)
14·96 
(14·42–
15·50)
11·28 
(10·21–
12·32)
18·32 
(17·49–
19·02)
13·74 
(12·46–
14·96)
14·95 
(14·25–
15·60)
11·21 
(10·13–
12·29)
19·70 
(17·93–
21·75)
14·78 
(12·86–
16·74)
16·19 
(14·38–
18·07)
12·16 
(10·51–
13·86)
Seychelles
16·08 
(15·70–
16·49)
12·20 
(11·15–
13·23)
12·46 
(12·07–
12·83)
9·44 
(8·59–
10·20)
17·04 
(16·59–
17·71)
12·84 
(11·62–
14·03)
13·77 
(13·52–
14·07)
10·34 
(9·39–
11·21)
17·73 
(17·02–
18·45)
13·37 
(12·11–
14·63)
14·42 
(13·57–
15·40)
10·83 
(9·78–
11·97)
Thailand
17·07 
(16·70–
17·44)
12·73 
(11·52–
13·82)
14·71 
(14·35–
15·08)
11·06 
(10·03–
11·97)
18·61 
(18·26–
18·95)
13·94 
(12·66–
15·12)
16·71 
(16·32–
17·12)
12·60 
(11·48–
13·67)
20·33 
(19·48–
21·10)
15·20 
(13·72–
16·69)
18·29 
(17·42–
19·15)
13·72 
(12·39–
15·05)
Timor-Leste
12·77 
(11·35–
14·28)
9·51 
(8·13–
10·90)
14·36 
(13·39–
15·51)
10·59 
(9·34–
11·75)
15·27 
(13·91–
16·46)
11·29 
(9·92–
12·61)
15·14 
(14·16–
16·34)
11·09 
(9·79–
12·44)
16·51 
(14·75–
18·09)
12·30 
(10·69–
14·01)
16·13 
(14·64–
17·71)
11·85 
(10·29–
13·35)
Vietnam
15·25 
(14·17–
16·51)
11·45 
(10·09–
12·89)
13·48 
(12·46–
14·35)
10·26 
(9·20–
11·37)
16·67 
(15·90–
18·27)
12·50 
(11·23–
14·01)
13·60 
(12·77–
14·67)
10·35 
(9·39–
11·47)
18·08 
(17·34–
18·54)
13·64 
(12·34–
14·82)
14·45 
(13·89–
15·11)
11·02 
(10·01–
11·98)
Oceania
11·30 
(10·70–
11·96)
8·31 
(7·36–
9·20)
10·56 
(10·16–
11·10)
7·90 
(7·10–
8·67)
11·38 
(10·70–
12·09)
8·32 
(7·36–
9·27)
10·91 
(10·42–
11·50)
8·13 
(7·29–
8·97)
12·01 
(11·22–
12·77)
8·76 
(7·75– 
9·74)
11·45 
(10·87–
12·11)
8·51 
(7·63–
9·39)
American 
Samoa
16·43 
(15·88–
17·15)
11·91 
(10·65–
13·22)
12·91 
(12·44–
13·49)
9·45 
(8·46–
10·44)
16·12 
(15·15–
16·94)
11·64 
(10·29–
13·04)
14·02 
(13·37–
14·63)
10·21 
(9·09–
11·29)
15·98 
(14·58–
17·47)
11·53 
(9·99–
12·99)
14·37 
(13·33–
15·54)
10·46 
(9·16–
11·80)
Federated 
States of 
Micronesia
12·64 
(11·69–
13·56)
9·39 
(8·27–
10·49)
11·23 
(10·67–
12·11)
8·45 
(7·58–
9·41)
12·76 
(11·43–
14·06)
9·42 
(8·17–
10·72)
12·21 
(11·45–
13·00)
9·14 
(8·10–
10·13)
12·75 
(11·38–
14·23)
9·42 
(8·06–
10·85)
12·04 
(10·95–
13·00)
9·00 
(7·87–
10·11)
Fiji
13·45 
(11·49–
15·47)
9·85 
(8·21–
11·54)
11·66 
(10·65–
12·89)
8·62 
(7·53–
9·83)
13·13 
(12·17–
14·29)
9·52 
(8·37–
10·74)
11·20 
(10·47–
12·23)
8·24 
(7·26–
9·23)
13·47 
(11·50–
15·69)
9·82 
(8·23–
11·61)
11·68 
(10·19–
13·64)
8·66 
(7·25–
10·35)
Guam
17·14 
(16·61–
17·86)
12·76 
(11·46–
13·97)
14·25 
(13·65–
14·71)
10·87 
(9·84–
11·79)
17·31 
(16·78–
17·86)
12·80 
(11·54–
14·04)
14·27 
(13·59–
14·70)
10·78 
(9·75–
11·72)
17·05 
(16·15–
18·10)
12·54 
(11·21–
13·92)
13·84 
(12·96–
14·80)
10·41 
(9·31–
11·48)
Kiribati
11·64 
(11·08–
12·19)
8·48 
(7·53–
9·40)
9·98 
(9·56–
10·37)
7·43 
(6·67–
8·17)
12·46 
(11·70–
13·23)
9·03 
(7·98–
10·11)
10·19 
(9·74–
10·71)
7·48 
(6·64–
8·27)
12·82 
(11·82–
13·94)
9·30 
(8·09–
10·54)
10·57 
(9·87– 
11·34)
7·77 
(6·83–
8·72)
Marshall Islands
13·63 
(13·11–
14·14)
9·82 
(8·76–
10·81)
11·30 
(10·95–
11·79)
8·31 
(7·48–
9·12)
12·03 
(11·25–
12·89)
8·65 
(7·56–
9·71)
11·28 
(10·73–
11·95)
8·21 
(7·31–
9·09)
12·74 
(11·41–
14·15)
9·15 
(7·80–
10·49)
11·80 
(10·93–
12·79)
8·57 
(7·50–
9·72)
Northern 
Mariana Islands
16·02 
(14·53–
17·64)
11·88 
(10·32–
13·46)
15·25 
(14·18–
16·44)
11·44 
(10·16–
12·73)
17·57 
(16·22–
18·95)
12·96 
(11·34–
14·42)
16·23 
(15·29–
17·11)
12·10 
(10·78–
13·31)
17·39 
(15·85–
19·01)
12·82 
(11·17–
14·47)
15·83 
(14·79–
16·83)
11·78 
(10·52–
13·01)
Papua New 
Guinea
10·42 
(9·66–
11·25)
7·67 
(6·73–
8·53)
9·85 
(9·29–
10·61)
7·38 
(6·59–
8·20)
10·53 
(9·67– 
11·44)
7·71 
(6·72–
8·70)
10·39 
(9·69–
11·28)
7·75 
(6·86–
8·70)
11·28 
(10·33–
12·24)
8·23 
(7·15– 
9·27)
11·06 
(10·33–
12·01)
8·23 
(7·31–
9·19)
Samoa
15·24 
(14·27–
16·22)
11·28 
(10·09–
12·57)
12·69 
(11·89–
13·41)
9·52 
(8·44–
10·48)
15·81 
(14·88–
16·91)
11·63 
(10·30–
13·03)
13·77 
(12·99–
14·79)
10·30 
(9·14–
11·42)
15·90 
(14·75–
17·11)
11·69 
(10·38–
13·14)
14·12 
(13·40–
15·41)
10·56 
(9·48–
11·80)
Solomon 
Islands
10·92 
(10·08–
11·94)
8·07 
(7·13–
9·17)
10·58 
(10·00–
11·27)
7·98 
(7·24–
8·80)
10·86 
(9·92–
11·88)
7·96 
(6·91–
9·01)
11·01 
(10·37–
11·63)
8·25 
(7·38–
9·11)
11·46 
(10·32–
12·63)
8·37 
(7·28– 
9·47)
11·54 
(10·65–
12·35)
8·62 
(7·64–
9·58)
Tonga
14·22 
(13·03–
15·53)
10·35 
(9·05–
11·70)
12·64 
(11·67–
13·59)
9·53 
(8·42–
10·67)
15·32 
(14·40–
16·39)
11·13 
(9·84–
12·46)
13·09 
(12·29–
13·88)
9·79 
(8·74–
10·85)
15·71 
(14·39–
16·99)
11·41 
(9·94–
12·84)
13·34 
(12·52–
14·34)
9·94 
(8·88–
11·04)
Vanuatu
11·74 
(10·88–
12·67)
8·66 
(7·59–
9·81)
10·89 
(10·39–
11·41)
8·21 
(7·39–
9·03)
11·80 
(10·72–
12·79)
8·69 
(7·56–
9·81)
11·19 
(10·57–
11·88)
8·45 
(7·62–
9·32)
12·30 
(11·03–
13·39)
9·02 
(7·80–
10·23)
11·65 
(10·89–
12·46)
8·76 
(7·81–
9·74)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1305
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
North Africa and 
Middle East
16·10 
(15·87–
16·32)
11·38 
(10·13–
12·52)
14·38 
(14·15–
14·64)
10·49 
(9·38–
11·50)
16·75 
(16·42–
17·03)
11·92 
(10·59–
13·15)
15·12 
(14·79–
15·41)
11·13 
(10·01–
12·13)
17·73 
(17·30–
18·17)
12·64 
(11·24–
13·95)
15·68 
(15·25–
16·08)
11·55 
(10·38–
12·65)
Afghanistan
10·00 
(9·46–
10·63)
6·86 
(5·96–
7·76)
10·76 
(10·11–
11·63)
7·65 
(6·62–
8·68)
9·82 
(9·30– 
10·39)
6·79 
(5·91–
7·66)
10·29 
(9·73–
11·04)
7·38 
(6·51–
8·28)
10·74 
(10·16–
11·32)
7·43 
(6·48– 
8·34)
10·88 
(10·37–
11·49)
7·79 
(6·90–
8·67)
Algeria
16·89 
(16·13–
17·53)
11·95 
(10·57–
13·27)
15·33 
(14·80–
15·99)
11·17 
(10·00–
12·32)
18·22 
(17·40–
18·59)
12·98 
(11·48–
14·36)
17·13 
(16·56–
17·81)
12·58 
(11·24–
13·85)
18·60 
(18·10–
18·98)
13·26 
(11·78–
14·59)
17·83 
(17·03–
18·63)
13·10 
(11·67–
14·42)
Bahrain
13·09 
(12·02–
14·15)
9·13 
(7·90–
10·42)
11·68 
(10·77–
12·67)
8·43 
(7·39–
9·58)
14·63 
(13·63–
15·74)
10·10 
(8·72–
11·43)
13·74 
(12·77–
14·84)
9·84 
(8·58–
11·14)
16·61 
(15·16–
18·32)
11·50 
(9·81–
13·22)
15·48 
(13·90–
17·23)
11·17 
(9·46–
12·88)
Egypt
15·50 
(15·07–
15·93)
11·06 
(9·86–
12·20)
12·95 
(12·55–
13·39)
9·54 
(8·51–
10·44)
16·19 
(15·69–
16·69)
11·47 
(10·14–
12·78)
13·56 
(13·10–
14·01)
9·97 
(8·91–
10·95)
16·72 
(15·54–
18·03)
11·92 
(10·41–
13·43)
13·96 
(12·98–
15·12)
10·31 
(9·14–
11·49)
Iran
17·07 
(16·17–
18·28)
12·17 
(10·65–
13·67)
14·78 
(13·74–
16·12)
10·85 
(9·56–
12·25)
16·26 
(14·70–
17·72)
11·68 
(10·13–
13·19)
15·30 
(13·83–
16·63)
11·37 
(9·85–
12·86)
18·06 
(16·88–
19·65)
12·95 
(11·35–
14·60)
16·33 
(14·88–
17·75)
12·06 
(10·57–
13·45)
Iraq
13·72 
(12·79–
14·82)
9·56 
(8·35–
10·78)
13·49 
(12·09–
14·54)
9·65 
(8·27–
10·90)
13·76 
(12·77–
14·59)
9·65 
(8·39–
10·83)
12·55 
(11·48–
13·61)
9·06 
(7·88–
10·27)
14·88 
(13·44–
16·39)
10·43 
(8·94–
11·94)
13·18 
(12·10–
15·66)
9·47 
(8·25–
11·13)
Jordan
15·78 
(14·71–
17·27)
11·01 
(9·60–
12·52)
15·55 
(14·57–
16·18)
11·19 
(9·90–
12·38)
15·72 
(14·19–
17·55)
11·12 
(9·45–
12·80)
15·81 
(14·23–
17·25)
11·54 
(9·99–
13·12)
18·37 
(16·45–
20·42)
13·04 
(11·13–
14·79)
16·92 
(14·71–
19·20)
12·39 
(10·66–
14·42)
Kuwait
16·73 
(15·39–
18·20)
12·00 
(10·35–
13·56)
16·73 
(15·43–
18·06)
12·32 
(10·88–
13·78)
15·91 
(14·87–
16·92)
11·36 
(9·91–
12·70)
18·03 
(16·86–
19·13)
13·21 
(11·72–
14·69)
17·30 
(14·97–
19·97)
12·47 
(10·50–
14·68)
19·83 
(17·44–
22·40)
14·59 
(12·52–
16·91)
Lebanon
15·94 
(14·78–
17·39)
11·49 
(9·98–
12·96)
13·80 
(12·96–
15·50)
10·21 
(8·93–
11·92)
18·57 
(18·21–
19·43)
13·42 
(11·99–
14·84)
18·19 
(17·02–
19·31)
13·50 
(11·95–
14·99)
20·08 
(18·94–
21·24)
14·52 
(12·82–
16·24)
18·59 
(17·30–
19·72)
13·74 
(12·16–
15·26)
Libya
17·46 
(16·60–
17·98)
12·39 
(10·97–
13·74)
15·95 
(15·37–
16·74)
11·67 
(10·46–
12·91)
17·84 
(16·53–
18·44)
12·67 
(11·04–
14·13)
16·49 
(15·92–
17·19)
12·07 
(10·79–
13·28)
18·09 
(17·32–
18·66)
12·86 
(11·32–
14·24)
15·41 
(14·67–
16·77)
11·32 
(9·98–
12·71)
Morocco
15·46 
(14·74–
16·09)
11·00 
(9·75–
12·24)
14·26 
(13·88–
14·63)
10·45 
(9·37–
11·45)
16·61 
(15·64–
17·43)
11·88 
(10·50–
13·23)
15·77 
(15·40–
16·10)
11·61 
(10·40–
12·67)
17·53 
(16·58–
18·42)
12·54 
(10·96–
14·05)
16·50 
(16·03–
16·94)
12·16 
(10·91–
13·32)
Palestine
15·00 
(13·73–
16·28)
10·89 
(9·51–
12·34)
14·34 
(13·52–
15·41)
10·64 
(9·47–
11·82)
14·74 
(14·53–
14·93)
10·71 
(9·56–
11·73)
12·89 
(12·77–
13·01)
9·58 
(8·66–
10·41)
13·60 
(13·20–
14·08)
9·83 
(8·77–
10·82)
12·89 
(12·58–
13·26)
9·51 
(8·54–
10·36)
Oman
16·33 
(15·44–
17·07)
11·56 
(10·15–
12·91)
15·16 
(14·75–
15·63)
10·98 
(9·77–
12·09)
17·98 
(17·43–
18·72)
12·83 
(11·35–
14·25)
15·39 
(14·77–
16·00)
11·27 
(10·08–
12·40)
18·96 
(18·60–
19·48)
13·60 
(12·06–
14·99)
16·04 
(15·69–
16·52)
11·78 
(10·58–
12·93)
Qatar
16·65 
(15·53–
18·29)
11·67 
(10·08–
13·46)
16·98 
(15·63–
18·37)
12·19 
(10·65–
13·70)
18·50 
(17·66–
19·71)
12·87 
(11·25–
14·40)
16·80 
(14·98–
18·63)
12·09 
(10·20–
13·90)
20·26 
(18·41–
22·92)
14·26 
(12·18–
16·59)
18·65 
(16·07–
21·28)
13·53 
(11·23–
15·85)
Saudi Arabia
16·00 
(15·23–
16·82)
11·33 
(10·04–
12·68)
15·74 
(15·05–
16·52)
11·54 
(10·23–
12·80)
14·17 
(13·81–
14·55)
10·19 
(9·07–
11·21)
15·17 
(14·82–
15·53)
11·28 
(10·17–
12·29)
16·76 
(16·12–
17·49)
12·11 
(10·82–
13·42)
16·20 
(15·60–
16·83)
12·09 
(10·88–
13·25)
Sudan
13·16 
(12·63–
13·67)
9·33 
(8·29–
10·38)
13·11 
(12·83–
13·41)
9·53 
(8·51–
10·50)
14·42 
(13·86–
15·03)
10·28 
(9·12–
11·33)
13·82 
(13·50–
14·28)
10·13 
(9·06–
11·08)
15·94 
(15·13–
16·53)
11·37 
(10·07–
12·58)
14·66 
(14·23–
15·09)
10·76 
(9·61–
11·79)
Syria
16·36 
(15·64–
17·09)
11·73 
(10·38–
13·00)
15·01 
(14·70–
15·35)
11·12 
(10·03–
12·15)
17·39 
(16·84–
17·82)
12·62 
(11·25–
13·85)
15·80 
(15·31–
16·25)
11·83 
(10·64–
12·92)
18·11 
(17·61–
18·87)
13·16 
(11·79–
14·53)
14·98 
(14·34–
15·88)
11·26 
(10·11–
12·48)
Tunisia
17·09 
(16·46–
17·78)
12·33 
(10·90–
13·71)
14·63 
(13·97–
15·32)
10·82 
(9·65–
11·91)
18·77 
(18·22–
20·04)
13·60 
(12·08–
15·20)
16·29 
(15·52–
17·38)
12·03 
(10·72–
13·37)
19·38 
(18·34–
21·04)
14·09 
(12·37–
16·01)
16·07 
(14·63–
17·96)
11·98 
(10·39–
13·69)
(Table 3 continues on next page)
 Global Health Metrics
1306 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Turkey
18·63 
(18·02–
19·22)
13·03 
(11·49–
14·46)
15·76 
(15·30–
16·22)
11·42 
(10·19–
12·57)
20·50 
(19·87–
21·15)
14·55 
(12·80–
16·16)
16·83 
(16·41–
17·34)
12·40 
(11·17–
13·55)
21·09 
(19·63–
22·58)
15·03 
(13·16–
16·95)
17·32 
(15·87–
18·72)
12·82 
(11·25–
14·43)
United Arab 
Emirates
15·95 
(14·69–
17·58)
11·24 
(9·71–
12·78)
15·28 
(13·37–
17·00)
11·05 
(9·25–
12·83)
18·38 
(17·63–
18·78)
13·05 
(11·59–
14·44)
16·29 
(15·71–
16·82)
11·84 
(10·58–
13·03)
18·38 
(17·08–
19·44)
13·15 
(11·56–
14·77)
16·00 
(14·78–
17·04)
11·73 
(10·23–
13·06)
Yemen
12·62 
(11·92–
13·47)
8·60 
(7·42–
9·84)
13·08 
(12·62–
13·58)
9·23 
(8·14–
10·29)
13·36 
(12·97–
13·99)
9·18 
(8·00–
10·29)
13·98 
(13·56–
14·42)
9·96 
(8·80–
11·02)
14·13 
(13·58–
14·54)
9·78 
(8·54–
10·85)
14·54 
(13·60–
15·37)
10·45 
(9·18–
11·66)
South Asia
12·72 
(12·50–
12·93)
9·03 
(8·05–
9·92)
12·13 
(11·95–
12·32)
8·79 
(7·91–
9·59)
14·25 
(14·04–
14·46)
10·15 
(9·10–
11·11)
13·15 
(12·97–
13·33)
9·55 
(8·65–
10·39)
15·20 
(14·95–
15·46)
10·84 
(9·72–
11·89)
13·80 
(13·58–
14·01)
10·03 
(9·06–
10·87)
Bangladesh
12·85 
(12·14–
13·57)
9·29 
(8·24–
10·32)
12·78 
(12·25–
13·38)
9·44 
(8·44–
10·39)
16·29 
(15·70–
16·71)
11·78 
(10·52–
12·93)
14·43 
(14·00–
14·92)
10·73 
(9·70–
11·65)
17·59 
(16·60–
18·34)
12·76 
(11·42–
14·11)
15·35 
(14·45–
16·11)
11·44 
(10·25–
12·56)
Bhutan
13·21 
(11·99–
14·44)
9·44 
(8·18–
10·72)
14·26 
(13·14–
15·32)
10·39 
(9·15–
11·56)
17·01 
(16·06–
17·93)
12·20 
(10·74–
13·53)
16·00 
(15·06–
16·91)
11·74 
(10·46–
13·07)
18·12 
(16·85–
19·04)
13·01 
(11·50–
14·54)
16·25 
(15·21–
17·40)
11·92 
(10·56–
13·23)
India
12·57 
(12·31–
12·83)
8·88 
(7·89–
9·77)
11·82 
(11·62–
12·02)
8·52 
(7·68–
9·30)
14·11 
(13·88–
14·36)
10·02 
(8·97–
10·99)
12·97 
(12·76–
13·17)
9·36 
(8·48–
10·19)
15·03 
(14·75–
15·31)
10·68 
(9·54–
11·73)
13·59 
(13·37–
13·82)
9·82 
(8·87–
10·67)
Nepal
12·41 
(11·89–
12·95)
9·01 
(8·08–
9·96)
12·65 
(12·25–
13·08)
9·23 
(8·33–
10·10)
14·02 
(13·54–
14·63)
10·20 
(9·12–
11·26)
13·94 
(13·53–
14·31)
10·26 
(9·27–
11·25)
15·17 
(14·78–
15·68)
11·04 
(9·94–
12·08)
14·74 
(14·00–
15·59)
10·89 
(9·75–
12·07)
Pakistan
14·20 
(13·66–
14·72)
10·32 
(9·18–
11·37)
14·12 
(13·60–
14·64)
10·42 
(9·35–
11·46)
13·81 
(13·02–
14·71)
10·02 
(8·89–
11·22)
13·36 
(12·92–
13·88)
9·86 
(8·89–
10·81)
14·78 
(13·59–
16·30)
10·73 
(9·35–
12·19)
14·06 
(13·20–
14·86)
10·45 
(9·31–
11·57)
Sub-Saharan Africa
12·74 
(12·55–
12·91)
9·47 
(8·54–
10·30)
12·58 
(12·37–
12·79)
9·28 
(8·40–
10·14)
13·08 
(12·84–
13·32)
9·77 
(8·86–
10·62)
12·68 
(12·50–
12·86)
9·41 
(8·49–
10·24)
14·39 
(14·11–
14·69)
10·82 
(9·81–
11·76)
13·67 
(13·39–
13·96)
10·19 
(9·19–
11·10)
Southern 
sub-Saharan 
Africa
17·26 
(16·87–
17·77)
12·84 
(11·61–
13·96)
14·86 
(14·48–
15·50)
11·01 
(9·97–
12·04)
14·05 
(13·62–
14·53)
10·38 
(9·39–
11·41)
11·54 
(11·35–
11·75)
8·46 
(7·63–
9·24)
16·73 
(16·29–
17·22)
12·38 
(11·16–
13·54)
13·40 
(13·08–
13·78)
9·82 
(8·86–
10·75)
Botswana
14·16 
(13·28–
15·74)
10·64 
(9·49–
12·02)
12·46 
(11·16–
14·04)
9·30 
(8·03–
10·69)
13·22 
(9·32– 
16·70)
9·97 
(6·91–
12·50)
10·59 
(8·92–
12·66)
7·74 
(6·34–
9·56)
15·80 
(12·73–
22·97)
11·93 
(9·25–
16·98)
12·81 
(11·28–
15·95)
9·42 
(7·95–
11·65)
Lesotho
13·46 
(12·52–
14·91)
10·05 
(8·86–
11·33)
11·00 
(10·18–
12·26)
8·22 
(7·27–
9·43)
11·03 
(9·65–
12·89)
8·14 
(6·84–
9·65)
8·55 
(8·05– 
9·14)
6·24 
(5·52–
6·91)
12·12 
(10·11–
15·73)
8·99 
(7·28–
11·33)
9·41 
(8·57–
10·38)
6·87 
(6·00–
7·78)
Namibia
13·16 
(12·77–
13·76)
9·91 
(8·96–
10·81)
11·31 
(10·78–
12·16)
8·46 
(7·58–
9·42)
13·82 
(11·53–
16·20)
10·43 
(8·36–
12·57)
10·66 
(9·92–
11·95)
7·90 
(6·93–
8·97)
16·82 
(14·39–
21·51)
12·83 
(10·52–
16·49)
12·69 
(11·71–
14·15)
9·48 
(8·32–
10·77)
South Africa
18·40 
(18·01–
18·79)
13·63 
(12·33–
14·85)
15·44 
(15·09–
15·77)
11·40 
(10·33–
12·40)
14·77 
(14·58–
14·97)
10·89 
(9·86–
11·85)
12·30 
(12·15–
12·47)
8·98 
(8·13–
9·81)
17·65 
(17·26–
18·05)
13·01 
(11·70–
14·24)
14·15 
(13·83–
14·47)
10·30 
(9·29–
11·29)
Swaziland
13·21 
(12·25–
14·33)
9·88 
(8·84–
11·02)
11·47 
(10·53–
12·85)
8·51 
(7·48–
9·70)
11·34 
(8·96– 
12·71)
8·32 
(6·53–
9·66)
9·12 
(8·24–
10·46)
6·51 
(5·58–
7·59)
14·69 
(11·75–
19·10)
10·94 
(8·33–
14·11)
11·06 
(9·92–
13·44)
8·00 
(6·83–
9·62)
Zimbabwe
14·08 
(13·05–
16·47)
10·73 
(9·46–
12·72)
14·17 
(12·92–
18·34)
10·74 
(9·24–
13·75)
11·44 
(9·75– 
13·85)
8·70 
(7·21–
10·70)
9·68 
(9·09–
10·45)
7·25 
(6·43–
8·12)
13·23 
(11·75–
15·66)
10·08 
(8·79–
11·82)
11·58 
(10·54–
13·13)
8·77 
(7·63–
10·19)
Western 
sub-Saharan 
Africa
13·26 
(12·87–
13·57)
9·75 
(8·69–
10·69)
13·41 
(12·98–
13·82)
9·81 
(8·75–
10·80)
13·96 
(13·52–
14·50)
10·35 
(9·33–
11·37)
13·66 
(13·28–
14·12)
10·09 
(9·09–
11·09)
14·99 
(14·49–
15·59)
11·19 
(10·09–
12·24)
14·55 
(14·02–
15·07)
10·82 
(9·73–
11·84)
Benin
13·82 
(13·26–
14·30)
9·99 
(8·81–
11·00)
12·69 
(12·26–
13·18)
9·14 
(8·10–
10·11)
14·25 
(13·38–
15·11)
10·46 
(9·29–
11·58)
12·69 
(12·42–
13·14)
9·30 
(8·36–
10·19)
14·29 
(13·38–
15·41)
10·59 
(9·32–
11·79)
13·34 
(12·96–
13·76)
9·84 
(8·79–
10·78)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1307
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burkina Faso
12·40 
(11·91–
13·17)
8·98 
(7·91–
10·05)
12·23 
(11·74–
13·15)
8·77 
(7·71–
9·88)
12·97 
(12·44–
13·46)
9·62 
(8·60–
10·58)
12·76 
(12·43–
13·05)
9·39 
(8·42–
10·30)
13·30 
(12·88–
13·77)
9·97 
(9·00–
10·91)
13·17 
(12·89–
13·50)
9·83 
(8·88–
10·73)
Cameroon
13·39 
(12·57–
14·32)
9·84 
(8·63–
10·89)
13·20 
(12·62–
14·04)
9·66 
(8·58–
10·75)
13·02 
(11·61–
14·67)
9·67 
(8·30–
11·14)
12·33 
(11·78–
12·90)
9·08 
(8·12–
9·98)
14·03 
(12·41–
16·13)
10·55 
(8·94–
12·39)
12·92 
(12·13–
13·78)
9·61 
(8·58–
10·65)
Cape Verde
16·82 
(16·36–
17·50)
12·57 
(11·34–
13·76)
13·64 
(13·30–
14·20)
10·22 
(9·26–
11·18)
18·52 
(17·54–
19·66)
13·89 
(12·35–
15·40)
13·37 
(12·54–
15·40)
10·05 
(8·97–
11·50)
18·81 
(18·11–
20·06)
14·20 
(12·74–
15·70)
13·99 
(13·16–
15·03)
10·55 
(9·38–
11·70)
Chad
13·10 
(12·56–
13·70)
9·58 
(8·49–
10·56)
12·80 
(12·43–
13·23)
9·33 
(8·30–
10·25)
13·59 
(12·63–
14·50)
9·91 
(8·71–
11·12)
12·52 
(11·98–
13·13)
9·12 
(8·10–
10·07)
14·31 
(13·21–
15·24)
10·53 
(9·28–
11·82)
13·14 
(12·60–
13·96)
9·64 
(8·60–
10·67)
Côte d’Ivoire
12·50 
(11·87–
13·22)
8·95 
(7·86–
10·06)
11·99 
(11·62–
12·35)
8·59 
(7·60–
9·49)
12·16 
(11·28–
13·45)
9·02 
(7·95–
10·20)
11·80 
(11·06–
12·26)
8·66 
(7·65–
9·57)
12·99 
(12·23–
14·00)
9·68 
(8·59–
10·82)
12·58 
(11·69–
13·06)
9·29 
(8·14–
10·21)
The Gambia
13·49 
(12·43–
14·56)
9·92 
(8·68–
11·15)
13·98 
(13·17–
14·71)
10·38 
(9·17–
11·49)
14·45 
(13·37–
15·71)
10·63 
(9·35–
12·04)
13·74 
(13·29–
14·36)
10·19 
(9·10–
11·18)
14·90 
(14·03–
16·33)
11·07 
(9·80–
12·57)
14·50 
(13·75–
15·08)
10·81 
(9·61–
11·81)
Ghana
12·72 
(11·81–
13·84)
9·50 
(8·43–
10·65)
13·03 
(12·47–
13·83)
9·68 
(8·64–
10·76)
13·55 
(12·53–
15·05)
10·28 
(9·00–
11·72)
12·93 
(12·69–
13·35)
9·70 
(8·75–
10·56)
14·31 
(13·63–
15·75)
10·88 
(9·79–
12·28)
13·93 
(13·19–
14·59)
10·44 
(9·34–
11·45)
Guinea
12·55 
(11·79–
13·20)
9·24 
(8·22–
10·27)
13·69 
(13·08–
14·38)
10·07 
(8·99–
11·13)
12·77 
(11·85–
13·85)
9·53 
(8·39–
10·57)
12·78 
(12·21–
13·55)
9·54 
(8·47–
10·54)
13·00 
(12·02–
14·44)
9·77 
(8·61–
11·03)
13·10 
(12·52–
13·93)
9·80 
(8·72–
10·84)
Guinea-Bissau
11·17 
(10·40–
12·25)
8·28 
(7·27–
9·32)
10·81 
(10·12–
11·46)
7·95 
(7·04–
8·81)
11·67 
(10·81–
13·00)
8·68 
(7·64–
9·85)
10·83 
(10·08–
11·85)
8·02 
(7·10–
9·02)
12·43 
(11·57–
13·29)
9·32 
(8·21–
10·33)
11·07 
(10·36–
12·17)
8·24 
(7·28–
9·25)
Liberia
12·87 
(12·19–
13·55)
9·19 
(8·12–
10·24)
13·32 
(12·76–
13·88)
9·44 
(8·35–
10·51)
12·85 
(11·97–
14·00)
9·26 
(8·08–
10·42)
13·39 
(12·82–
14·01)
9·62 
(8·49–
10·70)
13·39 
(12·92–
14·05)
9·80 
(8·69–
10·83)
13·87 
(13·47–
14·35)
10·11 
(9·03–
11·10)
Mali
11·41 
(10·78–
12·08)
8·45 
(7·48–
9·39)
12·64 
(12·18–
13·24)
9·22 
(8·21–
10·21)
13·50 
(12·59–
14·36)
10·03 
(8·88–
11·14)
14·23 
(13·49–
14·98)
10·45 
(9·31–
11·53)
14·28 
(12·68–
15·69)
10·70 
(9·24–
12·11)
14·69 
(13·35–
16·01)
10·91 
(9·54–
12·34)
Mauritania
12·41 
(11·70–
13·18)
9·15 
(8·13–
10·19)
13·14 
(12·66–
13·85)
9·59 
(8·50–
10·66)
14·11 
(13·03–
15·46)
10·45 
(9·16–
11·71)
15·56 
(14·62–
16·62)
11·41 
(10·07–
12·76)
15·12 
(13·82–
17·09)
11·31 
(9·75–
13·01)
16·12 
(14·81–
17·86)
11·90 
(10·35–
13·61)
Niger
13·13 
(12·55–
13·58)
9·80 
(8·78–
10·74)
12·73 
(12·10–
13·48)
9·45 
(8·40–
10·48)
13·86 
(12·92–
14·49)
10·38 
(9·23–
11·42)
13·34 
(12·71–
14·10)
9·97 
(8·96–
10·96)
14·14 
(12·56–
15·46)
10·68 
(9·22–
12·03)
13·47 
(12·69–
14·49)
10·11 
(9·00–
11·35)
Nigeria
13·88 
(12·99–
14·54)
10·20 
(9·05–
11·27)
14·32 
(13·34–
15·44)
10·51 
(9·27–
11·90)
15·00 
(14·02–
16·49)
11·09 
(9·84–
12·49)
14·95 
(13·99–
16·27)
11·05 
(9·81–
12·48)
16·78 
(15·59–
18·56)
12·49 
(10·97–
14·15)
16·32 
(14·96–
17·83)
12·14 
(10·60–
13·64)
São Tomé and 
Príncipe
14·67 
(13·71–
15·41)
11·04 
(9·88–
12·18)
14·05 
(13·33–
14·80)
10·41 
(9·27–
11·53)
13·91 
(13·52–
14·37)
10·51 
(9·54–
11·41)
13·97 
(13·51–
14·51)
10·38 
(9·32–
11·34)
15·21 
(14·52–
16·23)
11·55 
(10·38–
12·75)
14·59 
(13·22–
15·99)
10·89 
(9·37–
12·43)
Senegal
13·25 
(12·57–
13·91)
9·89 
(8·85–
10·95)
12·63 
(12·28–
13·06)
9·37 
(8·38–
10·26)
13·28 
(12·72–
14·02)
9·96 
(8·93–
11·01)
13·02 
(12·82–
13·40)
9·69 
(8·68–
10·58)
13·86 
(13·33–
14·26)
10·42 
(9·40–
11·37)
13·62 
(13·00–
14·31)
10·17 
(9·08–
11·22)
Sierra Leone
13·64 
(13·11–
14·12)
10·11 
(9·03–
11·09)
12·33 
(11·78–
12·96)
9·01 
(7·96–
9·99)
12·39 
(11·59–
13·22)
9·17 
(8·13–
10·23)
12·03 
(11·70–
12·50)
8·79 
(7·85–
9·68)
12·93 
(11·99–
14·20)
9·70 
(8·58–
10·91)
12·86 
(12·42–
13·49)
9·52 
(8·46–
10·54)
Togo
13·00 
(12·26–
13·76)
9·63 
(8·59–
10·69)
12·81 
(12·34–
13·30)
9·47 
(8·41–
10·42)
13·60 
(12·35–
15·28)
10·15 
(8·83–
11·60)
12·22 
(11·58–
12·65)
9·10 
(8·16–
10·03)
13·81 
(13·12–
15·13)
10·44 
(9·27–
11·72)
12·82 
(11·89–
13·45)
9·64 
(8·58–
10·61)
Eastern 
sub-Saharan 
Africa
11·12 
(10·88–
11·37)
8·41 
(7·63–
9·10)
11·42 
(11·16–
11·72)
8·54 
(7·69–
9·31)
12·35 
(11·95–
12·78)
9·37 
(8·48–
10·18)
12·29 
(12·03–
12·52)
9·23 
(8·34–
10·02)
13·67 
(13·20–
14·20)
10·43 
(9·47–
11·34)
13·18 
(12·71–
13·64)
9·94 
(8·96–
10·81)
(Table 3 continues on next page)
 Global Health Metrics
1308 
www.thelancet.com   Vol 390  September 16, 2017
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burundi
9·43 
(8·73–
10·38)
7·25 
(6·51–
8·09)
9·51 
(8·67–
10·67)
7·21 
(6·37–
8·26)
11·02 
(10·25–
11·74)
8·49 
(7·62–
9·38)
11·46 
(10·48–
12·32)
8·73 
(7·60–
9·77)
12·09 
(11·16–
13·02)
9·39 
(8·35–
10·40)
12·29 
(11·00–
13·34)
9·42 
(8·29–
10·56)
Comoros
12·25 
(11·44–
13·47)
9·26 
(8·20–
10·46)
12·63 
(12·08–
13·35)
9·35 
(8·37–
10·29)
13·82 
(12·96–
14·96)
10·53 
(9·39–
11·83)
13·71 
(13·27–
14·51)
10·31 
(9·29–
11·38)
14·31 
(13·57–
15·90)
10·96 
(9·83–
12·39)
14·28 
(13·44–
15·15)
10·79 
(9·64–
11·90)
Djibouti
14·87 
(14·23–
15·29)
11·27 
(10·14–
12·31)
12·89 
(12·58–
13·36)
9·75 
(8·81–
10·66)
14·72 
(12·98–
16·44)
11·21 
(9·45–
12·88)
13·05 
(12·38–
13·73)
9·86 
(8·78–
10·82)
15·34 
(13·92–
17·48)
11·73 
(10·11–
13·71)
13·91 
(12·86–
15·01)
10·52 
(9·34–
11·78)
Eritrea
10·29 
(9·80–
10·84)
7·80 
(7·00–
8·61)
10·64 
(9·97–
11·34)
7·99 
(7·13–
8·88)
12·03 
(11·31–
12·92)
9·19 
(8·18–
10·21)
12·61 
(11·58–
13·31)
9·50 
(8·41–
10·50)
12·49 
(11·73–
13·45)
9·61 
(8·63–
10·69)
12·75 
(11·68–
13·73)
9·67 
(8·49–
10·76)
Ethiopia
9·54 
(9·06–
10·09)
7·25 
(6·56–
7·97)
9·78 
(9·24–
10·50)
7·35 
(6·56–
8·14)
11·41 
(10·61–
12·18)
8·73 
(7·79–
9·69)
12·47 
(11·67–
12·84)
9·43 
(8·46–
10·31)
13·26 
(12·20–
14·32)
10·18 
(9·02–
11·38)
13·32 
(12·03–
14·75)
10·12 
(8·80–
11·52)
Kenya
13·41 
(13·09–
13·74)
10·31 
(9·40–
11·15)
13·74 
(13·38–
14·10)
10·44 
(9·47–
11·32)
14·05 
(13·65–
14·44)
10·79 
(9·84–
11·66)
13·14 
(12·83–
13·42)
9·97 
(9·05–
10·78)
15·37 
(14·93–
15·85)
11·79 
(10·73–
12·79)
14·14 
(13·81–
14·51)
10·69 
(9·71–
11·58)
Madagascar
11·92 
(11·31–
12·61)
9·05 
(8·19–
10·01)
12·13 
(11·79–
12·43)
9·11 
(8·22–
9·93)
12·57 
(11·72–
13·83)
9·61 
(8·49–
10·80)
12·78 
(12·19–
13·40)
9·66 
(8·70–
10·60)
13·10 
(11·71–
15·54)
10·11 
(8·76–
12·00)
13·05 
(11·51–
14·31)
9·93 
(8·66–
11·13)
Malawi
12·06 
(10·88–
13·26)
9·11 
(7·97–
10·40)
13·32 
(11·80–
16·19)
9·89 
(8·35–
12·03)
12·63 
(10·45–
14·93)
9·63 
(7·73–
11·73)
11·51 
(10·27–
13·33)
8·57 
(7·39–
10·06)
13·97 
(12·43–
16·42)
10·67 
(9·21–
12·67)
12·90 
(11·40–
14·06)
9·70 
(8·43–
10·99)
Mozambique
12·71 
(12·07–
13·26)
9·51 
(8·52–
10·49)
11·86 
(11·50–
12·31)
8·76 
(7·87–
9·60)
14·52 
(12·48–
16·02)
10·81 
(8·97–
12·42)
11·94 
(10·91–
12·86)
8·76 
(7·56–
9·86)
14·76 
(13·22–
16·48)
11·05 
(9·57–
12·65)
13·01 
(11·80–
14·04)
9·57 
(8·27–
10·72)
Rwanda
10·17 
(9·56–
10·82)
7·74 
(6·92–
8·55)
10·69 
(9·78–
11·65)
8·06 
(7·08–
9·05)
14·05 
(12·83–
15·21)
10·69 
(9·41–
11·91)
13·03 
(12·64–
13·77)
9·82 
(8·87–
10·78)
15·00 
(13·91–
16·44)
11·48 
(10·13–
12·98)
14·27 
(13·24–
15·18)
10·77 
(9·57–
11·89)
Somalia
10·21 
(9·54–
10·86)
7·76 
(6·89–
8·58)
11·58 
(10·94–
12·19)
8·72 
(7·78–
9·63)
10·34 
(9·69–
11·08)
7·87 
(7·03–
8·86)
11·59 
(10·64–
12·32)
8·77 
(7·76–
9·78)
10·85 
(10·08–
11·56)
8·29 
(7·35– 
9·17)
11·93 
(10·81–
12·75)
9·03 
(7·87–
10·03)
South Sudan
12·45 
(11·38–
13·56)
8·77 
(7·43–
10·01)
12·70 
(11·77–
13·88)
8·89 
(7·68–
10·13)
12·72 
(11·39–
14·54)
9·21 
(7·81–
10·90)
12·72 
(11·88–
13·89)
9·13 
(7·99–
10·42)
12·86 
(11·61–
14·69)
9·50 
(8·22–
11·12)
12·94 
(12·02–
13·95)
9·44 
(8·33–
10·58)
Tanzania
12·46 
(11·77–
13·34)
9·43 
(8·40–
10·53)
12·65 
(12·07–
13·54)
9·49 
(8·47–
10·54)
13·15 
(11·96–
15·19)
10·01 
(8·70–
11·77)
12·80 
(12·36–
13·65)
9·66 
(8·66–
10·64)
14·10 
(13·34–
15·98)
10·80 
(9·62–
12·29)
13·64 
(12·43–
14·45)
10·38 
(9·17–
11·42)
Uganda
10·95 
(10·45–
11·64)
8·14 
(7·30–
9·03)
11·31 
(10·58–
12·11)
8·27 
(7·27–
9·25)
12·01 
(11·33–
12·82)
9·01 
(8·03–
10·01)
11·81 
(10·83–
12·44)
8·76 
(7·74–
9·66)
13·61 
(12·73–
15·05)
10·35 
(9·21–
11·69)
12·79 
(11·72–
13·52)
9·58 
(8·43–
10·61)
Zambia
11·59 
(10·67–
13·24)
8·88 
(7·83–
10·24)
14·29 
(13·12–
15·19)
10·74 
(9·49–
11·99)
10·41 
(9·17– 
12·23)
7·93 
(6·83–
9·42)
9·47 
(8·91–
10·43)
7·12 
(6·34–
7·99)
13·01 
(11·11–
16·03)
9·95 
(8·29–
12·45)
10·99 
(9·92–
12·90)
8·27 
(7·19–
9·81)
Central 
sub-Saharan 
Africa
11·66 
(11·23–
12·15)
8·47 
(7·56–
9·35)
11·32 
(11·00–
11·66)
8·14 
(7·24–
8·98)
11·65 
(11·24–
12·11)
8·56 
(7·67–
9·40)
12·10 
(11·81–
12·39)
8·80 
(7·89–
9·69)
12·76 
(12·32–
13·22)
9·46 
(8·51–
10·35)
12·88 
(12·42–
13·25)
9·46 
(8·45–
10·39)
Angola
11·07 
(9·98–
12·74)
8·23 
(7·17–
9·58)
10·78 
(9·56–
11·90)
7·98 
(6·87–
9·08)
11·57 
(10·28–
13·28)
8·67 
(7·46–
10·05)
12·53 
(11·28–
13·71)
9·30 
(8·12–
10·51)
13·33 
(11·70–
15·06)
9·99 
(8·59–
11·47)
13·62 
(11·94–
15·00)
10·11 
(8·69–
11·47)
Central African 
Republic
10·33 
(9·69–
11·07)
7·60 
(6·71–
8·45)
9·17 
(8·60– 
9·84)
6·70 
(5·91–
7·52)
10·17 
(8·73– 
12·21)
7·56 
(6·31–
9·11)
8·94 
(8·24–
10·36)
6·58 
(5·71–
7·76)
10·65 
(9·27–
12·61)
7·97 
(6·73– 
9·62)
9·38 
(8·61– 
10·77)
6·95 
(6·09–
8·16)
Congo 
(Brazzaville)
10·23 
(9·47– 
11·12)
7·54 
(6·62–
8·50)
9·93 
(9·32–
10·88)
7·27 
(6·36–
8·22)
11·08 
(10·24–
12·10)
8·21 
(7·19–
9·20)
12·97 
(12·28–
13·52)
9·54 
(8·50–
10·51)
12·36 
(11·03–
13·94)
9·22 
(7·89–
10·70)
13·89 
(12·35–
15·53)
10·32 
(8·97–
11·90)
(Table 3 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1309
two countries for females (Lesotho and South Africa) and 
three for males (Lesotho, South Africa, and Swaziland). In 
2016, HALE at age 65 years was highest in Singapore for 
males (15·1 years [13·4–16·8]) and Japan for females 
(18·7 years [17·1–20·0]), whereas it was lowest for males in 
Lesotho (6·9 years [6·0–7·8]) and females in Afghanistan 
(7·4 years [6·5–8·3]).
The leading Level 3 causes of DALYs in 2016 varied by 
country, but with regional commonalities, described on 
the basis of GBD regions12 in figure 3. Across the 
46 countries within sub­Saharan Africa, the leading Level 3 
cause of DALYs for females was either HIV
/AIDS 
(17 countries), malaria (13 countries), or diarrhoeal diseases 
(nine countries). Cerebrovascular disease, ischaemic heart 
disease, and low back and neck pain were the most 
common leading Level 3 causes of all­age DALYs for 
females in all GBD regions except for Oceania, Andean 
Latin America and central Latin America, and all regions 
of sub­Saharan Africa. Among the 34 countries in the 
high­income super­region, low back and neck pain was the 
leading cause of DALYs for females in all but three 
countries. Exceptions within the region were Greece and 
the USA, for which ischaemic heart disease was the 
leading cause of DALYs, and Greenland, where self­harm 
was the highest cause of DALYs for females (and for 
males). For males, these regional commonalities also 
occurred, but with some notable differences in the leading 
causes by location compared with females. Leading causes 
of DALYs for males in sub­Saharan Africa were broadly 
similar to those for females: HIV
/AIDS (16 countries), 
malaria (11 countries), or lower respiratory infections 
(nine countries). Cerebrovascular disease or ischaemic 
heart disease was the leading cause of all­age DALYs for 
males in almost all GBD regions except for Andean Latin 
America, central Latin America, tropical Latin America, 
high­income Asia Pacific, and all regions of sub­Saharan 
Africa. Exceptions within the regions included Greenland, 
where self­harm was the leading cause of DALYs for males 
in 2016, Peru, where lower respiratory infection was the 
leading cause, and Nicaragua, where chronic kidney 
disease was the leading cause. The leading cause of DALYs 
for both males and females in Syria and Iraq was conflict 
and terrorism, reflecting the ongoing conflict.
Epidemiological transition
The shift in the global burden of DALYs from CMNN to 
NCDs is a clear indicator of the epidemiological 
transition.21 The ratios of DALYs from NCDs to those from 
CMNN diseases in 1990, 1995, 2000, 2006, 2010, and 2016 
are shown by SDI and at the global, GBD regional, and 
GBD super­regional scales for both males and females in 
figure 4. In 2016, 17 (of 21) GBD regions and six (of seven) 
GBD super­regions had a ratio of more than 1 for either 
men or women, representing the shift to more DALYs 
from NCDs than from CMNN diseases, compared with 
13 regions and five super­regions in 1990. In 2016, females 
had more DALYs due to NCDs relative to CMNN causes 
than did males, with higher ratios in 14 regions. This 
figure also shows how these ratios shift with increasing 
SDI, with 18·5 as the 2016 ratio for high SDI for men and 
20·5 for women and 0·52 for men in low SDI and 0·57 
for women. Several regions showed large shifts toward 
more NCD DALYs than CMNN DALYs, with 12 regions 
doubling in ratio from 1990 to 2016 for females and 
11 regions doubling for males over the same time period.
Expected age­standardised YLL rates decreased sub­
stantially with increasing SDI, most notably because of 
decreases in CMNN causes, such as diarrhoea, lower 
respiratory infections, and other common infectious 
diseases; NTDs and malaria; neonatal disorders; nu­
tritional deficiencies; and HIV
/AIDS and tuberculosis 
(figure 5A). Several causes had their largest expected age­
standardised rates at intermediate levels of SDI, such as 
diabetes, urogenital, blood, and endocrine diseases; 
cardio 
vascular diseases; and chronic respiratory diseases. 
Causes that increased in expected age­standardised YLL 
rates with increasing SDI included neoplasms and 
neurological disorders. Much less variation was estimated 
1990, at age 65 years
2006, at age 65 years
2016, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Democratic 
Republic of the 
Congo
12·12 
(11·58–
12·81)
8·73 
(7·67–
9·72)
12·06 
(11·75–
12·46)
8·55 
(7·57–
9·47)
11·83 
(11·37–
12·42)
8·65 
(7·71–
9·57)
12·25 
(11·94–
12·49)
8·84 
(7·89–
9·74)
12·78 
(12·31–
13·29)
9·45 
(8·42–
10·39)
12·92 
(12·42–
13·33)
9·46 
(8·43–
10·38)
Equatorial 
Guinea
9·99 
(9·12– 
11·11)
7·42 
(6·43–
8·39)
9·97 
(8·98–
11·29)
7·37 
(6·34–
8·47)
13·95 
(11·33–
16·90)
10·37 
(8·18–
12·78)
14·22 
(12·47–
16·55)
10·46 
(8·83–
12·43)
15·71 
(13·12–
19·29)
11·71 
(9·45–
14·15)
15·35 
(13·29–
18·00)
11·33 
(9·53–
13·46)
Gabon
12·61 
(11·83–
13·42)
9·26 
(8·22–
10·27)
10·76 
(10·09–
11·80)
7·93 
(7·01–
8·93)
12·21 
(11·38–
13·06)
8·98 
(7·94–
10·04)
13·15 
(11·99–
13·91)
9·72 
(8·51–
10·79)
14·23 
(13·07–
16·01)
10·51 
(9·24–
11·89)
14·30 
(12·61–
16·05)
10·62 
(9·01–
12·20)
Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. GBD=Global Burden of Disease. HALE=healthy life expectancy. 
SDI=Socio-demographic index.
Table 3: Global, regional, and GBD location-specific life expectancy and HALE at age 65 years, by sex, in 1990, 2006, and 2016
 Global Health Metrics
1310 
www.thelancet.com   Vol 390  September 16, 2017
for expected age­standardised YLD rates with SDI than 
for YLL rates. Although the relationship between 
disability and SDI was generally constant for most Level 2 
causes, nutritional deficiencies, NTDs, and malaria 
resulted in greater than expected levels of disability at 
lower SDI.
Compared with YLLs and YLDs expressed as all­age 
rates, the consequences of differences in population age 
structure become apparent for a number of causes 
(figure 5B). Cardiovascular diseases, in particular, result 
in greater YLLs at higher SDI in terms of all­age rates, 
reflecting the older age of populations at higher levels 
of SDI. By contrast, the pattern observed when 
standardising for age structure—YLLs accruing at 
intermediate SDI—highlights health loss from diseases 
that typically manifest at older ages undistorted by the 
lower overall age structure of the populations. The 
expected all­age YLD rates generally increased with 
rising SDI, particularly for mental and substance use 
disorders and musculoskeletal disorders, although 
variation with SDI remained substantially lower than 
for YLLs.
Figure 1: Trends of total DALYs (A) and age-standardised DALY rates (B) from 1990 to 2016 for GBD Level 1 cause groups by SDI quintile
Shaded areas show 95% uncertainty intervals. DALYs=disability-adjusted life-years. GBD=Global Burden of Disease. SDI=Socio-demographic Index.
Low SDI
0
200
400
600
Year
All-age total DALYs (millions)
A
B
1990
1995
2000
2006
2010
2016
Year
1990
1995
2000
2006
2010
2016
Year
1990
1995
2000
2006
2010
2016
Year
1990
1995
2000
2006
2010
2016
Year
1990
1995
2000
2006
2010
2016
0
20 000
40 000
60 000
Age-standardised DALY rate per 100 000
High SDI
High-middle SDI
Middle SDI
Low-middle SDI
Communicable,
maternal, neonatal,
and nutritional
diseases
Non-communicable
diseases
Injuries
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1311
(Figure 2 continues on next page)
Leading causes 1990
Leading causes 2006
Mean %
change,
number
of DALYs
1990–2006
Mean %
change,
all-age
DALY rate
1990–2006
Mean %
change, age-
standardised
DALY rate
1990–2006
Leading causes 2016
1 Lower respiratory infection
1 Ischaemic heart disease
1 Ischaemic heart disease
2 Diarrhoeal diseases
2 Lower respiratory infection
2 Cerebrovascular disease
3 Ischaemic heart disease
3 Diarrhoeal diseases
3 Lower respiratory infection
4 Neonatal preterm birth
4 Cerebrovascular disease
4 Low back and neck pain
5 Cerebrovascular disease
5 HIV/AIDS
5 Diarrhoeal diseases
6 Measles
6 Neonatal preterm birth
6 Road injuries
7 Congenital defects
7 Malaria
7 Sense organ diseases
8 Neonatal encephalopathy
8 Road injuries
8 COPD
9 Tuberculosis
9 Low back and neck pain
9 Neonatal preterm birth
10 Road injuries
10 Neonatal encephalopathy
10 HIV/AIDS
11 Malaria
11 COPD
11 Skin diseases
12 COPD
12 Congenital defects
12 Diabetes
13 Low back and neck pain
13 Tuberculosis
13 Malaria
14 Other neonatal
14 Sense organ diseases
14 Congenital defects
15 Skin diseases
15 Skin diseases
15 Neonatal encephalopathy
16 Sense organ diseases
16 Diabetes
16 Migraine
17 Self-harm
17 Migraine
17 Depressive disorders
18 Protein-energy malnutrition
18 Depressive disorders
18 Tuberculosis
19 Drowning
19 Self-harm
19 Lung cancer
20 Meningitis
20 Other neonatal
20 Falls
21 Migraine
21 Iron-deficiency anaemia
21 Self-harm
22 Depressive disorders
22 Lung cancer
22 Chronic kidney disease
23 Diabetes
23 Falls
23 Iron-deficiency anaemia
24 Iron-deficiency anaemia
24 Chronic kidney disease
24 Other musculoskeletal
25 Falls
25 Other musculoskeletal
25 Alzheimer's disease
26 Tetanus
26 Protein-energy malnutrition
26 Anxiety disorders
27 Neonatal sepsis
27 Neonatal sepsis
27 Other neonatal
28 Lung cancer
28 Meningitis
28 Asthma
29 Asthma
29 Interpersonal violence
29 Neonatal sepsis
30 Chronic kidney disease
30 Anxiety disorders
30 Interpersonal violence
31 Drowning
31 Interpersonal violence
31 Meningitis
32 Asthma
33 Other musculoskeletal
33 Protein-energy malnutrition
33 Alzheimer's disease
34 Anxiety disorders
38 Drowning
34 Measles
36 HIV/AIDS
85 Measles
79 Tetanus
43 Alzheimer's disease
116 Tetanus
1 Lower respiratory infection
1 Malaria
1 Lower respiratory infection
2 Diarrhoeal diseases
2 Diarrhoeal diseases
2 Malaria
3 Malaria
3 Lower respiratory infection
3 Diarrhoeal diseases
4 Measles
4 HIV/AIDS
4 HIV/AIDS
5 Protein-energy malnutrition
5 Neonatal preterm birth
5 Neonatal preterm birth
6 Neonatal preterm birth
6 Neonatal encephalopathy
6 Neonatal encephalopathy
7 Tuberculosis
7 Tuberculosis
7 Tuberculosis
8 Neonatal encephalopathy
8 Protein-energy malnutrition
8 Ischaemic heart disease
9 Meningitis
9 Congenital defects
9 Congenital defects
10 Congenital defects
10 Meningitis
10 Protein-energy malnutrition
11 HIV/AIDS
11 Neonatal sepsis
11 Meningitis
12 Neonatal sepsis
12 Ischaemic heart disease
12 Neonatal sepsis
13 Other neonatal
13 Other neonatal
13 Cerebrovascular disease
14 STDs
14 Cerebrovascular disease
14 Road injuries
15 Ischaemic heart disease
15 STDs
15 Other neonatal
16 Tetanus
16 Road injuries
16 Iron-deficiency anaemia
17 Cerebrovascular disease
17 Iron-deficiency anaemia
17 STDs
18 Conflict and terror
18 Measles
18 Skin diseases
19 Road injuries
19 Skin diseases
19 Low back and neck pain
20 Whooping cough
20 Whooping cough
20 Sense organ diseases
21 Iron-deficiency anaemia
21 Sense organ diseases
21 Diabetes
22 Skin diseases
22 Low back and neck pain
22 Depressive disorders
23 Low back and neck pain
23 COPD
23 Conflict and terror
24 Sense organ diseases
24 Diabetes
24 COPD
25 Drowning
25 Drowning
25 Migraine
26 COPD
26 Depressive disorders
26 Whooping cough
27 Hemoglobinopathies
27 Asthma
27 Asthma
28 Asthma
28 Haemoglobinopathies
28 Falls
29 Falls
29 Falls
29 Haemoglobinopathies
30 Depressive disorders
30 Migraine
30 Drowning
33 Tetanus
32 Diabetes
34 Measles
49 Conflict and terror
34 Migraine
60 Tetanus
B
A
13·7
4·0
–29·9
19·3
–34·7
–3·9
21·7
6·5
–23·6
–43·7
11·3
24·4
–27·3
–13·5
–22·0
14·3
13·2
–23·4
13·7
14·4
–6·3
20·0
7·5
14·1
37·5
13·1
–29·2
3·9
–8·5
–2·3
1·1
–7·5
–37·6
6·1
–41·9
–14·5
8·2
–5·3
–32·0
–49·9
–1·0
10·7
–35·3
–23·0
–30·7
1·6
0·7
–31·9
1·1
1·8
–16·7
6·8
–4·4
1·5
22·3
0·6
–37·0
–7·6
–18·6
–13·1
–11·9
–19·2
–34·4
–1·3
–39·9
–14·7
–1·9
–17·9
–24·1
–50·0
1·4
–1·7
–30·7
–16·2
–22·0
0·1
–3·6
–35·3
–11·7
–4·6
–17·7
–3·0
–1·8
–3·7
0·2
–0·7
–29·0
–12·2
–9·0
–12·0
–21·3
–32·4
–28·9
–44·5
–5·7
0·6
–10·5
24·3
8·1
–17·0
–4·2
3·3
18·6
15·2
–7·0
21·3
1·7
35·8
36·9
28·8
38·2
32·5
214·0
16·4
33·8
–26·0
15·6
17·2
6·5
–2·4
–40·5
–48·9
–46·2
–58·0
–28·7
–24·0
–32·3
–6·1
–18·3
–37·3
–27·6
–22·0
–10·3
–12·9
–29·7
–8·3
–23·2
2·7
3·4
–2·7
4·4
0·1
137·3
–12·0
1·2
–44·0
–12·7
–11·4
–19·5
–26·2
–31·3
–46·2
–38·4
–60·6
–24·2
–19·3
–32·2
–6·7
–14·0
–32·9
–22·3
–16·9
–10·3
–8·9
–25·9
–7·6
–19·1
3·1
1·3
–3·7
4·0
–2·3
119·8
–12·9
–0·5
–42·5
–15·0
–6·6
–15·0
–21·1
29·0
–35·3
–35·0
17·4
532·5
–28·0
27·9
14·7
29·8
–11·6
–0·4
–14·8
–16·4
39·0
24·6
67·4
32·3
32·4
4·0
–15·8
19·7
31·3
17·5
35·1
42·0
–26·3
5·3
–17·5
15·1
30·6
3·3
–48·2
–47·9
–6·0
406·5
–42·4
2·4
–8·2
3·9
–29·2
–20·2
–31·8
–33·1
11·3
–0·2
34·0
5·9
6·0
–16·7
–32·6
–4·2
5·2
–5·9
8·2
13·7
–41·0
–15·7
–33·9
–7·8
4·6
–13·0
–37·5
–39·3
–18·6
394·4
–28·8
23·2
–7·6
–7·4
–12·0
–30·9
–18·1
–38·1
0·1
1·8
16·8
–0·4
–1·7
–19·8
–16·0
1·5
–8·4
–9·9
–1·2
4·4
–28·9
4·1
–23·2
–8·4
–0·1
–19·2
–39·3
–42·6
186·2
–28·1
–19·6
–25·8
–43·7
–25·2
–33·2
–21·1
0·3
–28·6
–18·8
–32·3
–15·4
–10·0
–87·8
2·0
–27·5
–1·3
–2·5
–18·5
5·8
–27·0
–0·1
–24·2
–29·5
–20·1
1·3
–13·2
–30·2
–33·5
194·0
–21·3
–12·4
–22·9
–38·8
–18·7
–26·9
–13·8
1·9
–22·4
–14·4
–27·1
–9·9
–9·8
–87·1
1·7
–23·3
0·1
–2·2
–16·6
9·2
–22·0
–0·4
–22·1
–23·9
–13·2
0·5
27·7
-4·0
-9·2
352·5
13·7
27·1
-10·9
17·3
18·3
5·7
24·7
58·5
13·0
28·4
7·0
33·7
42·3
-80·7
61·3
14·7
56·1
54·1
28·8
67·3
15·4
57·9
19·9
11·4
26·3
60·2
Communicable, maternal, neonatal, and nutritional diseases
Non-communicable diseases
Injuries
Mean %
change,
number
of DALYs
2006–16
Mean %
change,
all-age
DALY rate
2006–16
Mean %
change, age-
standardised
DALY rate
2006–16
 Global Health Metrics
1312 
www.thelancet.com   Vol 390  September 16, 2017
1 Diarrhoeal diseases
1 Ischaemic heart disease
2 Lower respiratory infection
2 Diarrhoeal diseases
3 Neonatal preterm birth
3 Lower respiratory infection
4 HIV/AIDS
4 Neonatal preterm birth
5 Ischaemic heart disease
5 Cerebrovascular disease
6 Malaria
6 Malaria
7 Malaria
7 Neonatal encephalopathy
7 COPD
8 Other neonatal
8 Tuberculosis
8 Neonatal encephalopathy
9 Ischaemic heart disease
9 Cerebrovascular disease
9 HIV/AIDS
10 Congenital defects
10 Other neonatal
10 Road injuries
11 COPD
11 Congenital defects
11 Tuberculosis
12 Cerebrovascular disease
12 COPD
12 Iron-deficiency anaemia
13 Tetanus
13 Road injuries
13 Sense organ diseases
14 Protein-energy malnutrition
14 Iron-deficiency anaemia
14 Low back and neck pain
15 Iron-deficiency anaemia
15 Sense organ diseases
15 Congenital defects
16 Road injuries
16 Low back and neck pain
16 Skin diseases
17 Meningitis
17 Measles
17 Diabetes
18 Drowning
18 Skin diseases
18 Migraine
19 Intestinal infectious
19 Self-harm
19 Other neonatal
20 Sense organ diseases
20 Migraine
20 Depressive disorders
21 Neonatal sepsis
21 Diabetes
21 Self-harm
22 Low back andneck pain
22 Meningitis
22 Chronic kidney disease
23 Skin diseases
23 Neonatal sepsis
23 Falls
24 Self-harm
24 Protein-energy malnutrition
24 Neonatal sepsis
25 Asthma
25 Depressive disorders
25 Other musculoskeletal
26 Neonatal haemolytic
26 Intestinal infectious
26 Meningitis
27 Migraine
27 Falls
27 Asthma
28 Falls
28 Drowning
28 Protein-energy malnutrition
29 STDs
29 Chronic kidney disease
29 Intestinal infectious
30 Depressive disorders
30 Asthma
30 Anxiety disorders
31 Other musculoskeletal
32 Chronic kidney disease
31 Drowning
32 STDs
33 Diabetes
45 STDs
33 Anxiety disorders
34 Other musculoskeletal
58 Measles
37 Neonatal haemolytic
37 HIV/AIDS
59 Neonatal haemolytic
42 Tetanus
42 Anxiety disorders
96 Tetanus
1 Lower respiratory infection
1 Ischaemic heart disease
1 Ischaemic heart disease
2 Cerebrovascular disease
2 Cerebrovascular disease
2 Cerebrovascular disease
3 Neonatal preterm birth
3 Road injuries
3 Road injuries
4 Diarrhoeal diseases
4 HIV/AIDS
4 Low back and neck pain
5 Ischaemic heart disease
5 Lower respiratory infectio
5 Sense organ diseases
6 Congenital defects
6 COPD
6 Diabetes
7 Road injuries
7 Low back and neck pain
7 COPD
8 COPD
8 Neonatal preterm birth
8 Skin diseases
9 Neonatal encephalopathy
9 Sense organ diseases
9 Lower respiratory infection
10 Tuberculosis
10 Congenital defects
10 HIV/AIDS
11 Low back and neck pain
11 Diabetes
11 Lung cancer
12 Drowning
12 Skin diseases
12 Chronic kidney disease
13 Self-harm
13 Tuberculosis
13 Congenital defects
14 Skin diseases
14 Lung cancer
14 Neonatal preterm birth
15 Sense organ diseases
15 Depressive disorders
15 Migraine
16 Diabetes
16 Migraine
16 Depressive disorders
17 Interpersonal violence
17 Diarrhoeal diseases
17 Liver cancer
18 Depressive disorders
18 Self-harm
18 Other musculoskeletal
19 Migraine
19 Chronic kidney disease
19 Self-harm
20 Other neonatal
20 Neonatal encephalopathy
20 Interpersonal violence
21 Chronic kidney disease
21 Liver cancer
21 Falls
22 Stomach cancer
22 Interpersonal violence
22 Alzheimer's disease
23 Measles
23 Other musculoskeletal
23 Tuberculosis
24 Liver cancer
24 Stomach cancer
24 Stomach cancer
25 Lung cancer
25 Falls
25 Anxiety disorders
26 Falls
26 Drowning
26 Diarrhoeal diseases
27 Asthma
27 Anxiety disorders
27 Iron-deficiency anaemia
28 Other musculoskeletal
28 Asthma
28 Hypertensive heart disease
29 Anxiety disorders
29 Iron-deficiency anaemia
29 Asthma
30 Iron-deficiency anaemia
30 Alzheimer's disease
30 Neonatal encephalopathy
31 Other neonatal
32 Hypertensive heart disease
33 Drowning
32 Hypertensive heart disease
42 Alzheimer's disease
46 Other neonatal
82 Measles
98 HIV/AIDS
121 Measles
Leading causes 2006
Mean %
change,
number
of DALYs
1990–2006
Mean %
change,
all-age
DALY rate
1990–2006
Mean %
change, age-
standardised
DALY rate
1990–2006
Leading causes 2016
Mean %
change,
number
of DALYs
2006–16
Mean %
change
all-age
DALY rate
2006–16
Mean %
change, age-
standardised
DALY rate
2006–16
D
28·3
–38·7
–38·2
–27·7
12·0
–21·5
18·1
–25·4
–45·0
9·3
–25·6
6·4
22·9
26·0
–10·4
17·1
31·3
20·7
–36·3
16·1
0·2
18·9
15·9
–12·6
16·5
–15·6
3·5
–27·2
–20·2
19·2
10·0
–47·4
–47·0
–38·0
–4·0
–32·7
1·2
–36·0
–52·8
–6·3
–36·2
–8·8
5·4
8·1
–23·2
0·4
12·6
3·5
–45·4
–0·4
–14·1
1·9
–0·6
–25·0
–0·1
–27·6
–11·2
–37·6
–31·6
2·2
–2·3
–42·7
–37·5
–26·5
–15·3
–25·6
–11·1
–23·5
–55·0
–6·7
–39·9
–6·8
–3·9
–0·1
–12·3
2·4
1·8
–0·1
–34·8
–6·7
–15·4
–4·9
–3·7
–11·2
–6·5
–20·7
–18·5
–30·1
–26·8
–0·8
23·9
6·5
–8·2
19·0
22·1
25·6
–3·7
4–4
–31·2
–45·0
19·7
20·5
–26·7
–30·4
12·1
11·1
12·4
11·2
–13·4
–3·9
15·1
44·0
–30·0
–5·5
9·8
–35·9
3·2
27·1
1·1
–42·1
15·4
–0·8
–14·5
10·8
13·7
17·0
–10·3
–2·7
–35·9
–48·7
11·6
12·2
–31·8
–35·2
4·4
3·5
4·7
3·6
–19·3
–10·4
7·2
34·2
–34·8
–12·0
2·3
–40·3
–3·8
18·4
–5·8
–46·1
–6·6
–20·4
–15·2
–1·1
–3·2
–3·2
–29·2
1·6
–33·5
–48·1
–9·9
–4·2
–21·3
–23·3
2·2
–4·9
–12·6
–4·7
–21·3
–8·1
–2·6
0·7
–41·3
–28·6
0·1
–38·4
–1·7
–4·9
–12·4
–34·5
–36·5
–33·9
–19·1
644·5
56·5
30·8
–3·0
–21·3
33·8
–16·1
5·9
9·7
38·3
21·4
43·9
42·4
–64·2
37·3
22·1
45·4
101·5
–17·3
4·5
–30·6
48·3
–19·3
20·6
–26·6
33·1
–9·6
–53·3
–51·4
–40·5
447·8
15·1
–3·8
–28·6
–42·1
–1·6
–38·3
–22·1
–19·3
1·8
–10·7
5·9
4·8
–73·7
1·0
–10·1
7·0
48·3
–39·1
–23·1
–48·9
9·1
–40·6
–11·3
–46·0
–2·1
–33·5
–44·3
–39·1
–26·1
431·9
2·6
11·8
–11·4
–46·0
–10·9
–23·4
–7·5
–28·4
3·3
–7·4
–3·1
–6·2
–68·7
2·9
–13·1
0·1
33·8
–29·9
–4·6
–39·2
1·3
–34·4
–9·3
–37·8
–7·0
–37·1
59·2
20·8
15·7
3408·5
–57·9
–10·7
34·2
–48·0
41·7
–29·4
82·0
17·8
–31·8
64·1
31·0
35·5
–64·2
–19·2
40·3
–42·9
38·7
8·1
42·0
7·4
20·2
–48·6
29·6
–1·3
15·6
74·5
32·4
0·5
–3·8
2817·9
–65·0
–25·7
11·6
–56·8
17·9
–41·3
51·3
–2·1
–43·3
36·4
9·0
12·7
–70·2
–32·8
16·7
–52·5
15·4
–10·1
18·1
–10·7
–0·1
–57·3
7·8
–17·9
–3·9
45·1
Communicable, maternal, neonatal, 
and nutritional diseases
Non-communicable diseases
Injuries
2·2
–21·2
–3·8
2736·7
–52·2
–42·7
–8·0
–38·2
–1·9
–19·5
19·6
2·3
–52·2
6·8
–3·4
2·3
–61·7
–35·6
–1·4
–30·5
–8·7
–10·8
2·7
–30·1
–6·0
–49·2
0·7
–23·9
2·4
0·0
1 Diarrhoeal diseases
2 Lower respiratory infection
3 Neonatal preterm birth
4 Measles
5 Tuberculosis
6 Neonatal encephalopathy
Leading causes 1990
C
(Figure 2 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1313
1 Ischaemic heart disease
1 Ischaemic heart disease
1 Ischaemic heart disease
2 Cerebrovascular disease
2 Cerebrovascular disease
2 Cerebrovascular disease
3 Lower respiratory infection
3 Low back and neck pain
3 Low back and neck pain
4 Road injuries
4 Road injuries
4 Sense organ diseases
5 Low back and neck pain
5 Sense organ diseases
5 Road injuries
6 Neonatal preterm birth
6 Skin diseases
6 Skin diseases
7 Congenital defects
7 Depressive disorders
7 Diabetes
8 COPD
8 COPD
8 Depressive disorders
9 Sense organ diseases
9 Migraine
9 Migraine
10 Skin diseases
10 Lung cancer
10 Lung cancer
11 Lung cancer
11 Lower respiratory infection
11 Falls
12 Falls
12 Congenital defects
12 COPD
13 Self-harm
13 Diabetes
13 Alzheimer's disease
14 Migraine
14 Self-harm
14 Lower respiratory infection
15 Depressive disorders
15 Falls
15 Self-harm
16 Diabetes
16 Neonatal preterm birth
16 Congenital defects
17 Diarrhoeal diseases
17 Alcohol use disorders
17 Anxiety disorders
18 Stomach cancer
18 Interpersonal violence
18 Chronic kidney disease
19 Drowning
19 Drug use disorders
19 Alcohol use disorders
20 Interpersonal violence
20 Alzheimer's disease
20 Other musculoskeletal
21 Neonatal encephalopathy
21 Stomach cancer
21 Drug use disorders
22 Alcohol use disorders
22 Anxiety disorders
22 Neonatal preterm birth
23 Drug use disorders
23 Chronic kidney disease
23 Colorectal cancer
24 Anxiety disorders
24 Cardiomyopathy
24 Stomach cancer
25 Chronic kidney disease
25 Other musculoskeletal
25 Interpersonal violence
26 Tuberculosis
26 Colorectal cancer
26 Oral disorders
27 Alzheimer's disease
27 Liver cancer
27 Liver cancer
28 Asthma
28 Oral disorders
28 Cardiomyopathy
29 Other neonatal
29 Drowning
29 Osteoarthritis
30 Nature disaster
30 Tuberculosis
30 Breast cancer
31 Osteoarthritis
31 Other musculoskeletal
33 Asthma
32 Breast cancer
32 Liver cancer
40 Drowning
33 Asthma
33 Colorectal cancer
45 Tuberculosis
36 Neonatal encephalopathy
34 Cardiomyopathy
47 Neonatal encephalopathy
46 Other neonatal
35 Oral disorders
59 Diarrhoeal diseases
50 Diarrhoeal diseases
40 Breast cancer
62 Other neonatal
129 Nature disaster
42 Osteoarthritis
145 Nature disaster
1 Ischaemic heart disease
1 Ischaemic heart disease
1 Ischaemic heart disease
2 Low back and neck pain
2 Low back and neck pain
2 Low back and neck pain
3 Cerebrovascular disease
3 Cerebrovascular disease
3 Cerebrovascular disease
4 Road injuries
4 Lung cancer
4 Lung cancer
5 Lung cancer
5 Skin diseases
5 Alzheimer's disease
6 Skin diseases
6 Sense organ diseases
6 Sense organ diseases
7 Sense organ diseases
7 Diabetes
7 Skin diseases
8 Migraine
8 Alzheimer's disease
8 Diabetes
9 Depressive disorders
9 Depressive disorders
9 COPD
10 Diabetes
10 Migraine
10 Depressive disorders
11 Self-harm
11 Road injuries
11 Migraine
12 COPD
12 COPD
12 Falls
13 Falls
13 Self-harm
13 Self-harm
14 Alzheimer's disease
14 Falls
14 Road injuries
15 Colorectal cancer
15 Drug use disorders
15 Drug use disorders
16 Congenital defects
16 Colorectal cancer
16 Colorectal cancer
17 Anxiety disorders
17 Other musculoskeletal
17 Other musculoskeletal
18 Other musculoskeletal
18 Anxiety disorders
18 Anxiety disorders
19 Lower respiratory infection
19 Lower respiratory infection
19 Chronic kidney disease
20 Drug use disorders
20 Chronic kidney disease
20 Lower respiratory infection
21 Stomach cancer
21 Breast cancer
21 Oral disorders
22 Breast cancer
22 Oral disorders
22 Other cardiovascular
23 Other cardiovascular
23 Other cardiovascular
23 Breast cancer
24 Neonatal preterm birth
24 Congenital defects
24 Osteoarthritis
25 Oral disorders
25 Stomach cancer
25 Pancreatic cancer
26 Asthma
26 Asthma
26 Congenital defects
27 Chronic kidney disease
27 Alcohol use disorders
27 Stomach cancer
28 Alcohol use disorders
28 Pancreatic cancer
28 Alcohol use disorders
29 Interpersonal violence
29 Osteoarthritis
29 Asthma
30 HIV/AIDS
30 Liver cancer
30 Liver cancer
31 Neonatal preterm birth
32 Pancreatic cancer
37 Neonatal preterm birth
33 Interpersonal violence
34 Osteoarthritis
42 Interpersonal violence
60 HIV/AIDS
36 Liver cancer
71 HIV/AIDS
Leading causes 1990
Leading causes 2006
Mean %
change,
number
of DALYs
1990–2006
Mean %
change,
all-age
DALY rate
1990–2006
Mean %
change, age-
standardised
DALY rate
1990–2006
Leading causes 2016
Mean %
change,
number
of DALYs
2006–16
Mean %
change
all-age
DALY rate
2006–16
Mean %
change, age-
standardised
DALY rate
2006–16
F
E
–5·3
–10·6
17·7
19·5
–17·2
7·9
21·1
11·4
11·5
5·6
6·9
–7·0
35·1
–20·0
–18·7
–22·2
11·9
13·2
–11·0
19·9
2·1
–27·6
12·3
–10·9
–22·1
20·2
14·9
–5·3
30·0
3·9
–14·8
–19·6
5·9
7·5
–25·5
–2·9
9·0
0·3
0·3
–5·0
–3·8
–16·3
21·6
–28·0
–26·8
–30·0
0·7
1·9
–19·9
7·9
–8·1
–34·9
1·1
–19·8
–29·9
8·2
3·4
–14·8
17·0
–6·5
–26·0
–30·0
–2·3
–3·4
–26·0
1·7
–3·8
–3·8
–1·2
–17·3
–10·9
–27·6
–0·9
–33·8
–27·8
–26·4
0·7
–9·1
–24·2
2·5
–9·8
–30·1
–11·6
–29·6
–28·9
–1·5
–8·4
–22·0
1·8
–17·5
Communicable, maternal, neonatal, 
and nutritional diseases
Non-communicable diseases
Injuries
–3·6
11·1
–1·5
4·8
30·8
17·6
4·7
9·6
14·2
6·2
2·8
18·3
–2·4
–16·2
13·6
6·9
7·4
4·0
22·0
8·6
15·2
7·5
1·8
19·6
17·7
–7·9
–5·0
3·6
–0·6
12·0
–8·5
5·5
–6·5
–0·6
24·2
11·7
–0·6
4·1
8·5
0·8
–2·4
12·3
–7·3
–20·4
7·9
1·4
1·9
–1·2
15·8
3·1
9·3
2·0
–3·3
13·5
11·7
–12·6
–9·8
–1·6
–5·6
6·3
–21·4
0·9
–19·8
–13·0
–1·1
–1·0
0·5
–6·6
–6·2
0·6
–0·9
1·3
–6·3
–22·0
11·5
–10·8
–0·0
–0·3
1·1
–12·4
0·7
–10·4
–11·6
1·1
–2·2
–10·3
–21·0
–1·2
–5·8
–6·0
32·7
15·2
25·0
9·3
31·0
20·2
29·1
–13·7
26·2
17·1
–42·4
–37·7
44·8
20·0
10·3
–52·3
39·0
12·3
33·3
56·4
–11·9
30·1
27·0
53·7
42·2
34·7
22·6
31·0
–34·8
3·3
11·7
–3·0
5·2
–8·0
10·3
1·2
8·6
–27·3
6·2
–1·4
–51·5
–47·6
21·9
1·0
–7·1
–59·9
17·0
–5·5
12·2
31·7
–25·8
9·5
6·9
29·4
19·7
13·4
3·2
10·3
–45·1
–13·1
–6·3
–17·5
–7·6
–11·4
–2·1
3·2
–1·6
–37·9
–2·3
–13·0
–46·3
–33·2
6·1
–8·3
–14·6
–47·9
3·8
–10·8
3·7
5·4
–35·3
3·5
–4·4
11·8
7·6
–1·2
–10·3
–2·1
–40·6
–23·5
–27·0
16·0
–15·0
9·3
10·4
28·0
30·5
49·0
12·6
10·4
–26·0
17·3
5·7
14·1
38·5
10·8
22·1
12·6
1·5
28·1
2·4
20·5
3·1
–30·2
–21·3
–10·2
11·4
34·1
37·5
39·3
–33·5
5·8
–22·6
–0·5
0·5
16·6
18·8
35·6
2·5
0·5
–32·6
6·8
–3·8
3·9
26·1
0·9
11·2
2·5
–7·6
16·6
–6·8
9·7
–6·1
–36·5
–28·3
–18·3
1·4
22·1
25·2
26·8
–45·7
–3·4
–36·8
–16·7
3·2
–0·3
1·4
0·8
0·5
–0·8
–33·3
–11·9
–5·2
–9·4
31·8
–15·5
5·0
1·4
–25·3
–3·5
–20·8
–2·9
–21·1
–32·3
–40·0
–17·7
–1·9
2·3
5·3
6·4
Figure 2: Leading 30 Level 3 causes of total DALYs for 1990, 2006, and 2016, with percentage change in number of DALYs and all-age and age-standardised DALY rates, overall and by SDI quintile
Overall (A). Low SDI (B). Low-middle SDI (C). Middle SDI (D). High-middle SDI (E). High SDI (F). Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. 
For the time period of 1990–2006 and 2006–16, three measures of change are shown: percentage change in the number of DALYs, percentage change in the all-age DALY rate, and percentage change in 
the age-standardised DALY rate. Statistically significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. DALYs=disability-adjusted life-years. STDs=sexually transmitted diseases.
 Global Health Metrics
1314 
www.thelancet.com   Vol 390  September 16, 2017
The proportion of DALYs due to YLDs versus YLLs has 
shifted distinctly since 1990, and these changes are 
shown in figure 6. More all­age DALYs as a result of YLDs 
rather than YLLs indicates a reduction in premature 
death, with individuals living longer with disability than 
previously. Globally, 95·9% of countries increased in the 
proportion of all­age DALYs due to YLDs from 
1990 to 2016. In 2016, Kuwait (0·64), Qatar (0·63), and 
Bahrain (0·60) had the highest ratios of DALYs due to 
YLDs, whereas Chad (0·14), Niger (0·14), and the Central 
African Republic (0·13) had the lowest. This finding is a 
change from 1990, when the highest three proportions 
were 
for 
Andorra 
(0·49), 
Kuwait 
(0·48), 
and 
Iceland (0·47), and the lowest three were for 
Burundi (0·08), Malawi (0·08), and Niger (0·06).
Observed versus expected total and cause-specific burden
As shown in figure 7, 83 countries had greater than 
expected age­standardised DALY rates on the basis of SDI 
in 2016 (a ratio of observed to expected age­standardised 
DALY rate of greater than 1), generally within central 
Europe, eastern Europe, and central Asia (20 of 
29 countries) or in the super­region of sub­Saharan Africa 
(24 of 46 countries). Among the 34 locations in the five 
regions within the high­income GBD super­region, three 
had greater than expected DALYs relative to their SDI. The 
five locations with the lowest level of age­standardised 
DALYs relative to the level expected on the basis of SDI 
were Nicaragua, Costa Rica, the Maldives, Peru, and 
Israel. Countries within western Europe (eg, France, 
Norway, and Iceland), western sub­Saharan Africa (eg, 
The Gambia, Senegal, and Liberia), eastern sub­Saharan 
Africa (eg, Ethiopia, Rwanda, and Burundi), east Asia (eg, 
China), and a subset of countries in south and southeast 
Asia (eg, Bhutan and Bangladesh) all had ratios of 
observed to expected DALY rates of less than 1 in 2016. 
The five locations with the highest age­standardised DALY 
rates relative to the rates expected on the basis of SDI were 
Lesotho, Swaziland, South Africa, Fiji, and Botswana, with 
Lesotho’s ratio of observed to expected measured at 2·43 
in 2016.
Worldwide, ischaemic heart disease and stroke 
remained the two leading causes of DALYs, and 
expected levels were close to those observed at a global 
scale, with ratios of 0·84 for ischaemic heart disease 
and 1·0 for stroke (figure 8). The ratio of observed to 
expected DALYs ranged from 0·24 in Qatar to 3·33 in 
Ukraine for ischaemic heart disease and from 0·32 in 
Oman to 2·98 in Bulgaria for stroke. This ratio was 
less than 1 for 114 of 167 global locations for ischaemic 
heart disease and 91 of 145 for stroke. Low back and 
neck pain resulted in fewer than expected DALYs 
globally, with a ratio of 0·95 globally and 74 locations 
showing a ratio of less than 1. Of the ten leading causes 
for each location, observed levels of DALYs were 
frequently greater than expected on the basis of SDI 
for causes such as diabetes mellitus (ratio of observed 
to expected DALYs of greater than 1 in 95 global 
locations), sense organ diseases (79 locations), and 
skin and subcutaneous diseases (72 locations).
Causes that resulted in greater than expected DALYs for 
both sexes combined showed strong regional patterns. In 
the GBD high­income super­region, of the leading ten 
causes of DALYs, COPD had greater than expected DALYs 
in 14 of 34 locations and less than expected in none. 
Observed DALYs were frequently greater than expected 
for low back and neck pain (27 locations), although the 
ratio did not exceed 1·66 for any single location. Although 
drug use disorders were only within the leading ten 
causes for one location in the high­income super­region, 
the ratio of observed to expected DALYs in the USA was 
4·37
. In addition to being the most common leading 
causes of DALYs, ischaemic heart disease and stroke 
were sources of more DALYs than expected for most 
locations in the central Europe, eastern Europe, and 
central Asia super­region. Here, the highest ratio of 
observed to expected DALYs was 3·33 for ischaemic heart 
disease and 2·98 for stroke. Mental and substance use 
disorders were also notable in the region for the high 
levels of observed DALYs relative to those expected, 
particularly in eastern Europe, where the ratio for the 
Level 4 cause of alcohol use disorders was 5·38 and 
ranged from 3·33 in Moldova to 5·7 in Russia. For 
locations in the super­region of Latin America and 
Caribbean, the burden from interpersonal violence was 
greater than expected, with a ratio of 3·37 for the super­
region and ranging from 1·68 in Ecuador to 7·22 in 
Venezuela. Diabetes was also a source of greater than 
expected burden in this super­region, with DALYs 
exceeding expected levels in 19 of 37 locations. 
Additionally, diabetes contributed to a higher burden of 
DALYs in many locations in the super­region of southeast 
Asia, east Asia, and Oceania, with ratios of observed to 
expected levels ranging from 0·68 in the Maldives to 
10·48 in Fiji.
In south Asia, neonatal encephalopathy due to birth 
asphyxia and trauma caused greater than expected DALYs 
for two countries, with ratios of 1·01 in Nepal and 2·72 in 
Pakistan. Ongoing conflicts in north Africa and the 
Middle East were reflected in higher than expected 
DALYs in seven of the 21 locations in the region. Patterns 
of observed DALYs compared with those expected in sub­
Saharan Africa were dominated by the ongoing effect of 
HIV
/AIDS, particularly in southern sub­Saharan Africa. 
Observed levels of DALYs exceeded those expected in 
37 of 46 locations, ranging from a ratio of 8·10 in Burundi 
to 316·34 in Lesotho.
The five locations with the largest magnitude of 
improvement—a decrease in the difference between 
observed and expected all­cause age­standardised DALY 
rates from 1990 to 2016—included Greenland, the 
Maldives, 
Bermuda, 
Ethiopia, 
and 
Liberia. 
The 
five locations that showed the smallest decrease in the 
difference between observed and expected DALY rates 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1315
Figure 3: Leading Level 3 causes of all-age DALY rates by location for females (A) and males (B) in 2016
ATG=Antigua and Barbuda. DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the 
Grenadines. VUT=Vanuatu. WSM=Samoa.
Persian Gulf
Persian Gulf
A
B
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Tuberculosis
HIV/AIDS
Diarrhoeal diseases
Lower respiratory infections
Malaria
Neonatal preterm birth complications
Neonatal encephalopathy
Iron-deficiency anaemia
Ischaemic heart disease
Cerebrovascular disease
Chronic obstructive pulmonary disease
Diabetes mellitus
Low back and neck pain
Congenital birth defects
Skin and subcutaneous diseases
Self-harm
Conflict and terrorism
Tuberculosis
HIV/AIDS
Diarrhoeal diseases
Lower respiratory infections
Malaria
Neonatal preterm birth complications
Ischaemic heart disease
Cerebrovascular disease
Chronic obstructive pulmonary disease
Diabetes mellitus
Chronic kidney disease
Low back and neck pain
Congenital birth defects
Road injuries
Self-harm
Interpersonal violence
Conflict and terrorism
 Global Health Metrics
1316 
www.thelancet.com   Vol 390  September 16, 2017
over the period 1990–2016 were Lesotho, Swaziland, 
Syria, South Africa, and Botswana.
Discussion
General findings
Although the world has become healthier since 1990, 
this progress has been highly heterogeneous. From 1990 
to 2016, global HALE at birth increased. The total 
number of years of functional health lost (life expectancy 
minus HALE) increased from 1990 to 2016, indicating 
an absolute expansion of morbidity. YLL rates have 
fallen more rapidly than YLD rates so that non­fatal 
health loss as a proportion of DALYs has grown from 
1990 to 2016. This progress has been driven by marked 
reductions in DALYs due to CMNN causes and, to a 
lesser extent, by declines in age­standardised NCD and 
injury DALYs. Population growth in the past 27 years 
(from 5·27 billion to 7·39 billion) has resulted in a 
significant increase in total DALYs due to NCDs, coupled 
with a high total DALY burden in 2016, thus leading to 
an overall increasing toll on health systems.22,23 GBD 
2016 continues to unequivocally show an absolute 
Figure 4: Ratios of all-age DALY counts from NCDs to those from CMNN diseases by SDI quintile, GBD super-region, and region, for males and females separately, for 1990, 1995, 2000, 2006, 
2010, and 2016
Each point represents the ratio of DALYs from NCDs to those from CMNN diseases for each GBD region in a given year by sex. Ratios of more than 1·00 represent a greater number of DALYs from NCDs 
than from CMNN diseases. CMNN=communicable, maternal, neonatal, and nutritional. DALY=disability-adjusted life-year. GBD=Global Burden of Disease. NCDs=non-communicable diseases. 
SDI=Socio-demographic Index.
0·12
0·25
0·50
1·00
2·00
Ratio
4·00
8·00
16·0
32·0
Central sub-Saharan Africa
Eastern sub-Saharan Africa
Western sub-Saharan Africa
Southern sub-Saharan Africa
Sub-Saharan Africa
South Asia
North Africa and Middle East
Oceania
Southeast Asia
East Asia
Southeast Asia, east Asia, and  Oceania
Tropical Latin America
Caribbean
Andean Latin America
Central Latin America
Latin America and Caribbean
Central Asia
Central Europe
Eastern Europe
Central Europe, eastern Europe, and central Asia
Southern Latin America
Western Europe
High-income Asia Pacific
Australasia
High-income North America
High income
Low SDI
Low–middle SDI
Middle SDI
High–middle SDI
High SDI
Global
1990
1995
2000
2006
2010
2016
Males
Females
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1317
Figure 5: Expected relationship between age-standardised YLL and YLD rates (per 100 000 people) and SDI (A) and all-age YLL and YLD rates (per 100 000 people) and SDI (B) for 21 Level 2 causes
These stacked curves represent the average relationship between SDI and YLL and YLD rates for each cause observed across all geographies over the time period 1990–2016. In each figure, the y axis 
goes from lowest SDI to highest SDI. The left side shows rates for YLLs on a reflected axis and the right side shows rates for YLDs; higher rates are further from the midline in each direction. Differences 
in patterns between (A) and (B) is the effect of shifts in population age structure in relation to SDI. DALY=disability-adjusted life-year. SDI=Socio-demographic Index. YLDs=years lived with disability. 
YLLs=years of life lost.
YLL
YLD
YLL
YLD
0·25
0·5
0·75
SDI
SDI
0·25
0·5
0·75
200 000
180 000
160 000
140 000
120 000
100 000
80 000
60 000
40 000
20 000
0
10 000 20 000
All-age DALY rate (per 100 000)
150 000
135 000
120 000
105 000
90 000
75 000
60 000
Age-standardised DALY rate (per 100 000)
45 000
30 000
15 000
0
10 000 20 000
Forces of nature, conflict and terrorism, 
and executions and police conflict
Self-harm and interpersonal violence
Unintentional injuries
Transport injuries
Other non-communicable diseases
Musculoskeletal disorders
Diabetes, urogenital, blood, and 
endocrine diseases
Mental and substance use disorders
Neurological disorders
Digestive diseases
Cirrhosis and other chronic liver 
diseases
Chronic respiratory diseases
Cardiovascular diseases
Neoplasms
Other communicable, maternal,
neonatal, and nutritional diseases
Nutritional deficiencies
Neonatal disorders
Maternal disorders
Neglected tropical diseases and malaria
Diarrhoea, lower respiratory infections,
and other common infectious diseases
HIV/AIDS-tuberculosis
B
A
 Global Health Metrics
1318 
www.thelancet.com   Vol 390  September 16, 2017
Persian Gulf
Persian Gulf
A
B
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
<0·16
0·16–0·20
0·21–0·26
0·27–0·30
0·31–0·34
0·35–0·37
0·38–0·40
0·41–0·43
0·44–0·47
0·48–0·64
Ratio
<0·16
0·16–0·20
0·21–0·26
0·27–0·30
0·31–0·34
0·35–0·37
0·38–0·40
0·41–0·43
0·44–0·47
0·48–0·64
Ratio
Persian
Gulf
Persian
Gulf
Figure 6: Proportion of all-age DALY counts due to years lived with disability for all ages and both sexes combined for 1990 (A) and 2016 (B)
Locations are colour-coded in terms of the magnitude of the ratio. ATG=Antigua and Barbuda. DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. LCA=Saint Lucia. 
TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1319
expansion of morbidity4—that is, as life expectancy 
increases across a population, the absolute amount of 
functional health loss increases—but GBD 2016 also 
shows a relative compression of morbidity—that is, the 
proportion of total life spent ill per person decreases 
with increasing SDI.24 Substantial opportunities re­
main for innovation in human resources for health, 
development assistance for health, and targeted health 
policies to alleviate causes of old­age disability and 
transform the experience of later life for billions 
of people.25
From 1990 to 2016, life expectancy, HALE, and years 
lived with functional health loss all increased as 
populations moved through the SDI quintiles. These 
quintiles reflect in a geographical cross section of the 
world what is seen through time during the 
epidemiological transition. The rapid decrease in burden 
from CMNN diseases from low to high SDI quintile was 
most substantial. NCDs and injuries were also seen to 
decline, but at much more modest rates. Declines in 
fertility, increases in education, and increases in income 
per person (the triad of inputs into the SDI composite), 
were tightly coupled with population­based HALE 
outcomes.26 This finding suggests that the wide agendas 
of these three social determinants of health have roles 
within discussions of overall health system strengthening. 
Further dissection of the results clearly shows that a 
substantial impact has been made on the global burden 
of YLLs. A much more modest effect, however, has been 
made on the burden of large causes of YLDs at all levels 
of SDI. The contrast in this ratio is marked and illustrates 
another striking view of the epidemiological transition 
when looking at the proportion of DALYs due to YLDs 
globally. Although continued progress on reduction of 
YLLs prematurely is important, how to ameliorate the 
primary causes and underlying risks of YLDs globally 
should be reflected on (low back and neck pain, sense 
organ diseases, and skin diseases) to decrease the time 
that ageing populations live with functional health loss 
across the SDI spectrum. This persisting burden of 
morbidity highlights the importance, both in terms of 
relief of suffering and prevention of health­care costs, of 
placement of emphasis on prevention of disabling illness 
and mitigation of the ill effects of the disabling conditions 
that do occur.
Cross-cutting themes
The concept of the grand convergence—that levels of 
under­5 and maternal mortality, as well as selected 
infectious diseases, would converge across SDI quintiles 
within a generation—was promoted in the Lancet 
Commission on investing in health27 and discussed in the 
Figure 7: Ratio of observed to expected age-standardised DALY rates (per 100 000) on the basis of SDI alone for both sexes combined in 2016
Ratios are colour-coded in terms of the magnitude of differences between observed and expected age-standardised DALY rates. Blues indicate much lower observed DALY levels than expected on the 
basis of SDI, whereas reds reflect observed DALYs that far exceed expected levels given SDI. ATG=Antigua and Barbuda. DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. 
LCA=Saint Lucia. SDI=Socio-demographic Index. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. 
Persian Gulf
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
<0·816
0·816–0·901
0·902–1·01
1·02–1·21
≥1·22
Ratio
 Global Health Metrics
1320 
www.thelancet.com   Vol 390  September 16, 2017
1
2
3
4
5
6
7
8
9
10
Global
IHD
(0·84)
Stroke
(1·0)
LRI
(1·67)
Back+Neck
(0·95)
Diarrhoea
(4·94)
Road Inj
(0·81)
Sense
(1·13)
COPD
(1·27)
NN Preterm
(1·15)
HIV
(11·36)
High-income
IHD
(0·61)
Back+Neck
(1·09)
Stroke
(0·7)
Lung C
(1·0)
Alzheimer's
(1·51)
Skin
(1·1)
Sense
(1·1)
Diabetes
(1·26)
Depression
(1·15)
COPD
(1·4)
High-income North 
America
IHD
(0·72)
Back+Neck
(0·87)
Lung C
(1·11)
Drugs
(4·14)
Diabetes
(1·64)
COPD
(2·05)
Skin
(1·21)
Stroke
(0·65)
Depression
(1·26)
Alzheimer's
(1·11)
Canada
IHD
(0·55)
Back+Neck
(0·94)
Lung C
(1·08)
Skin
(1·18)
Diabetes
(1·26)
Sense
(0·93)
Stroke
(0·54)
Migraine
(1·0)
Oth MSK
(2·36)
Depression
(0·97)
Greenland
Self Harm
(6·21)
Lung C
(2·71)
IHD
(0·62)
Stroke
(1·0)
Back+Neck
(0·84)
Depression
(1·72)
COPD
(1·75)
Skin
(1·17)
Alcohol
(3·85)
Falls
(1·35)
USA
IHD
(0·74)
Back+Neck
(0·86)
Drugs
(4·37)
Lung C
(1·11)
COPD
(2·16)
Diabetes
(1·68)
Skin
(1·21)
Stroke
(0·66)
Depression
(1·29)
Road Inj
(1·11)
Australasia
Back+Neck
(1·01)
IHD
(0·45)
Skin
(1·04)
Depression
(1·25)
Migraine
(1·05)
Sense
(0·88)
Oth MSK
(2·45)
Stroke
(0·49)
Lung C
(0·68)
Alzheimer's
(0·93)
Australia
Back+Neck
(0·99)
IHD
(0·44)
Skin
(1·03)
Depression
(1·27)
Migraine
(1·06)
Oth MSK
(2·57)
Sense
(0·87)
Stroke
(0·48)
Lung C
(0·67)
Alzheimer's
(0·93)
New Zealand
Back+Neck
(1·19)
IHD
(0·54)
Skin
(1·1)
Stroke
(0·52)
Sense
(0·91)
Depression
(1·15)
Lung C
(0·77)
Migraine
(1·0)
COPD
(1·19)
Alzheimer's
(0·99)
High-income Asia Pacific
Back+Neck
(1·17)
Alzheimer's
(2·28)
Stroke
(0·93)
IHD
(0·4)
Sense
(1·38)
Skin
(1·0)
Self Harm
(1·38)
Lung C
(0·83)
Diabetes
(1·26)
Depression
(1·04)
Brunei
IHD
(0·43)
Diabetes
(2·22)
Back+Neck
(0·75)
Skin
(1·09)
Road Inj
(1·13)
Stroke
(0·54)
Migraine
(0·9)
Congenital
(1·48)
Falls
(0·82)
Sense
(0·58)
Japan
Back+Neck
(1·27)
Alzheimer's
(2·72)
IHD
(0·45)
Stroke
(0·96)
Sense
(1·55)
Skin
(1·0)
Lung C
(0·85)
Self Harm
(1·25)
LRI
(2·05)
Diabetes
(1·11)
Singapore
IHD
(0·46)
Back+Neck
(0·81)
Skin
(1·02)
Sense
(0·95)
LRI
(2·27)
Stroke
(0·46)
Alzheimer's
(0·97)
Migraine
(0·86)
Depression
(0·96)
Lung C
(0·58)
South Korea
Back+Neck
(0·95)
Stroke
(0·88)
Self Harm
(1·77)
Diabetes
(1·68)
IHD
(0·28)
Alzheimer's
(1·32)
Sense
(1·0)
Skin
(0·99)
Lung C
(0·79)
Depression
(1·16)
Western Europe
Back+Neck
(1·24)
IHD
(0·63)
Alzheimer's
(1·65)
Sense
(1·22)
Stroke
(0·68)
Lung C
(1·04)
Skin
(1·06)
Migraine
(1·11)
Depression
(1·12)
Falls
(1·08)
Andorra
Back+Neck
(1·57)
IHD
(0·62)
Alzheimer's
(1·65)
Skin
(1·13)
Sense
(1·08)
Stroke
(0·61)
Migraine
(1·14)
Lung C
(0·73)
Depression
(1·06)
Falls
(1·03)
Austria
IHD
(0·8)
Back+Neck
(1·11)
Alzheimer's
(1·48)
Sense
(1·12)
Lung C
(0·89)
Migraine
(1·22)
Skin
(0·98)
Falls
(1·25)
Stroke
(0·53)
Diabetes
(1·01)
Belgium
Back+Neck
(1·19)
IHD
(0·58)
Lung C
(1·21)
Alzheimer's
(1·64)
Stroke
(0·69)
Sense
(1·15)
Skin
(1·08)
COPD
(1·67)
Falls
(1·29)
Migraine
(1·11)
Cyprus
IHD
(0·7)
Back+Neck
(1·16)
Diabetes
(1·67)
Skin
(1·06)
Migraine
(1·2)
Stroke
(0·55)
Sense
(0·95)
Alzheimer's
(1·2)
Road Inj
(0·96)
Lung C
(0·64)
Denmark
Back+Neck
(1·66)
IHD
(0·52)
Lung C
(1·2)
Stroke
(0·73)
COPD
(2·15)
Skin
(1·16)
Migraine
(1·06)
Alzheimer's
(0·99)
Diabetes
(1·1)
Sense
(0·78)
Finland
IHD
(0·82)
Back+Neck
(1·24)
Stroke
(0·93)
Alzheimer's
(1·77)
Skin
(1·14)
Falls
(1·48)
Depression
(1·33)
Sense
(0·98)
Migraine
(1·09)
Lung C
(0·69)
France
Back+Neck
(1·11)
IHD
(0·42)
Lung C
(1·1)
Skin
(1·13)
Sense
(1·12)
Alzheimer's
(1·5)
Stroke
(0·56)
Depression
(1·23)
Migraine
(1·1)
Falls
(1·27)
Germany
IHD
(0·91)
Back+Neck
(1·37)
Sense
(1·42)
Stroke
(0·76)
Lung C
(1·11)
Alzheimer's
(1·52)
Skin
(1·0)
Diabetes
(1·28)
COPD
(1·5)
Migraine
(1·04)
Greece
IHD
(1·16)
Back+Neck
(1·3)
Stroke
(1·22)
Lung C
(1·33)
Alzheimer's
(1·97)
Sense
(1·28)
COPD
(1·7)
Migraine
(1·12)
Skin
(0·93)
Depression
(1·22)
Iceland
Back+Neck
(1·11)
IHD
(0·52)
Skin
(1·19)
Lung C
(0·82)
Migraine
(1·1)
Sense
(0·87)
Alzheimer's
(1·05)
Stroke
(0·49)
Depression
(0·88)
Falls
(0·83)
Ireland
IHD
(0·55)
Back+Neck
(1·02)
Skin
(1·1)
Migraine
(1·12)
Lung C
(0·76)
Sense
(0·88)
Depression
(1·11)
Stroke
(0·46)
Alzheimer's
(0·97)
COPD
(1·18)
Israel
Back+Neck
(1·1)
IHD
(0·34)
Skin
(1·11)
Sense
(0·97)
Migraine
(1·07)
Diabetes
(1·08)
Depression
(0·97)
Alzheimer's
(1·15)
Stroke
(0·36)
Lung C
(0·65)
Italy
Back+Neck
(1·29)
IHD
(0·65)
Alzheimer's
(2·4)
Sense
(1·43)
Stroke
(0·7)
Lung C
(1·08)
Migraine
(1·22)
Diabetes
(1·31)
Skin
(0·96)
Depression
(1·04)
Luxembourg
Back+Neck
(1·1)
IHD
(0·48)
Skin
(1·12)
Migraine
(1·23)
Stroke
(0·6)
Lung C
(0·79)
Sense
(0·93)
Oth Cardio
(1·79)
Falls
(0·96)
Depression
(1·0)
Malta
IHD
(0·88)
Back+Neck
(1·28)
Stroke
(0·65)
Skin
(1·14)
Sense
(1·13)
Migraine
(1·15)
Alzheimer's
(1·37)
Diabetes
(1·16)
Lung C
(0·8)
Falls
(1·09)
Netherlands
Back+Neck
(1·25)
IHD
(0·46)
Lung C
(1·23)
Skin
(1·15)
Stroke
(0·65)
Sense
(0·99)
COPD
(1·74)
Migraine
(1·14)
Alzheimer's
(1·14)
Depression
(1·09)
Norway
Back+Neck
(1·01)
IHD
(0·52)
Skin
(1·14)
Alzheimer's
(1·27)
Stroke
(0·57)
Lung C
(0·76)
Migraine
(0·99)
Sense
(0·83)
COPD
(1·48)
Falls
(1·02)
Portugal
Back+Neck
(1·45)
IHD
(0·57)
Stroke
(1·17)
Alzheimer's
(2·21)
Sense
(1·3)
Diabetes
(1·4)
Depression
(1·41)
Migraine
(1·19)
Skin
(0·99)
Lung C
(1·04)
Spain
Back+Neck
(1·09)
IHD
(0·47)
Alzheimer's
(2·04)
Sense
(1·26)
Lung C
(0·97)
Migraine
(1·21)
Stroke
(0·55)
Skin
(0·95)
Depression
(1·04)
COPD
(1·17)
Sweden
Back+Neck
(1·4)
IHD
(0·72)
Stroke
(0·69)
Skin
(1·22)
Alzheimer's
(1·51)
Depression
(1·33)
Sense
(0·92)
Diabetes
(1·21)
Lung C
(0·71)
COPD
(1·26)
Switzerland
Back+Neck
(1·29)
IHD
(0·52)
Alzheimer's
(1·43)
Skin
(1·1)
Sense
(1·02)
Migraine
(1·14)
Lung C
(0·77)
Stroke
(0·51)
Falls
(1·17)
Depression
(1·03)
(Figure 8 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1321
1
2
3
4
5
6
7
8
9
10
UK
Back+Neck
(1·27)
IHD
(0·58)
Lung C
(1·08)
Skin
(1·2)
Stroke
(0·68)
Sense
(1·12)
Alzheimer's
(1·47)
COPD
(1·58)
Migraine
(1·05)
Depression
(1·13)
England
Back+Neck
(1·28)
IHD
(0·55)
Skin
(1·21)
Lung C
(1·02)
Stroke
(0·64)
Sense
(1·14)
Alzheimer's
(1·44)
COPD
(1·54)
Migraine
(1·03)
Depression
(1·13)
Northern Ireland
IHD
(0·66)
Back+Neck
(1·12)
Lung C
(1·05)
Stroke
(0·67)
Skin
(1·14)
Alzheimer's
(1·33)
Migraine
(1·12)
Sense
(0·95)
COPD
(1·46)
Depression
(1·13)
Scotland
IHD
(0·79)
Back+Neck
(1·26)
Stroke
(0·94)
Lung C
(1·61)
COPD
(1·84)
Skin
(1·16)
Alzheimer's
(1·7)
Sense
(1·02)
Migraine
(1·18)
Depression
(1·19)
Wales
IHD
(0·76)
Back+Neck
(1·24)
Lung C
(1·32)
Stroke
(0·79)
Alzheimer's
(1·93)
Skin
(1·15)
COPD
(1·74)
Sense
(1·04)
Migraine
(1·11)
Depression
(1·13)
Southern Latin America
IHD
(0·57)
Back+Neck
(1·15)
Stroke
(0·67)
Skin
(1·07)
LRI
(1·59)
Sense
(0·98)
Road Inj
(0·71)
Diabetes
(1·01)
Migraine
(0·98)
Oth MSK
(1·98)
Argentina
IHD
(0·66)
Back+Neck
(1·12)
LRI
(1·91)
Stroke
(0·65)
Skin
(1·07)
Sense
(0·95)
Road Inj
(0·73)
Diabetes
(1·07)
Migraine
(0·97)
Oth MSK
(1·91)
Chile
Back+Neck
(1·22)
IHD
(0·36)
Stroke
(0·65)
Skin
(1·07)
Sense
(1·01)
Depression
(1·11)
Oth MSK
(2·18)
Migraine
(0·98)
Road Inj
(0·66)
Anxiety
(1·39)
Uruguay
IHD
(0·6)
Back+Neck
(1·18)
Stroke
(1·0)
Sense
(1·17)
Lung C
(1·5)
Skin
(1·08)
Road Inj
(0·76)
COPD
(1·23)
Self Harm
(1·12)
Migraine
(0·99)
Central Europe, eastern 
Europe, and central Asia
IHD
(1·94)
Stroke
(2·02)
Back+Neck
(1·12)
Sense
(1·36)
Falls
(1·86)
Self Harm
(1·47)
Road Inj
(1·02)
LRI
(2·04)
Lung C
(1·01)
Alcohol
(3·49)
Eastern Europe
IHD
(2·47)
Stroke
(2·56)
Back+Neck
(1·14)
Self Harm
(2·03)
Alcohol
(5·38)
Sense
(1·41)
Falls
(1·89)
CMP
(5·86)
Road Inj
(1·24)
Lung C
(0·93)
Belarus
IHD
(2·78)
Stroke
(1·94)
Back+Neck
(1·22)
Falls
(2·41)
Sense
(1·34)
Self Harm
(1·67)
Alcohol
(4·39)
Road Inj
(1·04)
Depression
(1·28)
Migraine
(1·15)
Estonia
IHD
(1·54)
Back+Neck
(1·15)
Stroke
(1·18)
HTN HD
(6·72)
Sense
(1·34)
Falls
(1·78)
Alcohol
(4·8)
Lung C
(0·91)
Depression
(1·25)
Migraine
(1·1)
Latvia
IHD
(2·1)
Stroke
(2·44)
Back+Neck
(1·24)
Sense
(1·57)
Falls
(2·03)
CMP
(5·83)
Lung C
(1·04)
Self Harm
(1·38)
Alcohol
(3·79)
Migraine
(1·12)
Lithuania
IHD
(2·12)
Stroke
(1·78)
Back+Neck
(1·2)
Self Harm
(2·3)
Falls
(2·28)
Sense
(1·48)
Lung C
(0·95)
Depression
(1·38)
Alcohol
(3·76)
Migraine
(1·06)
Moldova
IHD
(2·32)
Stroke
(1·88)
Back+Neck
(1·47)
Sense
(1·28)
Migraine
(1·26)
Alcohol
(3·33)
Falls
(1·84)
LRI
(1·15)
Cirr Alc
(5·2)
Self Harm
(1·17)
Russia
IHD
(2·24)
Stroke
(2·73)
Back+Neck
(1·06)
Self Harm
(2·27)
CMP
(7·66)
Alcohol
(5·7)
Sense
(1·41)
Road Inj
(1·35)
Falls
(1·88)
LRI
(2·06)
Ukraine
IHD
(3·33)
Stroke
(2·27)
Back+Neck
(1·43)
Sense
(1·46)
Alcohol
(4·8)
Falls
(1·95)
Self Harm
(1·47)
Depression
(1·36)
Road Inj
(0·91)
Migraine
(1·18)
Central Europe
IHD
(1·38)
Stroke
(1·69)
Back+Neck
(1·23)
Falls
(2·18)
Lung C
(1·4)
Sense
(1·5)
Diabetes
(1·22)
Migraine
(1·07)
Colorect C
(1·42)
Road Inj
(0·87)
Albania
IHD
(1·24)
Stroke
(1·65)
Back+Neck
(1·48)
Sense
(1·38)
Falls
(1·68)
Lung C
(1·35)
Migraine
(1·11)
Oth Cardio
(3·04)
Skin
(0·76)
Road Inj
(0·52)
Bosnia
IHD
(1·39)
Stroke
(1·91)
Back+Neck
(1·5)
Diabetes
(2·31)
Lung C
(2·41)
Sense
(1·66)
Falls
(1·92)
Migraine
(1·14)
Colorect C
(2·22)
Skin
(0·73)
Bulgaria
IHD
(2·29)
Stroke
(2·98)
Back+Neck
(1·25)
Sense
(1·62)
Falls
(2·01)
HTN HD
(6·4)
Lung C
(1·23)
Oth Cardio
(3·32)
Diabetes
(1·44)
COPD
(1·47)
Croatia
IHD
(1·46)
Stroke
(1·86)
Back+Neck
(1·29)
Lung C
(1·5)
Falls
(2·24)
Sense
(1·53)
Colorect C
(1·8)
Diabetes
(1·28)
Migraine
(1·06)
Alzheimer's
(1·24)
Czech Republic
IHD
(1·26)
Back+Neck
(1·24)
Stroke
(1·04)
Falls
(2·43)
Sense
(1·36)
Lung C
(1·03)
Diabetes
(1·49)
Migraine
(1·05)
Colorect C
(1·36)
Oth Cardio
(1·97)
Hungary
IHD
(1·65)
Stroke
(1·55)
Back+Neck
(1·34)
Lung C
(2·08)
Falls
(2·49)
Sense
(1·44)
COPD
(1·82)
Colorect C
(2·04)
Diabetes
(1·38)
Self Harm
(1·27)
Macedonia
Stroke
(2·52)
IHD
(1·13)
CMP
(11·79)
Back+Neck
(1·17)
Diabetes
(1·93)
Lung C
(1·49)
Sense
(1·31)
Falls
(1·65)
Migraine
(1·1)
Skin
(0·75)
Montenegro
IHD
(1·23)
Stroke
(2·42)
Back+Neck
(1·21)
Lung C
(1·68)
Sense
(1·34)
Falls
(1·59)
Diabetes
(1·34)
Migraine
(1·06)
Road Inj
(0·77)
Skin
(0·77)
Poland
IHD
(1·19)
Back+Neck
(1·12)
Stroke
(1·13)
Falls
(2·2)
Lung C
(1·38)
Sense
(1·57)
Migraine
(1·08)
Road Inj
(1·01)
Diabetes
(1·08)
Self Harm
(1·1)
Romania
IHD
(1·62)
Stroke
(2·64)
Back+Neck
(1·28)
Falls
(2·22)
Sense
(1·51)
Lung C
(1·27)
Migraine
(1·07)
HTN HD
(4·23)
LRI
(1·91)
Road Inj
(0·89)
Serbia
IHD
(1·28)
Stroke
(2·12)
Back+Neck
(1·44)
CMP
(10·46)
Lung C
(2·21)
Sense
(1·58)
Diabetes
(1·68)
Falls
(1·92)
Migraine
(1·09)
Colorect C
(2·09)
Slovakia
IHD
(1·44)
Back+Neck
(1·22)
Stroke
(1·17)
Falls
(2·11)
Sense
(1·23)
Lung C
(0·93)
Migraine
(1·08)
Colorect C
(1·44)
Skin
(0·79)
Road Inj
(0·86)
Slovenia
IHD
(0·73)
Back+Neck
(1·28)
Falls
(3·07)
Stroke
(0·89)
Sense
(1·4)
Lung C
(1·04)
Migraine
(1·05)
Alzheimer's
(1·11)
Self Harm
(1·15)
Colorect C
(1·28)
Central Asia
IHD
(1·45)
LRI
(3·07)
Stroke
(1·18)
Back+Neck
(0·9)
NN Enceph
(3·69)
Sense
(1·03)
Road Inj
(0·74)
Congenital
(1·17)
NN Preterm
(1·33)
Migraine
(0·98)
Armenia
IHD
(1·6)
Back+Neck
(1·13)
Stroke
(0·97)
Diabetes
(1·79)
Sense
(1·48)
Lung C
(1·35)
Migraine
(1·04)
Congenital
(1·08)
Skin
(0·75)
Falls
(1·19)
Azerbaijan
IHD
(1·67)
LRI
(3·69)
Stroke
(1·14)
Back+Neck
(0·93)
NN Enceph
(6·42)
Sense
(1·1)
Congenital
(1·42)
NN Preterm
(1·75)
Diabetes
(1·13)
Migraine
(1·01)
Georgia
IHD
(2·01)
Stroke
(2·37)
Back+Neck
(1·13)
Sense
(1·63)
Road Inj
(0·9)
Diabetes
(1·28)
Lung C
(1·16)
HTN HD
(3·6)
Migraine
(1·01)
Falls
(1·41)
Kazakhstan
IHD
(1·47)
Stroke
(1·42)
Back+Neck
(0·93)
Self Harm
(1·79)
Road Inj
(1·02)
Sense
(1·07)
Congenital
(1·37)
LRI
(1·4)
COPD
(1·09)
Falls
(1·37)
(Figure 8 continues on next page)
 Global Health Metrics
1322 
www.thelancet.com   Vol 390  September 16, 2017
1
2
3
4
5
6
7
8
9
10
Kyrgyzstan
IHD
(1·24)
Stroke
(1·09)
LRI
(1·27)
NN Preterm
(1·39)
NN Enceph
(2·38)
Back+Neck
(1·03)
Congenital
(1·04)
Road Inj
(0·67)
Sense
(0·98)
Iron
(2·0)
Mongolia
IHD
(1·15)
Stroke
(1·86)
Liver C
(10·82)
LRI
(1·72)
Road Inj
(1·0)
NN Enceph
(3·65)
Back+Neck
(0·93)
Self Harm
(1·86)
Alcohol
(4·1)
Congenital
(1·13)
Tajikistan
LRI
(1·89)
IHD
(0·9)
NN Preterm
(1·12)
Diarrhoea
(1·64)
NN Enceph
(1·69)
Stroke
(0·71)
Back+Neck
(1·03)
Congenital
(0·86)
Sense
(0·88)
Skin
(0·82)
Turkmenistan
IHD
(1·36)
LRI
(4·21)
Stroke
(1·3)
Congenital
(2·66)
NN Preterm
(2·44)
Back+Neck
(0·78)
NN Enceph
(4·86)
Sense
(0·88)
Migraine
(0·97)
Skin
(0·79)
Uzbekistan
IHD
(1·56)
LRI
(3·33)
Stroke
(0·93)
HTN HD
(5·73)
Back+Neck
(0·9)
NN Enceph
(3·53)
Road Inj
(0·75)
Iron
(3·48)
Diabetes
(1·05)
Sense
(0·96)
Latin America and 
Caribbean
IHD
(0·55)
Violence
(3·37)
Diabetes
(1·47)
Back+Neck
(0·83)
Road Inj
(0·86)
Sense
(1·1)
Stroke
(0·52)
Skin
(0·98)
LRI
(1·14)
Congenital
(0·98)
Central Latin America
IHD
(0·48)
Violence
(3·71)
Diabetes
(1·84)
CKD
(2·59)
Road Inj
(0·77)
Back+Neck
(0·67)
Sense
(1·06)
Skin
(0·92)
Congenital
(1·02)
Migraine
(0·97)
Colombia
Violence
(4·91)
IHD
(0·47)
Back+Neck
(0·8)
Sense
(1·18)
Skin
(0·96)
Road Inj
(0·64)
Migraine
(1·04)
Diabetes
(0·85)
Congenital
(0·74)
Stroke
(0·33)
Costa Rica
IHD
(0·43)
Sense
(1·28)
Back+Neck
(0·73)
Road Inj
(0·7)
Skin
(0·9)
Migraine
(1·02)
CKD
(1·67)
Diabetes
(0·8)
Depression
(0·9)
Congenital
(0·77)
El Salvador
Violence
(6·04)
IHD
(0·64)
CKD
(3·35)
Diabetes
(1·48)
Road Inj
(0·79)
Sense
(1·24)
Back+Neck
(0·79)
LRI
(0·74)
Alcohol
(3·17)
Skin
(0·94)
Guatemala
LRI
(1·13)
Violence
(3·31)
Diabetes
(1·44)
Diarrhoea
(1·07)
IHD
(0·39)
NN Preterm
(0·58)
Congenital
(0·76)
Road Inj
(0·55)
CKD
(1·54)
Skin
(1·02)
Honduras
IHD
(0·86)
Violence
(3·01)
Stroke
(0·58)
NN Preterm
(0·57)
CKD
(1·6)
Skin
(0·97)
Sense
(0·96)
Back+Neck
(0·81)
Road Inj
(0·46)
Diabetes
(0·81)
Mexico
Diabetes
(2·56)
IHD
(0·44)
CKD
(3·59)
Violence
(2·68)
Road Inj
(0·79)
Back+Neck
(0·62)
Sense
(1·04)
Congenital
(1·24)
Skin
(0·9)
Migraine
(0·94)
Nicaragua
CKD
(2·22)
IHD
(0·42)
Diabetes
(1·03)
Sense
(1·04)
Back+Neck
(0·81)
Skin
(0·96)
Congenital
(0·65)
Migraine
(1·08)
Road Inj
(0·44)
LRI
(0·39)
Panama
IHD
(0·37)
Diabetes
(1·42)
Sense
(1·18)
Violence
(3·01)
Back+Neck
(0·64)
Road Inj
(0·79)
Skin
(0·98)
Congenital
(1·25)
Stroke
(0·44)
Migraine
(0·95)
Venezuela
Violence
(7·22)
IHD
(0·62)
Road Inj
(1·28)
Diabetes
(1·52)
Sense
(1·01)
Back+Neck
(0·58)
Skin
(0·91)
Congenital
(1·15)
Stroke
(0·46)
NN Preterm
(1·25)
Andean Latin America
LRI
(1·51)
Back+Neck
(0·92)
IHD
(0·35)
Sense
(1·12)
Skin
(1·08)
Road Inj
(0·68)
Congenital
(0·95)
NN Preterm
(0·87)
Diabetes
(0·83)
Migraine
(0·96)
Bolivia
LRI
(1·64)
NN Preterm
(1·19)
IHD
(0·55)
Congenital
(1·18)
Back+Neck
(0·99)
Road Inj
(0·7)
Skin
(1·12)
Stroke
(0·53)
Sense
(1·09)
Diabetes
(0·96)
Ecuador
Road Inj
(0·97)
Back+Neck
(0·89)
IHD
(0·34)
LRI
(1·05)
Sense
(1·08)
NN Preterm
(1·03)
Skin
(1·04)
Diabetes
(1·06)
Congenital
(0·95)
Violence
(1·68)
Peru
LRI
(1·6)
Back+Neck
(0·91)
Sense
(1·15)
Skin
(1·08)
IHD
(0·29)
Congenital
(0·85)
Road Inj
(0·53)
Migraine
(0·99)
Diabetes
(0·66)
NN Preterm
(0·62)
Caribbean
IHD
(0·81)
Stroke
(0·92)
Diabetes
(1·73)
HIV
(17·88)
LRI
(1·49)
Back+Neck
(0·75)
Sense
(1·13)
Road Inj
(0·73)
Skin
(1·0)
Diarrhoea
(3·89)
Antigua
Diabetes
(2·43)
IHD
(0·47)
Stroke
(0·67)
Back+Neck
(0·65)
Skin
(1·01)
Sense
(0·97)
Migraine
(1·0)
CKD
(2·04)
LRI
(1·29)
Oth MSK
(1·6)
Bahamas
IHD
(0·65)
Diabetes
(2·23)
HIV
(27·02)
Stroke
(0·83)
Violence
(4·5)
Back+Neck
(0·65)
Skin
(1·06)
HTN HD
(4·72)
Road Inj
(0·87)
Sense
(1·0)
Barbados
Diabetes
(3·61)
IHD
(0·59)
Stroke
(1·03)
Back+Neck
(0·73)
Sense
(1·28)
Skin
(1·23)
LRI
(1·97)
Oth MSK
(2·33)
CKD
(2·32)
Migraine
(0·99)
Belize
Diabetes
(1·6)
IHD
(0·47)
Violence
(2·13)
HIV
(12·73)
Road Inj
(0·72)
LRI
(0·76)
Skin
(1·1)
NN Preterm
(0·74)
Back+Neck
(0·69)
Stroke
(0·43)
Bermuda
IHD
(0·53)
Diabetes
(1·42)
Back+Neck
(0·58)
Skin
(0·99)
Sense
(0·95)
Stroke
(0·48)
Migraine
(0·96)
Lung C
(0·71)
Oth MSK
(1·79)
Depression
(0·88)
Cuba
IHD
(0·9)
Stroke
(0·92)
Sense
(1·47)
Back+Neck
(0·73)
Lung C
(1·43)
Diabetes
(1·22)
Depression
(1·27)
Skin
(0·92)
Migraine
(1·02)
LRI
(1·37)
Dominica
Diabetes
(2·75)
IHD
(0·58)
Stroke
(0·77)
CKD
(2·86)
Skin
(1·15)
Back+Neck
(0·7)
Road Inj
(0·8)
Sense
(1·07)
LRI
(1·32)
Congenital
(1·14)
Dominican Republic
IHD
(0·68)
HIV
(26·69)
NN Preterm
(1·61)
Road Inj
(0·83)
Stroke
(0·61)
Back+Neck
(0·73)
NN Sepsis
(6·98)
Skin
(1·01)
Sense
(0·98)
Congenital
(1·03)
Grenada
IHD
(0·71)
Diabetes
(2·68)
Stroke
(1·02)
LRI
(1·82)
CKD
(2·51)
Skin
(1·11)
Back+Neck
(0·68)
Road Inj
(0·7)
Sense
(0·96)
Oth MSK
(2·04)
Guyana
IHD
(1·17)
Diabetes
(2·96)
Stroke
(1·34)
Self Harm
(2·58)
HIV
(16·87)
Road Inj
(0·83)
NN Preterm
(1·1)
Violence
(2·07)
LRI
(0·97)
Skin
(1·06)
Haiti
IHD
(1·25)
HIV
(30·88)
LRI
(0·5)
Diarrhoea
(0·74)
Stroke
(1·3)
NN Enceph
(1·12)
Congenital
(1·1)
Road Inj
(0·97)
Diabetes
(1·78)
Oth NN
(1·58)
Jamaica
Diabetes
(3·24)
Stroke
(1·06)
IHD
(0·48)
Violence
(3·15)
NN Preterm
(1·66)
Back+Neck
(0·73)
Skin
(1·1)
Sense
(1·08)
Congenital
(1·08)
CKD
(1·92)
Puerto Rico
Diabetes
(3·62)
IHD
(0·62)
Back+Neck
(0·61)
Sense
(1·21)
Violence
(6·05)
Skin
(1·04)
Stroke
(0·56)
CKD
(2·7)
LRI
(1·95)
Migraine
(0·97)
St Lucia
Diabetes
(2·42)
IHD
(0·47)
Stroke
(0·82)
Back+Neck
(0·77)
Sense
(1·12)
Skin
(1·04)
Violence
(2·39)
Road Inj
(0·69)
CKD
(1·97)
Migraine
(1·04)
St Vincent
Diabetes
(3·19)
IHD
(0·87)
Stroke
(1·0)
Violence
(2·38)
Back+Neck
(0·79)
Skin
(1·1)
LRI
(0·92)
HIV
(10·97)
Sense
(1·03)
CKD
(1·92)
Suriname
IHD
(0·78)
Stroke
(1·17)
Diabetes
(2·15)
NN Preterm
(1·96)
Self Harm
(1·85)
Road Inj
(0·89)
Congenital
(1·3)
LRI
(1·31)
Skin
(1·12)
CKD
(2·35)
(Figure 8 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1323
1
2
3
4
5
6
7
8
9
10
Trinidad and Tobago
Diabetes
(5·75)
IHD
(1·0)
Stroke
(0·98)
Violence
(4·03)
Back+Neck
(0·71)
Road Inj
(0·93)
Sense
(1·08)
CKD
(2·62)
Skin
(0·96)
HIV
(14·12)
Virgin Islands
IHD
(1·41)
Diabetes
(3·6)
Stroke
(1·07)
Back+Neck
(0·66)
Violence
(7·04)
Sense
(1·35)
CKD
(3·17)
Prostate C
(5·5)
Skin
(1·08)
HIV
(29·92)
Tropical Latin America
IHD
(0·62)
Violence
(4·1)
Back+Neck
(1·03)
Road Inj
(1·03)
Stroke
(0·68)
Sense
(1·13)
Skin
(1·03)
Diabetes
(1·14)
LRI
(1·09)
Migraine
(1·05)
Brazil
IHD
(0·61)
Violence
(4·27)
Back+Neck
(1·02)
Road Inj
(1·04)
Stroke
(0·68)
Sense
(1·13)
Skin
(1·03)
Diabetes
(1·13)
LRI
(1·13)
Migraine
(1·04)
Paraguay
IHD
(0·6)
Road Inj
(1·04)
Diabetes
(1·48)
Back+Neck
(0·91)
Stroke
(0·66)
Skin
(1·06)
Congenital
(1·0)
NN Preterm
(0·93)
Sense
(0·98)
Violence
(1·72)
Southeast Asia, east Asia, 
and Oceania
Stroke
(1·61)
IHD
(0·73)
Back+Neck
(0·89)
Road Inj
(0·95)
COPD
(1·51)
Sense
(1·18)
Diabetes
(1·09)
Lung C
(1·42)
Skin
(0·87)
Liver C
(4·25)
East Asia
Stroke
(1·83)
IHD
(0·73)
Back+Neck
(0·89)
Road Inj
(1·03)
COPD
(1·72)
Lung C
(1·68)
Sense
(1·2)
Liver C
(5·42)
Skin
(0·78)
Depression
(1·01)
China
Stroke
(1·83)
IHD
(0·74)
Back+Neck
(0·9)
Road Inj
(1·01)
COPD
(1·69)
Sense
(1·2)
Lung C
(1·71)
Liver C
(5·45)
Skin
(0·78)
Depression
(1·02)
North Korea
Stroke
(2·25)
IHD
(1·05)
COPD
(2·6)
Lung C
(7·46)
Road Inj
(0·96)
Congenital
(0·93)
NN Preterm
(0·56)
Back+Neck
(1·36)
Sense
(1·3)
LRI
(0·29)
Taiwan (Province of China) 
Diabetes
(2·5)
Back+Neck
(0·82)
IHD
(0·41)
Stroke
(0·81)
Sense
(1·19)
Liver C
(5·73)
Lung C
(0·84)
Road Inj
(1·05)
Skin
(0·84)
CKD
(2·23)
Southeast Asia
IHD
(0·75)
Stroke
(1·12)
Back+Neck
(0·95)
Diabetes
(1·4)
LRI
(1·19)
Road Inj
(0·75)
Sense
(1·13)
Skin
(1·07)
TB
(5·73)
NN Preterm
(0·87)
Cambodia
LRI
(1·01)
Stroke
(1·01)
IHD
(0·58)
NN Preterm
(0·67)
Road Inj
(0·73)
Back+Neck
(1·28)
Skin
(1·13)
Sense
(1·13)
NN Enceph
(0·77)
Malaria
(70·48)
Indonesia
IHD
(0·91)
Stroke
(1·26)
Diabetes
(1·69)
TB
(8·74)
Back+Neck
(0·94)
NN Preterm
(1·06)
Sense
(1·07)
Road Inj
(0·68)
Skin
(1·0)
Diarrhoea
(3·07)
Laos
LRI
(1·7)
NN Preterm
(1·69)
Congenital
(1·88)
IHD
(0·85)
NN Enceph
(1·83)
Stroke
(1·01)
Diarrhoea
(0·82)
Road Inj
(0·8)
Skin
(1·16)
Back+Neck
(1·02)
Malaysia
IHD
(0·79)
Stroke
(0·72)
Road Inj
(1·08)
LRI
(2·09)
Back+Neck
(0·68)
Skin
(1·14)
Diabetes
(1·29)
Sense
(0·72)
Depression
(0·89)
COPD
(0·9)
Maldives
IHD
(0·56)
Back+Neck
(0·79)
Skin
(1·15)
Sense
(0·97)
Iron
(2·9)
COPD
(0·88)
Stroke
(0·34)
Migraine
(0·81)
Diabetes
(0·68)
CKD
(1·21)
Mauritius
Diabetes
(5·86)
IHD
(0·97)
CKD
(5·25)
Stroke
(0·92)
Back+Neck
(0·9)
Sense
(1·33)
Skin
(1·0)
COPD
(1·08)
Iron
(3·78)
Depression
(0·99)
Myanmar
Stroke
(1·05)
LRI
(0·86)
Sense
(1·45)
Road Inj
(0·75)
IHD
(0·41)
Back+Neck
(1·04)
COPD
(1·25)
Diabetes
(1·11)
TB
(3·05)
Skin
(1·13)
Philippines
IHD
(0·92)
LRI
(1·66)
Stroke
(1·03)
Diabetes
(1·26)
Back+Neck
(0·92)
Skin
(1·22)
NN Preterm
(0·93)
TB
(4·99)
Congenital
(0·99)
CKD
(1·96)
Sri Lanka
IHD
(0·83)
Diabetes
(2·14)
Back+Neck
(0·93)
Sense
(1·39)
Stroke
(0·68)
Self Harm
(1·63)
Skin
(0·98)
COPD
(1·05)
Asthma
(2·37)
Road Inj
(0·52)
Seychelles
IHD
(0·69)
LRI
(2·18)
HTN HD
(5·93)
Back+Neck
(0·84)
Stroke
(0·74)
CKD
(2·92)
Sense
(1·19)
Diabetes
(1·23)
Skin
(0·98)
Road Inj
(0·63)
Thailand
Road Inj
(1·32)
IHD
(0·47)
Back+Neck
(1·01)
Stroke
(0·84)
Sense
(1·35)
LRI
(1·58)
Skin
(1·13)
Diabetes
(1·31)
COPD
(1·39)
Liver C
(5·35)
Timor-Leste
LRI
(0·77)
Diarrhoea
(1·46)
NN Preterm
(0·87)
IHD
(0·62)
Congenital
(0·94)
Stroke
(0·66)
NN Enceph
(1·07)
Skin
(1·13)
Sense
(1·09)
Back+Neck
(0·89)
Vietnam
Stroke
(1·28)
IHD
(0·54)
Road Inj
(0·93)
Back+Neck
(1·07)
Sense
(1·19)
Lung C
(2·31)
Diabetes
(1·03)
Skin
(1·0)
COPD
(1·02)
Congenital
(0·69)
Oceania
LRI
(0·94)
IHD
(1·39)
Stroke
(1·41)
Diabetes
(2·77)
COPD
(2·16)
NN Preterm
(0·68)
Congenital
(1·01)
Asthma
(3·88)
Road Inj
(0·76)
Diarrhoea
(0·52)
American Samoa
Diabetes
(3·44)
IHD
(0·57)
Skin
(1·25)
Stroke
(0·67)
Back+Neck
(0·68)
CKD
(2·45)
Sense
(0·74)
LRI
(0·99)
COPD
(0·87)
Asthma
(1·66)
Micronesia
IHD
(1·35)
Diabetes
(3·48)
Stroke
(1·51)
CKD
(2·71)
LRI
(0·91)
COPD
(1·4)
Self Harm
(1·98)
Road Inj
(0·69)
Skin
(1·2)
Back+Neck
(0·84)
Fiji
Diabetes
(10·48)
IHD
(1·54)
Stroke
(1·17)
CKD
(4·59)
LRI
(2·54)
Back+Neck
(0·78)
Asthma
(3·59)
Skin
(1·09)
NN Preterm
(1·48)
Congenital
(1·28)
Guam
IHD
(1·38)
Diabetes
(2·92)
Stroke
(1·09)
Back+Neck
(0·68)
Self Harm
(1·4)
Lung C
(1·07)
Skin
(1·04)
CKD
(2·84)
LRI
(2·06)
COPD
(1·44)
Kiribati
Diabetes
(5·26)
IHD
(1·39)
Stroke
(1·77)
LRI
(0·41)
NN Preterm
(0·65)
Congenital
(1·12)
TB
(1·56)
NN Enceph
(0·95)
Self Harm
(2·91)
Diarrhoea
(0·41)
Marshall Islands
Diabetes
(8·59)
IHD
(1·03)
Stroke
(1·05)
LRI
(0·77)
CKD
(2·43)
NN Preterm
(0·81)
Road Inj
(0·6)
Skin
(1·12)
Self Harm
(1·75)
Back+Neck
(0·88)
Northern Mariana Islands
Diabetes
(1·77)
Back+Neck
(0·62)
IHD
(0·28)
Skin
(0·97)
Stroke
(0·47)
Road Inj
(0·64)
Self Harm
(0·8)
Migraine
(0·7)
Sense
(0·6)
CKD
(1·53)
Papua New Guinea
LRI
(0·77)
IHD
(1·55)
Stroke
(1·61)
COPD
(2·7)
NN Preterm
(0·64)
Diabetes
(2·35)
Congenital
(1·08)
Asthma
(3·88)
Road Inj
(0·91)
Diarrhoea
(0·32)
Samoa
IHD
(0·97)
Diabetes
(2·31)
Stroke
(0·93)
LRI
(0·46)
Skin
(1·18)
CKD
(1·76)
Back+Neck
(0·95)
Sense
(0·99)
COPD
(0·81)
Self Harm
(1·17)
Solomon Islands
IHD
(1·56)
Stroke
(1·64)
Diabetes
(3·27)
LRI
(0·4)
CKD
(2·07)
NN Preterm
(0·46)
Congenital
(0·79)
COPD
(1·42)
Road Inj
(0·62)
Asthma
(2·52)
Tonga
Diabetes
(3·25)
IHD
(0·81)
Stroke
(0·7)
LRI
(0·65)
NN Preterm
(0·73)
CKD
(1·9)
Skin
(1·18)
Back+Neck
(0·93)
Sense
(0·94)
Road Inj
(0·49)
Vanuatu
IHD
(1·92)
Stroke
(1·73)
LRI
(0·66)
Diabetes
(2·53)
NN Preterm
(0·69)
Congenital
(1·05)
COPD
(1·43)
CKD
(1·85)
Road Inj
(0·63)
Iron
(1·41)
(Figure 8 continues on next page)
 Global Health Metrics
1324 
www.thelancet.com   Vol 390  September 16, 2017
1
2
3
4
5
6
7
8
9
10
North Africa and Middle 
East
IHD
(0·92)
Conflict 
Terror
(63·83)
Road Inj
(1·16)
Congenital
(1·69)
NN Preterm
(1·52)
Back+Neck
(1·06)
Stroke
(0·62)
Diabetes
(1·23)
LRI
(1·06)
Sense
(0·98)
North Africa and Middle 
East
IHD
(0·92)
Conflict 
Terror
(63·77)
Road Inj
(1·16)
Congenital
(1·69)
NN Preterm
(1·52)
Back+Neck
(1·06)
Stroke
(0·62)
Diabetes
(1·23)
LRI
(1·06)
Sense
(0·98)
Afghanistan
Conflict 
Terror
(32·51)
LRI
(0·48)
IHD
(2·44)
Congenital
(1·99)
Road Inj
(2·05)
NN Preterm
(0·66)
Stroke
(1·37)
Meningitis
(1·0)
TB
(0·71)
Diarrhoea
(0·11)
Algeria
IHD
(0·74)
Congenital
(1·66)
Back+Neck
(1·09)
NN Preterm
(1·53)
Road Inj
(0·96)
Diabetes
(1·25)
Sense
(1·1)
Stroke
(0·52)
Migraine
(1·18)
Skin
(0·88)
Bahrain
Diabetes
(2·48)
IHD
(0·43)
Back+Neck
(0·93)
Migraine
(1·19)
Skin
(0·95)
Depression
(1·22)
Road Inj
(0·63)
Sense
(0·83)
Oth MSK
(1·52)
Anxiety
(1·16)
Egypt
IHD
(1·3)
Road Inj
(1·09)
Stroke
(0·81)
Back+Neck
(1·08)
LRI
(1·22)
Diabetes
(1·36)
Congenital
(1·22)
Diarrhoea
(3·39)
Sense
(1·08)
Cirr HepC
(5·32)
Iran
IHD
(0·71)
Road Inj
(1·73)
Back+Neck
(0·94)
NN Preterm
(2·36)
Depression
(1·59)
Congenital
(1·8)
Diabetes
(1·39)
Migraine
(1·15)
Stroke
(0·5)
Sense
(0·92)
Iraq
Conflict 
Terror
(166·54)
NN Preterm
(1·3)
IHD
(1·24)
Congenital
(1·49)
Diabetes
(1·59)
NN Sepsis
(2·3)
Road Inj
(0·78)
Stroke
(0·68)
LRI
(0·29)
Back+Neck
(1·1)
Jordan
Congenital
(1·93)
IHD
(0·49)
NN Preterm
(1·56)
Back+Neck
(0·86)
Conflict 
Terror
(36·87)
Diabetes
(1·22)
Road Inj
(0·71)
Skin
(0·93)
Migraine
(1·09)
Sense
(0·86)
Kuwait
IHD
(0·42)
Back+Neck
(0·79)
Migraine
(1·2)
Road Inj
(0·94)
Congenital
(1·7)
Skin
(0·84)
Depression
(1·06)
Diabetes
(0·95)
Sense
(0·72)
Anxiety
(1·18)
Lebanon
IHD
(0·68)
Back+Neck
(0·82)
Conflict 
Terror
(29·91)
Sense
(1·1)
Migraine
(1·15)
Skin
(0·96)
Diabetes
(1·21)
Depression
(1·09)
Congenital
(1·23)
Anxiety
(1·31)
Libya
IHD
(0·72)
Conflict 
Terror
(51·15)
Back+Neck
(0·85)
Road Inj
(1·36)
Diabetes
(1·37)
Migraine
(1·13)
Stroke
(0·52)
Sense
(0·95)
Skin
(0·91)
Depression
(1·07)
Morocco
IHD
(1·1)
Back+Neck
(1·45)
Road Inj
(0·94)
Diabetes
(1·5)
Depression
(1·88)
Stroke
(0·59)
Sense
(1·15)
TB
(3·75)
NN Preterm
(0·73)
Migraine
(1·32)
Palestine
NN Preterm
(0·97)
IHD
(1·01)
Congenital
(1·23)
Stroke
(0·51)
Back+Neck
(1·09)
Road Inj
(0·52)
Diabetes
(1·06)
NN Sepsis
(1·26)
Skin
(0·92)
Depression
(1·32)
Oman
Road Inj
(2·14)
IHD
(0·58)
Back+Neck
(0·9)
Diabetes
(1·59)
Migraine
(1·15)
Skin
(0·83)
Depression
(1·04)
Sense
(0·68)
Stroke
(0·32)
Congenital
(0·72)
Qatar
Road Inj
(1·75)
Back+Neck
(0·84)
Diabetes
(1·43)
Migraine
(1·18)
IHD
(0·24)
Depression
(1·13)
Skin
(0·82)
Congenital
(1·22)
Sense
(0·63)
Anxiety
(1·14)
Saudi Arabia
IHD
(0·47)
Road Inj
(1·63)
Back+Neck
(0·84)
Migraine
(1·2)
Skin
(0·95)
Sense
(0·78)
Depression
(0·96)
Stroke
(0·39)
Diabetes
(0·89)
Congenital
(1·11)
Sudan
Congenital
(2·65)
NN Preterm
(1·54)
IHD
(1·09)
Road Inj
(1·45)
LRI
(0·6)
Stroke
(0·67)
Iron
(2·05)
Back+Neck
(1·26)
Diarrhoea
(0·76)
Skin
(0·97)
Syria
Conflict 
Terror
(851·38)
IHD
(1·17)
Back+Neck
(1·0)
Stroke
(0·5)
Sense
(0·94)
Migraine
(1·15)
Skin
(0·89)
Congenital
(0·69)
Depression
(1·01)
Road Inj
(0·4)
Tunisia
IHD
(0·93)
Back+Neck
(1·2)
Road Inj
(0·97)
Diabetes
(1·41)
Stroke
(0·61)
Sense
(1·18)
Migraine
(1·22)
Skin
(0·91)
Depression
(1·23)
Congenital
(0·93)
Turkey
IHD
(0·56)
Back+Neck
(1·09)
Diabetes
(1·36)
Sense
(1·07)
Congenital
(1·4)
Migraine
(1·12)
Skin
(0·84)
Stroke
(0·44)
Depression
(1·03)
Lung C
(0·98)
United Arab Emirates
Road Inj
(2·17)
IHD
(0·65)
Back+Neck
(0·92)
Stroke
(0·62)
Diabetes
(1·37)
Migraine
(1·14)
Skin
(0·79)
Sense
(0·76)
Depression
(0·9)
CKD
(1·64)
Yemen
Conflict 
Terror
(171·01)
NN Preterm
(1·4)
IHD
(1·15)
Congenital
(1·57)
Road Inj
(1·39)
Diarrhoea
(0·76)
Iron
(2·73)
LRI
(0·27)
Stroke
(0·7)
STD
(4·05)
South Asia
IHD
(1·19)
Diarrhoea
(1·95)
COPD
(2·01)
LRI
(0·79)
Stroke
(0·77)
NN Preterm
(0·8)
Iron
(2·49)
TB
(2·88)
Road Inj
(0·67)
Sense
(1·24)
South Asia
IHD
(1·19)
Diarrhoea
(1·95)
COPD
(2·01)
LRI
(0·79)
Stroke
(0·77)
NN Preterm
(0·8)
Iron
(2·49)
TB
(2·88)
Road Inj
(0·67)
Sense
(1·24)
Bangladesh
IHD
(0·8)
Stroke
(1·03)
LRI
(0·38)
Back+Neck
(1·19)
NN Enceph
(0·95)
Sense
(1·23)
COPD
(1·1)
Migraine
(1·41)
Oth NN
(1·6)
Skin
(0·95)
Bhutan
IHD
(0·73)
LRI
(0·73)
Iron
(2·89)
NN Preterm
(0·84)
Back+Neck
(0·96)
COPD
(1·24)
Congenital
(0·76)
Stroke
(0·48)
Migraine
(1·27)
Diabetes
(0·91)
India
IHD
(1·22)
COPD
(2·28)
Diarrhoea
(2·47)
LRI
(0·9)
Stroke
(0·74)
Iron
(3·0)
NN Preterm
(0·87)
TB
(3·61)
Sense
(1·3)
Road Inj
(0·69)
Nepal
IHD
(1·06)
LRI
(0·39)
NN Enceph
(1·01)
COPD
(1·67)
Stroke
(0·64)
Oth NN
(1·53)
Back+Neck
(1·23)
Diarrhoea
(0·34)
Road Inj
(0·52)
Skin
(1·0)
Pakistan
IHD
(1·3)
NN Enceph
(2·72)
Diarrhoea
(1·36)
NN Preterm
(0·86)
LRI
(0·56)
Stroke
(0·81)
Oth NN
(2·71)
Road Inj
(0·75)
TB
(1·81)
Congenital
(0·69)
Sub-Saharan Africa
Malaria
(138·47)
HIV
(54·6)
Diarrhoea
(1·23)
LRI
(0·78)
NN Enceph
(1·55)
NN Preterm
(0·77)
TB
(1·69)
PEM
(1·94)
NN Sepsis
(2·07)
Congenital
(0·91)
Southern sub-Saharan 
Africa
HIV
(226·35)
LRI
(3·43)
TB
(17·53)
Diarrhoea
(9·23)
Road Inj
(1·56)
Violence
(4·08)
Diabetes
(2·03)
NN Preterm
(1·6)
IHD
(0·42)
Stroke
(0·64)
(Figure 8 continues on next page)
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1325
1
2
3
4
5
6
7
8
9
10
Botswana
HIV
(166·06)
Diabetes
(1·95)
TB
(13·78)
LRI
(1·95)
Diarrhoea
(7·09)
IHD
(0·43)
Road Inj
(0·9)
Skin
(1·14)
Stroke
(0·57)
Back+Neck
(0·67)
Lesotho
HIV
(316·34)
TB
(14·68)
Diarrhoea
(5·4)
LRI
(1·71)
Road Inj
(1·51)
Violence
(3·5)
NN Preterm
(1·18)
Diabetes
(2·16)
Oth NN
(4·64)
Stroke
(1·0)
Namibia
HIV
(117·45)
Diarrhoea
(6·46)
LRI
(1·76)
Road Inj
(1·05)
TB
(6·58)
NN Preterm
(1·15)
Oth NN
(4·82)
Violence
(1·92)
IHD
(0·38)
Skin
(1·18)
South Africa
HIV
(287·36)
LRI
(3·97)
Road Inj
(1·99)
Violence
(6·29)
TB
(23·49)
Diabetes
(2·47)
IHD
(0·42)
Diarrhoea
(8·27)
Stroke
(0·63)
Back+Neck
(0·7)
Swaziland
HIV
(200·02)
Diarrhoea
(7·1)
LRI
(2·31)
TB
(8·93)
Road Inj
(1·29)
Diabetes
(2·1)
NN Preterm
(1·11)
Oth NN
(4·58)
Violence
(1·97)
IHD
(0·43)
Zimbabwe
HIV
(133·99)
Diarrhoea
(2·09)
LRI
(1·09)
TB
(3·84)
NN Enceph
(2·11)
NN Preterm
(1·04)
Congenital
(0·99)
PEM
(3·05)
NN Sepsis
(2·47)
Road Inj
(0·73)
Western sub-Saharan 
Africa
Malaria
(195·78)
Diarrhoea
(1·4)
LRI
(0·78)
HIV
(39·08)
NN Enceph
(1·95)
NN Preterm
(0·92)
Congenital
(1·44)
Meningitis
(2·83)
NN Sepsis
(2·32)
PEM
(1·6)
Benin
Malaria
(23·7)
Diarrhoea
(0·71)
LRI
(0·51)
NN Enceph
(1·18)
NN Preterm
(0·74)
Congenital
(1·2)
Meningitis
(1·31)
NN Sepsis
(1·16)
HIV
(9·78)
Iron
(1·06)
Burkina Faso
Malaria
(14·54)
LRI
(0·62)
Diarrhoea
(0·28)
Congenital
(1·7)
NN Preterm
(0·61)
Meningitis
(1·25)
NN Enceph
(0·7)
PEM
(0·77)
NN Sepsis
(1·18)
Iron
(1·32)
Cameroon
Malaria
(274·08)
HIV
(76·33)
LRI
(1·04)
Diarrhoea
(0·96)
Congenital
(1·78)
NN Preterm
(0·99)
NN Enceph
(1·53)
Meningitis
(2·84)
NN Sepsis
(2·14)
PEM
(1·52)
Cape Verde
IHD
(0·55)
HIV
(14·08)
LRI
(0·59)
Back+Neck
(0·99)
NN Preterm
(0·6)
Violence
(1·45)
Skin
(1·06)
Stroke
(0·48)
Congenital
(0·69)
Iron
(1·71)
Chad
Diarrhoea
(0·81)
LRI
(0·89)
HIV
(25·23)
Malaria
(5·13)
NN Enceph
(1·21)
NN Preterm
(0·8)
Meningitis
(1·66)
PEM
(1·17)
STD
(2·59)
Congenital
(1·29)
Côte d’Ivoire
Malaria
(89·87)
Diarrhoea
(1·04)
HIV
(50·5)
LRI
(0·75)
NN Preterm
(1·01)
Congenital
(1·64)
NN Enceph
(1·42)
IHD
(0·75)
NN Sepsis
(1·78)
Stroke
(0·79)
The Gambia
LRI
(0·39)
NN Preterm
(0·74)
Diarrhoea
(0·32)
HIV
(20·9)
NN Enceph
(0·9)
Congenital
(1·0)
NN Sepsis
(1·35)
Iron
(1·42)
Meningitis
(1·2)
Malaria
(4·5)
Ghana
Malaria
(431·66)
HIV
(32·92)
NN Enceph
(2·24)
LRI
(0·72)
Congenital
(1·11)
NN Sepsis
(3·02)
NN Preterm
(0·59)
Stroke
(0·69)
IHD
(0·49)
Meningitis
(2·84)
Guinea
Malaria
(19·15)
LRI
(0·7)
NN Enceph
(1·27)
Diarrhoea
(0·27)
NN Preterm
(0·68)
Congenital
(1·47)
HIV
(16·26)
Meningitis
(1·37)
TB
(0·78)
NN Sepsis
(1·2)
Guinea-Bissau
HIV
(45·01)
LRI
(0·49)
Diarrhoea
(0·4)
NN Enceph
(1·13)
NN Preterm
(0·75)
TB
(1·34)
STD
(3·3)
Meningitis
(1·72)
IHD
(1·02)
Congenital
(1·16)
Liberia
Diarrhoea
(0·57)
Malaria
(10·62)
LRI
(0·32)
HIV
(17·67)
NN Enceph
(0·86)
NN Preterm
(0·48)
Congenital
(0·97)
IHD
(0·61)
Meningitis
(0·92)
TB
(0·6)
Mali
Malaria
(11·12)
Diarrhoea
(0·55)
NN Enceph
(1·38)
NN Preterm
(0·91)
LRI
(0·3)
PEM
(1·08)
Congenital
(1·32)
STD
(2·03)
Meningitis
(1·1)
NN Sepsis
(1·17)
Mauritania
LRI
(0·62)
Diarrhoea
(1·04)
NN Preterm
(0·77)
NN Enceph
(1·22)
Congenital
(1·0)
NN Sepsis
(2·06)
IHD
(0·45)
Back+Neck
(1·13)
Iron
(1·43)
Skin
(1·11)
Niger
Malaria
(3·36)
Diarrhoea
(0·52)
LRI
(0·51)
Meningitis
(1·0)
NN Enceph
(0·74)
NN Preterm
(0·48)
Congenital
(1·0)
PEM
(0·5)
NN Sepsis
(0·93)
TB
(0·32)
Nigeria
Malaria
(594·41)
Diarrhoea
(2·59)
HIV
(50·48)
NN Enceph
(2·98)
LRI
(0·97)
NN Preterm
(1·15)
Congenital
(1·52)
NN Sepsis
(3·49)
Meningitis
(3·93)
PEM
(2·71)
São Tomé and Príncipe
LRI
(0·45)
Congenital
(0·83)
Diarrhoea
(0·34)
NN Enceph
(0·72)
NN Preterm
(0·43)
Stroke
(0·57)
NN Sepsis
(1·35)
Skin
(1·08)
Back+Neck
(0·95)
PEM
(0·94)
Senegal
Diarrhoea
(0·41)
LRI
(0·39)
NN Preterm
(0·58)
NN Enceph
(0·87)
Congenital
(1·11)
Malaria
(7·08)
Meningitis
(1·4)
NN Sepsis
(1·27)
IHD
(0·62)
TB
(0·75)
Sierra Leone
Malaria
(46·59)
Diarrhoea
(0·87)
LRI
(0·82)
NN Enceph
(1·63)
Congenital
(2·11)
NN Preterm
(0·76)
Meningitis
(2·1)
HIV
(17·7)
TB
(0·85)
NN Sepsis
(1·36)
Togo
Malaria
(83·04)
HIV
(38·48)
LRI
(0·49)
Diarrhoea
(0·47)
NN Enceph
(1·17)
NN Preterm
(0·7)
Congenital
(1·13)
IHD
(0·64)
TB
(0·87)
NN Sepsis
(1·34)
Eastern sub-Saharan 
Africa
HIV
(45·37)
LRI
(0·57)
Diarrhoea
(0·61)
Malaria
(17·5)
NN Enceph
(1·04)
TB
(1·35)
NN Preterm
(0·53)
PEM
(1·28)
Meningitis
(1·5)
NN Sepsis
(1·37)
Burundi
Diarrhoea
(0·63)
LRI
(0·52)
Malaria
(4·13)
TB
(1·73)
NN Enceph
(1·04)
PEM
(1·11)
NN Preterm
(0·65)
NN Sepsis
(1·24)
Meningitis
(0·85)
HIV
(8·1)
Comoros
LRI
(0·61)
Diarrhoea
(0·9)
NN Enceph
(1·04)
NN Preterm
(0·59)
TB
(1·53)
IHD
(0·47)
PEM
(1·5)
Skin
(1·24)
NN Sepsis
(1·57)
Meningitis
(1·78)
Djibouti
HIV
(44·64)
LRI
(0·67)
PEM
(2·36)
NN Preterm
(0·7)
TB
(1·61)
Diarrhoea
(0·41)
NN Enceph
(0·87)
NN Sepsis
(1·73)
IHD
(0·56)
Meningitis
(1·73)
Eritrea
Diarrhoea
(0·71)
LRI
(0·52)
TB
(1·99)
PEM
(1·5)
NN Enceph
(0·7)
NN Preterm
(0·42)
Meningitis
(1·51)
HIV
(11·79)
NN Sepsis
(1·2)
Skin
(1·2)
Ethiopia
Diarrhoea
(0·29)
LRI
(0·34)
TB
(0·98)
NN Enceph
(0·7)
NN Sepsis
(1·02)
IHD
(0·62)
HIV
(8·87)
NN Preterm
(0·31)
PEM
(0·61)
Meningitis
(0·85)
Kenya
HIV
(64·38)
Diarrhoea
(3·17)
LRI
(1·0)
NN Enceph
(1·3)
NN Preterm
(0·63)
Skin
(1·25)
TB
(1·6)
Malaria
(92·97)
NN Sepsis
(1·89)
Meningitis
(2·45)
Madagascar
Diarrhoea
(0·88)
LRI
(0·68)
PEM
(2·55)
NN Preterm
(0·85)
Stroke
(1·1)
Malaria
(9·15)
NN Sepsis
(1·48)
NN Enceph
(0·68)
STD
(2·54)
Meningitis
(1·27)
Malawi
HIV
(93·83)
Malaria
(18·86)
LRI
(0·6)
Diarrhoea
(0·45)
NN Enceph
(1·32)
NN Preterm
(0·65)
PEM
(1·13)
Meningitis
(1·47)
TB
(0·89)
NN Sepsis
(1·35)
Mozambique
HIV
(92·49)
Malaria
(8·96)
LRI
(0·46)
NN Enceph
(0·98)
TB
(1·18)
Diarrhoea
(0·19)
NN Preterm
(0·5)
NN Sepsis
(1·2)
Oth NN
(0·87)
STD
(1·41)
Rwanda
LRI
(0·55)
Diarrhoea
(0·41)
TB
(1·25)
NN Enceph
(0·86)
Malaria
(15·27)
HIV
(16·46)
PEM
(1·21)
NN Preterm
(0·42)
Meningitis
(1·41)
NN Sepsis
(1·22)
(Figure 8 continues on next page)
 Global Health Metrics
1326 
www.thelancet.com   Vol 390  September 16, 2017
GBD 2015 results.4 The conclusion that DALY convergence 
is likely to be accelerated by escalating increases in SDI 
remains valid. We have looked a step further in GBD 2016 
and highlighted countries that have most improved and 
showed the largest declines in their DALY performance 
relative to that expected on the basis of their SDI.
The pace and efficiency of a country’s transition 
through the SDI quintiles and the concurrent improve­
ments in population summary health metrics is by no 
means inevitable, however, and analysis derived from 
the ratio of observed to expected DALYs on the basis of 
SDI has been informative. The exemplars were 
Nicaragua, Costa Rica, the Maldives, Peru, and Israel, 
which had the lowest levels of age­standardised DALYs 
relative to the levels expected on the basis of SDI in 
2016. The appendix (pp 63–66) contains a full list of 
exemplars. These countries considerably outperformed 
health expectations relative to their development status. 
Conversely, Lesotho, Swaziland, South Africa, Fiji, and 
Botswana had the highest levels of age­standardised 
DALYs relative to those expected, reflecting a need for 
additional attention and examination of the reasons for 
these discrepancies. Lesotho had the highest ratio of 
age­standardised DALYs relative to that expected, which 
indicates poor performance in terms of health outcomes 
for mortality and morbidity relative to their SDI status.
The reasons for the success in health outcomes of the 
five exemplars merit in­depth analyses. Conversely, with 
the exception of Fiji (which is heavily impacted by the 
high levels of diabetes seen throughout Oceania), the 
poor performers in 2016 were clearly those that were 
most devastated by the continuing HIV
/AIDS epidemic 
and, although progress has been made in South Africa, 
Swaziland, Zimbabwe, and Lesotho are still dis­
proportionately affected. Many different locations within 
the top ten exemplars and ten poor performers would 
make excellent case studies to assess the reasons for 
their relative rankings, particularly given the different 
health challenges and successes for each nation.
By highlighting exemplars and poor performers across 
the SDI quintiles, we have seen that the underlying 
influences that have contributed to the relative successes 
and failures of nations are substantially heterogeneous. A 
clear corollary is that the policy implications for reform 
will not be the same between quintiles. Nation­by­nation 
complexity in how countries progress through the SDI 
continuum and how population health summaries track 
is clearly too voluminous to document in this study by 
1
2
3
4
5
6
7
8
9
10
Somalia
LRI
(0·63)
TB
(1·69)
Diarrhoea
(0·28)
PEM
(1·19)
Conflict 
Terror
(12·12)
Whooping
(2·02)
Malaria
(1·64)
NN Enceph
(0·61)
Meningitis
(0·89)
IHD
(0·94)
South Sudan
LRI
(0·62)
STD
(3·37)
Diarrhoea
(0·3)
HIV
(13·67)
PEM
(0·99)
NN Enceph
(0·88)
NN Preterm
(0·59)
Meningitis
(0·8)
TB
(0·66)
Measles
(0·28)
Tanzania
HIV
(52·38)
LRI
(0·78)
Diarrhoea
(0·68)
Malaria
(49·43)
NN Enceph
(1·37)
PEM
(1·83)
NN Preterm
(0·56)
TB
(1·14)
NN Sepsis
(1·59)
Meningitis
(1·8)
Uganda
HIV
(51·43)
Malaria
(32·48)
LRI
(0·49)
NN Enceph
(1·33)
Diarrhoea
(0·43)
TB
(1·74)
NN Preterm
(0·69)
Meningitis
(1·84)
PEM
(1·03)
NN Sepsis
(1·44)
Zambia
HIV
(112·98)
LRI
(1·06)
Diarrhoea
(1·22)
TB
(3·62)
Malaria
(96·01)
NN Enceph
(1·66)
PEM
(3·27)
NN Preterm
(0·7)
Meningitis
(3·39)
NN Sepsis
(2·12)
Central sub-Saharan 
Africa
Malaria
(81·1)
LRI
(0·68)
Diarrhoea
(0·8)
TB
(2·59)
HIV
(25·92)
PEM
(2·16)
NN Preterm
(0·73)
NN Enceph
(1·07)
Congenital
(1·05)
NN Sepsis
(2·04)
Angola
Diarrhoea
(1·12)
LRI
(0·66)
Malaria
(51·12)
HIV
(26·41)
NN Preterm
(0·66)
TB
(1·68)
PEM
(1·94)
NN Sepsis
(2·15)
NN Enceph
(0·87)
Congenital
(0·9)
Central African Republic
TB
(5·02)
HIV
(57·95)
Diarrhoea
(0·72)
LRI
(0·9)
Malaria
(10·77)
Measles
(1·76)
PEM
(1·65)
STD
(3·47)
NN Preterm
(0·74)
Road Inj
(1·64)
Congo (Brazzaville)
HIV
(63·82)
Malaria
(580·54)
Diarrhoea
(2·16)
LRI
(1·0)
TB
(3·24)
NN Preterm
(0·88)
NN Enceph
(1·29)
IHD
(0·51)
NN Sepsis
(3·14)
Road Inj
(0·76)
DR Congo
Malaria
(14·77)
LRI
(0·5)
TB
(1·7)
Diarrhoea
(0·31)
PEM
(1·3)
NN Preterm
(0·61)
NN Enceph
(0·85)
Congenital
(1·05)
HIV
(12·33)
NN Sepsis
(1·4)
Equatorial Guinea
HIV
(113·42)
Malaria
(11942·38)
LRI
(1·85)
NN Preterm
(1·4)
Road Inj
(0·74)
Back+Neck
(0·79)
Skin
(1·12)
NN Enceph
(2·46)
Congenital
(1·04)
NN Sepsis
(5·86)
Gabon
HIV
(38·64)
Malaria
(2134·02)
LRI
(1·62)
NN Preterm
(1·26)
Diarrhoea
(3·06)
NN Sepsis
(6·03)
Road Inj
(0·88)
Congenital
(1·13)
IHD
(0·43)
Skin
(1·17)
0·0–0·64
0·64–0·81
0·81–0·97
0·97–1·07
1·07–1·18
1·18–1·37
1·37–1·71
1·71–2·77
≥2·77
Figure 8: Leading ten causes of all-age DALYs with the ratio of observed to expected DALYs on the basis of Socio-demographic Index in 2016, by location
The ratio of observed to expected DALYs on the basis of Socio-demographic Index is provided in brackets for each cause and cells are colour-coded by ratio ranges (calculated to place a roughly equal 
number of cells into each bin). Shades of blue represent much lower observed DALY levels than expected on the basis of Socio-demographic Index, whereas red shows observed DALYs that exceed 
expected levels. Alcohol=alcohol use disorders. Alzheimer’s=Alzheimer’s disease and other dementias. Anxiety=anxiety disorders. Back+Neck=low back and neck pain. Cirr alc=cirrhosis due to alcohol 
use. Cirr HepC=cirrhosis due to hepatitis C. CKD=chronic kidney disease. CMP=cardiomyopathy and myocarditis. Colorect C=colon and rectum cancer. Conflict Terror=conflict and terrorism. 
Congenital=congenital anomalies. COPD=chronic obstructive pulmonary disease. Depression=depressive disorders. Diabetes=diabetes mellitus. Diarrhoea=diarrhoeal diseases. DR Congo=Democratic 
Republic of the Congo. Drugs=drug use disorders. HIV=HIV/AIDS. HTN HD=hypertensive heart disease. IHD=ischaemic heart disease. Iron=iron-deficiency anaemia. Liver C=liver cancer. LRI=lower 
respiratory infections. Lung C=lung, bronchus, and trachea cancers. NN Enceph=neonatal encephalopathy due to birth asphyxia and trauma. NN Preterm=neonatal preterm birth complications. 
NN Sepsis=neonatal sepsis and other neonatal infections. Oth Cardio=other cardiovascular and circulatory diseases. Oth MSK=other musculoskeletal disorders. Oth NN=Other neonatal disorders. 
PEM=protein-energy malnutrition. Prostate C=prostate cancer. Road Inj=road injuries. Sense=sense organ diseases. Skin=skin and subcutaneous diseases. STD=sexually transmitted diseases excluding 
HIV. Stomach C=stomach cancer. Stroke=Cerebrovascular disease. TB=tuberculosis. Violence=interpersonal violence. 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1327
nation, but we hope that the results of this study will 
spawn a plethora of derivative and policy­relevant research.
We have highlighted key exemplar nations and those 
whose progress could be improved, but there are clearly 
more general lessons that can be learned from the 
epidemiological transition across all causes and 
locations. The collection of London Declaration NTDs, 
along with malaria28 and HIV, all show how effective 
domestic and international collaborations in fighting of 
specific infectious diseases can be. Whether or not these 
collaborations provide evidence of health­care improve­
ments in one area, whether or not the benefits cascade, 
and whether or not non­health­specific interventions, 
such as poverty alleviation, education,29 and family 
planning, are having synergistic effects are hard to 
differentiate,28,30 but a host of online tools exist that 
enable national experts to examine performance of and 
changes in the leading causes of disease burden, 
compare them with peers, and objectively assess what 
can be improved.
Since the concept of the DALY was introduced two 
decades ago,31 it has become a key metric for monitoring 
of population health and prioritisation within health 
sectors.32–39 The following are examples of policy makers, 
funders, or foundations that use DALYs in decision 
making: WHO, the World Bank, the National Institutes 
of Health, the US Centers for Disease Control and 
Prevention, the Bill & Melinda Gates Foundation, Gavi, 
the US President’s Emergency Plan for AIDS Relief, the 
Global Fund, and the Wellcome Trust, as well as the 
Chinese Politburo, the National Institute for Health and 
Care Excellence, Indonesia Bappenas, and Public Health 
England at the national level.
Comparison of GBD 2016 with other global estimates 
and GBD 2015
The GBD study is the only source of comprehensive 
quantification of population health summary measures, 
including YLLs, YLDs, DALYs, and HALE. Specific 
efforts that are relevant to policy makers are being made 
to estimate burden within other organisations. Since 
GBD 2015, most organisations that we assessed have not 
produced updated estimates for DALYs or HALE. The 
exception to this is WHO, which has released updated 
Global Health Estimates for DALYs and HALE for 
183 countries from 2000 to 2015.40 These estimates draw 
heavily on the GBD 2015 results, with revisions to the 
all­cause mortality envelope40,41 as detailed in the GBD 
2016 cause­specific mortality publication10 and to selected 
cause­specific disability weights and severity distrib­
utions for YLDs.42 WHO­adjusted disability weights for 
various causes are further detailed in the WHO Global 
Health Estimates Technical Paper.41
Disease-specific considerations
The SDI transition was prominent for many CMNN 
conditions, especially diarrhoea, lower respiratory 
infection, HIV after 2005 (the year of the global peak), 
maternal disorders, and vaccine­preventable diseases 
like measles, tetanus, diphtheria, and pertussis. 
Focused programmes with community­wide targeting 
of health interventions—such as access to antenatal 
care,43,44 vaccination, malaria vector control (insecticide­
treated bednets and indoor residual spraying),45 and 
artemisinin 
combination 
therapies,46 
water 
and 
sanitation efforts,47 and ART and prevention of mother­
to­child transmission of HIV30,48,49—are potentially 
responsible for DALY reductions in these conditions.50 
Further scale­up and maintenance of these interventions 
should continue, including a transition from non­
governmental organ 
isations to local ownership and 
financing. Corre 
sponding improvements in health 
system functions related to survival of mothers and 
their children have not occurred,51 shown by the 
comparatively slow improvement in DALYs due to 
maternal and neonatal disorders compared with other 
CMNN causes and the growing burden of congenital 
birth defects, haemo 
globinopathies and haemolytic 
anaemias, and sudden infant death syndrome, espec­
ially in the under­5 age group. Early detection of 
complications of pregnancy like micronutrient def­
iciencies, hypertensive disorders of pregnancy, preg­
nancy­transmitted and sexually trans 
mitted infec 
tions, 
and congenital birth defects can help identify the 
pregnant women and newborns at highest risk, help 
ensure that appropriate curative treatments are 
administered, and put the females and newborns in a 
position to receive timely perinatal care when it is 
needed. Newborn screening for congenital birth defects 
and haemoglobinopathies can, at the very least, identify 
children with these conditions and facilitate maternal 
education about the importance of presentation for care 
early when a mother’s child gets sick. Delays in seeking 
care can have deadly consequences, particularly for 
children with acute conditions. Education of mothers 
and fathers, especially first­time parents, about how to 
best care for their babies can help reduce avoidable 
injuries and deaths. At the same time, stark increases 
in neonatal sepsis DALYs, in which nosocomial 
infections of the newborn are included, highlight the 
crucial importance of being vigilant in infection control 
within hospitals and clinics.
This iteration of GBD estimated diseases and injuries for 
5 year age groups older than 80 years for the first time: 
80–84 years, 85–89 years, 90–94 years, and 95 years and 
older. This addition has provided a clearer picture than 
from previous GBD publications of the burden of disease 
in ageing populations, who are disproportionately affected 
by dementias and other NCDs compared with younger age 
groups. Ageing populations have increased substantially 
in size since 1990. As a result of this population shift and 
the epidemiological transition (which increases the pro­
portion of burden of disease due to NCDs), age groups 
older than 80 years had increases in all­age DALYs between 
 Global Health Metrics
1328 
www.thelancet.com   Vol 390  September 16, 2017
1990 and 2016, with increases across all SDI quintiles. The 
proportion due to NCDs also increased. Therefore, 
research into these age groups and the diseases that 
continue to affect them over time should be prioritised.
Tuberculosis
We made important changes to the modelling strategy for 
tuberculosis in GBD 2016. For fatal tuberculosis, we first 
modelled the prevalence of active disease and latent 
infection, which we then used as covariates for the Cause 
of Death Ensemble model. For non­fatal tuberculosis, we 
strengthened our statistical triangulation approach, which 
enforces consistency between data for different parameters 
by modelling tuberculosis incidence, prevalence, and 
mortality among those with latent infection. Application 
of MIRs estimated on the basis of SDI to better reflect 
incidence in low­income and middle­income countries 
has also enhanced consistency between fatal and non­fatal 
estimates of tuberculosis. All of these changes have 
resulted in global tuberculosis DALYs that are 15% higher 
than in GBD 2015 for the year 2010, with prominent 
increases occurring in several African countries, including 
Uganda, the Central African Republic, and Zambia.
HIV/AIDS
A major HIV methods change for GBD 2016 was the 
distribution of ART coverage by age, sex, and CD4­
positive cell count. We used two AIDS Indicator 
Surveys52,53 to predict the age­sex­CD4 cell distribution of 
ART coverage and applied the distributions to the input 
counts of people receiving ART in our HIV estimation 
model. This method shifted the coverage distribution to 
groups with higher CD4 cell counts, as was seen in the 
data. All of these changes have resulted in higher global 
HIV
/AIDS DALYs than in GBD 2015 for the year 2010, 
with the most prominent increases occurring in several 
African countries, including South Africa, Botswana, 
Lesotho, and Swaziland. We have also systematically 
updated other key input parameters to the HIV
/AIDS 
estimation process, such as the on­ART mortality rate 
and other demographic inputs, including HIV­free 
mortality.
Lower respiratory infection and diarrhoea
Total lower respiratory infection (increased by 0·701%) 
and diarrhoeal disease (increased by 15·5%) DALYs 
increased compared with GBD 2015 estimates for the 
year 2010. Like most CMNN causes, the lower 
respiratory infection and diarrhoeal disease DALY 
burden is due primarily to YLLs; more than 90% of 
global DALYs are from these causes. Several changes 
have been made to the under­5 mortality models that 
have large impacts on the DALY totals for these causes. 
We added several new model covariates on the basis of 
risk factors associated with lower respiratory infections 
and diarrhoeal diseases, including childhood stunting 
and suboptimal breastfeeding. Additionally, because of 
India’s large population size and disease burden, its 
Sample 
Registration 
System 
data 
changed 
the 
magnitude of YLLs. Inclusion of diarrhoeal diseases as 
a fatal discontinuity in YLL estimation also affected the 
overall estimation for GBD 2016. Overall, the YLLs due 
to lower respiratory infections decreased slightly (by 
0·626%) for the year 2010 from GBD 2015 to GBD 2016 
and those due to diarrhoeal diseases increased (by 
14·3%). We believe that these modelling changes 
improved under­5 mortality estimates for lower 
respiratory 
infections 
and 
diarrhoea. 
Although 
responsible for a smaller contribution to DALYs than 
cause of death models, the non­fatal models of lower 
respiratory infections and diarrhoea included new data 
sources and processing. An example is that we now 
account 
for 
seasonality 
from 
the 
population­
representative surveys that provide most prevalence 
data from sub­Saharan Africa and south Asia in the 
lower respiratory infection and diarrhoeal disease 
models. Another major update is a change in the 
estimated mean duration of illness on the basis of a set 
of updated systematic reviews. The duration of diarrhoea 
remained nearly the same as in GBD 2015, but that of 
lower respiratory infection decreased by about 20% 
compared with GBD 2015.
Malaria
Refinements to the methodological approach and 
addition of substantially more data than in GBD 2015 
have led to changes in estimates of both malaria 
mortality and morbidity estimates in the GBD 2016 
iteration, with resulting changes in DALYs. Globally, 
predicted trends in malaria were similar to GBD 2015, 
rising to a peak in 2005 before steadily declining. Overall 
malaria DALYs are lower in GBD 2016 than in GBD 2015, 
reflecting mainly lower estimates outside of Africa and 
particularly for India. Outside of Africa, and for lower­
burden countries within Africa, estimates were informed 
for the first time by extensive subnational case­reporting 
data from routine surveillance systems. These were 
subsequently adjusted to account for under­reporting, 
misdiagnosis, and incompleteness, and then entered 
into a spatiotemporal geostatistical model to infer 
continuous surfaces of incidence rate before re­
aggregating them to national and subnational totals. 
This approach led to notable reductions in estimated 
cases, YLDs, and DALYs in India, Myanmar, Indonesia, 
and Pakistan. In high­burden countries in sub­Saharan 
Africa, where the methods remained similar to GBD 
2015, changes were relatively modest and reflected the 
inclusion of newly available cross­sectional parasite rate 
surveys or updates to data for malaria intervention 
coverage in recent years.
London Declaration diseases
The London Declaration was established in 2012 as a 
partnership of pharmaceutical companies, private 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1329
foundations, and global health organisations, com 
mitted 
to providing resources and expertise for controlling, 
eliminating, or eradicating ten NTDs: human African 
trypanosomiasis, Chagas disease, Guinea worm disease, 
leprosy, lymphatic filariasis, oncho 
cerciasis, schistoso­
miasis, soil­transmitted hel 
minths, blinding trachoma, 
and visceral leishmaniasis.54 With this year’s addition of 
Guinea worm disease to the GBD cause list, we now 
estimate DALYs for all ten of the London Declaration 
diseases and GBD estimates can, therefore, offer insight 
into progress. We estimate that total DALYs from the 
London Declaration NTDs have declined by 21·1% from 
11·4 million (95% UI 6·8 million to 18·5 million) DALYs 
in 2010 before the London Declaration in 2012 to 
9·0 million (5·3 million to 14·5 million) in 2016. 
Moreover, we find that DALY rates have declined for all 
ten of the London Declaration NTDs between 1990 and 
2016, with the largest declines occurring for Guinea 
worm disease, reflecting the particular effectiveness of 
the Guinea worm eradication initiative,55 and for human 
African trypanosomiasis.56
Zika virus disease 
The appearance of Zika virus cases in the Americas in 
2015, along with the reported associations between Zika 
virus infection and microcephaly and Guillain­Barré 
syndrome, led WHO to declare Zika virus a Public Health 
Emergency of International Concern in February 2016.57–59 
We estimated Zika virus disease for GBD 2016 in 
response to this heightened global concern and interest. 
We estimated four non­fatal outcomes of Zika virus 
infection: asympto 
matic infection, symptomatic infec­
tion, Guillain­Barré syndrome caused by Zika virus 
infection, and congenital Zika syndrome. Despite the 
high incidence observed in the Americas in 2016 and 
understandable public concern, especially surrounding 
congenital Zika syndrome, we estimate that less than 
0·01% of Zika virus infections result in Guillain­Barré 
syndrome, congenital Zika syndrome, or death. We 
estimate that 7·60 million (95% UI 5·70 million to 
10·7 million) infections occurred in 2016, resulting in 
2·70 million symptomatic Zika virus cases, 1880 cases 
of Zika­attributable Guillain­Barré syndrome, and 
2400 congenital Zika syndrome births.8 Our estimate for 
congenital Zika syndrome is in line with official reports 
from the Pan American Health Organization of circa 
2500 congenital Zika syndrome births.60 However, those 
born with congenital Zika syndrome will have future 
disability.
Injuries
Global DALYs due to injuries generally contributed to a 
lower proportion of total burden than did those due to 
CMNN diseases and NCDs, and remained relatively 
stable as a proportion of total DALYs over time. Exam­
ination of these trends by SDI quintile, region, and 
cause of injury reveals much more variable patterns 
than the global pattern, which are potentially related to 
a confluence of demographic changes, policy adoption 
and enforcement, access to high­quality trauma care, 
and political stability. Among high­SDI and high­
middle­SDI countries, all­age DALYs due to road 
injuries have substantially declined since 1990, while 
DALYs due to road injuries in low­middle­SDI and low­
SDI countries have risen, a trend that is particularly 
evident in recent years. By contrast, DALYs from 
drowning markedly declined among middle­SDI and 
low­middle­SDI countries. Disease burden from falls 
rose across the development spectrum, a trend prim­
arily driven by population growth and ageing. Finally, 
the consequences of ongoing conflict, particularly in 
north Africa and the Middle East, and interpersonal 
violence, particularly in Latin America, on population 
health cannot be overlooked.61 Fatalities due to such 
conflict and violence have resulted in stagnated or 
decreasing life expectancy in many of these countries,7,62 
and for those who survive, the long­term effects of such 
injuries could easily result in impaired movement 
and functioning, heightened risk of other disorders 
(eg, musculoskeletal conditions), and mental health 
challenges for an extended period after the end of 
the conflict.
Cerebrovascular disease
For GBD 2016, we modelled each stroke subtype 
independently to produce more reliable ratios of ischaemic 
to haemorrhagic stroke than for GBD 2015 and better 
match our independent estimation of subtype­specific 
stroke mortality. We avoided undercounting of stroke by 
reclassifying hospital admissions and deaths ascribed to 
unspecified stroke. Despite this method, haemorrhagic 
stroke remains a heterogeneous category that includes 
neonatal intraventricular haemorrhage and all other non­
traumatic intracranial bleeding. These deaths in children 
younger than 5 years result in many more YLLs, and 
therefore many more DALYs, than from ischaemic stroke. 
Consistent with population­based and multinational 
studies of stroke subtype, GBD estimates higher incidence 
but much lower case fatality and YLLs due to ischaemic 
stroke among adults than due to haemorrhagic stroke.63 
This pattern appears true even for locations where this 
pattern was not previously thought to be the case, such as 
in China.64 Future estimates can be improved by 
production of separate estimates of non­traumatic 
subarachnoid haemorrhage and paediatric stroke.
Mental and substance use disorders
Throughout multiple iterations of GBD, mental and 
substance use disorders have consistently been shown as 
the leading causes of YLDs worldwide, with burden 
present in both sexes across the lifespan. They are also 
strongly associated with premature mortality, although 
this association is not reflected in GBD YLL estimates for 
mental disorders as they are rarely coded as the direct 
 Global Health Metrics
1330 
www.thelancet.com   Vol 390  September 16, 2017
cause of death. Nevertheless, they contribute a substantial 
number of DALYs and this large contribution to burden 
has remained constant across time in all countries, 
including those with high or substantially improving SDI. 
Treatment rates remain very low65–67 and, even in high­
income countries where treatment coverage has increased, 
the prevalence of the most common disorders has not 
changed.68 To reduce the burden of these disorders, 
improved treatment coverage needs to include a focus on 
the quality of the intervention delivered. Additionally, 
identification and quantification of modifiable risk factors 
for mental and substance use disorders are vital for 
development of effective prevention strategies and are an 
area noted for expansion in future iterations of GBD.
Diabetes
We made several important improvements to the process 
of estimation of diabetes prevalence, including use of 
more data sources than GBD 2015 and development of a 
novel approach to standardise the definition of diabetes 
across different sources. In our assessment of diagnostic 
criteria for diabetes across different surveys, we 
identified more than 50 different definitions for diabetes 
based on various biomarkers (eg, fasting plasma glucose 
concentration, oral glucose tolerance test result, and 
glycated haemoglobin A1c concentration) and different 
levels of each biomarker. To standardise the definition of 
diabetes, we mostly focused on the surveys that had 
included fasting plasma glucose concentration as a 
diagnostic criterion and developed an ensemble model 
to characterise the distribution of fasting plasma glucose 
concentration at the population level in each age and sex 
group. Then, we used the fasting plasma glucose 
concentration distribution to convert various definitions 
of diabetes into the standard case definition. Using the 
ensemble model, we also estimated the prevalence of 
diabetes on the basis of the mean fasting plasma glucose 
concentration in places for which we only had data for 
mean fasting plasma glucose concentration. These 
changes allowed us to be more consistent than in GBD 
2015 in our estimation of the prevalence of diabetes 
across countries and over time. As a result, our estimates 
of the prevalence of diabetes globally and in most 
regions are slightly lower than those reported in GBD 
2015. The strong relationship between SDI and 
diabetes remained, mirroring global rises in overweight 
and obesity.69
Cancer
DALYs for cancer have changed compared with 
GBD 2015; this change is predominantly due to lower 
YLD estimates for GBD 2016 than for GBD 2015. These 
improvements stem from adjustments made in the 
modelling of MIRs to better reflect differences in MIR 
based on SDI in data­sparse locations than in GBD 2015. 
In addition to stricter inclusion criteria for data used in 
the MIR modelling than in GBD 2015, we changed the 
modelling approach and used the most parsimonious 
model with just SDI as a predictor of MIR.8 MIRs are 
used to estimate cancer incidence and prevalence from 
GBD cancer mortality estimates and therefore directly 
determine YLDs. Until cancer registry incidence data 
and accurate mortality statistics are widely available, 
validation of MIR is difficult in countries that lack these 
data sources. The Global Initiative for Cancer Registry 
Development and expansion of civil registration systems 
are therefore crucial to further improve estimation of 
cancer burden.
Future directions
Challenging data gaps exist in the severity distributions 
across sequelae for most diseases in the YLD literature. 
Most data sources for severity are from high­income 
countries, which probably leads to an underestimation of 
YLDs in low­income and middle­income countries where 
the severity of presentation of non­fatal illnesses might be 
worse than in high­income countries, frequently as a result 
of late diagnosis and underdiagnosis. Improvements can 
be made if disease­specific research focuses on routine use 
of a single established measure of severity in surveys and 
patient populations and if countries are able to link survey 
data to a general health assessment instrument, along with 
improvements in early diagnosis and treatment procedures 
before illnesses progress to high­severity presentations. 
Although uncertainty and sample variance will persist at 
various levels, gaining of greater geographical information 
on severity of diseases than at present will increase the 
accuracy of GBD models.
Potential is clearly huge for exploration of this work in 
relation to development assistance for health,70,71 as the 
connection between health financing and outcomes needs 
better understanding than at present. Improved under­
standing will probably help identify the reasons why 
certain countries have such an impressive record, whereas 
others are so ineffective with the resources that they have 
available, at all levels of SDI. More precise measurement of 
health burden than at present, across countries and at the 
subnational level, could be tied to health services financing 
and delivery to identify systematic associations and causal 
relationships. Additionally, risk factor data, health outcome 
data, health financing data, and other socioeconomic 
indicators can be combined to measure and assess health 
system performance. Furthermore, a core focus moving 
forward with GBD is to progressively increase the spatial 
resolution at which we implement estimations to help 
realise aspirations in precision public health.72 A key goal 
of a geographically refined DALY, at 5 × 5 km spatial 
resolution—starting with some key CMNN causes and 
under­5 mortality—is part of a long­term aspiration.73
Finally, upcoming GBD work will focus on exploration 
of future health scenarios, examining the likely burden 
of disease under different possible trajectories of 
independent drivers of health. This framework will 
capture the complex past trends and interdependent 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1331
relationships in socioeconomic development, risk 
factors, 
interventions, 
morbidity, 
mortality, 
and 
population to both estimate the likely future burden of 
disease and enable comparison between scenarios based 
on different sets of assumptions. For instance, it can be 
used to analyse the likely effect of the introduction and 
scale­up of a new type of vaccination or different trends 
in funding for ART for HIV
/AIDS. Extension of this 
work through to DALY and HALE analyses is also part of 
these future plans.
To look at cause­deleted HALE would also be valuable so 
that we could understand the remaining DALY burden in 
the absence of diseases and injuries that might be highly 
amenable to preventive or curative measures. Compelling 
examples would include HIV, vaccine­preventable and 
malnutrition­related diseases, a subset of NCDs that are 
particularly amenable to health­care or preventive 
measures (eg, tobacco­related or alcohol­related or some 
congenital birth defects), and injuries (eg, firearms or 
transport injuries). This approach would not be fully 
counterfactual, but would be a first and more rigorous way 
of showing what conditions contributed to the changes in 
HALE from 1990 (or 2006) to 2016 than was possible in 
this study.
Limitations
Despite our continued methodological advancements and 
data enrichments, this study has limitations. First, all 
limitations documented in the elements of the GBD 
estimation process that allow for DALY and HALE 
estimation2–4,12 will contribute to uncertainty in these 
summary measures. Second, these summary measures 
will also be influenced by data availability. Time lags in the 
reporting of health information by national authorities 
and thus their subsequent incorporation into the GBD 
estimation mean that some of the most recent changes in 
health states will not be captured. Relatedly, data 
deficiencies from populations in conflict zones (eg, 
Syria, Iraq, Yemen, South Sudan, and Afghanistan), 
autonomous subnational regions, and certain non­
geographically based subpopulations (ie, migrants, 
refugees, and some indigenous people) limit the precision 
of some of our estimated levels and trends of disease 
burden.74 Third, the relationship between DALYs, HALE, 
and SDI, although explanatory, cannot be viewed as 
causal. Fourth, a non­trivial assumption of the analyses is 
the independence of the uncertainty calculated for YLLs 
and YLDs. Because of the link between death and 
prevalence, a positive correlation probably exists between 
these uncertainties that we do not capture. As such, we 
probably underestimate the aggregated uncertainty for 
DALYs, although the primary source of uncertainty for 
DALYs comes from uncertainty in disability weights, 
which are unaffected by this limitation. In future iterations 
of GBD, this potential correlation will be explored 
using copula, a statistical method that models the 
dependence structure among multiple independent 
marginal probability distributions to estimate correlation 
between them.75
Conclusion
Many improvements have been made to GBD 2016 to 
allow for a clearer and more nuanced picture of the 
changing picture of global health than in GBD 2015. 
Among these improvements are inclusion of new studies 
and subnational data (notably in India) and many 
substantial improvements to modelling and analyses. 
Prominent results of these changes include higher global 
DALY estimates for tuberculosis, HIV
/AIDS, lower 
respiratory infection, and diarrhoeal disease than in GBD 
2015. We have for the first time discussed our DALY 
exemplars, countries with the lowest ratio of observed to 
expected DALYs, as well as our poor performers, those 
with the largest ratio of observed to expected DALYs. 
These exemplars and poor performers suggest a need to 
learn lessons from those with clear health gains and 
implement system­based strategies for those struggling. 
This analysis and increasingly more detailed results will 
allow for more informed public policy and health 
financing decisions as the world faces an absolute 
expansion of morbidity.
Globally, individuals could expect to live substantially 
longer lives in 2016 than they could in 1990. This 
improvement was due to a rapid decline in YLLs and 
more modest age­standardised declines in YLDs, leading 
to lower age­standardised DALY rates across the entire 
socioeconomic development spectrum in 2016 than in 
1990, with a decrease of approximately a third for all 
causes. At the same time, populations can expect to spend 
more time with functional health loss due to absolute 
morbidity expansion than previously. Such improvements 
have been accompanied by rapid population growth and 
ageing and, against the backdrop of the epidemiological 
transition, have resulted in the paradox of a total 
expansion in DALY burden and thus an ever­increasing 
demand on health systems, domestic health financing, 
development assistance for health, and associated global 
health organisations. This increasing demand on health 
systems is ubiquitous across time, location, GBD region, 
and SDI, posing a huge opportunity for health­care 
innovators in prevention and treatment for morbidity 
reduction. Our analysis of exemplars and poor performers 
is also indicative of various practices that can hasten or 
slow the epidemiological transition and warrant deep 
investigation.
GBD 2016 DALYs and HALE Collaborators 
Simon I Hay, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, 
Cristiana Abbafati, Kaja M Abbas, Foad Abd­Allah, 
Abdishakur M Abdulle, Teshome Abuka Abebo, Semaw Ferede Abera, 
Victor Aboyans, Laith J Abu­Raddad, Ilana N Ackerman, 
Isaac A Adedeji, Olatunji Adetokunboh, Ashkan Afshin, 
Rakesh Aggarwal, Sutapa Agrawal, Anurag Agrawal, 
Aliasghar Ahmad Kiadaliri, Muktar Beshir Ahmed, 
Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, 
Sneha Aiyar, Tomi F Akinyemiju, Nadia Akseer, Faris Hasan Al Lami, 
 Global Health Metrics
1332 
www.thelancet.com   Vol 390  September 16, 2017
Fares Alahdab, Ziyad Al­Aly, Khurshid Alam, Noore Alam, 
Tahiya Alam, Deena Alasfoor, Kefyalew Addis Alene, Raghib Ali, 
Reza Alizadeh­Navaei, Juma M Alkaabi, Ala’a Alkerwi, François Alla, 
Peter Allebeck, Christine Allen, Fatma Al­Maskari, 
Mohammad AbdulAziz AlMazroa, Rajaa Al­Raddadi, Ubai Alsharif, 
Shirina Alsowaidi, Benjamin M Althouse, Khalid A Altirkawi, 
Nelson Alvis­Guzman, Azmeraw T Amare, Erfan Amini, 
Walid Ammar, Yaw Ampem Amoako, Mustafa Geleto Ansha, 
Carl Abelardo T Antonio, Palwasha Anwari, Johan Ärnlöv, 
Megha Arora, Al Artaman, Krishna Kumar Aryal, 
Solomon W Asgedom, Tesfay Mehari Atey, Niguse Tadele Atnafu, 
Leticia Avila­Burgos, Euripide Frinel G Arthur Avokpaho, 
Ashish Awasthi, Shally Awasthi, Beatriz Paulina Ayala Quintanilla, 
Mahmoud Reza Azarpazhooh, Peter Azzopardi, 
Tesleem Kayode Babalola, Umar Bacha, Alaa Badawi, 
Kalpana Balakrishnan, Marlena S Bannick, Aleksandra Barac, 
Suzanne L Barker­Collo, Till Bärnighausen, Simon Barquera, 
Lope H Barrero, Sanjay Basu, Robert Battista, Katherine E Battle, 
Bernhard T Baune, Shahrzad Bazargan­Hejazi, Justin Beardsley, 
Neeraj Bedi, Yannick Béjot, Bayu Begashaw Bekele, Michelle L Bell, 
Derrick A Bennett, James R Bennett, Isabela M Bensenor, 
Jennifer Benson, Adugnaw Berhane, Derbew Fikadu Berhe, 
Eduardo Bernabé, Balem Demtsu Betsu, Mircea Beuran, 
Addisu Shunu Beyene, Anil Bhansali, Samir Bhatt, Zulfiqar A Bhutta, 
Sibhatu Biadgilign, Kelly Bienhoff, Boris Bikbov, Charles Birungi, 
Stan Biryukov, Donal Bisanzio, Habtamu Mellie Bizuayehu, 
Fiona M Blyth, Dube Jara Boneya, Dipan Bose, Ibrahim R Bou­Orm, 
Rupert R A Bourne, Michael Brainin, Carol E G Brayne, 
Alexandra Brazinova, Nicholas J K Breitborde, Paul S Briant, 
Gabrielle Britton, Traolach S Brugha, Rachelle Buchbinder, 
Lemma Negesa Bulto Bulto, Blair Bumgarner, Zahid A Butt, 
Lucero Cahuana­Hurtado, Ewan Cameron, 
Ismael Ricardo Campos­Nonato, Hélène Carabin, Rosario Cárdenas, 
David O Carpenter, Juan Jesus Carrero, Austin Carter, Felix Carvalho, 
Daniel Casey, Carlos A Castañeda­Orjuela, Jacqueline Castillo Rivas, 
Chris D Castle, Ferrán Catalá­López, Jung­Chen Chang, 
Fiona J Charlson, Pankaj Chaturvedi, Honglei Chen, 
Mirriam Chibalabala, Chioma Ezinne Chibueze, 
Vesper Hichilombwe Chisumpa, Abdulaal A Chitheer, 
Rajiv Chowdhury, Devasahayam Jesudas Christopher, 
Liliana G Ciobanu, Massimo Cirillo, Danny Colombara, 
Leslie Trumbull Cooper, Cyrus Cooper, Paolo Angelo Cortesi, 
Monica Cortinovis, Michael H Criqui, Elizabeth A Cromwell, 
Marita Cross, John A Crump, Abel Fekadu Dadi, Koustuv Dalal, 
Albertino Damasceno, Lalit Dandona, Rakhi Dandona, José das Neves, 
Dragos V Davitoiu, Kairat Davletov, Barbora de Courten, Diego De Leo, 
Hans De Steur, Louisa Degenhardt, Selina Deiparine, 
Robert P Dellavalle, Kebede Deribe, Amare Deribew, Don C Des Jarlais, 
Subhojit Dey, Samath D Dharmaratne, Preet K Dhillon, Daniel Dicker, 
Shirin Djalalinia, Huyen Phuc Do, Klara Dokova, David Teye Doku, 
E Ray Dorsey, Kadine Priscila Bender dos Santos, Tim R Driscoll, 
Manisha Dubey, Bruce Bartholow Duncan, Beth E Ebel, 
Michelle Echko, Ziad Ziad El­Khatib, Ahmadali Enayati, 
Aman Yesuf Endries, Sergey Petrovich Ermakov, Holly E Erskine, 
Setegn Eshetie, Babak Eshrati, Alireza Esteghamati, Kara Estep, 
Fanuel Belayneh Bekele Fanuel, Tamer Farag, Carla Sofia e Sa Farinha, 
André Faro, Farshad Farzadfar, Mir Sohail Fazeli, Valery L Feigin, 
Andrea B Feigl, Seyed­Mohammad Fereshtehnejad, João C Fernandes, 
Alize J Ferrari, Tesfaye Regassa Feyissa, Irina Filip, Florian Fischer, 
Christina Fitzmaurice, Abraham D Flaxman, Nataliya Foigt, 
Kyle J Foreman, Richard C Franklin, Joseph J Frostad, Nancy Fullman, 
Thomas Fürst, Joao M Furtado, Neal D Futran, Emmanuela Gakidou, 
Alberto L Garcia­Basteiro, Teshome Gebre, 
Gebremedhin Berhe Gebregergs, Tsegaye Tewelde Gebrehiwot, 
Johanna M Geleijnse, Ayele Geleto, Bikila Lencha Gemechu, 
Hailay Abrha Gesesew, Peter W Gething, Alireza Ghajar, 
Katherine B Gibney, Richard F Gillum, 
Ibrahim Abdelmageem Mohamed Ginawi, Melkamu Dedefo Gishu, 
Giorgia Giussani, William W Godwin, Kashish Goel, Shifalika Goenka, 
Ellen M Goldberg, Philimon N Gona, Amador Goodridge, 
Sameer Vali Gopalani, Richard A Gosselin, Carolyn C Gotay, 
Atsushi Goto, Alessandra Carvalho Goulart, Nicholas Graetz, 
Harish Chander Gugnani, Rajeev Gupta, Prakash C Gupta, 
Tanush Gupta, Vipin Gupta, Rahul Gupta, Reyna A Gutiérrez, 
Vladimir Hachinski, Nima Hafezi­Nejad, Alemayehu Desalegne Hailu, 
Gessessew Bugssa Hailu, Randah Ribhi Hamadeh, Samer Hamidi, 
Mouhanad Hammami, Alexis J Handal, Graeme J Hankey, 
Yuantao Hao, Hilda L Harb, Habtamu Abera Hareri, Josep Maria Haro, 
Kimani M Harun, James Harvey, Mohammad Sadegh Hassanvand, 
Rasmus Havmoeller, Roderick J Hay, Mohammad T Hedayati, 
Delia Hendrie, Nathaniel J Henry, Ileana Beatriz Heredia­Pi, 
Pouria Heydarpour, Hans W Hoek, Howard J Hoffman, 
Masako Horino, Nobuyuki Horita, H Dean Hosgood, Sorin Hostiuc, 
Peter J Hotez, Damian G Hoy, Aung Soe Htet, Guoqing Hu, 
John J Huang, Chantal Huynh, Kim Moesgaard Iburg, 
Ehimario Uche Igumbor, Chad Ikeda, Caleb Mackay Salpeter Irvine, 
Kathryn H Jacobsen, Nader Jahanmehr, Mihajlo B Jakovljevic, 
Peter James, Simerjot K Jassal, Mehdi Javanbakht, Sudha P Jayaraman, 
Panniyammakal Jeemon, Paul N Jensen, Vivekanand Jha, 
Guohong Jiang, Denny John, Catherine O Johnson, 
Sarah Charlotte Johnson, Jost B Jonas, Mikk Jürisson, Zubair Kabir, 
Rajendra Kadel, Amaha Kahsay, Ritul Kamal, Chittaranjan Kar, 
Nadim E Karam, André Karch, Corine Kakizi Karema, Seyed M Karimi, 
Chante Karimkhani, Amir Kasaeian, Getachew Mullu Kassa, 
Nicholas J Kassebaum, Nigussie Assefa Kassaw, Anshul Kastor, 
Srinivasa Vittal Katikireddi, Anil Kaul, Norito Kawakami, 
Peter Njenga Keiyoro, Laura Kemmer, Andre Pascal Kengne, 
Andre Keren, Chandrasekharan Nair Kesavachandran, 
Yousef Saleh Khader, Ibrahim A Khalil, Ejaz Ahmad Khan, 
Young­Ho Khang, Abdullah T Khoja, Ardeshir Khosravi, 
Jagdish Khubchandani, Christian Kieling, Yun Jin Kim, Daniel Kim, 
Ruth W Kimokoti, Yohannes Kinfu, Adnan Kisa, 
Katarzyna A Kissimova­Skarbek, Niranjan Kissoon, Mika Kivimaki, 
Ann Kristin Knudsen, Yoshihiro Kokubo, Dhaval Kolte, Jacek A Kopec, 
Soewarta Kosen, Georgios A Kotsakis, Parvaiz A Koul, Ai Koyanagi, 
Michael Kravchenko, Kristopher J Krohn, Barthelemy Kuate Defo, 
Burcu Kucuk Bicer, G Anil Kumar, Pushpendra Kumar, Hmwe H Kyu, 
Anton Carl Jonas Lager, Dharmesh Kumar Lal, Ratilal Lalloo, 
Tea Lallukka, Nkurunziza Lambert, Qing Lan, Van C Lansingh, 
Anders Larsson, Janet L Leasher, Paul H Lee, James Leigh, 
Cheru Tesema Leshargie, Janni Leung, Ricky Leung, Miriam Levi, 
Yichong Li, Yongmei Li, Xiaofeng Liang, Misgan Legesse Liben, 
Stephen S Lim, Shai Linn, Angela Liu, Patrick Y Liu, Shiwei Liu, 
Yang Liu, Rakesh Lodha, Giancarlo Logroscino, Katharine J Looker, 
Alan D Lopez, Stefan Lorkowski, Paulo A Lotufo, Rafael Lozano, 
Timothy C D Lucas, Raimundas Lunevicius, Ronan A Lyons, 
Erlyn Rachelle King Macarayan, Emilie R Maddison, 
Hassan Magdy Abd El Razek, Mohammed Magdy Abd El Razek, 
Carlos Magis­Rodriguez, Mahdi Mahdavi, Marek Majdan, 
Reza Majdzadeh, Azeem Majeed, Reza Malekzadeh, Rajesh Malhotra, 
Deborah Carvalho Malta, Abdullah A Mamun, Helena Manguerra, 
Treh Manhertz, Lorenzo G Mantovani, Chabila C Mapoma, 
Lyn M March, Laurie B Marczak, Jose Martinez­Raga, Paulo Henrique 
Viegas Martins, Francisco Rogerlândio Martins­Melo, Ira Martopullo, 
Winfried März, Manu Raj Mathur, Mohsen Mazidi, Colm McAlinden, 
Madeline McGaughey, John J McGrath, Martin McKee, Suresh Mehata, 
Toni Meier, Kidanu Gebremariam Meles, Peter Memiah, 
Ziad A Memish, Walter Mendoza, Melkamu Merid Mengesha, 
Mubarek Abera Mengistie, Desalegn Tadese Mengistu, 
George A Mensah, Atte Meretoja, Tuomo J Meretoja, 
Haftay Berhane Mezgebe, Renata Micha, Anoushka Millear, 
Ted R Miller, Shawn Minnig, Mojde Mirarefin, Erkin M Mirrakhimov, 
Awoke Misganaw, Shiva Raj Mishra, Philip B Mitchell, 
Karzan Abdulmuhsin Mohammad, Alireza Mohammadi, 
Shafiu Mohammed, Kedir Endris Mohammed, 
Muktar Sano Kedir Mohammed, Murali B V Mohan, Ali H Mokdad, 
Sarah K Mollenkopf, Lorenzo Monasta, 
Julio Cesar Montañez Hernandez, Marcella Montico, 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1333
Maziar Moradi­Lakeh, Paula Moraga, Lidia Morawska, Rintaro Mori, 
Shane D Morrison, Mark Moses, Cliff Mountjoy­Venning, 
Kalayu Birhane Mruts, Ulrich O Mueller, Kate Muller, 
Michele E Mudoch, Srinivas Murthy, 
Gudlavalleti Venkata Satyanarayana Murthy, Kamarul Imran Musa, 
Jean B Nachega, Gabriele Nagel, Mohsen Naghavi, Aliya Naheed, 
Kovin S Naidoo, Vinay Nangia, Jamal T Nasher, 
Gopalakrishnan Natarajan, Dumessa Edessa Negasa, Ionut Negoi, 
Ruxandra Irina Negoi, Charles R Newton, Josephine Wanjiku Ngunjiri, 
Cuong Tat Nguyen, Quyen Le Nguyen, 
Grant Nguyen, Trang Huyen Nguyen, Minh Nguyen, Emma Nichols, 
Dina Nur Anggraini Ningrum, Vuong Minh Nong, Ole F Norheim, 
Bo Norrving, Jean Jacques N Noubiap, Alypio Nyandwi, Carla 
Makhlouf Obermeyer, Martin J O’Donnell, Felix Akpojene Ogbo, 
In­Hwan Oh, Anselm Okoro, Olanrewaju Oladimeji, 
Andrew Toyin Olagunju, Tinuke Oluwasefunmi Olagunju, 
Helen E Olsen, Bolajoko Olubukunola Olusanya, 
Jacob Olusegun Olusanya, Kanyin Ong, John Nelson Opio, Eyal Oren, 
Alberto Ortiz, Richard H Osborne, Aaron Osgood­Zimmerman, 
Majdi Osman, Erika Ota, Mayowa O Owolabi, Mahesh PA, 
Rosana E Pacella, Basant Kumar Panda, Jeyaraj D Pandian, 
Christina Papachristou, Eun­Kee Park, Charles D Parry, 
Mahboubeh Parsaeian, Snehal T Patil, Scott B Patten, George C Patton, 
Deepak Paudel, Katherine Paulson, Neil Pearce, David M Pereira, 
Krystle Marie Perez, Norberto Perico, Konrad Pesudovs, 
Carrie Beth Peterson, William Arthur Petri, Max Petzold, 
Michael Robert Phillips, Geoffrey Phipps, David M Pigott, 
Julian David Pillay, Christine Pinho, Michael A Piradov, Dietrich Plass, 
Martin A Pletcher, Svetlana Popova, Richie G Poulton, 
Farshad Pourmalek, Dorairaj Prabhakaran, Narayan Prasad, 
Carrie Purcell, Manorama Purwar, Mostafa Qorbani, 
Rynaz H S Rabiee, Amir Radfar, Anwar Rafay, Kazem Rahimi, 
Afarin Rahimi­Movaghar, Vafa Rahimi­Movaghar, Mahfuzar Rahman, 
Muhammad Aziz Rahman, Mohammad Hifz Ur Rahman, 
Rajesh Kumar Rai, Sasa Rajsic, Usha Ram, Chhabi Lal Ranabhat, 
Thara Rangaswamy, Zane Rankin, Paturi Vishnupriya Rao, Puja C Rao, 
Salman Rawaf, Sarah E Ray, Robert C Reiner, Nikolas Reinig, 
Marissa Reitsma, Giuseppe Remuzzi, Andre M N Renzaho, 
Serge Resnikoff, Satar Rezaei, Antonio L Ribeiro, Hirbo Shore Roba, 
Stephen R Robinson, David Rojas­Rueda, Mohammad Bagher Rokni, 
Luca Ronfani, Gholamreza Roshandel, Gregory A Roth, 
Dietrich Rothenbacher, Ambuj Roy, Enrico Rubagotti, 
George Mugambage Ruhago, Soheil Saadat, Mahdi Safdarian, 
Saeid Safiri, Rajesh Sagar, Ramesh Sahathevan, 
Mohammad Ali Sahraian, Joseph Salama, 
Muhammad Muhammad Saleh, Joshua A Salomon, 
Sundeep Santosh Salvi, Abdallah M Samy, Juan Ramon Sanabria, 
Maria Dolores Sanchez­Niño, Damian Santomauro, João Vasco Santos, 
Itamar S Santos, Milena M Santric Milicevic, Benn Sartorius, 
Maheswar Satpathy, Monika Sawhney, Sonia Saxena, 
Kathryn Schelonka, Maria Inês Schmidt, Ione J C Schneider, 
Ben Schöttker, Aletta E Schutte, David C Schwebel, Falk Schwendicke, 
Soraya Seedat, Sadaf G Sepanlou, Edson E Servan­Mori, 
Amira Shaheen, Masood Ali Shaikh, Mansour Shamsipour, 
Sheikh Mohammed Shariful Islam, Rajesh Sharma, Jayendra Sharma, 
Jun She, Peilin Shi, Kenji Shibuya, Chloe Shields, 
Mekonnen Sisay Shiferaw, Mika Shigematsu, Rahman Shiri, 
Reza Shirkoohi, Shreya Shirude, Kawkab Shishani, Haitham Shoman, 
Soraya Siabani, Abla Mehio Sibai, Inga Dora Sigfusdottir, 
Donald H Silberberg, João Pedro Silva, Diego Augusto Santos Silva, 
Dayane Gabriele Alves Silveira, Jasvinder A Singh, Virendra Singh, 
Om Prakash Singh, Narinder Pal Singh, Dhirendra Narain Sinha, 
Eirini Skiadaresi, Vegard Skirbekk, Erica Leigh Slepak, David L Smith, 
Mari Smith, Badr H A Sobaih, Eugene Sobngwi, Michael Soljak, 
Reed J D Sorensen, Tatiane Cristina Moraes Sousa, Luciano A Sposato, 
Chandrashekhar T Sreeramareddy, Vinay Srinivasan, 
Jeffrey D Stanaway, Vasiliki Stathopoulou, Nicholas Steel, Dan J Stein, 
Caitlyn Steiner, Sabine Steinke, Mark Andrew Stokes, 
Lars Jacob Stovner, Bryan Strub, Michelle Subart, 
Muawiyyah Babale Sufiyan, Rizwan Suliankatchi Abdulkader, 
Bruno F Sunguya, Patrick J Sur, Soumya Swaminathan, Bryan L Sykes, 
Dillon Sylte, Cassandra E I Szoeke, Rafael Tabarés­Seisdedos, 
Santosh Kumar Tadakamadla, Getachew Redae Taffere, Jukka S Takala, 
Nikhil Tandon, David Tanne, Yihunie L Tarekegn, 
Mohammad Tavakkoli, Nuno Taveira, Hugh R Taylor, 
Teketo Kassaw Tegegne, Arash Tehrani­Banihashemi, 
Tesfalidet Tekelab, Girma Temam Shifa, Abdullah Sulieman Terkawi, 
Dawit Jember Tesfaye, Belay Tesssema, JS Thakur, 
Ornwipa Thamsuwan, Alice M Theadom, Andrew M Theis, 
Katie E Thomas, Nihal Thomas, Robert Thompson, Amanda G Thrift, 
Ruoyan Tobe­Gai, Myriam Tobollik, Marcello Tonelli, 
Roman Topor­Madry, Miguel Tortajada, Mathilde Touvier, 
Jefferson Traebert, Bach Xuan Tran, Christopher Troeger, Thomas 
Truelsen, Derrick Tsoi, Emin Murat Tuzcu, Hayley Tymeson, 
Stefanos Tyrovolas, Kingsley Nnanna Ukwaja, Eduardo A Undurraga, 
Chigozie Jesse Uneke, Rachel Updike, Olalekan A Uthman, 
Benjamin S Chudi Uzochukwu, Job F M van Boven, 
Santosh Varughese, Tommi Vasankari, Lennert J Veerman, 
S Venkatesh, Narayanaswamy Venketasubramanian, 
Ramesh Vidavalur, Lakshmi Vijayakumar, Francesco S Violante, 
Abhishek Vishnu, Sergey K Vladimirov, Vasiliy Victorovich Vlassov, 
Stein Emil Vollset, Theo Vos, Fiseha Wadilo, Tolassa Wakayo, 
Mitchell T Wallin, Yuan­Pang Wang, Scott Weichenthal, 
Elisabete Weiderpass, Robert G Weintraub, 
Daniel J Weiss, Andrea Werdecker, Ronny Westerman, 
Harvey A Whiteford, Tissa Wijeratne, Hywel C Williams, 
Charles Shey Wiysonge, Belete Getahun Woldeyes, Charles D A Wolfe, 
Rachel Woodbrook, Anthony D Woolf, Abdulhalik Workicho, 
Denis Xavier, Gelin Xu, Simon Yadgir, Mohsen Yaghoubi, 
Bereket Yakob, Lijing L Yan, Yuichiro Yano, Pengpeng Ye, 
Mahari Gidey Yihdego, Hassen Hamid Yimam, Paul Yip, 
Naohiro Yonemoto, Seok­Jun Yoon, Marcel Yotebieng, 
Mustafa Z Younis, Chuanhua Yu, Zoubida Zaidi, 
Maysaa El Sayed Zaki, Elias Asfaw Zegeye, 
Zerihun Menlkalew Zenebe, Xueying Zhang, Yingfeng Zheng, 
Maigeng Zhou, Ben Zipkin, Sanjay Zodpey, Leo Zoeckler, 
Liesl Joanna Zuhlke, Christopher J L Murray.
Affiliations
Institute for Health Metrics and Evaluation (Prof S I Hay DSc, 
A Afshin MD, S Aiyar, T Alam MPH, C Allen BA, M Arora BSA, 
M S Bannick BS, J R Bennett BA, K Bienhoff MA, S Biryukov BS, 
P S Briant BS, B Bumgarner MBA, A Carter BS, D Casey MPH, 
C D Castle BA, F J Charlson PhD, D Colombara MPH, 
E A Cromwell PhD, Prof L Dandona MD, Prof R Dandona PhD, 
Prof L Degenhardt PhD, S Deiparine, D Dicker BS, M Echko BSc, 
H E Erskine PhD, K Estep MPA, T Farag PhD, A J Ferrari PhD, 
C Fitzmaurice MD, A D Flaxman PhD, K J Foreman PhD, 
J J Frostad MPH, N Fullman MPH, E Gakidou PhD, W W Godwin BS, 
E M Goldberg BS, N Graetz MPH, J Harvey BS, N J Henry BS/BA, 
C Huynh BA, C Ikeda BS, C M S Irvine BA, C O Johnson PhD, 
S C Johnson MSc, N J Kassebaum MD, L Kemmer PhD, 
I A Khalil MD, K J Krohn BA, H H Kyu PhD, Prof S S Lim PhD, 
P Y Liu MPH, A Liu BS, E R Maddison BS, H Manguerra BS, 
T Manhertz BA, L B Marczak PhD, I Martopullo MPH, 
M McGaughey BA, A Millear BA, S Minnig MS, M Mirarefin MPH, 
A Misganaw PhD, A H Mokdad PhD, S K Mollenkopf, M Moses MHS, 
K Muller MPH, Prof M Naghavi PhD, C Mountjoy­Venning BA, 
G Nguyen MPH, M Nguyen BS, E Nichols BA, H E Olson MA, 
K Ong PhD, A Osgood­Zimmerman MS, K Paulson BS, 
G Phipps PhD, D M Pigott DPhil, C Pinho BA, M Pletcher BS, 
C Purcell BS, Z Rankin MPH, P C Rao MPH, S E Ray BS, 
R C Reiner PhD, N Reinig BS, M B Reitsma BS, G A Roth MD, 
J Salama MSc, D Santomauro PhD, K Schelonka BA, C Shields BS, 
S Shirude MPH, E L Slepak MLIS, D L Smith PhD, M Smith MPA, 
R J D Sorensen MPH, V Srinivasan BA, J D Stanaway PhD, 
C Steiner MPH, B Strub BS, M Subart BA, P J Sur BA, D Sylte BA, 
O Thamsuwan PhD, A M Theis BA, K E Thomas PhD, 
R Thompson PhD, C Troeger MPH, D Tsoi BS, H Tymeson BA, 
 Global Health Metrics
1334 
www.thelancet.com   Vol 390  September 16, 2017
R Updike AB, Prof S E Vollset DrPH, T Vos PhD, 
Prof H A Whiteford PhD, R Woodbrook MLIS, S Yadgir BS, 
Prof M Zhou PhD, B Zipkin BA, L Zoeckler BA, 
Prof C J L Murray DPhil), Harborview Injury Prevention and Research 
Center (B E Ebel MD), Division of Hematology, Department of 
Medicine (C Fitzmaurice MD), Center for Health Trends and Forecasts, 
Institute for Health Metrics and Evaluation (Prof M B Jakovljevic PhD), 
School of Dentistry (G A Kotsakis DDS), University of Washington, 
Seattle, WA, USA (B M Althouse PhD, N D Futran MD, 
K M Harun MPH, P N Jensen PhD, J Leung PhD, S D Morrison MD, 
K M Perez MD); Oxford Big Data Institute, Li Ka Shing Centre for 
Health Information and Discovery (K E Battle DPhil, D Bisanzio PhD, 
E Cameron PhD, P W Gething PhD, Prof S I Hay DSc, 
T C D Lucas PhD, D J Weiss PhD), Nuffield Department of Population 
Health (D A Bennett PhD), Nuffield Department of Medicine 
(D Bisanzio PhD, A Deribew PhD), NIHR Musculoskeletal Biomedical 
Research Centre (Prof C Cooper MD), University of Oxford, Oxford, 
UK (R Ali MSc, Prof V Jha DM, K Rahimi DM); School of Public 
Health (A A Abajobir MPH, F J Charlson PhD, H E Erskine PhD, 
A J Ferrari PhD, J Leung PhD, D Santomauro PhD, L J Veerman PhD, 
Prof H A Whiteford PhD), School of Dentistry (Prof R Lalloo PhD), 
University of Queensland, Brisbane, QLD, Australia 
(S R Mishra MPH); Department of Epidemiology, College of Health 
Sciences (M B Ahmed MPH), Jimma University, Jimma, Ethiopia 
(K H Abate MS, T T Gebrehiwot MPH, H A Gesesew MPH, 
M A Mengistie MS, T Wakayo MS, A Workicho MPH); La Sapienza 
University, Rome, Italy (C Abbafati PhD); Virginia Tech, Blacksburg, 
VA, USA (Prof K M Abbas PhD); Department of Neurology, Cairo 
University, Cairo, Egypt (Prof F Abd­Allah MD); New York University 
Abu Dhabi, Abu Dhabi, United Arab Emirates (A M Abdulle PhD); 
Hawassa University College of Medicine and Health Sciences, 
Hawassa, Ethiopia (T A Abebo MPH, D J Tesfaye MPH); School of 
Public Health (S F Abera MSc, G B Gebregergs MPH, 
K G Meles MPH, G R Taffere PhD), School of Pharmacy 
(D F Berhe MS), College of Health Sciences (D T Mengistu MS, 
K E Mohammed MPH), Mekelle University, Mekelle, Ethiopia 
(S W Asgedom PhD, T M Atey MS, B D Betsu MS, G B Hailu MSc, 
A Kahsay MPH, H B Mezgebe MS, Z M Zenebe MS); Food Security 
and Institute for Biological Chemistry and Nutrition, University of 
Hohenheim, Stuttgart, Germany (S F Abera MSc); Dupuytren 
University Hospital, Limoges, France (Prof V Aboyans PhD); Infectious 
Disease Epidemiology Group, Weill Cornell Medical College in Qatar, 
Doha, Qatar (L J Abu­Raddad PhD); Department of Epidemiology and 
Preventive Medicine, School of Public Health and Preventive Medicine 
(I N Ackerman PhD, Prof R Buchbinder PhD), Department of 
Medicine, School of Clinical Sciences at Monash Health 
(Prof A G Thrift PhD), Monash University, Melbourne, VIC, 
Australia (Prof B de Courten PhD); Department of Psychiatry 
(Prof C D Parry PhD), Stellenbosch University, Cape Town, South 
Africa (O Adetokunboh MD, Prof J B Nachega PhD, 
Prof S Seedat PhD, Prof C S Wiysonge PhD); Olabisi Onabanjo 
University, Ago­Iwoye, Nigeria (I A Adedji MS); Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, Lucknow, India 
(Prof R Aggarwal MD); Centre for Control of Chronic Conditions 
(P Jeemon PhD), Public Health Foundation of India, Gurugram, India 
(S Agrawal PhD, Prof L Dandona MD, Prof R Dandona PhD, 
P K Dhillon PhD, S Goenka PhD, G A Kumar PhD, D K Lal MD, 
M R Mathur PhD, Prof S Zodpey PhD); CSIR ­ Institute of Genomics 
and Integrative Biology, Delhi, India (A Agrawal PhD); Department of 
Internal Medicine, Baylor College of Medicine, Houston, TX, USA 
(A Agrawal PhD); Department of Clinical Sciences Lund, Orthopedics, 
Clinical Epidemiology Unit (A Ahmad Kiadaliri PhD), Skane 
University Hospital, Department of Clinical Sciences Lund, Neurology 
(Prof B Norrving PhD), Lund University, Lund, Sweden; University 
Ferhat Abbas of Setif, Setif, Algeria (A N Aichour BS); National 
Institute of Nursing Education, Setif, Algeria (I Aichour MS); High 
National School of Veterinary Medicine, Algiers, Algeria 
(M T Aichour MD); Department of Epidemiology 
(T F Akinyemiju PhD), University of Alabama at Birmingham, 
Birmingham, AL, USA (D C Schwebel PhD, J A Singh MD); Centre for 
Global Child Health, The Hospital for Sick Children, Toronto, ON, 
Canada (N Akseer MSc, Z A Bhutta PhD); Dalla Lana School of Public 
Health (N Akseer MSc), Department of Nutritional Sciences, Faculty of 
Medicine (A Badawi PhD), Centre for Addiction and Mental Health 
(S Popova PhD), University of Toronto, Toronto, ON, Canada; Baghdad 
College of Medicine, Baghdad, Iraq (F H Al Lami PhD); Mayo Clinic 
Foundation for Medical Education and Research, Rochester, MN, USA 
(F Alahdab MD); Syrian American Medical Society, Washington, DC, 
USA (F Alahdab MD); Washington University in St Louis, St Louis, 
MO, USA (Z Al­Aly MD); Murdoch Childrens Research Institute 
(K Alam PhD, P Azzopardi PhD, Prof G C Patton MD, 
R G Weintraub MBBS), Department of Paediatrics (P Azzopardi PhD), 
Melbourne School of Population and Global Health 
(Prof A D Lopez PhD), Department of Medicine (A Meretoja PhD), 
Institute of Health and Ageing (Prof C E I Szoeke PhD), Center for 
Youth Mental Health (L Vijayakumar PhD), The University of 
Melbourne, Melbourne, VIC, Australia (K Alam PhD, 
M A Rahman PhD, Prof H R Taylor AC, Prof T Wijeratne MD); Sydney 
School of Public Health (Prof T R Driscoll PhD), The University of 
Sydney, Sydney, NSW, Australia (K Alam PhD, F M Blyth PhD, M 
Cross PhD, J Leigh PhD, Prof L M March PhD); Department of Health, 
Queensland, Brisbane, QLD, Australia (N Alam MAppEpid); Ministry 
of Health, Al Khuwair, Oman (D Alasfoor MSc); Department of 
Epidemiology and Biostatistics, Institute of Public Health 
(K A Alene MPH), College of Medical and Health Sciences 
(B B Bekele PhD), University of Gondar, Gondar, Ethiopia 
(Prof A F Dadi MPH, S Eshetie MS, B Tesssema PhD); Department of 
Global Health, Research School of Population Health, Australian 
National University, Canberra, ACT, Australia (K A Alene MPH); 
Gastrointestinal Cancer Research Center (R Alizadeh­Navaei PhD), 
Department of Medical Mycology and Parasitology, School of Medicine 
(Prof M T Hedayati PhD), Mazandaran University of Medical Sciences, 
Sari, Iran; College of Medicine and Health Sciences, United Arab 
Emirates University, Al Ain, United Arab Emirates (J M Alkaabi MD, 
Prof F Al­Maskari PhD, S Alsowaidi MD); Luxembourg Institute of 
Health, Strassen, Luxembourg (A Alkerwi PhD); School of Public 
Health, University of Lorraine, Nancy, France (Prof F Alla PhD); 
Department of Public Health Sciences (P Allebeck PhD, 
Z Z El­Khatib PhD, R H S Rabiee MPH), Department of Neurobiology, 
Care Sciences and Society, Division of Family Medicine and Primary 
Care (Prof J Ärnlöv PhD, S Fereshtehnejad PhD), Department of 
Medical Epidemiology and Biostatistics (Prof J J Carrero PhD, 
E Weiderpass PhD), Karolinska Institutet, Stockholm, Sweden 
(R Havmoeller PhD, A C J Lager PhD); Saudi Ministry of Health, 
Riyadh, Saudi Arabia (M A AlMazroa MD, Prof Z A Memish MD); 
Joint Program of Family and Community Medicine, Jeddah, Saudi 
Arabia (R Al­Raddadi PhD); Charité Universitätsmedizin, Berlin, 
Germany (U Alsharif MPH); Institute for Disease Modeling, Bellevue, 
WA, USA (B M Althouse PhD); King Saud University, Riyadh, Saudi 
Arabia (K A Altirkawi MD, B H A Sobaih MD); Universidad de 
Cartagena, Cartagena de Indias, Colombia (Prof N Alvis­Guzman PhD); 
School of Medicine (A T Amare MPH, Prof B T Baune PhD, 
L G Ciobanu MS), Discipline of Psychiatry, School of Medicine 
(A T Olagunju MS), University of Adelaide, Adelaide, SA, Australia; 
College of Medicine and Health Sciences, Bahir Dar University, Bahir 
Dar, Ethiopia (A T Amare MPH); Uro­Oncology Research Center 
(E Amini MD), Endocrinology and Metabolism Research Center 
(Prof A Esteghamati MD, N Hafezi­Nejad MD, A Kasaeian PhD), 
Non­Communicable Diseases Research Center (E Amini MD, 
F Farzadfar MD, A Khosravi PhD, M Parsaeian PhD), Department of 
Internal Medicine (A Ghajar MD), Center for Air Pollution Research, 
Institute for Environmental Research (M S Hassanvand PhD), Multiple 
Sclerosis Research Center, Neuroscience Institute (P Heydarpour MD, 
M A Sahraian MD), Hematology­Oncology and Stem Cell 
Transplantation Research Center (A Kasaeian PhD), Institute of Health 
Policy and Management (M Mahdavi PhD), Knowledge Utilization 
Research Center and Community Based Participatory Research Center 
(Prof R Majdzadeh PhD), Digestive Diseases Research Institute 
(Prof R Malekzadeh MD, G Roshandel PhD, S G Sepanlou PhD), 
Department of Epidemiology and Biostatistics, School of Public Health 
(M Parsaeian PhD), Iranian National Center for Addiction Studies 
(INCAS) (A Rahimi­Movaghar MD), Sina Trauma and Surgery 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1335
Research Center (Prof V Rahimi­Movaghar MD, S Saadat PhD, 
M Safdarian MD), Institute for Environmental Research 
(M Shamsipour PhD), Cancer Research Center 
(Prof R Shirkoohi PhD), Tehran University of Medical Sciences, 
Tehran, Iran (Prof M B Rokni PhD); Ministry of Public Health, Beirut, 
Lebanon (W Ammar PhD, I R Bou­Orm MD, H L Harb MPH); 
Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, 
Ghana (Y A Amoako MD); West Hararghe Zonal Health Department, 
Chiro, Ethiopia (M G Ansha MPH); Department of Health Policy and 
Administration, College of Public Health, University of the Philippines 
Manila, Manila, Philippines (C A T Antonio MD); Self­employed, 
Kabul, Afghanistan (P Anwari MS); School of Health and Social 
Studies, Dalarna University, Falun, Sweden (Prof J Ärnlöv PhD); 
University of Manitoba, Winnipeg, MB, Canada (A Artaman PhD); 
Nepal Health Research Council, Kathmandu, Nepal (K K Aryal MPH); 
University of Oslo, Oslo, Norway (K K Aryal MPH, A S Htet MPhil); 
Department of Public Health, College of Health Sciences 
(M G Yihdego MPH), Mizan Tepi University, Mizan Teferi, Ethiopia 
(N T Atnafu MS, M S K Mohammed MS, H H Yimam MPH); 
PMA 2020, Addis Ababa, Ethiopia (N T Atnafu MS); National Institute 
of Public Health, Cuernavaca, Mexico (L Avila­Burgos PhD, 
S Barquera PhD, L Cahuana­Hurtado PhD, I R Campos­Nonato PhD, 
I B Heredia­Pi PhD, R Lozano PhD, J C Montañez Hernandez MSc, 
Prof E E Servan­Mori MSc); Institut de Recherche Clinique du Bénin 
(IRCB), Cotonou, Benin (E F G A Avokpaho MPH); Laboratoire 
d’Etudes et de Recherche­Action en Santé (LERAS Afrique), Parakou, 
Benin (E F G A Avokpaho MPH); Indian Institute of Public Health, 
Gandhinagar, India (A Awasthi PhD); King George’s Medical 
University, Lucknow, India (S Awasthi MD); The Judith Lumley Centre 
for Mother, Infant and Family Health Research 
(B P Ayala Quintanilla PhD), La Trobe University, Melbourne, VIC, 
Australia (M A Rahman PhD); Peruvian National Institute of Health, 
Lima, Peru (B P Ayala Quintanilla PhD); Ghaem Hospital, Mashhad 
University of Medical Sciences, Mashhad, Iran 
(M R Azarpazhooh MD); Department of Clinical Neurological 
Sciences, London, ON, Canada (M R Azarpazhooh MD); Burnet 
Institute, Melbourne, VIC, Australia (P Azzopardi PhD); 
Wardliparingga Aboriginal Research Unit, South Australian Health 
and Medical Research Institute, Adelaide, South Australia, Australia 
(P Azzopardi PhD); Department of Community Health and Primary 
Care (T K Babalola MS), Department of Psychiatry, College of Medicine 
(A T Olagunju MS), University of Lagos, Lagos, Nigeria; School of 
Health Sciences, University of Management and Technology, Lahore, 
Pakistan (U Bacha PhD); Public Health Agency of Canada, Toronto, 
ON, Canada (A Badawi PhD); Department of Environmental Health 
Engineering, Sri Ramachandra University, Chennai, India 
(K Balakrishnan PhD); Institute of Social Medicine 
(M M Santric Milicevic PhD), Centre School of Public Health and 
Health Management (M M Santric Milicevic PhD), Faculty of Medicine 
(A Barac PhD), University of Belgrade, Belgrade, Serbia; School of 
Psychology, University of Auckland, Auckland, New Zealand 
(S L Barker­Collo PhD); Department of Global Health and Population 
(Prof T Bärnighausen MD, A B Feigl ScD, J A Salomon PhD), 
Harvard T H Chan School of Public Health (I R Campos­Nonato PhD), 
Ariadne Labs (E R K Macarayan PhD), Harvard Medical School 
(M Osman MD), Harvard University, Boston, MA, USA; Africa Health 
Research Institute, Mtubatuba, South Africa 
(Prof T Bärnighausen MD); Institute of Public Health, Heidelberg 
University, Heidelberg, Germany (Prof T Bärnighausen MD, 
S Mohammed PhD); Department of Industrial Engineering, School of 
Engineering, Pontificia Universidad Javeriana, Bogota, Colombia 
(L H Barrero ScD); Stanford University, Stanford, CA, USA 
(S Basu PhD); Doctor Evidence, Santa Monica, CA, USA 
(R Battista MBA, M S Fazeli MD); College of Medicine, Charles R Drew 
University of Medicine and Science, Los Angeles, CA, USA 
(Prof S Bazargan­Hejazi PhD); David Geffen School of Medicine, 
University of California at Los Angeles, Los Angeles, CA, USA 
(Prof S Bazargan­Hejazi PhD); Oxford University, Ho Chi Minh City, 
Vietnam (J Beardsley MBChB); College of Public Health and Tropical 
Medicine, Jazan, Saudi Arabia (N Bedi MD); University Hospital and 
Medical School of Dijon, University of Burgundy, Dijon, France 
(Prof Y Béjot PhD); Department of Public Health, College of Health 
Sciences (M G Yihdego MPH), Mizan Tepi University, Mizan Aman, 
Ethiopia (B B Bekele PhD); Yale University, New Haven, CT, USA 
(Prof M L Bell PhD, J J Huang MD); Center for Clinical and 
Epidemiological Research Center, Hospital Universitario 
(A C Goulart PhD), Internal Medicine Department 
(Prof I S Santos PhD), University of São Paulo, São Paulo, Brazil 
(I M Bensenor PhD, Prof P A Lotufo DrPH); College of Health 
Sciences (A Berhane PhD), Public Health Department, College of 
Health (K B Mruts MPH), Debre Berhan University, Debre Berhan, 
Ethiopia; Department of Psychiatry (Prof H W Hoek MD), University 
Medical Center Groningen (D F Berhe MS), University of Groningen, 
Groningen, Netherlands (J F M van Boven PhD); Division of Health 
and Social Care Research (Prof C D Wolfe MD), King’s College 
London, London, UK (E Bernabé PhD, Prof R J Hay DM); Carol Davila 
University of Medicine and Pharmacy, Bucharest, Romania 
(Prof M Beuran PhD, D V Davitoiu PhD, S Hostiuc PhD, I Negoi PhD, 
R I Negoi PhD); Emergency Hospital of Bucharest, Bucharest, 
Romania (Prof M Beuran PhD, I Negoi PhD); College of Health and 
Medical Sciences (A S Beyene MPH, M M Mengesha MPH, 
H S Roba MPH), Haramaya University, Harar, Ethiopia 
(L N B Bulto MS, A Geleto MPH, M D Gishu MS, D E Negasa MS, 
M S Shiferaw MS); Postgraduate Institute of Medical Education and 
Research, Chandigarh, India (A Bhansali DM); Department of 
Infectious Disease Epidemiology (S Bhatt DPhil, T Fürst PhD), 
Department of Primary Care & Public Health (Prof A Majeed MD, 
M Soljak PhD), Imperial College London, London, UK 
(K J Foreman PhD, Prof S Rawaf MD, S Saxena MD, 
H Shoman MPH); Centre of Excellence in Women and Child Health, 
Aga Khan University, Karachi, Pakistan (Z A Bhutta PhD); 
Independent Public Health Consultants, Addis Ababa, Ethiopia 
(S Biadgilign MPH); IRCCS ­ Istituto di Ricerche Farmacologiche 
Mario Negri, Bergamo, Italy (B Bikbov MD, M Cortinovis Biotech D, 
N Perico MD, Prof G Remuzzi MD); Department of Epidemiology and 
Public Health (Prof M Kivimaki PhD), University College London, 
London, UK (C Birungi MS, M R Mathur PhD); Department of Public 
Health (D J Boneya MPH), Debre Markos University, Debre Markos, 
Ethiopia (H M Bizuayehu MPH, G M Kassa MS, C T Leshargie MPH, 
T K Tegegne MPH); World Bank, Washington, DC, USA (D Bose PhD); 
Vision & Eye Research Unit, Anglia Ruskin University, Cambridge, UK 
(Prof R R A Bourne MD); Danube­University Krems, Krems, Austria 
(Prof M Brainin PhD); Cambridge Institute of Public Health, 
Cambridge, UK (Prof C E G Bryane MD); Faculty of Health Sciences 
and Social Work, Department of Public Health, Faculty of Medicine, 
Comenius University, Bratislava, Slovakia (A Brazinova MD); The Ohio 
State University, Columbus, OH, USA (Prof N J K Breitborde PhD, 
M Yotebieng PhD); INDICASAT AIP, Panama, Panama 
(G Britton PhD); University of Leicester, Leicester, UK 
(Prof T S Brugha PhD); Monash Department of Clinical Epidemiology, 
Cabrini Institute, Melbourne, VIC, Australia (Prof R Buchbinder PhD); 
Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan (Z A Butt PhD); 
Department of Biostatistics and Epidemiology, University of Oklahoma 
Health Sciences Center, Oklahoma City, OK, USA (H Carabin PhD); 
Metropolitan Autonomous University, Mexico City, Mexico 
(R Cárdenas ScD); University at Albany, Rensselaer, NY, USA 
(Prof D O Carpenter MD); Faculty of Pharmacy (Prof F Carvalho PhD), 
i3S ­ Instituto de Investigação e Inovação em Saúde (J das Neves PhD), 
INEB ­ Instituto de Engenharia Biomédica (J das Neves PhD), Faculty 
of Medicine (J V Santos MD), UCIBIO@REQUIMTE, Toxicology 
Group, Faculty of Pharmacy (J P Silva PhD), University of Porto, Porto, 
Portugal; Colombian National Health Observatory, Instituto Nacional 
de Salud, Bogota, Colombia (C A Castañeda­Orjuela MSc); 
Epidemiology and Public Health Evaluation Group, Public Health 
Department, Universidad Nacional de Colombia, Bogota, Colombia 
(C A Castañeda­Orjuela MSc); Caja Costarricense de Seguro Social, 
San Jose, Costa Rica (Prof J Castillo Rivas MPH); Universidad de Costa 
Rica, San Pedro, Montes de Oca, Costa Rica 
(Prof J Castillo Rivas MPH); Department of Medicine, University of 
Valencia, INCLIVA Health Research Institute and CIBERSAM, 
Valencia, Spain (F Catalá­López PhD, Prof R Tabarés­Seisdedos PhD); 
Clinical Epidemiology Program, Ottawa Hospital Research Institute, 
 Global Health Metrics
1336 
www.thelancet.com   Vol 390  September 16, 2017
Ottawa, ON, Canada (F Catalá­López PhD); School of Nursing, College 
of Medicine, National Taiwan University, Taipei, Taiwan 
(Prof J Chang PhD); Queensland Centre for Mental Health Research, 
Brisbane, QLD, Australia (F J Charlson PhD, H E Erskine PhD, 
A J Ferrari PhD, D Santomauro PhD, Prof H A Whiteford PhD); Tata 
Memorial Hospital, Mumbai, India (Prof P Chaturvedi MD); Michigan 
State University, East Lansing, MI, USA (H Chen PhD); Crowd Watch 
Africa, Lusaka, Zambia (M Chibalabala BS); National Center for Child 
Health and Development, Setagaya ku, Japan (C E Chibueze PhD); 
University of Zambia, Lusaka, Zambia (V H Chisumpa MPhil, 
C C Mapoma PhD); University of Witwatersrand, Johannesburg, 
South Africa (V H Chisumpa MPhil); Ministry of Health, Baghdad, 
Iraq (A A Chitheer MD); Department of Public Health and Primary 
Care, University of Cambridge, Cambridge, UK (R Chowdhury PhD); 
Christian Medical College, Vellore, India (Prof D J Christopher MD, 
Prof S Varughese DM); University of Salerno, Baronissi, Italy 
(Prof M Cirillo MD); Mayo Clinic, Jacksonville, FL, USA 
(L T Cooper MD); MRC Lifecourse Epidemiology Unit and NIHR 
Biomedical Research Centre, University of Southampton, 
Southampton, UK (Prof C Cooper MD); Research Centre on Public 
Health (CESP), University of Milan­Bicocca, Monza, Italy 
(P A Cortesi PhD); VA San Diego (S K Jassal MD), University of 
California, San Diego, La Jolla, CA, USA (M H Criqui MD); Centre for 
International Health, Dunedin School of Medicine 
(Prof J A Crump MD), University of Otago, Dunedin, New Zealand 
(Prof R G Poulton PhD); Flinders University, Adelaide, South Australia, 
Australia (Prof A F Dadi MPH, H A Gesesew MPH, 
Prof K Pesudovs PhD); Centre for Injury Prevention and Safety 
Promotion, School of Health and Medical Sciences, Orebro University, 
Orebro, Sweden (Prof K Dalal PhD); Faculty of Medicine, Eduardo 
Mondlane University, Maputo, Mozambique (Prof A Damasceno PhD); 
Republican Institute of Cardiology and Internal Diseases, Almaty, 
Kazakhstan (K Davletov PhD); School of Public Health, Kazakh 
National Medical University, Almaty, Kazakhstan (K Davletov PhD); 
Griffith University, Brisbane, QLD, Australia (Prof D De Leo DSc); 
Ghent University, Ghent, Belgium (H De Steur PhD, 
A Workicho MPH); National Drug and Alcohol Research Centre 
(Prof L Degenhardt PhD), Brien Holden Vision Institute 
(Prof S Resnikoff MD), School of Optometry and Vision Science 
(Prof S Resnikoff MD), University of New South Wales, Kensington, 
NSW, Australia (Prof P B Mitchell MD); University of Colorado School 
of Medicine and the Colorado School of Public Health, Aurora, CO, 
USA (R P Dellavalle MD); Brighton and Sussex Medical School, 
Brighton, UK (K Deribe MPH); School of Public Health 
(K Deribe MPH, A D Hailu MPH), Addis Ababa University, 
Addis Ababa, Ethiopia (H A Hareri MS, N A Kassaw MPH, 
G Temam Shifa MPH, B G Woldeyes MPH, M G Yihdego MPH); 
KEMRI­Wellcome Trust Research Programme, Kilifi, Kenya 
(A Deribew PhD); Mount Sinai Beth Israel, New York, NY, USA 
(Prof D C Des Jarlais PhD); Icahn School of Medicine at Mount Sinai, 
New York, NY, USA (Prof D C Des Jarlais PhD, A Vishnu PhD); 
Department of Community Medicine, Faculty of Medicine, University 
of Peradeniya, Peradeniya, Sri Lanka (S D Dharmaratne MD); 
Undersecretary for Research & Technology, Ministry of Health & 
Medical Education, Tehran, Iran (S Djalalinia PhD); Institute for 
Global Health Innovations, Duy Tan University, Da Nang, Vietnam 
(H P Do MSc, C T Nguyen MSc, Q L Nguyen MD, T H Nguyen MSc, 
V M Nong MSc); Department of Social Medicine, Faculty of Public 
Health, Medical University ­ Varna, Varna, Bulgaria (K Dokova PhD); 
University of Cape Coast, Cape Coast, Ghana (D T Doku PhD); 
University of Tampere, Tampere, Finland (D T Doku PhD); University 
of Rochester Medical Center, Rochester, NY, USA (E R Dorsey MD); 
Universidade do Estado de Santa Catarina, Florianópolis, Brazil 
(Prof K P B dos Santos MA); International Institute for Population 
Sciences, Mumbai, India (M Dubey MPhil, A Kastor MPhil, 
P Kumar MPhil, B K Panda MPhil, M H U Rahman MPhil, 
Prof U Ram PhD); Federal University of Rio Grande do Sul, Porto 
Alegre, Brazil (B B Duncan PhD, C Kieling MD, 
Prof M I Schmidt MD); University of North Carolina, Chapel Hill, NC, 
USA (B B Duncan PhD); Department of Global Health and Social 
Medicine, Harvard Medical School, Kigali, Rwanda 
(Z Z El­Khatib PhD); School of Public Health and Health Sciences 
Research Center, Sari, Iran (Prof A Enayati PhD); Arba Minch 
University, Arba Minch, Ethiopia (A Y Endries MPH, 
G Temam Shifa MPH); The Institute of Social and Economic Studies 
of Population, Russian Academy of Sciences, Moscow, Russia 
(Prof S P Ermakov DSc); Federal Research Institute for Health 
Organization and Informatics, Ministry of Health of the Russian 
Federation, Moscow, Russia (Prof S P Ermakov DSc); Ministry of 
Health and Medical Education, Tehran, Iran (B Eshrati PhD); Arak 
University of Medical Sciences, Arak, Iran (B Eshrati PhD); Hawassa 
University, Hawassa, Ethiopia (F B B Fanuel MPH); Wolaita Sodo 
University, Wolaita Sodo, Ethiopia (F B B Fanuel MPH, F Wadilo MS); 
DGS Directorate General of Health, Lisboa, Portugal 
(C S E S Farinha MSc); Universidade Aberta, Lisboa, Portugal 
(C S E S Farinha MSc); Federal University of Sergipe, Aracaju, Brazil 
(Prof A Faro PhD); National Institute for Stroke and Applied 
Neurosciences (V L Feigin PhD), Auckland University of Technology, 
Auckland, New Zealand (A M Theadom PhD); CBQF ­ Center for 
Biotechnology and Fine Chemistry ­ Associate Laboratory, Faculty of 
Biotechnology, Catholic University of Portugal, Porto, Portugal 
(J C Fernandes PhD); Wollega University, Nekemte, Ethiopia 
(T R Feyissa MPH, T Tekelab MS); Kaiser Permanente, Fontana, CA, 
USA (I Filip MD); School of Public Health, Bielefeld University, 
Bielefeld, Germany (F Fischer PhD); Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA (C Fitzmaurice MD); Institute of 
Gerontology, Academy of Medical Science, Kyiv, Ukraine 
(N Foigt PhD); James Cook University, Townsville, QLD, Australia 
(R C Franklin PhD); Department of Epidemiology and Public Health 
(T Fürst PhD), Swiss Tropical and Public Health Institute, Basel, 
Switzerland (C K Karema MSc); University of Basel, Basel, Switzerland 
(T Fürst PhD); Faculdade de Medicina de Ribeirão Preto, Universidade 
de São Paulo, Ribeirão Preto, Brazil (J M Furtado MD); Manhiça 
Health Research Center, Manhiça, Mozambique 
(A L Garcia­Basteiro MSc); Barcelona Institute for Global Health, 
Barcelona, Spain (A L Garcia­Basteiro MSc); The Task Force for Global 
Health, Decatur, GA, USA (T Gebre PhD); Division of Human 
Nutrition, Wageningen University, Wageningen, Netherlands 
(J M Geleijnse PhD); University of Newcastle, Newcastle, NSW, 
Australia (A Geleto MPH, T Tekelab MS); Madda Walabu University, 
Bale Goba, Ethiopia (B L Gemechu MPH); The Peter Doherty Institute 
for Infection and Immunity, The University of Melbourne & The Royal 
Melbourne Hospital, Melbourne, VIC, Australia (K B Gibney MBBS); 
Howard University, Washington, DC, USA (R F Gillum MD); College 
of Medicine, University of Hail, Hail, Saudi Arabia (I A Ginawi MD); 
Kersa Health and Demographic Surveillance System, Harar, Ethiopia 
(M D Gishu MS); IRCCS ­ Istituto di Ricerche Farmacologiche Mario 
Negri, Milan, Italy (G Giussani BiolD); Mayo Clinic, Rochester, MN, 
USA (K Goel MD); University of Massachusetts Boston, Boston, MA, 
USA (Prof P N Gona PhD); Instituto de Investigaciones Cientificas y 
Servicios de Alta Tecnologia ­ INDICASAT­AIP, Cuidad del Saber, 
Panama (A Goodridge PhD); Department of Health and Social Affairs, 
Government of the Federated States of Micronesia, Palikir, Federated 
States of Micronesia (S V Gopalani MPH); University of California, 
San Francisco, San Francisco, CA, USA (R A Gosselin MD); University 
of British Columbia, Vancouver, BC, Canada (C C Gotay PhD, 
Prof N Kissoon MD, J A Kopec PhD, S Murthy MD, F Pourmalek PhD); 
Division of Epidemiology, Center for Public Health Sciences, National 
Cancer Center, Tokyo, Japan (A Goto PhD); Center of Check of 
Hospital Sirio Libanes, São Paulo, Brazil (A C Goulart PhD); 
Departments of Microbiology and Epidemiology & Biostatistics, Saint 
James School of Medicine, The Quarter, Anguilla 
(Prof H C Gugnani PhD); Eternal Heart Care Centre and Research 
Institute, Jaipur, India (R Gupta PhD); Healis ­ Sekhsaria Institute for 
Public Health, Navi Mumbai, India (P C Gupta DSc); Montefiore 
Medical Center, Bronx, NY, USA (T Gupta MD); Albert Einstein 
College of Medicine, Bronx, NY, USA (T Gupta MD, Prof H D Hosgood 
PhD); Department of Anthropology, University of Delhi, Delhi, India 
(V Gupta PhD); West Virginia Bureau for Public Health, Charleston, 
WV, USA (R Gupta MD); National Institute of Psychiatry Ramon de la 
Fuente, Mexico City, Mexico (R A Gutiérrez PhD); Department of 
Clinical Neurological Sciences (L A Sposato MD), Western University, 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1337
London, ON, Canada (Prof V Hachinski DSc, T O Olagunju MD); 
Department of Psychosocial Science (A K Knudsen PhD), Department 
of Global Public Health and Primary Care (Prof S E Vollset DrPH), 
University of Bergen, Bergen, Norway (A D Hailu MPH, 
Prof O F Norheim PhD); Kilte Awlaelo Health and Demographic 
Surveillance System, Mekelle, Ethiopia (G B Hailu MSc); Arabian Gulf 
University, Manama, Bahrain (Prof R R Hamadeh DPhil); Hamdan 
Bin Mohammed Smart University, Dubai, United Arab Emirates 
(S Hamidi DrPH); Wayne County Department of Health and Human 
Services, Detroit, MI, USA (M Hammami MD); University of New 
Mexico, Albuquerque, NM, USA (A J Handal PhD); School of Medicine 
and Pharmacology, University of Western Australia, Perth, WA, 
Australia (Prof G J Hankey MD); Harry Perkins Institute of Medical 
Research, Nedlands, WA, Australia (Prof G J Hankey MD); Western 
Australian Neuroscience Research Institute, Nedlands, WA, Australia 
(Prof G J Hankey MD); School of Public Health (Prof Y Hao PhD), 
Zhongshan Ophthalmic Center (Y Zheng MD), Sun Yat­sen University, 
Guangzhou, China; Parc Sanitari Sant Joan de Déu ­ CIBERSAM, Sant 
Boi de Llobregat (Barcelona), Spain (J M Haro MD); Kenyatta 
University, Nairobi, Kenya (K M Harun MPH); International 
Foundation for Dermatology, London, UK (Prof R J Hay DM); School 
of Public Health (D Hendrie PhD), Centre for Population Health 
(T R Miller PhD), Curtin University, Perth, WA, Australia; Department 
of Epidemiology, Mailman School of Public Health 
(Prof H W Hoek MD), Columbia University, New York, NY, USA 
(Prof V Skirbekk PhD); Epidemiology and Statistics Program, National 
Institute on Deafness and Other Communication Disorders 
(H J Hoffman MA), Center for Translation Research and 
Implementation Science, National Heart, Lung, and Blood Institute 
(G A Mensah MD), National Institutes of Health, Bethesda, MD, USA; 
Bureau of Child, Family & Community Wellness, Nevada Division of 
Public and Behavioral Health, Carson City, NV, USA (M Horino MPH); 
Department of Pulmonology, Yokohama City University Graduate 
School of Medicine, Yokohama, Japan (N Horita MD); College of 
Medicine, Baylor University, Houston, Texas, USA (P J Hotez PhD); 
Public Health Division, The Pacific Community, Noumea, New 
Caledonia (D G Hoy PhD); International Relations Division, Ministry 
of Health, Nay Pyi Taw, Myanmar (A S Htet MPhil); Department of 
Epidemiology and Health Statistics, School of Public Health, Central 
South University, Changsha, China (G Hu PhD); National Centre for 
Register­Based Research, Aarhus School of Business and Social 
Sciences (Prof J J McGrath PhD), Aarhus University, Aarhus, Denmark 
(K M Iburg PhD); US Centers for Disease Control and Prevention, 
Pretoria, South Africa (Prof E U Igumbor PhD); School of Public 
Health, University of the Western Cape, Cape Town, South Africa 
(Prof E U Igumbor PhD); Department of Global and Community 
Health, George Mason University, Fairfax, VA, USA 
(K H Jacobsen PhD); School of Public Health, Shahid Beheshti 
University of Medical Sciences, Tehran, Iran (N Jahanmehr PhD); 
Faculty of Medical Sciences, University of Kragujevac, Kragujevac, 
Serbia (Prof M B Jakovljevic PhD); Department of Epidemiology, 
Harvard T H Chan School of Public Health, Channing Division of 
Network Medicine, Brigham & Women’s Hospital, Harvard Medical 
School, Boston, MA, USA (P James ScD); University of Aberdeen, 
Aberdeen, UK (M Javanbakht PhD); Department of Surgery, Virginia 
Commonwealth University, Richmond, VA, USA (S P Jayaraman MD); 
Centre for Chronic Disease Control, New Delhi, India (P Jeemon PhD, 
D Prabhakaran DM); The George Institute for Global Health, New 
Delhi, India (Prof V Jha DM); Tianjin Centers for Disease Control and 
Prevention, Tianjin, China (G Jiang MD); International Center for 
Research on Women, New Delhi, India (D John MPH); Department of 
Ophthalmology, Medical Faculty Mannheim, Ruprecht­Karls­University 
Heidelberg, Mannheim, Germany (Prof J B Jonas MD); Institute of 
Family Medicine and Public Health, University of Tartu, Tartu, Estonia 
(M Jürisson MD); University College Cork, Cork, Ireland 
(Z Kabir PhD); London School of Economics and Political Science, 
London, UK (R Kadel MPH); CSIR ­ Indian Institute of Toxicology 
Research, Lucknow, India (R Kamal MSc, C N Kesavachandran PhD); 
SCB Medical College, Cuttack, India (Prof C Kar DM); University of 
Balamand, Beirut, Lebanon (N E Karam MD); Epidemiological and 
Statistical Methods Research Group, Helmholtz Centre for Infection 
Research, Braunschweig, Germany (A Karch MD); Hannover­
Braunschweig Site, German Center for Infection Research, 
Braunschweig, Germany (A Karch MD); Quality and Equity Health 
Care, Kigali, Rwanda (C K Karema MSc); University of Washington 
Tacoma, Tacoma, WA, USA (S M Karimi PhD); Case Western 
University Hospitals, Cleveland, OH, USA (C Karimkhani MD); 
MRC/CSO Social & Public Health Sciences Unit, University of 
Glasgow, Glasgow, UK (S V Katikireddi PhD); Oklahoma State 
University, Tulsa, OK, USA (A Kaul MD); School of Public Health 
(Prof N Kawakami MD), University of Tokyo, Tokyo, Japan 
(K Shibuya MD); Institute of Tropical and Infectious Diseases, Nairobi, 
Kenya (P N Keiyoro PhD); School of Continuing and Distance 
Education, Nairobi, Kenya (P N Keiyoro PhD); UKZN Gastrointestinal 
Cancer Research Centre (Prof B Sartorius PhD), South African Medical 
Research Council, Cape Town, South Africa (A P Kengne PhD,); 
Department of Psychiatry (Prof D J Stein PhD), University of 
Cape Town, Cape Town, South Africa (A P Kengne PhD, 
J J N Noubiap MD); Assuta Hospitals, Assuta Hashalom, Tel Aviv, 
Israel (Prof A Keren MD); Department of Community Medicine, 
Public Health and Family Medicine, Jordan University of Science and 
Technology, Irbid, Jordan (Prof Y S Khader ScD); Health Services 
Academy, Islamabad, Pakistan (E A Khan MD); Department of Health 
Policy and Management, Seoul National University College of 
Medicine, Seoul, South Korea (Prof Y Khang MD); Institute of Health 
Policy and Management, Seoul National University Medical Center, 
Seoul, South Korea (Prof Y Khang MD); Iranian Ministry of Health 
and Medical Education, Tehran, Iran (A Khosravi PhD); Mohammed 
Ibn Saudi University, Riyadh, Saudi Arabia (A T Khoja MD); Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 
(A T Kjoja MD, Prof J B Nachega PhD); Department of Nutrition and 
Health Science, Ball State University, Muncie, IN, USA 
(J Khubchandani PhD); Hospital de Clinicas de Porto Alegre, Porto 
Alegre, Brazil (C Kieling MD); School of Medicine, Xiamen University 
Malaysia Campus, Sepang, Malaysia (Y J Kim PhD); Department of 
Health Sciences, Northeastern University, Boston, MA, USA 
(Prof D Kim DrPH); Simmons College, Boston, MA, USA 
(R W Kimokoti MD); Centre for Research and Action in Public Health, 
Canberra, ACT, Australia (Y Kinfu); Oslo University, Oslo, Norway 
(Prof A Kisa PhD); Institute of Public Health, Faculty of Health 
Sciences (R Topor­Madry PhD), Jagiellonian University Medical 
College, Krakow, Poland (K A Kissimova­Skarbek PhD); Clinicum, 
Faculty of Medicine (Prof M Kivimaki PhD), Finnish Institute of 
Occupational Health, Work Organizations, Work Disability Program, 
Department of Public Health, Faculty of Medicine (T Lallukka PhD, 
R Shiri PhD), University of Helsinki, Helsinki, Finland 
(T J Meretoja PhD); Center for Disease Burden (A K Knudsen PhD, 
Prof S E Vollset DrPH), Norwegian Institute of Public Health, Oslo, 
Norway (Prof V Skirbekk PhD); Department of Preventive Cardiology, 
National Cerebral and Cardiovascular Center, Suita, Japan 
(Y Kokubo PhD); Division of Cardiology, Brown University, 
Providence, RI, USA (D Kolte MD); Center for Community 
Empowerment, Health Policy and Humanities, National Institute of 
Health Research & Development, Jakarta, Indonesia (S Kosen MD); 
Sher­i­Kashmir Institute of Medical Sciences, Srinagar, India 
(Prof P A Koul MD); Research and Development Unit, Parc Sanitari 
Sant Joan de Deu (CIBERSAM), Barcelona, Spain (A Koyanagi MD); 
Research Center of Neurology, Moscow, Russia (M Kravchenko PhD, 
Prof M A Piradov DSc); Department of Social and Preventive Medicine, 
School of Public Health (Prof B Kuate Defo PhD), Department of 
Demography and Public Health Research Institute 
(Prof B Kuate Defo PhD), University of Montreal, Montreal, QC, 
Canada; Institute of Public Health, Hacettepe University, Ankara, 
Turkey (B Kucuk Bicer PhD); Centre for Epidemiology and Community 
Medicine, Stockholm County Council, Solna, Sweden 
(A C J Lager PhD); Ministry of Public Health and Fight Against AIDS, 
Mukaza, Burundi (N Lambert MD); National Cancer Institute, 
Rockville, MD, USA (Q Lan PhD); Help Me See, Inc, New York, NY, 
USA (V C Lansingh PhD); Instituo Mexicano de Oftalmologia, 
Queretaro, Mexico (V C Lansingh PhD); Department of Medical 
Sciences, Uppsala University, Uppsala, Sweden (Prof A Larsson PhD); 
College of Optometry, Nova Southeastern University, Fort Lauderdale, 
 Global Health Metrics
1338 
www.thelancet.com   Vol 390  September 16, 2017
FL, USA (J L Leasher OD); Hong Kong Polytechnic University, Hong 
Kong, China (P H Lee PhD); State University of New York, Albany, 
Rensselaer, NY, USA (R Leung PhD); Tuscany Regional Centre for 
Occupational Injuries and Diseases, Florence, Italy (M Levi PhD); 
Department of Data Management, Peking University Clinical Research 
Institute, Beijing, China (Y Li PhD); National Center for Chronic and 
Noncommunicable Disease Control and Prevention (Y Li PhD, 
S Liu PhD, P Ye MPH, Prof M Zhou PhD), Chinese Center for Disease 
Control and Prevention, Beijing, China (Prof X Liang MD); San 
Francisco VA Medical Center, San Francisco, CA, USA (Y Li PhD); 
Samara University, Samara, Ethiopia (M L Liben MPH); University of 
Haifa, Haifa, Israel (Prof S Linn MD); Emory University, Atlanta, GA, 
USA (Prof Y Liu PhD, Prof M R Phillips MD); All India Institute of 
Medical Sciences, New Delhi, India (R Lodha MD, 
Prof R Malhotra MS, A Roy DM, R Sagar MD, Prof N Tandon PhD); 
University of Bari, Bari, Italy (Prof G Logroscino PhD); University of 
Bristol, Bristol, UK (K J Looker PhD); Institute of Nutrition, 
Friedrich Schiller University Jena, Jena, Germany 
(Prof S Lorkowski PhD); Competence Cluster for Nutrition and 
Cardiovascular Health (nutriCARD) Halle­Jena­Leipzig, Jena, Germany 
(Prof S Lorkowski PhD); Aintree University Hospital National Health 
Service Foundation Trust, Liverpool, UK (Prof R Lunevicius PhD); 
School of Medicine, University of Liverpool, Liverpool, UK 
(Prof R Lunevicius PhD); Farr Institute, Swansea University, Swansea, 
UK (Prof R A Lyons MD); Ateneo de Manila University, Manila, 
Philippines (E R K Macarayan PhD); Mansoura Faculty of Medicine, 
Mansoura, Egypt (H Magdy Abd El Razek MBBCh); Aswan University 
Hospital, Aswan Faculty of Medicine, Aswan, Egypt 
(M Magdy Abd El Razek MBBCh); National Center for the Prevention 
and Control of HIV/AIDS, Secretariat of Health, Mexico City, Mexico 
(C Magis­Rodriguez PhD); Erasmus University Rotterdam, Rotterdam, 
Netherlands (M Mahdavi PhD); Faculty of Health Sciences and Social 
Work, Department of Public Health, Trnava University, Trnava, 
Slovakia (M Majdan PhD); National Institute of Health Research, 
Tehran, Iran (Prof R Majdzadeh PhD); Universidade Federal de Minas 
Gerais, Belo Horizonte, Brazil (Prof D C Malta PhD, P H V Martins 
PhD); The University of Queensland, Brisbane, QLD, Australia 
(Prof A A Mamun PhD); University of Milano Bicocca, Monza, Italy 
(Prof L G Mantovani DSc); Hospital Universitario Doctor Peset, 
Valencia, Spain (J Martinez­Raga PhD, M Tortajada PhD); CEU 
Cardinal Herrera University, Moncada, Spain (J Martinez­Raga PhD); 
Federal Institute of Education, Science and Technology of Ceará, 
Caucaia, Brazil (F R Martins­Melo PhD); Synlab Academy, Mannheim, 
Germany (Prof W März MD); Clinical Institute of Medical and 
Chemical Laboratory Diagnostics, Medical University of Graz, Graz, 
Austria (Prof W März MD); Key State Laboratory of Molecular 
Developmental Biology, Institute of Genetics and Developmental 
Biology, Chinese Academy of Sciences, Beijing, China (M Mazidi PhD); 
University Hospitals Bristol NHS Foundation Trust, Bristol, UK 
(C McAlinden PhD); Public Health Wales, Swansea, UK 
(C McAlinden PhD); Queensland Centre for Mental Health Research, 
The Park Centre for Mental Health, Wacol, QLD, Australia 
(Prof J J McGrath PhD); Queensland Brain Institute 
(Prof J J McGrath PhD), University of Queensland, Brisbane, QLD, 
Australia (S R Mishra MPH); London School of Hygiene and Tropical 
Medicine, London, UK (Prof M McKee DSc, Prof G V S Murthy MD, 
Prof N Pearce PhD); Ipas Nepal, Kathmandu, Nepal (S Mehata PhD); 
Martin Luther University Halle­Wittenberg, Halle (Saale), Germany 
(T Meier PhD); University of West Florida, Pensacola, FL, USA 
(P Memiah PhD); College of Medicine, Alfaisal University, Riyadh, 
Saudi Arabia (Prof Z A Memish MD); United Nations Population 
Fund, Lima, Peru (W Mendoza MD); Department of Neurology 
(A Meretoja PhD), Comprehensive Cancer Center, Breast Surgery Unit 
(T J Meretoja PhD), Helsinki University Hospital, Helsinki, Finland; 
Friedman School of Nutrition Science and Policy (R Micha PhD), Tufts 
University, Boston, MA, USA (P Shi PhD); Pacific Institute for 
Research & Evaluation, Calverton, MD, USA (T R Miller PhD); Hunger 
Action Los Angeles, Los Angeles, CA, USA (M Mirarefin MPH); 
Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan 
(Prof E M Mirrakhimov PhD); National Center of Cardiology and 
Internal Disease, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov PhD); 
Nepal Development Society, Chitwan, Nepal (S R Mishra MPH); 
University of Salahaddin, Erbil, Iraq (K A Mohammad PhD); ISHIK 
University, Erbil, Iraq (K A Mohammad PhD); Neuroscience Research 
Center, Baqiyatallah University of Medical Sciences, Tehran, Iran 
(A Mohammadi PhD); Health Systems and Policy Research Unit 
(S Mohammed PhD), Ahmadu Bello University, Zaria, Nigeria 
(M B Sufiyan MBA); Narayana Health, Bangalore, India 
(Prof M B V Mohan MD); Institute for Maternal and Child Health, 
IRCCS “Burlo Garofolo”, Trieste, Italy (L Monasta DSc, 
M Montico MSc, L Ronfani PhD); Department of Community 
Medicine, Preventive Medicine and Public Health Research Center 
(M Moradi­Lakeh MD, A Tehrani­Banihashemi PhD), Gastrointestinal 
and Liver Disease Research Center (GILDRC; M Moradi­Lakeh MD), 
Iran University of Medical Sciences, Tehran, Iran (M Yaghoubi MSc); 
Lancaster Medical School, Lancaster University, Lancaster, UK 
(P Moraga PhD); International Laboratory for Air Quality and Health 
(L Morawska PhD), Institute of Health and Biomedical Innovation 
(R E Pacella PhD), Queensland University of Technology, Brisbane, 
QLD, Australia; National Center for Child Health and Development, 
Setagaya, Japan (R Mori PhD, R Tobe­Gai PhD); Competence Center 
Mortality­Follow­Up of the German National Cohort 
(A Werdecker PhD), Federal Institute for Population Research, 
Wiesbaden, Germany (Prof U O Mueller PhD, R Westerman PhD); 
Indian Institute of Public Health, Public Health Foundation of India, 
Hyderabad, India (Prof G V S Murthy MD); School of Medical 
Sciences, University of Science Malaysia, Kubang Kerian, Malaysia 
(K I Musa MD); Graduate School of Public Health, University of 
Pittsburgh, Pittsburgh, PA, USA (Prof J B Nachega PhD); International 
Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, 
Bangladesh (A Naheed PhD, S M Shariful Islam PhD); Public Health 
Medicine, School of Nursing and Public Health (Prof B Sartorius PhD), 
Discipline of Public Health Medicine, School of Nursing and Public 
Health (B Yakob PhD), University of KwaZulu­Natal, Durban, South 
Africa (Prof K S Naidoo PhD, E A Zegeye MS); Suraj Eye Institute, 
Nagpur, India (V Nangia MD); Ministry of Public Health and 
Population, Sana’a, Yemen (J T Nasher MSc); Madras Medical College, 
Chennai, India, India (Prof G Natarajan DM); KEMRI Wellcome Trust, 
Kilifi, Kenya (Prof C R Newton MD); University of Nairobi, Nairobi, 
Kenya (J W Ngunjiri PhD); Department of Public Health, Semarang 
State University, Semarang City, Indonesia (D N A Ningrum MPH); 
Graduate Institute of Biomedical Informatics, College of Medical 
Science and Technology, Taipei Medical University, Taipei City, Taiwan 
(D N A Ningrum MPH); Medical Diagnostic Centre, Yaounde, 
Cameroon (J J N Noubiap MD); Rwanda Ministry of Health, Kigali, 
Rwanda (A Nyandwi MPH); American University of Beirut, Beirut, 
Lebanon (Prof C M Obermeyer DSc, Prof A M Sibai PhD); National 
University of Ireland Galway, Galway, Ireland (M J O’Donnell PhD); 
Centre for Health Research (F A Ogbo MPH), Western Sydney 
University, Penrith, NSW, Australia (Prof A M N Renzaho PhD); 
Department of Preventive Medicine, School of Medicine, Kyung Hee 
University, Seoul, South Korea (Prof I Oh PhD); Society for Family 
Health, Abuja, Nigeria (A Okoro MPH); Human Sciences Research 
Council (HSRC), South Africa and University of KwaZulu­Natal, 
Durban, South Africa (O Oladimeji MS); Department of Psychiatry, 
Lagos University Teaching Hospital, Lagos, Nigeria 
(A T Olagunju MS); McMaster University, Hamilton, ON, Canada 
(T O Olagunju MD); Center for Healthy Start Initiative, Lagos, Nigeria 
(B O Olusanya PhD, J O Olusanya MBA); Lira District Local 
Government, Lira Municipal Council, Uganda (J N Opio MPH); 
University of Arizona, Tucson, AZ, USA (Prof E Oren PhD); IIS­
Fundacion Jimenez Diaz­UAM, Madrid, Spain (Prof A Ortiz PhD); 
Deakin University, Geelong, VIC, Australia (Prof R H Osborne PhD); 
YBank, Cambridge, MA, USA (M Osman MD); St Luke’s International 
University, Tokyo, Japan (E Ota PhD); Department of Medicine, 
Ibadan, Nigeria (M O Owolabi Dr Med); Blossom Specialist Medical 
Center, Ibadan, Nigeria (M O Owolabi Dr Med); JSS Medical College, 
JSS University, Mysore, India (Prof M PA DNB) Christian Medical 
College Ludhiana, Ludhiana, India (J D Pandian DM); Charité 
University Medicine Berlin, Berlin, Germany (C Papachristou PhD); 
Department of Medical Humanities and Social Medicine, College of 
Medicine, Kosin University, Busan, South Korea (E Park PhD); Alcohol, 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1339
Tobacco & Other Drug Research Unit (Prof C D Parry PhD), South 
African Medical Research Council, Cape Town, South Africa 
(A P Kengne PhD,); Krishan Institute of Medical Sciences, Deemed 
University, School of Dental Sciences, Karad, India (S T Patil MDS); 
Department of Community Health Sciences (Prof S B Patten PhD), 
University of Calgary, Calgary, AB, Canada (Prof M Tonelli MD); UK 
Department for International Development, Lalitpur, Nepal 
(D Paudel PhD); REQUIMTE/LAQV, Laboratório de Farmacognosia, 
Departamento de Química, Faculdade de Farmácia, Universidade do 
Porto, Porto, Portugal (Prof D M Pereira PhD); Aalborg University, 
Aalborg Esst, Denmark (C B Peterson PhD); Department of 
Anesthesiology (A S Terkawi MD), University of Virginia, 
Charlottesville, VA, USA (W A Petri MD); Health Metrics Unit, 
University of Gothenburg, Gothenburg, Sweden (Prof M Petzold PhD); 
University of the Witwatersrand, Johannesburg, South Africa 
(Prof M Petzold PhD); Shanghai Jiao Tong University School of 
Medicine, Shanghai, China (Prof M R Phillips MD); Durban University 
of Technology, Durban, South Africa (J D Pillay PhD); Exposure 
Assessment and Environmental Health Indicators, German 
Environment Agency, Berlin, Germany (D Plass DrPH, M Tobollik 
MPH); Sanjay Gandhi Post Graduate Institute of Medical Sciences, 
Lucknow, India (Prof N Prasad DM); Intergrowth 21st Study Research 
Centre, Nagpur, India (Prof M Purwar MD); 
Non­Communicable Diseases Research Center, Alborz University of 
Medical Sciences, Karaj, Iran (M Qorbani PhD); A T Still University, 
Kirksville, MO, USA (A Radfar MD); Contech International Health 
Consultants, Lahore, Pakistan (A Rafay MS); Contech School of Public 
Health, Lahore, Pakistan (A Rafay MS); Research and Evaluation 
Division, BRAC, Dhaka, Bangladesh (M Rahman PhD); Society for 
Health and Demographic Surveillance, Suri, India (R K Rai MPH); 
ERAWEB Program, University for Health Sciences, Medical 
Informatics and Technology, Hall in Tirol, Austria (S Rajsic MD); 
Department of Preventive Medicine, Wonju College of Medicine, 
Yonsei University, Wonju, South Korea (C L Ranabhat PhD); Health 
Science Foundation and Study Center, Kathmandu, Nepal 
(C L Ranabhat PhD); Schizophrenia Research Foundation, Chennai, 
India (T Rangaswamy PhD); Diabetes Research Society, Hyderabad, 
India (Prof P V Rao MD); Diabetes Research Center, Hyderabad, India 
(Prof P V Rao MD); Azienda Socio­Sanitaria Territoriale, Papa 
Giovanni XXIII, Bergamo, Italy (Prof G Remuzzi MD); Department of 
Biomedical and Clinical Sciences “L Sacco”, University of Milan, 
Milan, Italy (Prof G Remuzzi MD); Research Center for Environmental 
Determinants of Health, School of Public Health (S Rezaei PhD), 
Kermanshah University of Medical Sciences, Kermanshah, Iran 
(S Siabani PhD); Hospital das Clínicas da Universidade Federal de 
Minas Gerais, Belo Horizonte, Brazil (Prof A L Ribeiro MD); RMIT 
University, Bundoora, VIC, Australia (Prof S R Robinson PhD); 
Campus MAR, Barcelona Biomedical Research Park (PRBB), ISGlobal 
Instituto de Salud Global de Barcelona, Barcelona, Spain 
(D Rojas­Rueda PhD); Golestan Research Center of Gastroenterology 
and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran 
(G Roshandel PhD); Institute of Epidemiology and Medical Biometry, 
Ulm University, Ulm, Germany (Prof G Nagel PhD, 
Prof D Rothenbacher MD); Universidad Tecnica del Norte, Ibarra, 
Ecuador (E Rubagotti PhD); Muhimbili University of Health and Allied 
Sciences, Dar es Salaam, Tanzania (G M Ruhago PhD, 
B F Sunguya PhD); Managerial Epidemiology Research Center, 
Department of Public Health, School of Nursing and Midwifery, 
Maragheh University of Medical Sciences, Maragheh, Iran 
(S Safiri PhD); Universiti Kebangsaan Malaysia Medical Centre, Kuala 
Lumpur, Malaysia (R Sahathevan PhD); Ballarat Health Service, 
Ballarat, VIC, Australia (R Sahathevan PhD); Development Research 
and Projects Center, Abuja, Nigeria (M M Saleh MPH); Chest Research 
Foundation, Pune, India (S S Salvi MD); Faculty of Science, Ain Shams 
University, Cairo, Egypt (A M Samy PhD); J Edwards School of 
Medicine (J R Sanabria MD), Department of Public Health 
(M Sawhney PhD), Marshall University, Huntington, WV, USA; Case 
Western Reserve University, Cleveland, OH, USA (J R Sanabria MD); 
IIS­Fundacion Jimenez Diaz, Madrid, Spain (M D Sanchez­Niño PhD); 
Department of Community Medicine, Information and Health 
Decision Sciences, Center for Health Technology and Services 
Research ­ CINTESIS, Porto, Portugal (J V Santos MD); Centre of 
Advanced Study in Psychology, Utkal University, Bhubaneswar, India 
(M Satpathy PhD); Federal University of Santa Catarina, Florianópolis, 
Brazil (I J C Schneider PhD); Division of Clinical Epidemiology and 
Ageing Research, German Cancer Research Center, Heidelberg, 
Germany (B Schöttker MPH); Institute of Health Care and Social 
Sciences, FOM University, Essen, Germany (B Schöttker MPH); 
Hypertension in Africa Research Team (HART), North­West 
University, Potchefstroom, South Africa (Prof A E Schutte PhD); 
UKZN Gastrointestinal Cancer Research Centre 
(Prof B Sartorius PhD), South African Medical Research Council, 
Potchefstroom, South Africa (Prof A E Schutte PhD); Charité Berlin, 
Berlin, Germany (F Schwendicke PhD); Department of Public Health, 
An­Najah University, Nablus, Palestine (A Shaheen PhD); Independent 
Consultant, Karachi, Pakistan (M A Shaikh MD); The George Institute 
for Global Health, Sydney, NSW, Australia (S M Shariful Islam PhD); 
Indian Institute of Technology Ropar, Rupnagar, India (R Sharma MA); 
Ministry of Health, Thimphu, Bhutan (J Sharma MPH); Department 
of Pulmonary Medicine, Zhongshan Hospital, Fudan University, 
Shanghai, China (J She MD); National Institute of Infectious Diseases, 
Tokyo, Japan (M Shigematsu PhD); Sandia National Laboratories, 
Albuquerque, NM, USA (M Shigematsu PhD); Washington State 
University, Spokane, WA, USA (K Shishani PhD); University of 
Technology Sydney, Sydney, NSW, Australia (S Siabani PhD); Reykjavik 
University, Reykjavik, Iceland (I D Sigfusdottir PhD); Federal 
University of Santa Catarina, Florianopolis, Brazil (D A S Silva PhD); 
Brasília University, Brasília, Brazil (D G A Silveira MD); University of 
Pennsylvania, Philadelphia, PA, USA (D H Silberberg MD); Asthma 
Bhawan, Jaipur, India (V Singh MD); Department of Medicine, 
Institute of Medical Sciences, Banaras Hindu University, Varanasi, 
India (O P Singh PhD); Max Hospital, Gaziabad, India 
(Prof N P Singh MD); School of Preventive Oncology, Patna, India 
(D N Sinha PhD); WHO FCTC Global Knowledge Hub on Smokeless 
Tobacco, National Institute of Cancer Prevention, Noida, India 
(D N Sinha PhD); Hywel Dda University Health Board, Carmarthen, 
UK (E Skiadaresi MD); Bristol Eye Hospital, Bristol, UK 
(E Skiadaresi MD); King Khalid University Hospital, Riyadh, Saudi 
Arabia (B H A Sobaih MD); University of Yaoundé, Yaoundé, 
Cameroon (Prof E Sobngwi PhD); Yaoundé Central Hospital, Yaoundé, 
Cameroon (Prof E Sobngwi PhD); National School of Public 
Health/Oswaldo Cruz Foundation, Rio de Janeiro, Brazil 
(Prof T C M Sousa MPH); Department of Community Medicine, 
International Medical University, Kuala Lumpur, Malaysia 
(C T Sreeramareddy MD); Attikon University Hospital, Athens, Greece 
(V Stathopoulou PhD); University of East Anglia, Norwich, UK 
(Prof N Steel PhD); Public Health England, London, UK 
(Prof N Steel PhD); South African Medical Research Council Unit on 
Anxiety & Stress Disorders, Cape Town, South Africa 
(Prof D J Stein PhD); Department of Dermatology, University Hospital 
Muenster, Muenster, Germany (S Steinke DrMed); Deakin University, 
Burwood, VIC, Australia (Prof M A Stokes PhD); Department of 
Neuroscience, Norwegian University of Science and Technology, 
Trondheim, Norway (Prof L J Stovner PhD); Norwegian Advisory Unit 
on Headache, St Olavs Hospital, Trondheim, Norway 
(Prof L J Stovner PhD); Ministry of Health, KSA, Riyadh, Saudi Arabia 
(R Suliankatchi Abdulkader MD); Indian Council of Medical Research, 
New Delhi, India (S Swaminathan MD); Departments of Criminology, 
Law & Society, Sociology, and Public Health, University of California, 
Irvine, Irvine, CA, USA (Prof B L Sykes PhD); Griffith University, Gold 
Coast, QLD, Australia (S K Tadakamadla PhD); WSH Institute, 
Ministry of Manpower, Singapore, Singapore (J S Takala DSc); 
Tampere University of Technology, Tampere, Finland (J S Takala DSc); 
Chaim Sheba Medical Center, Tel Hashomer, Israel 
(Prof D Tanne MD); Tel Aviv University, Tel Aviv, Israel 
(Prof D Tanne MD); Ethiopian Public Health Association, Addis Ababa, 
Ethiopia (Y L Tarekegn MS); New York Medical Center, Valhalla, NY, 
USA (M Tavakkoli MD); Instituto Superior de Ciências da Saúde Egas 
Moniz, Almada, Portugal (Prof N Taveira PhD); Faculty of Pharmacy, 
Universidade de Lisboa, Lisboa, Portugal (Prof N Taveira PhD); 
Department of Anesthesiology, King Fahad Medical City, Riyadh, 
Saudi Arabia (A S Terkawi MD); Outcomes Research Consortium 
 Global Health Metrics
1340 
www.thelancet.com   Vol 390  September 16, 2017
(A S Terkawi MD), Cleveland Clinic, Cleveland, OH, USA 
(Prof E M Tuzcu MD); School of Public Health, Post Graduate Institute 
of Medical Education and Research, Chandigarh, India 
(Prof J Thakur MD); Christian Medical College Vellore, Vellore, India 
(Prof N Thomas PhD); Faculty of Health Sciences, Wroclaw Medical 
University, Wroclaw, Poland (R Topor­Madry PhD); School of Medicine, 
University of Valencia, Valencia, Spain (M Tortajada PhD); INSERM 
(French National Institute for Health and Medical Research), Paris, 
France (M Touvier PhD); University of Southern Santa Catarina, 
Palhoça, Brazil (Prof J Traebert PhD); Johns Hopkins University, 
Baltimore, MD, USA (B X Tran PhD); Department of Neurology, 
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 
(T Truelsen DMSc); Hanoi Medical University, Hanoi, Vietnam 
(B X Tran PhD); Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de 
Déu, Universitat de Barcelona, CIBERSAM, Barcelona, Spain 
(S Tyrovolas PhD); Department of Internal Medicine, Federal Teaching 
Hospital, Abakaliki, Nigeria (K N Ukwaja MD); School of Government, 
Pontificia Universidad Catolica de Chile, Santiago, Chile 
(E A Undurraga PhD); Ebonyi State University, Abakaliki, Nigeria 
(C J Uneke PhD); Warwick Medical School, University of Warwick, 
Coventry, UK (O A Uthman PhD); University of Nigeria, Nsukka, 
Enugu Campus, Enugu, Nigeria (Prof B S C Uzochukwu MD); UKK 
Institute for Health Promotion Research, Tampere, Finland 
(Prof T Vasankari PhD); National Centre for Disease Control, Delhi, 
India (S Venkatesh MD); Raffles Neuroscience Centre, Raffles Hospital, 
Singapore, Singapore (N Venketasubramanian MBBS); Weill Cornell 
Medical College, New York, NY, USA (R Vidavalur MD); VHS SNEHA, 
Chennai, India (L Vijayakumar PhD); University of Bologna, Bologna, 
Italy (Prof F S Violante MD); Federal Research Institute for Health 
Organization and Informatics, Moscow, Russia (S K Vladimirov PhD); 
National Research University Higher School of Economics, Moscow, 
Russia (Prof V V Vlassov MD); VA Medical Center, Washington, DC, 
USA (M T Wallin MD); Neurology Department, Georgetown 
University, Washington, DC, USA (M T Wallin MD); University of 
São Paulo Medical School, São Paulo, Brazil (Y Wang PhD); McGill 
University, Ottawa, ON, Canada (S Weichenthal PhD); Department of 
Research, Cancer Registry of Norway, Institute of Population­Based 
Cancer Research, Oslo, Norway (E Weiderpass PhD); Department of 
Community Medicine, Faculty of Health Sciences, University of 
Tromsø, The Arctic University of Norway, Tromsø, Norway 
(E Weiderpass PhD); Genetic Epidemiology Group, Folkhälsan 
Research Center, Helsinki, Finland (E Weiderpass PhD); Royal 
Children’s Hospital, Melbourne, VIC, Australia 
(R G Weintraub MBBS); University of Melbourne, Melbourne, VIC, 
Australia (R G Weintraub MBBS); German National Cohort 
Consortium, Heidelberg, Germany (R Westerman PhD); West Herts 
Hospitals NHS Trust, Watford, UK (M E Murdoch MD); Western 
Health, Footscray, VIC, Australia (Prof T Wijeratne MD); Centre of 
Evidence Based Dermatology, University of Nottingham, Nottingham, 
UK (Prof H C Williams DSc); South African Medical Research Council, 
Cochrane South Africa, Cape Town, South Africa 
(Prof C S Wiysonge PhD); National Institute for Health Research 
Comprehensive Biomedical Research Centre, Guy’s & St Thomas’ NHS 
Foundation Trust and King’s College London, London, UK 
(Prof C D Wolfe MD); Royal Cornwall Hospital, Truro, UK 
(Prof A D Woolf MBBS); St John’s Medical College and Research Institute, 
Bangalore, India (Prof D Xavier MD); Department of Neurology, Jinling 
Hospital, Nanjing University School of Medicine, Nanjing, China 
(Prof G Xu PhD); School of Public Health, University of Saskatchewan, 
Saskatoon, SK, Canada (M Yaghoubi MSc); Global Health Research 
Center, Duke Kunshan University, Kunshan, China (Prof L L Yan PhD); 
Department of Preventive Medicine, Northwestern University, Chicago, 
IL, USA (Y Yano MD); Social Work and Social Administration 
Department (Prof P Yip PhD), The Hong Kong Jockey Club Centre for 
Suicide Research and Prevention (Prof P Yip PhD), University of Hong 
Kong, Hong Kong, China; Department of Biostatistics, School of Public 
Health, Kyoto University, Kyoto, Japan (N Yonemoto MPH); Department 
of Preventive Medicine, College of Medicine, Korea University, Seoul, 
South Korea (S Yoon PhD); School of Public Health, University of 
Kinshasa, Kinshasa, Democratic Republic of the Congo 
(M Yotebieng PhD); Jackson State University, Jackson, MS, USA 
(Prof M Z Younis DrPH); Department of Epidemiology and Biostatistics, 
School of Public Health and Global Health Institute, Wuhan University, 
Wuhan, China (Prof C Yu PhD); University Hospital of Setif, Setif, Algeria 
(Prof Z Zaidi DSc); Faculty of Medicine, Mansoura University, Mansoura, 
Egypt (Prof M E Zaki PhD); Ethiopian Public Health Institute, Addis 
Ababa, Ethiopia (E A Zegeye MS); University of Texas School of Public 
Health, Houston, TX, USA (X Zhang MS); MD Anderson Cancer Center, 
Houston, TX, USA (X Zhang MS); and Red Cross War Memorial 
Children’s Hospital, Cape Town, South Africa (L J Zuhlke PhD).
Contributors
Please see the appendix for more detailed information about individual 
authors’ contributions to the research, divided into the following 
categories: managing the estimation process; writing the first draft of 
the manuscript; providing data or critical feedback on data sources; 
developing methods or computational machinery; applying analytical 
methods to produce estimates; providing critical feedback on methods 
or results; drafting the work or revising it critically for important 
intellectual content; extracting, cleaning, or cataloguing data; designing 
or coding figures and tables; and managing the overall research 
enterprise. 
Declaration of interests
Laith J Abu­Raddad acknowledges the support of the Qatar National 
Research Fund (NPRP 9­040­3­008) who provided the main funding for 
generating the data provided to the GBD­IHME effort. Anurag Arawal 
acknowledges support from the Wellcome Trust DBT India Alliance 
Senior Fellowship; and reports personal fees from AstraZeneca. 
Ashish Awasthi received funding from DST, Government of India 
through INSPIRE Faculty scheme. The scientific work of 
Aleksandra Barac is part of the Project No III45005 granted by Ministry 
of Education, Science and Technological Development of the Republic 
of Serbia. Till Bärnighausen was supported by the Alexander von 
Humboldt Foundation through the Alexander von Humboldt Professor 
award, funded by the Federal Ministry of Education and Research; the 
Wellcome Trust; the European Commission; the Clinton Health Access 
Initiative; and from NICHD of NIH (R01­HD084233), NIA of NIH 
(P01­AG041710), NIAID of NIH (R01­AI124389 and R01­AI112339) as 
well as FIC of NIH (D43­TW009775); this research was supported by 
NIH National Center for Advancing Translational Science (NCATS) 
UCLA CTSI Grant Number UL1TR001881. Yannick Béjot reports 
grants and personal fees from AstraZeneca, personal fees from 
Daiichi­Sankyo, personal fees from Pfizer­BMS, personal fees from 
MSD, personal fees from Bayer, personal fees from Covidiem, and 
grants and personal fees from Boehringer­Ingelheim. Boris Bikbov has 
received funding from the European Union’s Horizon 2020 research 
and innovation programme under Marie Sklodowska­Curie grant 
agreement No 703226; and acknowledges that work related to this 
paper has been done on the behalf of the GBD Genitourinary Disease 
Expert Group supported by the International Society of Nephrology 
(ISN). Rupert Bourne acknowledges support from the Brien Holden 
Vision Institute. Rachelle Buchbinder is funded by an Australian 
National Health and Medical Research Council (NHMRC) Senior 
Principal Research Fellowship. Lucero Cahuana­Hurtado acknowledges 
support from the Instituto Nacional de Salud Pública (INSP) in 
Mexico. Juan­Jesus Carrero acknowledges support from Stockholm 
County Council Swedish Heart and Lung Foundation. Cyrus Cooper 
reports personal fees from Alliance for Better Bone Health, Amgen, 
Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Servier, Takeda, and 
UCB. José das Neves was supported in his contribution to this work by 
a Fellowship from Fundação para a Ciência e a Tecnologia, Portugal 
(SFRH/BPD/92934/2013.; Barbora de Courten is supported by National 
Heart Foundation Future Leader Fellowship (100864). Louisa 
Degenhardt is supported by an Australian National Health and Medical 
Research Council (NHMRC) Principal Research Fellowship; the 
National Drug and Alcohol Research Centre at the University of NSW 
is supported by funding from the Australian Government under the 
Substance Misuse Prevention and Service Improvements Grants Fund. 
Kebede Deribe is funded by a Wellcome Trust Intermediate Fellowship 
in Public Health and Tropical Medicine (grant number 201900); 
Mir Sohail Fazeli reports personal fees from Doctor Evidence LLC. 
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1341
João Fernandes gratefully acknowledges funding from FCT—Fundação 
para a Ciência e a Tecnologia (grant number UID/Multi/50016/2013). 
Katherine B Gibney is supported by an NHMRC Early Career 
Fellowship. Shifalika Goenka is supported by the Bernard Lown 
Scholars in Cardiovascular Health Program, Harvard School of Public 
Health (2015−17) and a Wellcome Trust (Grant No 096735/B/11/Z). 
Amador Goodridge acknowledges support from Sistema Nacional de 
Investigación (SNI) de Panamá and Secretaría Nacional de Ciencia, 
Tecnología e Innovación (SENACYT). Simon I Hay is funded by grants 
from the Bill & Melinda Gates Foundation (OPP1106023, OPP1119467, 
OPP1093011, and OPP1132415). Shariful Islam received postdoctoral 
research fellowship from The George Institute for Global Health and 
career transition grants from High Blood Pressure Research 
Foundation of Australia; the Ministry of Education Science and 
Technological Development of the Republic of Serbia has co­financed 
Serbian parts of this GBD related contribution throughout the Grant 
OI 175 014; publication of results was not contingent upon Minsitry’s 
prior censorship or approval. Peter James is supported by R00 
CA201542 from NCI. Panniyammakal Jeemon acknowledges support 
from the Clinical and public health intermediate fellowship from the 
Wellcome Trust and Department of Biotechnology, India Alliance 
(2015­2020). Srinivasa Vittal Katikireddi reports grants from Chief 
Scientist Office and grants from Medical Research Council, during the 
conduct of the study. Anil Kaul has received funding (HR14­065) from 
the Oklahoma Council for Advancement of Science & Technology 
(OCAST). Christian Kieling has received support from Brazilian 
governmental research funding agencies Conselho Nacional de 
Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de 
Amparo à Pesquisa do Estado do Rio Grande do Sul (Fapergs), and 
Hospital de Clínicas de Porto Alegre (FIPE/HCPA). Ai Koyanagi’s work 
was supported by the Miguel Servet contract financed by the 
CP13/00150 and PI15/00862 projects, integrated into the National 
R + D + I and funded by the ISCIII—General Branch Evaluation and 
Promotion of Health Research—and the European Regional 
Development Fund (ERDF­FEDER). Tea Lallukka is supported by the 
Academy of Finland (Grants #287488 and #294096). Cheru T Leshargie 
would like to thank Debremarkos University for the arrangement of 
internate service to communicate for tasks such as registering and 
communicating with GBD organiser and to download the manuscript 
and other supportive document, send on comments, and sending the 
co­author form for the GBD. Miriam Levi acknowledges institutional 
support received from CeRIMP, Regional Centre for Occupational 
Diseases and Injuries, Local Health Unit Tuscany Center, Florence, 
Italy. Katharine J Looker thanks the National Institute for Health 
Research Health Protection Research Unit (NIHR HPRU) in 
Evaluation of Interventions at the University of Bristol, in partnership 
with Public Health England (PHE), for research support; and received 
separate funding from the World Health Organization and Sexual 
Health 24 during the course of this study; the views expressed are 
those of the authors and not necessarily those of the National Health 
Service, the NIHR, the Department of Health or Public Health 
England. Azeem Majeed and Imperial College London are grateful for 
support from the NW London NIHR Collaboration for Leadership in 
Applied Health Research & Care. Francisco Martins­Melo 
acknowledges support from the postdoctoral Fellowship, Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; Brazilian 
public agency). Winifred März reports grants and personal fees from 
Siemens Diagnostics, grants and personal fees from Aegerion 
Pharmaceuticals, grants and personal fees from AMGEN, grants and 
personal fees from AstraZeneca, grants and personal fees from 
Danone Research, personal fees from Hoffmann LaRoche, personal 
fees from MSD, grants and personal fees from Pfizer, personal fees 
from Sanofi, personal fees from Synageva, grants and personal fees 
from BASF, grants from Abbott Diagnostics, grants and personal fees 
from Numares AG, grants and personal fees from Berlin­Chemie, and 
other support from Synlab Holding Deutschland GmbH. Mohsen 
Mazidi was supported by The World Academy of Sciences studentship 
of the Chinese Academy of Sciences. John McGrath received John 
Cade Fellowship APP1056929 from the National Health and Medical 
Research Council, and Niels Bohr Professorship from the Danish 
National Research Foundation. Toni Meier would like to acknowledge 
institutional support from the “Competence Cluster of Nutrition and 
Cardiovascular Health (nutriCARD)—Jena­Halle­Leipzig. 
Philip Mitchell’s research is supported by an Australian NHMRC 
Program Grant number 1037196. Ulrich Mueller has received financial 
support from the German National Cohort Study (grant 01ER1511D). 
Charles Newton is supported by the Wellcome Trust, UK. 
Olanrewaju Oladimeji is a Senior Research Specialist at the Human 
Sciences Research Council (HSRC), South Africa and Doctoral 
Candidate at the University of KwaZulu­Natal (UKZN), South Africa; 
we acknowledge the institutional support by leveraging on the existing 
organizational research facilities at HSRC and UKZN. AO was 
supported by intensificacion ISCIII FEDER funds and RETIC 
REDINREN. Richard Osborne was funded in part through an 
Australian National Health and Medical Research Council (NHMRC) 
Senior Research Fellowship #APP1059122. MO is supported by 
U54HG007479 from the NIH, USA. Charles Parry would like to 
acknowledge support from the South African Medical Research 
Council. Norberto Perico acknowledges that work related to this paper 
has been done on behalf of the GBD Genitourinary Disease Expert 
Group supported by the International Society of Nephrology (ISN). 
Konrad Pesudovs is support by Flinders University. William Petri is 
support by NIH grant AI043596; Kazem Rahimi is funded by an NIHR 
Career Development Fellowship and is supported by the National 
Institute for Health Research (NIHR) Biomedical Research Centre 
(BRC) and the Oxford Martin School. Giuseppe Remuzzi acknowledges 
that the work related to this paper has been done on behalf of GBD 
Genitourinary Disease Expert Group supported by the International 
Society of Nephrology (ISN). Maria Dolores Sanchez­Niño is supported 
by FIS PI15/00298 (ISCIII, Spanish Government). Aletta E Schutte 
received support from the South African Medical Research Council 
and National Research Foundation (DST/NRF SARChI Programme). 
Jeffrey Stanaway reports grants from Merck. Cassandra E I Szoeke 
reports grants from National Medical Health Research Council, during 
the conduct of the study; grants from Lundbeck, grants from 
Alzheimer’s Association, outside the submitted work; and has a patent 
PCT/AU2008/001556 issued; Rafael Tabarés­Seisdedos was supported 
in part by grant PROMETEOII/2015/021 from Generalitat Valenciana 
and the national grands PI14/00894 and PIE14/00031 from ISCIII­
FEDER. Amanda G Thrift was provided fellowship support from the 
National Health & Medical Resarch Council (NHMRC; 1042600). 
Stefano Tyrovola’s work was supported by the Foundation for 
Education and European Culture (IPEP), the Sara Borrell postdoctoral 
programme (reference no CD15/00019 from the Instituto de Salud 
Carlos III (ISCIII ­ Spain) and the Fondos Europeo de Desarrollo 
Regional (FEDER). Job F M van Boven’s work was supported by the 
University Medical Center Groningen, University of Groningen, The 
Netherlands. Ronny Westerman would like to acknowledge that this 
work is on behalf of the German National Cohort funded by the 
German Ministry of Education and Research. Lijing L Yan is partly 
supported by the National Natural Sciences Foundation of China 
grants (71233001 and 71490732). Marcel Yotebieng is partially supported 
by the NIAID U01AI096299­01 and the NICHD R01HD087993. 
All other authors declare no competing interests.
Acknowledgments
Research reported in this publication was supported by the Bill & 
Melinda Gates Foundation, the National Institute on Aging of the 
National Institutes of Health (award P30AG047845), and the National 
Institute of Mental Health of the National Institutes of Health (award 
R01MH110163). The content is solely the responsibility of the authors 
and does not necessarily represent the official views of the Bill & 
Melinda Gates Foundation or the National Institutes of Health. The 
Palestinian Central Bureau of Statistics granted the researchers access 
to relevant data in accordance with licence number SLN2014­3­170, after 
subjecting data to processing aiming to preserve the confidentiality of 
individual data in accordance with the General Statistics Law ­ 2000. 
The researchers are solely responsible for the conclusions and 
inferences drawn upon available data. We thank the Russia Longitudinal 
Monitoring Survey, RLMS­HSE, conducted by the National Research 
University Higher School of Economics and ZAO “Demoscope” 
together with the Carolina Population Center, University of North 
 Global Health Metrics
1342 
www.thelancet.com   Vol 390  September 16, 2017
Carolina at Chapel Hill, and the Institute of Sociology RAS for making 
these data available. This study has been realised using the data 
collected by the Swiss Household Panel (SHP), which is based at the 
Swiss Centre of Expertise in the Social Sciences FORS. The project is 
financed by the Swiss National Science Foundation from the 
Framingham Heart Study of the National Heart Lung and Blood 
Institute of the National Institutes of Health and Boston University 
School of Medicine. This work was supported by the National Heart, 
Lung and Blood Institute’s Framingham Heart Study (contract number 
N01­HC­25195). The Health and Retirement Study (HRS) is sponsored 
by the National Institute on Aging (grant number NIA U01AG009740) 
and is conducted by the University of Michigan. This research used data 
from the National Health Survey 2003. We are grateful to the Ministry of 
Health, Survey copyright owner, allowing him to have the database. All 
results of the study are those of the authors and in no way committed to 
the Ministry. This research used data from the National Health Survey 
2009–10. All results of the study are those of the authors and in no way 
committed to the Ministry. This research uses data from Add Health, a 
programme project designed by J Richard Udry, Peter S Bearman, and 
Kathleen Mullan Harris, and funded by a grant P01­HD31921 from the 
Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, with cooperative funding from 17 other agencies. Special 
acknowledgment is due to Ronald R Rindfuss and Barbara Entwisle for 
assistance in the original design. People interested in obtaining data 
files from Add Health should contact Add Health, Carolina Population 
Center, 123 West Franklin Street, Chapel Hill, NC 27516­2524, USA 
(addhealth@unc.edu). No direct support was received from grant P01­
HD31921 for this analysis. The data reported here have been supplied by 
the US Renal Data System (USRDS). The interpretation and reporting 
of these data are the responsibility of the author(s) and in no way should 
be seen as an official policy or interpretation of the US Government. 
HBSC is an international study carried out in collaboration with WHO/
EURO. The International Coordinator of the 1997–98, 2001–02, 2005–06 
and 2009–10 surveys was Candace Currie and the Data Bank Manager 
for the 1997–98 survey was Bente Wold, whereas for the following 
survey, Oddrun Samdal was the Databank Manager. A list of principal 
investigators in each country can be found at http://www.hbsc.org. Data 
used in the preparation of this article were obtained from the Pooled 
Resource Open­Access ALS Clinical Trials (PRO­ACT) Database. In 
2011, Prize4Life, in collaboration with the Northeast ALS Consortium, 
and with funding from the ALS Therapy Alliance, formed the Pooled 
Resource Open­Access ALS Clinical Trials (PRO­ACT) Consortium. The 
data available in the PRO­ACT Database has been volunteered by PRO­
ACT Consortium members. This paper uses data from SHARE Waves 1, 
2, 3 (SHARELIFE), 4, 5, and 6 (DOIs: 10.6103/SHARE.w1.600, 10.6103/
SHARE.w2.600, 10.6103/SHARE.w3.600, 10.6103/SHARE.w4.600, 
10.6103/SHARE.w5.600, 10.6103/SHARE.w6.600); see Börsch­Supan 
and colleagues (2013) for methodological details. The SHARE data 
collection has been primarily funded by the European Commission 
through FP5 (QLK6­CT­2001­00360), FP6 (SHARE­I3: RII­
CT­2006­062193, COMPARE: CIT5­CT­2005­028857, SHARELIFE: 
CIT4­CT­2006­028812), and FP7 (SHARE­PREP: 211909, SHARE­LEAP: 
227822, SHARE M4: 261982). Additional funding from the German 
Ministry of Education and Research, the Max Planck Society for the 
Advancement of Science, the US National Institute on Aging (U01_
AG09740­13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_
AG025169, Y1­AG­4553­01, IAG_BSR06­11, OGHA_04­064, 
HHSN271201300071C), and various national funding sources is 
gratefully acknowledged (see www.share­project.org). This manuscript is 
based on data collected and shared by the International Vaccine Institute 
(IVI). This manuscript was not prepared in collaboration with 
investigators of IVI and does not necessarily reflect the opinions or 
views of IVI. Collection of these data was made possible by the US 
Agency for International Development (USAID) under the terms of 
cooperative agreement GPO­A­00­08­000_D3­00. The opinions 
expressed are those of the authors and do not necessarily reflect the 
views of USAID or the US Government. Data for this research was 
provided by MEASURE Evaluation, funded by the US Agency for 
International Development (USAID). Views expressed do not 
necessarily reflect those of USAID, the US Government, or 
MEASURE Evaluation.
References
1 
Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD. 
Healthy life expectancy in 191 countries, 1999. Lancet 2001; 
357: 1685–91.
2 
Murray CJ, Vos T, Lozano R, et al. Disability­adjusted life years 
(DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2197–223.
3 
Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and 
national disability­adjusted life years (DALYs) for 306 diseases and 
injuries and healthy life expectancy (HALE) for 188 countries, 
1990–2013: quantifying the epidemiological transition. Lancet 2015; 
386: 2145–91.
4 
Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and 
national disability­adjusted life­years (DALYs) for 315 diseases and 
injuries and healthy life expectancy (HALE), 1990–2015: a systematic 
analysis for the Global Burden of Disease Study 2015. Lancet 2016; 
388: 1603–58.
5 
Murray CJ, Salomon JA, Mathers CD, Lopez AD. Summary measures 
of population health. Concepts, ethics, measurement and 
applications. Geneva: World Health Organization, 2002.
6 
Murray CJ. Quantifying the burden of disease: the technical basis for 
disability­adjusted life years. Bull World Health Organ 1994; 
72: 429–45.
7 
GBD 2016 Mortality Collaborators. Global, regional, and national 
under­5 mortality, adult mortality, age­specific mortality, and life 
expectancy, 1970–2016: a systematic analysis for the Global Burden of 
Disease Study 2016. Lancet 2017; 390: 1084–50.
8 
GBD 2016 Disease and Injury Incidence and Prevalence 
Collaborators. Global, regional, and national incidence, prevalence, 
and years lived with disability for 328 diseases and injuries for 
195 countries, 1990–2016: a systematic analysis for the Global Burden 
of Disease Study 2016. Lancet 2017; 390: 1211–59.
9 
Sullivan DF. A single index of mortality and morbidity. 
HSMHA Health Rep 1971; 86: 347–54.
10 
GBD 2016 Causes of Death Collaborators. Global, regional, and 
national age­sex specific mortality for 264 causes of death, 1980–2016: 
a systematic analysis for the Global Burden of Disease Study 2016. 
Lancet 2017; 390: 1151–210. 
11 
GBD 2016 Risk Factors Collaborators. Global, regional, and national 
comparative risk assessment of 84 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 1990–2016: 
a systematic analysis for the Global Burden of Disease Study 2016. 
Lancet 2017; 390: 1343–420.
12 
Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, 
definitions, and metrics. Lancet 2012; 380: 2063–66.
13 
Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
Lancet 2016; 388: e19–23.
14 
Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
PLoS Med 2016; 13: e1002056.
15 
Wang H, Naghavi M, Allen C, et al. Global, regional, and national life 
expectancy, all­cause mortality, and cause­specific mortality for 
249 causes of death, 1980–2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet 2016; 388: 1459–544.
16 
Flaxman AD, Vos T, Murray CJ, eds. An integrative metaregression 
framework for descriptive epidemiology, first edn. Seattle: University 
of Washington Press, 2015.
17 
Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of 
dengue: an analysis from the Global Burden of Disease Study 2013. 
Lancet Infect Dis 2016; 16: 712–23.
18 
Gething PW, Casey DC, Weiss DJ, et al. Mapping 
Plasmodium falciparum mortality in Africa between 1990 and 2015. 
N Engl J Med 2016; 375: 2435–45.
19 
Salomon JA, Vos T, Hogan DR, et al. Common values in assessing 
health outcomes from disease and injury: disability weights 
measurement study for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2129–43.
20 Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the 
Global Burden of Disease 2013 study. Lancet Glob Health 2015; 
3: e712–23.
21 
Omran AR. The epidemiologic transition: a theory of the 
epidemiology of population change. Milbank Q 2005; 83: 731–57
.
 Global Health Metrics
www.thelancet.com   Vol 390  September 16, 2017 
1343
22 WHO. The world health report 2000. Health systems: improving 
performance. Geneva: World Health Organization, 2000.
23 Bloom DE, Cafiero ET, Jané­Llopis E, Abrahams­Gessel S, 
Bloom LR. The global economic burden of noncommunicable 
diseases. Geneva: World Economic Forum, 2011.
24 Fries JF. Aging, natural death, and the compression of morbidity. 
N Engl J Med 1980; 303: 130–35.
25 Mundel T. Honing the priorities and making the investment case 
for global health. PLoS Biol 2016; 14: e1002376.
26 Institute for Health Metrics and Evaluation. A hand up: global 
progress towards universal education. Seattle, Institute for 
Health Metrics and Evaluation, 2015.
27 
Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: 
a world converging within a generation. Lancet 2013; 
382: 1898–955.
28 Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control 
on Plasmodium falciparum in Africa between 2000 and 2015. 
Nature 2015; 526: 207–11.
29 Gakidou E, Cowling K, Lozano R, Murray CJ. Increased 
educational attainment and its effect on child mortality in 
175 countries between 1970 and 2009: a systematic analysis. Lancet 
2010; 376: 959–74.
30 Wang H, Wolock TM, Carter A, et al. Estimates of global, regional, 
and national incidence, prevalence, and mortality of HIV, 
1980–2015: the Global Burden of Disease Study 2015. Lancet HIV 
2016; 3: e361–87
.
31 
Murray CJ, Lopez AD, eds. Global Burden of Disease: a 
comprehensive assessment of mortality and disability from 
diseases, injuries, and risk factors in 1990 and projected to 2020, 
1st edn. Cambridge: Harvard School of Public Health, 1996.
32 Stuckler D, King L, Robinson H, McKee M. WHO’s budgetary 
allocations and burden of disease: a comparative analysis. Lancet 
2008; 372: 1563–69.
33 Catalá­López F, García­Altés A, Álvarez­Martín E, 
Gènova­Maleras R, Morant­Ginestar C. Does the development of 
new medicinal products in the European Union address global 
and regional health concerns? Popul Health Metr 2010; 8: 34.
34 
Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase 
value and reduce waste when research priorities are set. Lancet 
2014; 383: 156–65.
35 Emdin CA, Odutayo A, Hsiao AJ, et al. Association between 
randomised trial evidence and global burden of disease: cross 
sectional study (Epidemiological Study of Randomized Trials—
ESORT). BMJ 2015; 350: h117
.
36 Lam J, Lord SJ, Hunter KE, Simes RJ, Vu T, Askie LM. 
Australian clinical trial activity and burden of disease: an analysis 
of registered trials in National Health Priority Areas. 
Med J Australia 2015; 203: 97–101.
37 
Mitchell RJ, McClure RJ, Olivier J, Watson WL. Rational allocation 
of Australia’s research dollars: does the distribution of NHMRC 
funding by National Health Priority Area reflect actual disease 
burden? Med J Australia 2009; 191: 648–52.
38 Aoun S, Pennebaker D, Pascal R. To what extent is health and 
medical research funding associated with the burden of disease in 
Australia? Aust N Z J Public Health 2004; 28: 80–86.
39 Lamarre­Cliche M, Castilloux AM, LeLorier J. Association between 
the burden of disease and research funding by the Medical 
Research Council of Canada and the National Institutes of Health. 
A cross­sectional study. Clin Invest Med 2001; 24: 83–89.
40 
WHO. Global Health Estimates 2015: deaths by cause, age, sex, by 
country and by region, 2000–2015. Geneva: World Health 
Organization, 2016. http://www.who.int/healthinfo/global_
burden_disease/estimates/en/index1.html (accessed 
March 14, 2017).
41 
WHO. WHO methods and data sources for global burden of 
disease estimates 2000–2015. Geneva: World Health Organization, 
2017
.
42 
WHO. WHO Member State DALY estimates, 2000–2015. 
http://www.who.int/healthinfo/global_burden_disease/estimates/
en/ (accessed April 24, 2017).
43 
Kuznik A, Lamorde M, Nyabigambo A, Manabe YC. Antenatal 
syphilis screening using point­of­care testing in sub­Saharan 
African countries: a cost­effectiveness analysis. PLoS Med 
10: e1001545.
44 
Vogel JP, Habib NA, Souza JP, et al. Antenatal care packages with 
reduced visits and perinatal mortality: a secondary analysis of the 
WHO Antenatal Care Trial. Reprod Health 2013; 10: 19.
45 
Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control 
on Plasmodium falciparum in Africa between 2000 and 2015. 
Nature 2015; 526: 207–11.
46 
Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005; 
352: 1565–77
.
47 
Fewtrell L, Kaufmann RB, Kay D, Enanoria W, Haller L, 
Colford JM. Water, sanitation, and hygiene interventions to reduce 
diarrhoea in less developed countries: a systematic review and 
meta­analysis. Lancet Infect Dis 2005; 5: 42–52.
48 
Quinn TC. HIV epidemiology and the effects of antiviral therapy on 
long­term consequences. AIDS 2008; 22: S7–12.
49 
Stover J, Johnson P, Hallett T, Marston M, Becquet R, Timaeus IM. 
The Spectrum projection package: improvements in estimating 
incidence by age and sex, mother­to­child transmission, HIV 
progression in children and double orphans. Sex Transm Infect 2010; 
86: ii16–21.
50 WHO. Towards a grand convergence for child survival and health. 
A strategic review of options for the future building on lessons 
learnt from IMNCI. Geneva: World Health Organization, 2016.
51 
GBD 2015 Healthcare Access and Quality Collaborators. Healthcare 
Access and Quality Index based on mortality from causes amenable 
to personal health care in 195 countries and territories, 1990–2015: 
a novel analysis from the Global Burden of Disease Study 2015. 
Lancet 2017; 390: 231–66.
52 National AIDS and STI Control Programme. Kenya AIDS Indicator 
Survey 2012: final report. Nairobi: National AIDS and STI Control 
Programme, 2014.
53 Ministry of Health. Uganda AIDS Indicator Survey 2011. Kampala: 
Ministry of Health, 2012.
54 
Uniting to Combat Neglected Tropical Diseases. The London 
Declaration on neglected tropical diseases. http://unitingtocombat 
ntds.org/resource/london­declaration (accessed May 8, 2017).
55 Hopkins DR. Disease eradication. N Engl J Med 2013; 368: 54–63.
56 Brun R, Blum J, Chappuis F, Burri C. Human African 
trypanosomiasis. Lancet 2010; 375: 148–59.
57 
WHO. Fifth meeting of the Emergency Committee under the 
International Health Regulations (2005) regarding microcephaly, 
other neurological disorders and Zika virus. Nov 18, 2016. 
http://www.who.int/mediacentre/news/statements/2016/zika­fifth­
ec/en/ (accessed May 8, 2017).
58 Bogoch II, Brady OJ, Kraemer MU, et al. Potential for Zika virus 
introduction and transmission in resource­limited countries in 
Africa and the Asia­Pacific region: a modelling study. 
Lancet Infect Dis 2016; 16: 1237–45.
59 Wikan N, Smith DR. Zika virus: history of a newly emerging 
arbovirus. Lancet Infect Dis 2016; 16: e119–26.
60 Pan American Health Organization. Zika cumulative cases. 
http://www.paho.org/hq/index.php?option=com_content&view=arti
cle&id=12390:zika­cumulative­cases&catid=8424:contents&Itemid=4
2090&lang=en (accessed May 8, 2017).
61 
GBD 2015 Eastern Mediterranean Region Collaborators, 
Mokdad AH. Danger ahead: the burden of diseases, injuries, and 
risk factors in the eastern Mediterranean region, 1990–2015. 
Int J Public Health 2017; published online Aug 3. DOI:10.1007/
s00038­017­1017­y.
62 Gómez­Dantés H, Fullman N, Lamadrid­Figueroa H, et al. 
Dissonant health transition in the states of Mexico, 1990–2013: 
a systematic analysis for the Global Burden of Disease Study 2013. 
Lancet 2016; 388: 2386–402.
63 O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic 
and intracerebral haemorrhagic stroke in 22 countries 
(the INTERSTROKE study): a case­control study. Lancet 2010; 
376: 112–23.
64 
Zhang LF, Yang J, Hong Z, et al. Proportion of different subtypes of 
stroke in China. Stroke 2003; 34: 2091–96.
65 Andrade LH, Alonso J, Mneimneh Z, et al. Barriers to mental health 
treatment: results from the WHO World Mental Health surveys. 
Psychol Med 2014; 44: 1303–17
.
66 Degenhardt L, Glantz M, Evans­Lacko S, et al. Estimating treatment 
coverage for people with substance use disorders: an analysis of data 
from the World Mental Health surveys. World Psychiatry (in press).
 Global Health Metrics
1344 
www.thelancet.com   Vol 390  September 16, 2017
67 
Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, 
treatment, and care services for people who inject drugs: 
a systematic review of global, regional, and national coverage. 
Lancet 2010; 375: 1014–28.
68 Jorm AF, Patten SB, Brugha TS, Mojtabai R. Has increased 
provision of treatment reduced the prevalence of common mental 
disorders? Review of the evidence from four countries. 
World Psychiatry 2017; 16: 90–99.
69 Ng M, Fleming T, Robinson M, et al. Global, regional, and national 
prevalence of overweight and obesity in children and adults during 
1980–2013: a systematic analysis for the Global Burden of Disease 
Study 2013. Lancet 2014; 384: 766–81.
70 
Global Burden of Disease Health Financing Collaborator Network. 
Evolution and patterns of global health financing 1995–2014: 
development assistance for health, and government, prepaid 
private, and out­of­pocket health spending in 184 countries. 
Lancet 389: 1981–2004.s
71 
Global Burden of Disease Health Financing Collaborator Network. 
Future and potential spending on health 2015–40: development 
assistance for health, and government, prepaid private, and 
out­of­pocket health spending in 184 countries. Lancet 
389: 2005–30.
72 
Dowell SF, Blazes D, Desmond­Hellmann S. Four steps to 
precision public health. Nature 2016; 540: 189–91.
73 
Golding N, Burstein R, Longbottom J, et al. Mapping under­5 and 
neonatal mortality in Africa, 2000–15: a baseline analysis for the 
Sustainable Development Goals. Lancet 2017
. http://dx.doi.org/
S0140­6736(17)31758­0 (in press).
74 
Roberts L. Hunger amplifies infectious diseases for millions 
fleeing the violence of Boko Haram. April 6, 2017
. http://www.
sciencemag.org/news/2017/04/hunger­amplifies­infectious­
diseases­millions­fleeing­violence­boko­haram (accessed March 
24, 2017).
75 
Hoff PD. A first course in Bayesian statistical methods. New York: 
Springer New York, 2009.
